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Cognitive dysfunction is one of the most common and burdensome symptoms experienced by 
breast cancer survivors.  This exploratory, ancillary study investigated the hypothesis that 
heterogeneity in the biology of breast cancers, including differences in clinicopathologic tumor 
features (CTFs) and host DNA variation in genes used clinically for breast cancer 
prognostication, may account for a proportion of variability in pretreatment (i.e., prior to 
initiation of systemic adjuvant therapy) cognitive performance among postmenopausal women 
diagnosed with early-stage breast cancer.  The parent study, Cognitive Impairment Related to 
Anastrozole Use in Women, provided pretreatment cognitive function data, CTF information 
from surgical pathology reports of women with breast cancer prescribed to initiate 
anastrozole±chemotherapy (n=329) at a future time, and biospecimens for the women with breast 
cancer (n=138) and age- and education-matched healthy controls (n=82), who were identically 
assessed for cognitive function.  We genotyped 131 single nucleotide polymorphisms (SNPs) 
representing 25 breast cancer-associated candidate genes (AURKA, BAG1, BCL2, BIRC5, 
CCNB1, CD68, CENPA, CMC2, CTSL2, DIAPH3, ERBB2, ESR1, GRB7, GSTM1, MELK, 
MKI67, MMP11, MYBL2, NDC80, ORC6, PGR, RACGAP1, RFC4, RRM2, and SCUBE2).  
Genetic risk/protection scores (GRSs) were calculated for each cognitive function composite to 
evaluate the collective effect of possession of multiple SNPs on cognitive performance.  Multiple 
linear regression modeling was used to determine if CTFs, SNPs, and/or interactions between 
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CTFs and GRSs accounted for variability in cognitive performance.  We found that CTFs related 
to cancer stage, tumor size, tumor focality, tumor location, histologic type and grade, hormone 
receptor and HER2 expression, cellular proliferation, as well as Oncotype DX® Breast Cancer 
Assay Recurrence Score® and Magee Equation recurrence score were individually significantly 
(p<0.05) associated with performance for one or more cognitive function composites.  With the 
exception of CMC2, MMP11, and RACGAP1, significant (p<0.05) SNP main effect and/or SNP-
by-prescribed treatment group interactions were observed individually between at least one 
cognitive function composite and one or more SNPs.  Each GRS was significantly (p<0.001) 
associated with its respective cognitive function composite score.  The findings from this 
dissertation study lay the foundation for a line of research to identify pathophysiologic 
mechanisms of and clinically relevant biomarkers for breast cancer-related cognitive 
dysfunction. 
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1.0  PROPOSAL INTRODUCTION AND SPECIFIC AIMS 
The overall purpose of this dissertation study, Cognitive Function and Breast Cancer:  Genomics 
and Disease Characteristics, is to gain a greater understanding of the biological foundations of 
cancer- and treatment-related cognitive decline in early-stage breast cancer survivors.  Based on 
an extensive review of the literature and preliminary work conducted by the student and her 
mentoring team, it is hypothesized that differences in clinicopathologic tumor features (CTFs) 
and DNA variation in genes used to characterize the biology of breast cancer will be associated 
with changes in cognitive function in women with early-stage breast cancer.  The specific aims 
of this dissertation study are threefold and depicted in the conceptual model (Figure 1): 
Specific Aim 1:  Investigate the relationship between CTFs of breast cancer and cognitive 
function in postmenopausal women with early-stage breast cancer. 
Specific Aim 2:  Explore DNA variation in genes used to clinically evaluate the biology 
of breast cancer for association with susceptibility to or protection from cognitive decline in 
postmenopausal women with early-stage breast cancer. 
Specific Aim 3:  Explore interactions between CTFs of breast cancer and DNA variation 
in genes used to clinically evaluate the biology of breast cancer on cognitive function. 
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Figure 1:  Conceptual Model 
 
The proposed dissertation study is an ancillary study to a large, ongoing longitudinal 
study, Cognitive Impairment Related to Anastrozole Use in Women (AIM) Study (R01CA107408; 
PI:  Dr. Catherine Bender).  The AIM Study explores the impact of the adjuvant (i.e., therapy 
after primary surgery to reduce disease recurrence and overall mortality), anti-estrogen therapy, 
anastrozole, on changes in cognitive function longitudinally (prior to initiation of adjuvant 
therapy, every six months throughout the first two years of therapy, annually for the final three 
years of therapy and twelve months after the conclusion of therapy) in four cohorts of 
postmenopausal women:  1) women which breast cancer who receive chemotherapy plus 
anastrozole; 2) women with breast cancer who receive chemotherapy alone; 3) women with 
breast cancer who receive anastrozole alone; and 4) a healthy control group of women 
frequency-matched on age and years of education to the cohorts of women with breast cancer.  
Specifically, the AIM Study will provide data on demographics, certain CTFs, mood, fatigue, 
pain, breast cancer treatment, and cognitive function.  The AIM Study will also provide banked 
DNA samples.  DNA samples were obtained as part of a separate ancillary study (PIs: Drs. 
Bender and Yvette Conley) that allowed for the collection and biobanking of genetic specimens 
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from a subset of AIM Study participants. Drs. Bender and Conley have given the student 
permission to access the biobank and databank for her dissertation study.  New genotype data 
will be generated using the biobanked DNA samples, and additional CTF data will be collected 
from the medical records of AIM Study participants for the proposed study.  Please note that 
previous genetic investigations using the biobanked specimens have focused on DNA repair and 
oxidative stress genetic variants known to affect cognitive functioning.  The proposed ancillary 
study adds and extends previous investigations through an innovative examination of genes used 
to characterize the biology of breast cancer. 
1.1 SIGNIFICANCE AND INNOVATION 
Breast cancer is the most prevalent form of cancer, excluding skin cancer, among women in the 
United States with an estimated 232,670 new cases of invasive breast cancer and 62,570 new 
cases of carcinoma in situ diagnosed in 2014 (American Cancer Society, 2014).  Fortunately, 
advancements in detection and treatment have decreased breast cancer mortality rates and breast 
cancer survivors represent the largest group of cancer survivors in the United States at 2.8 
million women (American Cancer Society, 2014).  This increase in survival has transformed the 
care of breast cancer from that of a lethal diagnosis to a manageable, chronic disorder, 
accompanied by many burdensome cancer- and treatment-related symptoms.  Changes in 
cognitive function or cognitive decline, defined as a decrease or loss in one or more of the 
domains of cognitive function including attention, learning, memory, psychomotor speed, mental 
flexibility, executive function, and visuospatial ability, is one of the most common and 
problematic phenomena experienced by breast cancer survivors.  In fact, between 21 and 95% of 
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breast cancer survivors report some form of subjective cognitive complaints following adjuvant 
chemotherapy and/or anti-estrogen therapy (Downie, Mar Fan, Houédé-Tchen, Yi, & Tannock, 
2006; Hurria et al., 2006; Jenkins et al., 2006; Mehnert et al., 2007; Schagen et al., 1999; 
Schilder et al., 2009; Shilling & Jenkins, 2007). These reported deficits have been objectively 
verified (Ahles et al., 2002; Bender et al., 2006, 2010; Brezden, Phillips, Abdolell, Bunston, & 
Tannock, 2000; Castellon et al., 2004; Fan et al., 2005; Jansen, Dodd, Miaskowski, Dowling, & 
Kramer, 2008; Jenkins et al., 2006; Jenkins, Shilling, Fallowfield, Howell, & Hutton, 2004; 
Lejbak, Vrbancic, & Crossley, 2010; Paganini-Hill & Clark, 2000; Quesnel, Savard, & Ivers, 
2009; Schagen et al., 1999; Shilling, Jenkins, Fallowfield, & Howell, 2003; Tager et al., 2010; 
Tchen et al., 2003; van Dam et al., 1998; Von Ah et al., 2009; Wefel, Saleeba, Buzdar, & 
Meyers, 2010), and while the majority of breast cancer survivors do not exhibit profound 
cognitive impairments (Bender et al., 2006; Brezden et al., 2000; Castellon et al., 2004; Jim et 
al., 2009; Stewart, Bielajew, Collins, Parkinson, & Tomiak, 2006), even subtle changes in 
cognitive function can have a major impact on a survivor’s quality of life, affecting relationships 
with family and friends, educational and career decisions, job performance, emotional state, 
ability to make informed treatment decisions, and adherence to cancer therapy (Bender et al., 
2013; Boykoff, Moieni, & Subramanian, 2009; Munir, Burrows, Yarker, Kalawsky, & Bains, 
2010; Myers, 2012; Tchen et al., 2003; Von Ah, Habermann, Carpenter, & Schneider, 2012). 
More recently, studies that incorporate a pretreatment evaluation have found that 
compared to healthy controls or published normative data, women with breast cancer have 
poorer cognitive function prior to initiation of adjuvant chemotherapy and/or anti-estrogen 
therapy even after controlling for potential confounders, including age, estimated intelligence, 
depression, anxiety, and fatigue (Bender et al., 2006; Hermelink et al., 2007; Schilder et al., 
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2010; Wefel et al., 2004, 2010), suggesting that inherent disease-related factors of breast cancer 
may contribute to the cognitive decline seen in women with breast cancer prior to adjuvant 
treatment (Ahles et al., 2011; Jim et al., 2009; Seigers et al., 2010; Wefel et al., 2004). 
Additionally, there is considerable variation in the incidence of cognitive decline among women, 
the severity of the cognitive decline, and the specific cognitive domains affected (Falleti, 
Sanfilippo, Maruff, Weih, & Phillips, 2005; Wefel & Schagen, 2012).  These incongruities 
across findings of studies and between individual women lend themselves to and have the 
potential to be explained by genetic variation (Ahles & Saykin, 2007; Ahles et al., 2003; Small et 
al., 2011; Vardy, Wefel, Ahles, Tannock, & Schagen, 2008).   
The proposed study aims to be an initial and integral step in establishing a relationship 
between traditional CTFs of breast cancer, DNA variability within genes used to clinically 
evaluate the biology of breast cancer, and cancer- and treatment-related cognitive decline.  The 
proposed study will build upon the student’s previous research experiences, as part of her 
mentoring team, investigating relationships between genes known to affect cognitive function 
and cognitive decline in women with breast cancer through exploration of a complementary, but 
novel dissertation hypothesis supported by the scientific literature:  inherent, disease-related 
clinicopathologic and genetic features of breast cancer tumors can be used to personalize the 
prediction of cognitive decline in women with and receiving treatment for breast cancer.   The 
proposed study, as well as the innovative line of investigation that this foundational study has the 
potential to generate, has significant implications for breast cancer survivors as (1) the results 
will add to our understanding of changes in cognitive function of women with and receiving 
treatment for breast cancer and (2) the knowledge generated has the potential to expand the 
utility of  traditional CTFs and prognostic multigene expression profiles, indicate clinically 
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relevant biomarkers of susceptibility to or protection from cognitive decline in women with and 
receiving treatment for breast cancer, inform research into novel treatments for women 
experiencing cognitive decline, and provide a means for determining which women are most at 
risk for cognitive decline and would potentially benefit from earlier and/or more intensive 
interventions. 
1.2 BACKGROUND 
A comprehensive, systematic literature review (not limited by year of publication) was 
conducted of professional, published literature.  Combinations of key words were entered into 
three electronic databases, PubMed, Ovid MEDLINE, and Google Scholar (Figure 2).  All 
results produced by PubMed and Ovid MEDLINE and the first four pages of results on Google 
Scholar were reviewed. 
 
Figure 2: Literature Review Search Terms 
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1.2.1 Support for investigation of CTFs and cognitive decline 
Ahles et al. found that at pretreatment, women with early-stage breast cancer (Stages 1-3) had 
significantly poorer reaction time than healthy controls; in contrast, subjects with noninvasive 
cancer (Stage 0) did not perform more poorly than healthy controls (2011).  In a preliminary 
analysis of CTFs in a subset of available AIM Study data, it was found that positive estrogen 
receptor status, higher tumor grade, and high Oncotype DX® Breast Cancer Recurrence Score® 
predicted poorer pretreatment cognitive function in women with breast cancer.  These findings 
all suggest that CTFs may impact cognitive function in women with early-stage breast cancer 
and warrant more extensive investigation.   
1.2.2 Support for investigation of a genetic component of cognitive decline 
While limited in number, studies have explored the relationship between DNA genetic variation 
and cognitive function in women with breast cancer and provide support for the hypothesis that 
DNA variation has the potential to influence cognitive function.  Small et al. found that catechol-
o-methyltransferase valine carriers treated with chemotherapy performed more poorly on tests of 
attention than healthy women who were also valine carriers (Small et al., 2011).  Ahles et al. also 
found that genetic variation affects cognitive function in breast cancer survivors revealing that in 
a cohort of long-term breast cancer and lymphoma survivors treated with standard-dose 
chemotherapy, the APOE E4 allele is associated with poorer visual memory, spatial ability, and 
psychomotor functioning (Ahles et al., 2003).  
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1.3 PRELIMINARY STUDIES 
To support and extend the previously reported evidence, the student and her mentoring team’s 
own analysis of the relationship between cognitive function in postmenopausal women with 
breast cancer and APOE genotype revealed that pretreatment performance and/or changes in 
performance on tasks of executive function, attention, verbal learning and memory, and visual 
learning and memory were found to be influenced by APOE genotype and/or interactions 
between APOE genotype and breast cancer treatment (Koleck et al., 2014; Appendix F).   
An analysis of 39 functional or tagging polymorphisms of select oxidative stress (CAT, 
GPX1, SEPP1, SOD1, and SOD2) and DNA repair (ERCC2, ERCC3, ERCC5, and PARP1) 
genes and pretreatment cognitive function was also conducted.  Each cognitive function 
composite evaluated as part of the study was significantly associated with one or more oxidative 
stress and DNA repair gene polymorphisms through either single nucleotide polymorphism 
(SNP) main effects and/or SNP-by-prescribed breast cancer treatment group interactions, further 
suggesting that genetic variation has the potential to influence cognitive function (Koleck et al., 
2016; Appendix J). 
1.3.1 Milestones 
The following table (Table 1) lists the milestones that have been achieved since entrance into the 
BSN-to-PhD program at the University of Pittsburgh School of Nursing in May 2011.  All 
milestones support the scientific merit of the proposed dissertation study. 
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Table 1:  BSN-to-PhD Program Milestones 
Milestone Date 
 Targeted Research and Academic Training Program for Nurses in Genomics 
(T32NR009759) fellowship appointment 
 
May 2011 
University of Pittsburgh School of Nursing Bessie Li Sze Memorial Scholarship 
 
Aug 2012 
Aug 2013 
 
University of Pittsburgh Institutional Review Board Approval for  
Cognitive Function and Breast Cancer: Genomics and Disease Characteristics 
(expedited review, PRO13040672; Appendix C) 
 
June 2013 
Preliminary Examination  
 
July 2013 
Cognitive Function and Breast Cancer: Genomics and Disease Characteristics 
(F31NR014590) funded by National Institute of Nursing Research 
 
Dec 2013 
Sigma Theta Tau International Eta Chapter Research Award 
 
Mar 2014 
Nightingale Awards of Pennsylvania PhD Degree Scholarship 
 
Apr 20214 
American Cancer Society  
Doctoral Degree Scholarship in Cancer Nursing (DSCN-14-076-01-SCN) 
 
July 2014 
University of Pittsburgh School of Nursing  
Ruth and Bill Fincke PhD Student  Research Award 
 
July 2014 
Comprehensive Examination and Overview 
 
Dec 2014 
 
1.4 DESIGN AND METHODOLOGY 
The proposed ancillary study will utilize regression modeling (Aim 1), candidate gene 
association (Aim 2), and moderation analyses (i.e., statistical interactions) (Aim 3) to explore 
changes in cognitive function in cohorts of women with breast cancer prior to and over time 
following the initiation of adjuvant therapy.  The anticipated timeline for completion of study 
aims is provided below (Table 2).   
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Table 2:  Study Timeline 
 
Year 1 
5/11 – 4/12 
Year 2 
5/12 – 4/13 
Year 3 
5/13 – 4/14 
Year 4 
5/14 – 4/15 
Year 5 
5/15-4/16 
Coursework      
Summer Genetics Institute 
June 2012 
       
F31 Submitted 
Dec 2012 
       
IRB Approval 
June 2013 
       
Preliminary Exam 
Completed 
July 2013 
       
F31 Funding 
Dec 2013 – Apr 2016 
      
Genotype Data Collection  
at the University of Pittsburgh 
School of Nursing  
Molecular Genomics Laboratory  
     
Admission to Candidacy 
Dec 2014 
       
Abstraction of 
Clinicopathologic Tumor 
Feature Data  
from medical records at 
University of Pittsburgh  
Medical Center (UPMC) facilities 
      
Data Analysis and  
Interpretation 
       
Preparation of Research 
Presentations and  
Manuscript Development 
     
Dissertation Defense 
April 2016 
      
 
1.4.1 Setting and sample 
As the proposed study is an ancillary study to the AIM Study, the target population and 
eligibility criteria are consistent with those of the AIM Study. Women with breast cancer were 
recruited from the Comprehensive Breast Cancer Program of the University of Pittsburgh Cancer 
Institute. Healthy women were recruited using a variety of approaches including referral from 
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women in the breast cancer cohorts, advertisements, and random digit dialing.  Inclusion criteria 
consist of being female, postmenopausal (defined as amenorrhea persisting for an entire year, 
oophorectomy, or hysterectomy and age greater than 51 years, the average age of menopause in 
the United States), maximum age of 75 years, able to speak and read English, and completion of 
a minimum of 8 years of education. Exclusion criteria for all participants consist of self-report of 
hospitalization for psychiatric illness within the last 2 years and having a prior diagnosis of 
neurologic illness. Additional inclusion criteria for participants with breast cancer are being 
diagnosed with early-stage (1, 2, or 3a) breast cancer based on the TNM Classification of 
Malignant Tumors system (Edge et al., 2010) with confirmation by each participant’s medical 
oncologist, and eligible to receive either chemotherapy plus anastrozole, chemotherapy alone, or 
anastrozole alone.  Further exclusion criteria for participants with breast cancer are clinical 
evidence of distant metastases or a prior diagnosis of cancer. Additional inclusion criteria for the 
control group include no current or history of any cancer and not currently taking (for at least 3 
months) any form of hormone replacement therapy. 
1.4.2 Definition of cognitive decline 
Cognitive decline will be defined as poorer performance on cognitive measures within 
participants over time or poorer performance on cognitive measures in women with breast cancer 
compared to healthy controls.  Cognitive function was evaluated at each time point using a 
comprehensive neuropsychological test battery (Table 3).  In order to mitigate the influence of 
practice effects, cognitive tests with alternate, equivalent versions were administered at follow-
up testing.  Scores from the control group also allow for statistical control of potentially 
confounding practice effects.  Please note that data reduction methods are conducted as part of 
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the AIM Study to reduce the dimensionality of the cognitive function data.  Eight cognitive 
function composites were identified and composite z-scores will be utilized as the 
dependent/outcome variables in this study:  attention, concentration, executive function, mental 
flexibility, psychomotor speed, verbal memory, visual memory, and visual working memory. 
Table 3:  AIM Study Neuropsychological Test Battery 
Cognitive 
Domain 
Neuropsychological Test Reliability and Validity References 
Attention 
 
Digit Vigilance Test 
(Lafayette Clinical Insturments Company, 1989) 
 
 
CANTAB Rapid Visual Information Processing Test 
(Owen, Sahakian, Semple, Polkey, & Robbins, 1995) 
 
Bender et al., 2000; Ryan, Williams, 
Orchard, & Finegold, 1992; Ryan & 
Williams, 1993 
 
Sahakian & Coull, 1993 
Learning 
and 
Memory 
 
CANTAB Paired Associates Learning Test  
(Owen et al., 1995) 
 
Rivermead Behavioral Memory Test 
(Wilson, Cockburn, Baddeley, & Hiorns, 1989) 
 
Rey Auditory Verbal Learning Test  
(Rey, 1941) 
 
Rey Complex Figure Test  
(Osterrieth, 1944) 
 
CANTAB Spatial Working Memory Test 
(Owen et al., 1995; Robbins et al., 1997) 
 
Lowe & Rabbitt, 1998; Owen et al., 1995; 
Robbins et al., 1997 
 
Cockburn & Smith, 1993; Jenkins et al., 
2004; Wilson et al., 1989 
 
Powell, Cripe, & Dodrill, 1991 
 
 
Berry, Allen, & Schmitt, 1991 
 
 
Lowe & Rabbitt, 1998; Owen et al., 1995 
Psychomotor 
Speed 
 
Grooved Pegboard Test 
(Lafayette Clinical Insturments Company, 1989) 
 
Digit Symbol Substitution Test  
(Wechsler, 1981) 
Matthews, Cleeland, & Hopper, 1970; 
Wieneke & Dienst, 1995 
 
Jenkins et al., 2004; Snow, Tierney, 
Zorzitto, Fisher, & Reid, 1989; 
Youngjohn, Larrabee, & Crook, 1992 
 
Mental 
Flexibility 
 
Trail Making Test-B  
(Reitan & Wolfson, 1985) 
 
 
D-KEFS Color-Word Interference Test  
(Delis, Kaplan, & Kramer, 2001) 
 
Bornstein, 1985; Moertel, Reitmeier, 
Bolton, & Schorter, 1964; Reitan, 1958; 
Wieneke & Dienst, 1995 
 
Delis et al., 2001 
Executive 
Function 
 
CANTAB Stockings of Cambridge Test 
(Owen et al., 1995; Robbins et al., 1997) 
 
D-KEFS Verbal Fluency Test 
(Delis et al., 2001) 
 
Capuron, Ravaud, & Dantzer, 2001; Lowe 
& Rabbitt, 1998; Owen et al., 1995 
 
Delis et al., 2001 
Visuospatial 
Ability 
Rey Complex Figure Test  
(Osterrieth, 1944) 
 
Berry et al., 1991; Wieneke & Dienst, 
1995 
 
Note. CANTAB=Cambridge Neuropsychological Test Automated Battery; D-KEFS=Delis-Kaplan Executive 
Function System 
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1.4.3 Clinicopathologic tumor features (CTFs) 
CTFs, independent variables of interest, are used to characterize breast cancer tumor pathology. 
CTF data not originally collected as part of the AIM Study will be obtained from pathology 
reports. A number of CTFs will be evaluated and are detailed in Table 4.   
Table 4:  CTF Description 
Feature Classification/Evaluation Method Scale 
Overall TNM Stage Stage 1, 2a, 2b, or 3a (Edge et al., 2010) Nominal 
Tumor Stage Stage T1a, T1b, T1c, T2, T3 (Edge et al., 2010) Nominal 
Lymph Node 
Involvement 
Positive or negative 
Number positive nodes 
Nominal 
Ratio 
Tumor site Laterality: left or right breast 
Clock position/octant location: upper outer, upper inner, lower outer, 
lower inner, upper middle, lower middle, inner middle, outer middle 
Nominal 
Nominal 
 
Tumor focality Single or multiple Nominal 
Primary tumor size Measured to nearest millimeter Ratio 
Aggregate tumor 
size 
Measured to nearest millimeter Ratio 
Histologic type Invasive ductal, invasive lobular, both (Tavassoli & Devilee, 2003) Nominal 
Histological grade Glandular/tubular differentiation score (1-3) 
Nuclear pleomorphism score (1-3) 
Mitotic activity/count score (1-3) 
Nottingham Score (3-9) 
Nottingham Grade (Elston & Ellis, 1991): 
    Grade 1 (low), 2 (intermediate), or 3 (high) 
Ordinal 
Ordinal 
Ordinal 
Ordinal 
Nominal 
LV invasion Presence or absence Nominal 
Estrogen and  
progesterone 
receptor 
Positive or negative 
H-score quantitation (0-300) 
Oncotype DX quantitative gene scores (Genomic Health Inc., 2016) 
    ER:  0-12.5+; Negative <6.5, Positive ≥6.5 
    PR:  0-10+; Negative <5.5, Positive ≥5.5 
Nominal 
Ratio 
Ratio 
HER2/neu Positive or negative 
IHC classification score (Wolff et al., 2007):   
    0, 1+ (Negative), 2+ (Equivocal), or 3+ (Positive) 
Oncotype DX quantitative gene scores (Genomic Health Inc., 2016) 
    0-13+; Negative <10.7, Equivocal 10.7-11.5, Positive ≥11.5 
Nominal 
Ordinal 
 
Ratio 
Ki67  Classification: low, moderate, high, or very high 
% Index (0-100) 
Nominal 
Ratio 
Oncotype DX 
Recurrence Score® 
Prognostic gene expression algorithm (0-100)  
(Paik et al., 2004, 2006) 
Interval 
Note.  HER2=Human epidermal growth factor receptor 2; IHC=Immunohistochemistry; LV=Lymphovascular; 
Oncotype DX=Genomic Health Inc. Oncotype DX® Breast Cancer Assay. 
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1.4.4 Justification of candidate gene selection 
One common clinical tool used to evaluate the underlying biology of breast cancer cells is the 
prognostic multigene expression profile for breast cancer.  Several multigene expression profiles 
have been developed, including the 11-gene expression signature, marketed as the  Breast Cancer 
IndexSM  by bioTheranostics, Inc., San Diego, CA (Jerevall et al., 2011); the 14-gene prognostic 
expression signature described in Tutt et al. (2008); the 21-gene breast cancer assay, marketed as 
the Oncotype DX® Breast Cancer Assay by Genomic Health, Inc., Redwood City, CA (Paik et 
al., 2004, 2006); the 50-gene breast cancer prognostic gene signature assay, marketed as the 
Prosigna® Breast Cancer Prognostic Gene Signature Assay by NanoString Technologies, Inc., 
Seattle, WA (Dowset et al., 2013; NanoString Technologies Inc., 2013), based on the PAM50 
Breast Cancer Intrinsic Classifier (Parker et al., 2009); and the 70-gene breast cancer recurrence 
assay, marketed as the MammaPrint® 70 Gene Breast Cancer Recurrence Assay by Agendia, 
Irvine, CA (Buyse et al., 2006; Veer et al., 2002).  Briefly, multigene expression profiles for 
breast cancer enhance the knowledge received from traditional CTFs and utilize predictive 
algorithms to clinically evaluate the underlying biology of the cancer cells, individualizing 
treatment through estimation of adjuvant therapy benefit and distant cancer recurrence or 
metastasis risk; thus, each profile is comprised of genes that play an important role in breast 
cancer development and progression, and, consequently, represent ideal candidates for a genetic 
association study exploring our hypotheses.  Characteristics of the previously listed profiles and 
the prioritization of candidate genes included in these profiles are discussed in detail in the 
article “Identification and prioritization of candidate genes for symptom variability in breast 
cancer survivors based on disease characteristics at the cellular level” (Koleck & Conley, 2016; 
Appendix H).    
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1.4.5 Candidate genes and polymorphisms selected for investigation  
As described in the article “Identification and prioritization of candidate genes for symptom 
variability in breast cancer survivors based on disease characteristics at the cellular level,” genes 
utilized in two or more multigene expression profiles for breast cancer were prioritized for 
investigation (Koleck & Conley, 2016; Appendix H).  The remaining genes used in the 21-gene 
breast cancer assay predictive algorithm were also included, as this profile is utilized by AIM 
Study recruitment sites.  In total, 25 candidate genes were selected:  AURKA, BAG1, BCL2, 
BIRC5, CCNB1, CD68, CENPA, CMC2, CTSL2, DIAPH3, ERBB2, ESR1, GRB7, GSTM1, 
MELK, MKI67, MMP11, MYBL2, NDC80, ORC6, PGR, RACGAP1, RFC4, RRM2, and 
SCUBE2.   
 Single nucleotide polymorphisms (SNPs) within these genes will be analyzed as 
independent variables.  Please refer to Table 6 in Appendix A for a list of proposed SNPs for 
each candidate gene.  Functional polymorphisms were first selected from the literature.  When a 
functional polymorphism was not identified and/or did not fully represent the gene of interest, 
tagging SNPs were selected using the Phase III HapMap database.  Because the profiles rely 
upon gene expression data, evaluation of DNA variability was extended ±2,500bps beyond the 
gene to capture the UTR-5’ and UTR-3’ regulatory regions.   Criteria for selecting tagging SNPs 
included: R2 of ≥ 0.8, minor allele frequency of ≥ 0.20 (except where otherwise noted), and 
selected for Caucasian ancestry, which represents the majority of AIM Study participants.  
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1.4.6 Covariates and confounders 
Demographic information, including age, years of education, and estimated verbal intelligence 
(National Adult Reading Test-Revised) were collected at the initial study time point (Nelson, 
1982). Treatment information and menopausal status was verified via the participant’s medical 
record.  Depression, Beck Depression Inventory-II (Beck, Steer, & Brown, 1996); anxiety, 
POMS (Profile of Mood States) Tension-Anxiety subscale (McNair, Lorr, & Droppleman, 1992); 
fatigue, POMS Fatigue-Inertia subscale (McNair et al., 1992); and pain, Brief Pain Inventory 
(Cleeland, 1989) were also evaluated at each time point.   
1.4.7 Genotype data collection and quality checks 
The choice of genotyping platform was determined based on the number of participants and the 
number of SNPs to be evaluated. The Sequenom® iPLEX® MassARRAY platform will be used 
for genotype data collection. This approach allows for high throughput genotyping using a 
multiplex approach. This platform is available through the University of Pittsburgh Clinical and 
Translational Science Institute supported Genomics and Proteomics Core Laboratory. Blind 
duplicates are included within each assay to control for plate to plate variability. SNPs not 
amenable to multiplexing or with less than a 90% call rate will be (re)genotyped with a different 
platform, specifically ABI TaqMan® allelic discrimination, or eliminated from the analyses.  
Each SNP will be tested for Hardy-Weinberg Equilibrium in an effort to detect potential 
genotyping errors. 
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1.4.8 Sample size justification  
Three-hundred and fifty-one women with early-stage breast cancer and 136 healthy controls have 
complete baseline/pretreatment assessments in the AIM Study.  Of these participants, 242 have 
banked DNA and demographic and cognitive function data for one or more assessment time 
points.  Due to depreciation in sample size, the current study will focus on the first three time 
points.  Current sample breakdown for T0, T1, and T2 are presented in Table 5. All CTFs (Aim 
1), with the exception of Oncotype DX® Breast Cancer Assay data (only available for eligible 
women who completed testing), are evaluated as part of a standard pathology report and will be 
analyzed in all study participants with breast cancer.  Genetic variation in candidate genes used 
to clinically evaluate the biology of breast cancer (Aim 2) will be explored in all women with a 
biobanked genetic sample including healthy controls.  Interactions between CTFs and DNA 
variation (Aim 3) will be analyzed in an exploratory manner in women with breast cancer who 
also have a biobanked genetic sample.  Based on our preliminary analyses and available sample, 
the proposed study would have .80 power to detect small effect sizes (R2) of 0.022 and 0.020 for 
individual CTFs without adjustment and with adjustment of a set of 8 covariates explaining 
moderate variability in the outcome variable (R2=0.09), respectively, for Aim 1 using an F-test at 
a significance level of 0.05 for two-sided hypothesis testing.  When modeling the change in 
cognitive function using linear mixed-effects regression with three time points, effects for 
individual CTFs as small as f=0.16 can be detected with 0.80 power at a two-tailed significance 
level of 0.05.  For Aim 2, a sample size of 242 achieves 0.80 power to detect small effect sizes 
(R2) of 0.031 and 0.025 for individual candidate genes without adjustment and with adjustment 
of a set of 8 covariates explaining variability in the outcome variable of R2=0.20, respectively, 
using an F-test with a significance level of 0.05.  Interactions between CTFs and DNA variation 
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will be analyzed in an exploratory manner in women with breast cancer who also have a 
biobanked genetic sample. 
Table 5:  AIM Study Sample Size (Genetic Sample Size) by Time Point 
 T0 T1 T2 
Chemotherapy plus Anastrozole 125 (55) 101 (56) 68 (49) 
Chemotherapy Alone 28 (15) 26 (15) 24 (15) 
Anastrozole Alone 198 (83) 139 (79) 94 (66) 
Healthy Controls 136 (83) 111 (77) 95 (64) 
Total 487 (236) 377 (227) 281 (194) 
Note. All women with breast cancer completed a pretreatment (T0) cognitive assessment after 
primary surgery but prior to initiation of systemic adjuvant therapy. Women with breast cancer 
prescribed chemotherapy plus anastrozole completed follow-up cognitive assessments after 
chemotherapy but prior to initiation of anastrozole (T1) and six months after anastrozole initiation 
(T2). Women with breast cancer prescribed chemotherapy alone completed follow-up assessments 
after chemotherapy (T1) and six months after completion of chemotherapy (T2).  Women with 
breast cancer prescribed anastrozole alone completed follow-up cognitive assessments six (T1) and 
twelve (T2) months after initiation of anastrozole. Healthy controls were assessed at comparable 
time points, i.e., baseline (T0) and six (T1) and twelve (T2) months after baseline. 
1.4.9 Data analysis 
Results of interest for all aims are the estimated regression coefficients and 95% confidence 
intervals, and the tests of significance of these coefficients at a two-tailed significance level of 
0.05. Estimates of the proportion of variance explained in cognitive function composites will 
also be obtained by each CTF and allele and/or genotype. 
1.4.9.1 Descriptive statistics Standard descriptive statistics will be computed for all 
independent, dependent, and potentially confounding/covariate variables based on the variable’s 
measurement level and observed distribution.  For nominal data, simple frequencies, 
percentages, ranges and modes will be examined.  Ordinal data descriptive statistics will further 
include semi- and inter-quartile ranges and medians.  For continuous type (interval or ratio 
scaled) data, frequencies, variances, means, medians, and ranges, including standard deviations 
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and quartiles, will be described.  Variable distributions will be examined using univariate or 
bivariate frequency distributions, such as cross-tabulation contingency tables, and appropriate 
graphical displays, including histograms, boxplots, and scatterplots.  Differences in baseline 
confounder/covariate data by study cohort and/or genotype and/or CTF (with continuous CTFs 
being meaningful categorized) will be evaluated using factorial ANOVA to determine statistical 
and clinical significance of mean group differences.  The comparability of baseline 
confounder/covariate data and baseline cognitive ability between participants included in the 
proposed study analysis and remaining participants from the AIM Study will be assessed using 
two-sample t-tests to evaluate equality of means. 
1.4.9.2 Data screening procedures Data will be screened for anomalies prior to the analyses for 
study aims.  This preliminary analysis will be used to assess 1) accuracy of inputted data, 2) 
potential outliers and influential points, 3) the amount and pattern of missing data, and 4) 
potential violation of assumptions necessary for the planned analyses.   
Screening for accuracy will be accomplished through examination of descriptive statistics 
and graphical representations of variables.  For continuous variables, minimum values, 
maximum values, means, and standard deviations will be examined for plausibility.  For discrete 
variables, data will be assessed for out-of-range category values and inaccurately programmed 
missing value codes.  Out-of-range values will be checked for accuracy, amended, and retained 
in the analysis if possible.   
Missingness of data will first be examined by participant; if a participant is contributing 
very little useable information, she will be dropped from the analysis.  Missing values for all 
variables at each time point will then be described using frequencies and percentages.  Reasons 
for missing data (e.g., laboratory error, participant refusal, etc.) will be noted.  A missing values 
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analysis will be undertaken to explore patterns of missingness and potential violations in 
assuming that data are missing completely at random (MCAR).  Separate variance t-tests will be 
used to investigate possible systemic missingness between the missingness for one variable and 
the observed values of any other variable.  Little’s MCAR test will be used to determine if data 
are missing completely at random.  If only a few cases (i.e., <5%) have missing data and appear 
to be a random subset of the entire sample, simple deletion of missing cases will be used to 
handle missingness. Alternatively, if data are missing from a large number of cases or missing 
values are not randomly distributed, an imputation method will be applied to estimate missing 
data. Imputation methods that will be considered include expectation maximization and multiple 
imputation.   
Outliers not due to incorrect data entry or having incorrectly specified missing value 
indicators will also be investigated.  Univariate and multivariate outliers for both continuous and 
discrete variables will be examined.  For discrete variables, uneven category splits will be 
identified using frequency distributions.  Because regression analyses are planned, ungrouped 
data will be used for identification of univariate outliers in continuous variables. Histograms and 
boxplots will be used to identify points far removed from the distribution.  Z-scores will be 
calculated and cases with extreme values (i.e., <-3.29 or >3.29) will be noted as potential 
outliers.  The presence of multivariate outliers will be assessed using bivariate scatterplots and 
Mahalanobis distances.  Outliers and influential points will also be evaluated for each regression 
model generated.  Outliers in Y will be assessed using jackknifed (deleted studentized) residuals, 
and outliers in X will be assessed using leverage statistics; generated values will be depicted 
graphically (i.e., residual/leverage value boxplots and residual by leverage plots) to elucidate 
potential outliers.  To explore how an observation may impact predicted values and individual 
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regression coefficients, the influence of the i-th observation on predicted values (DFFITS) and 
individual regression coefficients (DFBETAS) will be calculated.  In order to determine if the i-
th observation exerts undue influence on a set of coefficients, Cook’s distance will be calculated.  
Additionally, covariance ratios (COVARATIO) will be generated to determine if the i-th 
observation improves or worsens the estimation ability of the model.   
To evaluate the robustness of findings, regression models excluding points determined to 
be influential, as well as a robust regression models utilizing Huber and biweight iterations, will 
be generated.  Models eliminating potentially influential multivariate-outlier cases and/or 
diminishing the weight of potentially influential univariate-outlier cases will be created as part of 
the sensitivity analysis as well. 
Underlying assumptions for each regression model will be assessed.  To evaluate 
independence among residuals, jackknifed residuals will be plotted against fitted values.  A 
Durbin-Watson test will also be conducted to detect potential autocorrelation.  A histogram of 
jackknifed residuals will be created to evaluate the normality of residuals. Measures of skewness 
and kurtosis of jackknifed residuals will also be generated; values deviating from zero will be 
further investigated.  Added variable plots and component-plus-residuals plots will be generated 
to assess linearity.  Homoscedasticity will be evaluated using the Breusch-Pagan/Cook-Weisberg 
test for heteroscedasticity.  Variance inflation factors and conditioning indices and variance 
decomposition proportions will be used to assess for multicollinearity.    
1.4.9.3 Analysis for Specific Aim 1 Multiple linear regression modeling will be performed to 
evaluate the effect of each CTF on all cognitive function composites for each time point (i.e., T0, 
T1, and T2).  Models will initially include single CTFs to yield unadjusted estimators.  
Subsequently, in order to obtain adjusted estimators (i.e., minimally confounded estimates of 
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effect), confounders/covariates will be considered for inclusion in each model in a hierarchical 
fashion.  Age, estimated verbal intelligence, and study cohort will be included in regression 
models as potential time-invariant (i.e., fixed) confounders/covariates. Depression, anxiety, 
fatigue, and pain will be included as time-dependent confounders/covariates. Due to the known 
influence of age and estimated verbal intelligence on cognitive function, these variables will be 
incorporated in the first block of the hierarchical regression analysis and retained in all models 
regardless of statistical significance.  The second block will include depression, anxiety, fatigue, 
and pain.  Decisions on whether to retain or eliminate this set of predictors will be based on 
model R2 change and influence on predicted regression coefficients.  The third and fourth blocks 
will include the treatment regimen and a CTF, respectively, the predictors of interest.   Because 
we are interested in how the effect of each CTF is potentially modified by treatment regimen, 
interactions between CTFs and study cohort will be initially examined in the multivariable model 
in an additional block, block 5.  If no significant interactions are observed, the main effects 
model will be utilized.  Similarly, linear mixed-effects regression models will be used to evaluate 
the effect of CTFs on each cognitive function factor over time.    
1.4.9.4 Analysis for Specific Aim 2 Multiple linear regression modeling will also be used to 
examine the relationship between each cognitive function factor and the presence (i.e., 
heterozygous and homozygous minor variant) or absence (i.e., homozygous wild type) of a 
candidate gene allele at T0, T1, and T2.  If the allelic distribution allows, relationships between 
each cognitive function factor and participant genotype will be examined to elucidate allele 
dosage effects.  Models will be fitted considering each candidate gene’s SNPs separately to yield 
unadjusted regression coefficients.  Using the same hierarchical regression strategy as proposed 
for analysis of Aim 1, models will be expanded to include potential confounders/covariates to 
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yield adjusted regression coefficients.  Linear-mixed effects regression modeling will be used to 
model the change in individual cognitive function factors over time as a function of the presence 
of an allele and/or genotype.  In addition, genetic risk/protection scores (GRSs) will be 
calculated to evaluate the collective effect of multiple candidate gene variants on cognitive 
function in women with breast cancer.  Both a simple count and weighted method will be 
employed.  For the simple count method, values of 1 will be assigned to SNP variants associated 
with poorer cognitive function factor scores and values of -1 will be assigned to SNP variants 
associated with improved cognitive function factor scores.  Assuming an additive model of SNP 
effect, values will be summed across SNPs to produce a GRS for each participant.  The weighted 
method will utilize regression coefficients from univariate SNP models to assign greater risk to 
SNPs with stronger associations.  GRS will be calculated for each candidate gene and overall 
across all candidate genes.  GRS will be evaluated as predictors in the multiple linear regression 
models and linear mixed-effects regression models as the presence of a candidate gene allele was 
explained previously.       
1.4.9.5 Analysis for Specific Aim 3 Multiple linear regression models and linear-mixed effects 
regression models will be expanded to include the main effects for both individual CTFs and the 
presence of a particular allele and/or genotype and their interaction(s).  Interaction terms will be 
created as the products of individual CTFs and the presence of a particular allele and/or 
genotype. 
 
24 
1.5 POTENTIAL LIMITATIONS AND ALTERNATIVE APPROACHES 
While the sample sizes are appreciable, the student acknowledges that this study aims to explore 
many variables and recognizes that it may be underpowered for some aspects of the study.  
Likewise, while the reported minimum detectable R2s are comparable to the genetic effects 
found in our previous and ongoing investigations of cognitive function in women with breast 
cancer, research has shown that variation in individual candidate genes typically accounts for a 
small amount (often 1% or less) of the variance in any given observed phenotype, with the 
additive combination of multiple genetic polymorphisms (and/or multiple CTFs) explaining a 
clinically meaningful proportion of the variability.  Therefore, results from this study will need to 
be interpreted with a degree of caution.  Findings from this study will serve as the foundation for 
future investigations. 
 In the case that genotype data cannot be collected for a particular SNP, another highly 
informative SNP in linkage disequilibrium with the original polymorphism will be selected. In 
addition, if a priority SNP is not amenable to multiplexing with the Sequenom® iPLEX® 
MassARRAY platform and does not have an available TaqMan® allelic discrimination assay, 
alternative approaches including custom assay and restriction fragment length polymorphism 
design will be employed in an attempt to obtain genotype information.   
1.6 HAZARDOUS MATERIAL AND PROCEDURES 
While working in the laboratory, the student will be exposed to bodily fluids and chemicals.  
Personal protective equipment, including gloves and a laboratory coat, will be worn and safety 
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protocols will be followed. The student has received blood borne pathogen training and chemical 
hygiene training.  All experiments will be conducted in an appropriately equipped laboratory.     
1.7 RESEARCH PARTICIPANT RISK AND PROTECTIONS 
This dissertation study was originally submitted, reviewed, and approved by the University of 
Pittsburgh Institutional Review Board (IRB) in June 2013 (PRO13040672; Appendix C). 
1.7.1 Human subjects involvement, characteristics, and design 
The proposed study will use biobanked, de-identified genetic samples from a genetic ancillary 
study to a larger, ongoing parent study (AIM Study) that explores cognitive decline in women 
with and receiving treatment for breast cancer. The ancillary study developed a biobank of 
genomic material from these women and has explored variability in candidate genes involved in 
DNA repair and protection from oxidative damage. Participants are still being actively recruited 
for the AIM Study and genetic samples continue to be collected and biobanked. Women with 
breast cancer are recruited from the Comprehensive Breast Care Program of the University of 
Pittsburgh Cancer Institute. Control group candidates are accrued by utilizing the services of the 
University Center for Social and Urban Research and by referral from women in the breast 
cancer groups. 
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1.7.2 Sources of materials 
Genetic samples are/were collected from participants in the AIM Study in the following manner: 
Participants that previously completed cognitive function data collection for the AIM Study were 
re-contacted for the purpose of obtaining a biological sample for DNA extraction and 
biobanking. Only individuals who agreed to being re-contacted were re-contacted for the 
ancillary study. Participants that are currently undergoing data collection for the AIM Study are 
asked about their interest in participating in the ancillary genetics study during one of their 
data/sample collection visits. If they indicated interest in the genetic portion of the study, they 
were fully informed about the study prior to signing an informed consent document. It is 
important to note that for candidate gene analysis of DNA, it does not matter at what time point 
the genetic sample collection occurs; therefore, sample collection can occur at any time point. A 
sample of 3cc of whole blood or 2cc of saliva is collected from each participant who agrees to 
participate in the genetic portion of the study. Samples are processed and DNA is extracted and 
biobanked. The stock samples are placed in a -80°C freezer for long-term storage. The stock 
samples will be aliquoted and diluted for genotyping in this dissertation study. 
1.7.3 Potential risks 
As the proposed study involves the use of identifiable medical information, potential risks to 
study participants includes the risk of breach of confidentiality of data and the risk of anonymity 
of participants. Actions, as detailed below, are taken to keep any information obtained as 
confidential/anonymous as possible. 
27 
1.7.4 Protection against risk 
A signed addendum informed consent for the collection and analysis of genetic samples was 
obtained from participants prior to sample collection. The use of the sample for investigation of 
genetic aspects of cognitive function related to breast cancer is explained to participants prior to 
obtaining their informed consent. Within the consent, participants agree to have their genetic 
material available for analysis of any gene(s) that may be involved in cognitive function within 
the context of breast cancer.  The University of Pittsburgh IRB has approved the consent form 
and protocols used for recruitment and specimen collection.  These documents are reviewed on 
an annual basis.  All participants are assigned a unique code number under which all data are 
stored.  Security of data is upheld through the use of password protection and restricted access to 
users. Consent forms and a list of the match between participant names and code names are 
retained in a discrete locked file cabinet in Dr. Catherine Bender’s office. All staff and students 
who interact with study participants and/or who have access to participant identifiers are required 
to sign a confidentiality agreement and to complete online education modules sponsored by the 
Research Conduct and Compliance Office of the University of Pittsburgh prior to contact with 
any participants or access to medical records and/or data. Risk to the confidentiality of the 
genetic information generated by the proposed study is a very minimal risk given that all of the 
samples arrive in the laboratory already de-identified and all databases related to the genetic 
material will be de-identified.  Each sample and piece of genetic data will be associated only 
with a unique code.  Every precaution will be taken to minimize exposure of the data to persons 
outside the project by using passwords for all computer files and keeping all hard copies of data 
within the genomics laboratory, which is locked and accessible only to authorized personnel. 
Data from this project will be reported in aggregate only. 
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1.7.5 Potential benefits  
Research participants will likely receive no direct benefit from taking part in the proposed 
research study.  Nevertheless, the proposed dissertation study has the potential to improve 
cognitive function in women with and receiving treatment for breast cancer by indicating 
clinically relevant biomarkers of susceptibility to or protection from cognitive decline in women 
with and receiving treatment for breast cancer, inform research into novel treatments for women 
experiencing cognitive decline, and provide a means for determining which women are most 
likely at risk for cognitive decline and would potentially benefit from earlier and/or more 
intensive interventions. Considering the minimal risk to research participants, the proposed study 
is an advantageous undertaking. 
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2.0  SUMMARY OF STUDY 
The purpose of this dissertation research was to: (1) investigate the relationship between 
clinicopathologic tumor features (CTFs) of breast cancer and cognitive function in 
postmenopausal women with early-stage breast cancer; (2) explore DNA variation in genes used 
to clinically evaluate the biology of breast cancer for associations with susceptibility to or 
protection from cognitive decline in postmenopausal women with early-stage breast cancer; and 
(3) explore interactions between CTFs of breast cancer and DNA variation in genes used to 
clinically evaluate the biology of breast cancer on cognitive function.  Four articles, not 
including articles generated from the three aims noted above, that were written during the course 
of PhD training are provided in Appendices D, F, H, and J.  The first article, published in the 
Annual Review of Nursing Research and entitled “Molecular genomic research designs” 
discusses key considerations for designing studies with a molecular genetic or genomic focus 
(Appendix D).  The data-based article “Apolipoprotein E genotype and cognitive function in 
postmenopausal women with early-stage breast cancer,” published in Oncology Nursing Forum, 
complements the hypothesis of this dissertation research and examines the role of APOE 
genotype in cognitive function of postmenopausal women with early-stage breast cancer prior to 
initiation of adjuvant therapy and over time with treatment (Appendix F).  A second data-based 
manuscript, which also complements this dissertation research by examining relationships 
between polymorphisms in oxidative stress and DNA repair genes and pre-adjuvant therapy 
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cognitive function in postmenopausal women diagnosed with early-stage breast cancer, was 
published in SpringerPlus (Koleck et al., 2016; Appendix J).  The forth manuscript, entitled 
“Identification and prioritization of candidate genes for symptom variability in breast cancer 
survivors based on disease characteristics at the cellular level,” was published in Breast Cancer:  
Targets and Therapy.  This article provides a detailed background to support the hypothesis 
underlying this dissertation work and discusses the novel approach that was employed to select 
candidate genes to test the hypothesis (Appendix H).  The results for Specific Aims 1, 2, and 3 
are presented in the data-based manuscript, “The impact of variation in clinicopathologic tumor 
features and breast cancer-related genetic polymorphisms on pretreatment cognitive function in 
women with breast cancer:  an exploratory analysis,” included in this document. 
2.1 PRELIMINARY WORK ON DISSERTATION STUDY 
Prior to the comprehensive examination and overview, significant progress was made in the 
collection of genotype data related to Aim 2.  First, the student finalized single nucleotide 
polymorphism (SNP) selection, categorizing and ranking SNPs from highest to lowest priority 
within each gene in the following manner:  1) functional consequence, 2) tagging in a regulatory 
region, and 3) related to breast cancer risk or cognitive phenotype.  One hundred and sixty-three 
SNPs, representing the 25 candidate genes, were identified in total.  With the assistance of the 
University of Pittsburgh School of Nursing Molecular Genetics Laboratory manager, the student 
designed genotyping assays for selected SNPs using the Sequenom® iPLEX® MassARRAY 
platform (University of Pittsburgh Genomics and Proteomics Core Laboratories).  One hundred 
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and forty-nine SNPs were amenable to inclusion in the iPLEX® MassARRAY.  The student 
prepared 96 well plates of diluted DNA for processing.   
 Fourteen SNPs were not amenable to multiplexing.  Of these 14 SNPs, four were deemed 
essential (due to functional consequence, location within the gene, or lack of alternative SNPs 
within a given gene) for inclusion.  TaqMan® allelic discrimination assays were ordered for these 
four SNPs. All were successfully genotyped by the student using TaqMan® allelic discrimination 
in the School of Nursing Molecular Genetics Laboratory.   
 The multiplex results were received from the Core Laboratories and organized by the 
student. Thirteen SNPs included on the iPLEX® MassARRAY had call rates <90%.  Of these 13 
SNPs, five were deemed essential (due to functional consequence, location within the gene, or 
lack of alternative SNPs within a given gene).  TaqMan® allelic discrimination assays were 
ordered for these five SNPs.  Out of the five SNPs, two were successfully genotyped using 
TaqMan® allelic discrimination in the School of Nursing Molecular Genetics Laboratory.  The 
remaining SNPs were not successfully genotyped using TaqMan® allelic discrimination.  These 
SNPs were also not amenable to genotyping using a restriction fragment length polymorphism 
(RFLP) approach.  Consequently, alternative SNPs were selected.  Two of the substitute SNPs 
were successfully genotyped using TaqMan® allelic discrimination assays, while the third was 
successfully genotyped using RFLP. 
Out of all of the 145 SNPs that were successfully genotyped, 14 were excluded due to 
minor allele frequencies in our sample of less than 0.05.  In total, 131 SNPs are available to be 
included in the genetic analysis.  Please refer to Figure 3 for a depiction of the genotyping 
workflow for this dissertation project.   
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2.2 PROPOSAL CHANGES 
Several changes were made to the dissertation proposal and approved by the dissertation 
committee members at the student’s comprehensive examination and overview.  These changes, 
along with the rationale for these changes, are provided below.   
2.2.1 Focus on pretreatment cognitive function assessment time point 
The dissertation study originally proposed to investigate CTFs and DNA variation for 
associations with pretreatment cognitive function performance as well as cognitive decline with 
treatment at the first two assessment time points after initiation of systemic adjuvant therapy.  
Due to the fact that pretreatment findings were the impetus for this work and because of the 
hypothesis driving this study (i.e., disease-related factors inherent in breast cancer and/or host 
characteristics that predispose an individual to cancer as well as cognitive dysfunction may be a 
major determinant of cognitive changes in women with breast cancer), it was decided that all 
efforts related to this dissertation study should focus on the pretreatment assessment time point.  
Evaluation of CTFs and DNA variation for associations with treatment-related cognitive decline 
will be completed in a future study. 
2.2.2 Omission of chemotherapy only treatment group 
Originally, the dissertation study proposed to include a cohort of women with breast cancer 
prescribed/receiving chemotherapy alone.  However, due to the limited sample size available for 
this cohort, in combination with the potential differences in the biology of breast cancers not 
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treated with anti-estrogen therapies, the dissertation committee members favored omission of the 
chemotherapy alone cohort from the data analysis.   
2.2.3 Statistical analysis 
Several changes have been made to the proposed statistical analysis as well.  Use of both robust 
multiple linear regression models and standard multiple linear regression models eliminating 
potentially influential points to evaluate robustness of findings as part of a sensitivity analysis 
was originally proposed; however, due to the very large number of models, potential for error in 
eliminating individual points, improved model properties, and consistency in reporting results, 
the student, committee statistician, and committee chair made the decision to use a robust 
multiple linear regression model approach. 
 Because of the modification to focus on the pretreatment assessment time point, no 
multiple linear regression modeling at T1 or T2 will be performed for Aims 1, 2, or 3.  Likewise, 
no linear mixed-effects regression modeling will be performed to evaluate the influence of CTF 
variation, DNA variation, and accompanying interactions over time for Aims 1, 2, or 3.  
Additionally for Aim 1, treatment cohort will no longer be included in models, and interactions 
between treatment cohort and CTF will not be considered due to the elimination of the 
longitudinal analyses.   
 Finally, since the original proposal, much work has been completed by the student and 
her committee on the development of a method to calculate and evaluate genetic risk/protection 
scores (GRSs) related to Aim 2.  Weighted GRS will be calculated from regression coefficients 
from individual SNP models to assign greater risk/protection to SNPs with stronger associations.  
Overall GRS will be calculated across all candidate genes.  Please refer to Appendix J to review 
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how our method was used to evaluate the collective effect of multiple oxidative stress and DNA 
repair variants on pretreatment cognitive function performance in postmenopausal women with 
breast cancer.  In addition, interactions between GRSs and individual CTFs will be generated, 
instead of interactions between individual SNPs and CTFs, as originally proposed, to evaluate 
interaction effects as part of Aim 3.    
2.3 STUDY STRENGTHS AND LIMITATIONS 
This hypothesis-driven dissertation project is the first study to formally examine the impact of 
variation in CTFs of breast cancer and host DNA variation in genes used to clinically evaluate 
the biology of breast cancer on cognitive performance in postmenopausal women with early-
stage breast cancer.  Additional strengths of this dissertation project include the following:  
selection of biologically plausible candidate genes, representation of the variability in candidate 
genes through inclusion of both functional and tagging polymorphisms, well-characterized 
cognitive function phenotypes assessed with a battery of reliable and valid neuropsychological 
tests, adjustment for potential covariates and confounders of cognitive function performance, 
consideration of breast cancer heterogeneity through use of prescribed treatment group and 
inclusion of a matched healthy control group in the candidate gene analysis, and evaluation of 
the collective effect of possession of multiple risk or protection polymorphisms using weighted 
GRSs.     
 Study limitations should also be acknowledged.  Small samples sizes limited the 
interpretability of results from the CTF-by-GRS interaction analysis and the full 
clinicopathologic and genetic predictive model analysis as well as our ability to evaluate gene-
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dosage effects.  The study sample was comprised of primarily white postmenopausal women 
with hormone receptor positive early-stage breast cancer; the generalizability of our findings to 
more diverse populations and breast cancers is unknown.  For CTF data, we were limited to 
information available in surgical pathology reports obtained from the medical record.  In 
addition, we did not account for the potentially confounding effects of surgery and/or anesthesia 
exposure on pretreatment cognitive performance in our analysis. 
2.4 FUTURE STUDIES AND IMPLICATIONS FOR NURSING 
Findings from this dissertation study need to be confirmed in larger, more diverse populations 
and cancers.  Ideally, future studies will include a cognitive function assessment prior to primary 
surgery as a means to more fully capture the influence of breast cancer heterogeneity, and 
subsequent tumor removal, on cognitive performance.  Future analyses should also investigative 
the effect of variation in CTFs of breast cancer and host DNA in genes used to clinically evaluate 
the biology of breast cancer, on cognitive function throughout and following completion of 
adjuvant therapy.  Because candidate genes evaluated as part of this dissertation project were 
identified from prognostic multigene expression profiles for breast cancer and many of our 
significant findings were related to polymorphisms with functional consequences and/or located 
in regulatory regions of genes, tumor gene expression levels should be prioritized as an 
additional focus of investigation. 
The findings from this dissertation project inform current knowledge related to biological 
underpinnings for pretreatment cognitive dysfunction in women with breast cancer and provide 
the foundation for a line of research to identify clinically relevant biomarkers and novel therapies 
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for breast cancer survivors experiencing cognitive dysfunction.  We envision a future where 
women with breast cancer will not only receive a refined breast cancer diagnosis based on 
clinicopathologic and genetic characteristics but also tailored symptom prediction and proactive 
symptom management.  Nurses will be at the forefront of patient education related to symptom 
prediction, administration and coordination of biomarker testing, and creation of holistic, patient-
centered care plans that feature interventions intended to help mitigate negative cancer- and 
cancer treatment-related cognitive symptoms.      
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3.0  DATA-BASED MANUSCRIPT:  THE IMPACT OF VARIATION IN 
CLINICOPATHOLOGIC TUMOR FEATURES AND BREAST CANCER-RELATED 
GENETIC POLYMORPHISMS ON PRETREATMENT COGNITIVE FUNCTION IN 
WOMEN WITH BREAST CANCER:  AN EXPLORATORY ANALYSIS 
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3.1 ABSTRACT 
Breast cancer is a heterogeneous disease characterized by molecular and pathologic diversity.  
Based on previous work, we hypothesized that the cellular heterogeneity in breast cancers may 
account for variability in the presence and/or severity of cognitive dysfunction among women 
diagnosed with breast cancer, especially prior to initiation of systemic adjuvant therapy.  The 
purpose of this study was to investigate relationships between clinicopathologic tumor features 
(CTFs) of breast cancer or host DNA variation in genes used to clinically evaluate the biology of 
breast cancer and cognitive performance in postmenopausal women with early-stage breast 
cancer.  Interactions between CTFs and DNA variation were also explored.  Pretreatment 
cognitive function assessment occurred after surgery but before initiation of systemic adjuvant 
therapy.  CTF data were obtained from surgical pathology reports for women with breast cancer 
scheduled to receive adjuvant anastrozole therapy ± chemotherapy (n=329).  Genotypes for 131 
functional/tagging single nucleotide polymorphisms (SNPs) related to 25 biologically plausible 
breast cancer-related candidate genes (AURKA, BAG1, BCL2, BIRC5, CCNB1, CD68, CENPA, 
CMC2, CTSL2, DIAPH3, ERBB2, ESR1, GRB7, GSTM1, MELK, MKI67, MMP11, MYBL2, 
NDC80, ORC6, PGR, RACGAP1, RFC4, RRM2, and SCUBE2) were determined for three groups 
of women:  women with breast cancer, prescribed chemotherapy followed by anastrozole (n=55); 
women with breast cancer prescribed anastrozole only (n=83); and postmenopausal age- and 
education-matched controls without cancer (n=82).  Standard and robust multiple linear 
regression models were used to determine if CTFs and SNPs accounted for variability in 
cognitive performance scores.  Weighted multi-gene, multi-SNP genetic risk/protection scores 
(GRSs) were calculated based on significant (p<0.05) individual SNP results as a means to 
evaluate the collective effect of multiple SNPs on cognitive performance.  Interactions between 
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CTFs and GRSs were also assessed using linear regression models.  Significant (p<0.05) 
relationships were reported between cognitive performance on one or more cognitive function 
composites and the following CTFs:  cancer stage; tumor size; tumor focality; tumor laterality; 
tumor location octant; invasive type; Nottingham Score; Nottingham Grade; estrogen receptor 
(ER) H-score; progesterone receptor (PR) status; HER2 status; HER2 immunohistochemistry 
classification score; Ki67 classification; Ki67 index; Oncotype DX® Breast Cancer Assay 
Recurrence Score®; Oncotype DX® Breast Cancer Assay quantitative single gene ER, PR, and 
HER2 scores; and Magee Equation recurrence score.  Significant (p<0.05) SNP main effect 
and/or SNP-by-prescribed treatment group interactions were observed between at least one 
cognitive function composite and one or more SNPs of all candidate genes evaluated with the 
exception of CMC2, MMP11, and RACGAP1.  Each computed GRS was found to be 
significantly (p<0.001) and positively (i.e., as overall genetic protection increases, cognitive 
performance score increases indicating better performance) associated with its corresponding 
cognitive function composite score.  Only one significant interaction, between tumor location 
octant and visual working memory GRS, was noted.  Overall, results from this exploratory study 
suggest that clinicopathologic and breast cancer-related genetic variation influence pretreatment 
cognitive performance in women with breast cancer and merit additional investigation.     
Keywords:  breast neoplasms; cognition; genetics; pathology; pretreatment  
3.2 BACKGROUND 
Breast cancer is not a single disease, but rather a heterogeneous collection of diseases 
characterized by high degrees of molecular and pathologic diversity both among breast cancers 
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diagnosed in different individuals (i.e., inter-tumor) and within the same breast tumor (i.e., intra-
tumor) (Martelotto, Ng, Piscuoglio, Weigelt, & Reis-Filho, 2014; Polyak, 2011; Rivenbark, 
Connor, & Coleman, 2013).  Despite the well-established inter-tumor and intra-tumor 
heterogeneity in breast cancers, few studies have examined how variation in the biology of 
cancer itself may impact the presence and/or severity of cognitive symptoms experience by many 
women diagnosed with breast cancer (Ahles & Saykin, 2007; Ahles, Root, & Ryan, 2012).   
 Previous investigations have focused on the direct neurotoxic effects of adjuvant 
chemotherapy and the anti-estrogen effects of adjuvant aromatase inhibitors and selective 
estrogen receptor modulators on cognitive performance in breast cancer survivors over time with 
treatment (Ono et al., 2015; Zwart, Terra, Linn, & Schagen, 2015).  However, as succinctly 
summarized in a recent review by Wefel, Kesler, Noll, and Schagen, a number of studies have 
also reported evidence of cognitive dysfunction in women diagnosed with breast cancer prior to 
initiation of adjuvant chemotherapy and/or anti-estrogen therapy, unrelated to distress, fatigue, 
comorbidities, or surgery-related factors (2015).   
 While multiple pathophysiological mechanisms likely underlie cognitive changes in 
women with breast cancer, these pretreatment findings support the hypothesis that disease-
related factors inherit to breast cancer, including clinicopathologic tumor features (CTFs) of 
breast cancer and host DNA variation in genes used to clinically evaluate the biology of breast 
cancer, may contribute to cognitive dysfunction symptomatology and warrant more in depth 
investigation (Ahles & Saykin, 2007; Ahles et al., 2012; Wefel et al., 2015).  We further 
hypothesize that the heterogeneity in disease-related factors of breast cancer at the cellular level 
may account for a significant proportion of observed variability in cognitive dysfunction among 
41 
women diagnosed with breast cancer, especially prior to initiation of systemic adjuvant therapy 
(Koleck & Conley, 2016).   
 Although limited, evidence exists to support the investigation of CTFs and a genetic 
component of cognitive dysfunction in women with breast cancer.  In relation to CTFs, Ahles 
and colleagues found that at pretreatment, women diagnosed with invasive early-stage breast 
cancer (Stages 1-3) had significantly poorer reaction time than healthy controls; in contrast, 
participants diagnosed with noninvasive cancer (Stage 0) did not perform more poorly than 
healthy controls (2011).  Mandelblatt and colleagues reported that older women (≥ 60 years of 
age) diagnosed with Stage 2-3 breast cancer had lower pretreatment executive function scores 
compared to participants with Stage 0-1 breast cancer (2014).  In support of the genetic 
component of cognitive dysfunction, four published studies have reported associations between 
APOE genotype and cognitive performance in women with breast cancer (Ahles et al., 2011; 
Ahles et al., 2003; Koleck et al., 2014; Lengacher et al., 2015).  Associations with 
polymorphisms in ANKK1, BDNF, COMT, MTHFR, and SLC64A have also been reported 
(Lengacher et al., 2015; Ng et al., 2015; Small et al., 2011).   
 However, to our knowledge, no study to date has formally investigated the mechanistic 
merit of the previously stated hypotheses.  Therefore, the purpose of the current exploratory 
study is to investigate how heterogeneity in breast cancers at the molecular and pathologic levels 
is related to reported variability in pretreatment neuropsychological performance in 
postmenopausal women diagnosed with early-stage breast cancer.  Specifically, the three 
distinct, but interrelated, aims of this study are as follows: (1) to investigate the relationship 
between CTFs of breast cancer, evaluated as part of standard surgical pathology reports, and 
cognitive function in postmenopausal women with early-stage breast cancer; (2) to explore DNA 
42 
variation in genes used to clinically evaluate the biology of breast cancer, as part of prognostic 
multigene expression profiles for breast cancer, for association with susceptibility to or 
protection from cognitive decline in postmenopausal women with early-stage breast cancer; and 
(3) to explore interactions between CTFs of breast cancer and DNA variation in genes used to 
clinically evaluate the biology of breast cancer on cognitive function. 
3.3 METHODS 
3.3.1 Study sample 
Participants in this exploratory, ancillary study were originally recruited as part of a larger, 
ongoing parent study investigating the effects of adjuvant chemotherapy and the adjuvant anti-
estrogen therapy, anastrozole, on changes in cognitive function in postmenopausal women with 
breast cancer (Bender et al., 2015).  The current study analyzes three interrelated subgroups of 
participants:  (1) the subgroup for the CTF analysis was comprised of 329 postmenopausal 
women  newly diagnosed with Stage 1, 2, or 3a breast cancer, with no evidence of metastases, 
scheduled to receive either chemotherapy followed by anastrozole or anastrozole only; (2) the 
subgroup for the genetic analysis (N=220) included the cohort of women from subgroup #1 who 
provided a specimen for genetic evaluation (n=138) in addition to postmenopausal age-and 
education-matched healthy controls without breast cancer (n=82) who also provided a genetic 
specimen; and, lastly, (3) the subgroup for the interaction analysis was limited to women with 
breast cancer with both CTF and genetic data available. 
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 All study participants were postmenopausal, 75 years of age or younger, able to speak 
and read English, and completed a minimum of eight years of education.  Participants were 
excluded from the parent study, and consequently this ancillary study, if they had a prior history 
of neurologic disease or cancer or were hospitalized for psychiatric illness within the past two 
years.  Informed consent was obtained from all study participants.  Both the ancillary and parent 
studies were approved by the University of Pittsburgh Institutional Review Board. 
3.3.2 Evaluation of cognitive function 
Cognitive function was evaluated using a battery of 13 reliable, validated neuropsychological 
measures intended to assess multiple cognitive domains.  Rationale for  selection of individual 
tests has been described previously (Bender et al., 2015).  Women in the breast cancer cohorts 
completed the cognitive function test battery after primary surgery but before initiation of 
systemic adjuvant therapy.  Healthy women completed the same cognitive function test battery.  
Tests were administered to participants and scored by trained research nurses.  Due to the 
number of cognitive measures, an exploratory factor analysis with principal component 
extraction was previously employed to reduce the dimensionality of the cognitive function data 
(Bender et al., 2015). This data reduction technique identified eight cognitive function 
composites:  attention [Cambridge Neuropsychological Test Automated Battery (CANTAB) 
Rapid Visual Information Processing Test (Robbins et al., 1994)], concentration [Digit Vigilance 
Test (Lafayette Clinical Insturments Company, 1989)], mental flexibility [Delis Kaplan 
Executive Function System Color-Word Interference Test (Delis et al., 2001)], executive 
function [CANTAB Stockings of Cambridge Test (Robbins et al., 1994) and CANTAB Spatial 
Working Memory Test (Robbins et al., 1994)], psychomotor speed [Grooved Pegboard Test 
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(Klove, 1963) and Digit Symbol Substitution Test (Wechsler, 1998)], verbal memory [Rey 
Auditory Verbal Learning Test (Rey, 1941), Delis Kaplan Executive Function Verbal Fluency 
Test (Delis et al., 2001), and Rivermead Story Test (Cockburn & Smith, 1993)], visual memory 
[CANTAB Paired Associates Learning Test (Robbins et al., 1994) and Rey Complex Figure Test 
(Osterrieth, 1944)], and visual working memory [CANTAB Stockings of Cambridge Test 
(Robbins et al., 1994) and Rey Complex Figure Test (Osterrieth, 1944)].  The eight cognitive 
function composites are utilized as the outcome variables for this study.  Participant cognitive 
function composite z-scores were calculated such that more positive scores are associated with 
better cognitive performance and more negative scores are associated with poorer cognitive 
performance. 
3.3.3 Assessment of potential covariates and confounders 
Potential covariates and confounders of cognitive function were assessed in all cohorts of study 
participants at the same time as cognitive function assessment and included:  age (in years); 
estimated verbal intelligence – National Adult Reading Test-Revised (Nelson, 1982), depressive 
symptoms – Beck Depression Inventory-II (Beck et al., 1996); anxiety – Profile of Mood States 
Tension-Anxiety subscale (McNair et al., 1992); fatigue – Profile of Mood States Fatigue-Inertia 
subscale (McNair et al., 1992); and current pain – Brief Pain Inventory (Cleeland, 1989).  Only 
participants with complete covariate/confounder information were included in analyses.     
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3.3.4 Evaluation of CTFs 
CTF data were obtained from surgical pathology reports of study participants and included the 
following:  TNM Classification of Malignant Tumors overall stage (Stage 1, 2a, 2b, or 3a) (Edge 
et al., 2010); TNM Classification of Malignant Tumors tumor stage (Stage T1a, T1b, T1c, T2, 
T3) (Edge et al., 2010); lymph node status (positive or negative); number of positive lymph 
nodes; tumor site laterality (left or right breast); tumor location within breast [clock position 
and/or quadrant location (upper outer, upper inner, lower outer, or lower inner)]; tumor focality 
(single or multiple); primary tumor size (measured to the nearest millimeter); aggregate tumor 
size if multifocal (measured to the nearest millimeter); histologic type (invasive ductal, invasive 
lobular, or both) (Tavassoli & Devilee, 2003); combined histologic Nottingham Score [score 3-9; 
sum of three subscores:  glandular/tubular differentiation score (1-3), nuclear pleomorphism 
score (1-3), and mitotic activity/count score (1-3)] (Elston & Ellis, 1991); combined histologic 
Nottingham Grade [Grade 1 (low), Grade 2 (intermediate), or Grade 3 (high)] (Elston & Ellis, 
1991); lymphovascular invasion (presence or absence); estrogen receptor (ER) status (positive or 
negative); ER H-score (extent of nuclear immunoreactivity) quantitation score (score 0-300); ER 
Oncotype DX® Breast Cancer Assay quantitative single gene score (score 0-12.5+; Negative 
<6.5, Positive ≥6.5) (Genomic Health Inc., 2016); progesterone receptor (PR) status (positive or 
negative); PR H-score (extent of nuclear immunoreactivity) quantitation (score 0-300);  PR 
Oncotype DX® Breast Cancer Assay quantitative single gene score (score 0-10+; Negative <5.5, 
Positive ≥5.5) (Genomic Health Inc., 2016); HER2 immunohistochemistry (IHC) classification 
score [0, 1+ (Negative), 2+ (Equivocal), or 3+ (Positive)] (Wolff et al., 2007); HER2/neu status 
(positive or negative based on IHC test and/or FISH amplification); HER2 Oncotype DX® Breast 
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Cancer Assay quantitative single gene score (score 0-13+; Negative <10.7, Equivocal 10.7-11.5, 
Positive ≥11.5) (Genomic Health Inc., 2016); Ki67 index (0-100%; percentage of total number of 
tumor cells with nuclear staining); Ki67 proliferative rate classification [Low (≤10%), Moderate 
(11-25%), High (26-50%), or Very High (>50%)]; and Oncotype DX® Breast Cancer Assay 
Recurrence Score® (score 0-100 from multigene expression algorithm) (Paik et al., 2004, 2006).  
In instances where a participant had more than one primary breast tumor in the same breast or 
bilateral breast cancer, characteristics of the tumor contributing to the highest overall breast 
cancer stage were used in analyses.         
  Please note that clock position and quadrant information collected to describe the 
location of the tumor within the breast was combined and condensed into eight tumor locations:  
upper outer, upper inner, lower outer, lower inner, upper middle (12 o’clock), lower middle (6 
o’clock), outer middle (left breast-3 o’clock; right breast-9 o’clock), and inner middle (left 
breast-9 o’clock; right breast-3 o’clock).  Due to limited numbers, retroareolar tumors were 
classified by clock position, if provided, or omitted from the analysis.  In the case of multifocal 
tumors with foci identified in multiple quadrants, the average clock position was used if 
continuous between foci or the case was omitted from the analysis.  These eight locations are 
referred to as tumor location octants throughout the text.   
 As a supplement to Oncotype DX® Breast Cancer Assay Recurrence Scores®, Magee 
Equation recurrence scores were calculated using the three equations described in Klein et al. 
(2013).  The three equations, which produce very similar results, use different combinations of 
Nottingham Score, ER H-score, PR H-score, HER2 status (negative, equivocal, or positive), 
tumor size, and/or Ki67 index to estimate Oncotype DX® Breast Cancer Assay Recurrence 
Scores® and corresponding recurrence risk category assignment (i.e., low, intermediate, or high).  
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Thus, up to three scores were calculated for each participant based on available information.  
Scores from the three equations were reduced into a single variable giving preference to 
generated scores in the following sequence:  equation 1 > equation 2 > equation 3.  Scores from 
equation 1 were prioritized as this equation was found to most accurately replicate extreme 
values (i.e., assignment into the low and high recurrence risk categories).  If a score from 
equation 1 was not available for a participant, the score from equation 2 was selected due to its 
concordance with Oncotype DX® Breast Cancer Assay risk category overall and comparable 
performance to equation 3 when the intermediate risk category was omitted.  
3.3.5 Candidate gene selection and genotype data collection 
In total, 25 biologically plausible candidate genes (AURKA, BAG1, BCL2, BIRC5, CCNB1, 
CD68, CENPA, CMC2, CTSL2, DIAPH3, ERBB2, ESR1, GRB7, GSTM1, MELK, MKI67, 
MMP11, MYBL2, NDC80, ORC6, PGR, RACGAP1, RFC4, RRM2, and SCUBE2), that are 
theorized to represent the biology of breast cancer at the cellular level, were selected for 
investigation.  The rationale behind the identification and prioritization of candidate genes from 
multigene expression profiles for breast cancer has been described previously (Koleck & Conley, 
2016).  Briefly, because multigene expression profiles for breast cancer enhance knowledge 
received from traditional CTFs via algorithm-driven estimation of adjuvant therapy benefit and 
risk of distant metastasis or recurrence, genes from these profiles play an important role in breast 
cancer aggressiveness and progression, complement the collected CTF data, and are ideal for 
exploring the overall study hypotheses.   
 Single nucleotide polymorphisms (SNPs) representing each candidate gene were 
identified.  Functional polymorphisms within, directly upstream of, and/or found to influence 
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expression levels of candidate genes, were identified from the literature.  When a functional 
polymorphism was not identified and/or did not fully represent the gene of interest, tagging 
SNPs were selected using the Phase III HapMap database.  Because the profiles from which 
candidate genes were selected rely upon gene expression data, evaluation of DNA variability was 
extended ±2,500bps beyond the gene to capture the UTR-5’ and UTR-3’ regulatory regions. 
Criteria for selection of tagging SNPs were as follows:  R2 of ≥ 0.8, minor allele frequency 
(MAF) of ≥ 0.20, and selected for Caucasian ancestry, which represents the majority of study 
participants.  One-hundred and sixty-three functional and tagging SNPs were identified to 
represent the variability in the 25 candidate genes.     
 Genetic samples were collected from participants between June 2008 and May 2014.  
Three milliliters of whole blood or two milliliters of saliva were obtained for genotyping.  DNA 
was extracted from peripheral blood leukocytes using a simple salting out procedure (Miller, 
Dykes, & Polesky, 1988) or from saliva following the protocol and reagents supplied with the 
Oragene® DNA collection kits (DNA Genotek Inc., 2012).  The Sequenom® iPLEX® 
MassARRAY platform (Sequenom, San Diego, CA) was used as the primary genotyping method 
for this study due to the number of SNPs and participants evaluated.  SNPs were also genotyped 
using TaqMan® allele discrimination with the ABI Prism 7000 Sequence Detection System 
(SDS) and SDS software v1.2.3 (Thermo Fisher Scientific Inc., Waltham, MA) as well as a 
restriction fragment length polymorphism approach.  
 Negative controls were included with all analyses.  Genotypes were double called by 
individuals blinded to participant phenotypes and discrepancies were addressed by reviewing 
raw data or re-genotyping.  Participant genotypes were classified for data analysis based on the 
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presence or absence of the minor allele (homozygous wild type compared to the combination of 
heterozygotes and homozygous variant genotypes). 
3.3.6 Data cleaning and quality assurance 
Collected CTF data were independently entered into a computer database by two individuals 
blinded to outcome and genetic data and compared for discrepancies.  Discrepancies were 
adjudicated by a third individual by independent review of raw data.  SNPs with call rates less 
than 90% or MAFs of less than 0.05 were omitted.  For SNPs not meeting the 90% call rate 
threshold but deemed essential for inclusion in the study (due to functional consequence, location 
within a candidate gene, or lack of alternative SNPs available within a given gene) secondary 
genotyping approaches were attempted.  Alternatives were selected for essential SNPs in 
instances of multiple failed genotyping attempts and/or lack of availability of alternative 
genotyping methods. 
 Furthermore, detailed data screening procedures were performed to ensure data accuracy.  
Data from individual CTFs were cross-checked with other, directly corresponding CTFs (e.g., 
tumor stage and tumor size).  Inconsistencies were addressed by reviewing raw data from CTF 
collection forms and/or the original pathology reports.  Each SNP was tested for Hardy-
Weinberg Equilibrium (HWE), using chi-square goodness-of-fit or Fisher’s exact tests, to 
identify potential genotyping errors. 
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3.3.7 Statistical analysis 
Analyses were performed using Stata® Data Analysis and Statistical Software SE Version 14.1 
(StataCorp, College Station, TX) and IBM® SPSS® Statistics Version 23 (IBM Corp., Armonk, 
NY).  Standard descriptive statistics were computed for all predictors, outcomes, and covariates/ 
confounders.  Separate overall participant demographic, covariate/confounder, and cognitive 
function composite z-score summary statistics were calculated for both the CTF and genetic data 
analyses.  Overall CTF data were summarized using means, standard deviations, minimum and 
maximum values, frequencies, and percentages.  Additionally, due to findings from the 
individual CTF regression analyses related to tumor location octant, tumor characteristics were 
compared by tumor location octant using one-way ANOVAs to compare means of continuous 
variables and Fisher’s exact tests, computed using 2-sided Monte Carlo sampling based on 
10,000 sampled tables, to examine associations between categorical variables.  For the genetic 
analysis, differences in demographics, covariates/confounders, cognitive function composite z-
scores, and CTFs by study cohort were evaluated using one-way ANOVAs and Pearson’s chi-
square tests of independence (when expected cell counts ≥5), Fisher’s exact tests (for 2×2 
contingency tables with expected cell counts ≤5), or Fisher’s exact tests computed using 2-sided 
Monte Carlo sampling based on 10,000 sampled tables (for contingency table larger than 2×2 
with expected cell counts ≤5).  The comparability of covariate/confounder data and cognitive 
function performance z-scores between participants included in the CTF and genetic analyses 
and remaining participants from the parent study were also assessed. 
For the CTF analysis, standard multiple linear regression models and complementary 
robust multiple linear regression models using Huber weighting and biweighting iterations were 
fit to estimate associations between individual CTFs and each cognitive function composite 
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score.  In order to evaluate potential nonlinear (e.g., quadratic) relationships between continuous 
CTFs and cognitive function composites, squared versions of all continuous CTFs were 
computed. Both standard and robust linear regression models with the original and squared 
version of a particular CTF were produced.  Furthermore, all two-way interactions between 
marginally significant (p<0.20) CTF predictors, identified via the robust regression models with 
linear and squared terms, were evaluated using standard and robust multiple linear regression 
modeling.  In cases of significant squared predictors, interactions were generated with both the 
original and squared variable and all terms were included in the model.  All models controlled 
for age, estimated intelligence, and levels of depressive symptoms, anxiety, fatigue, and pain.   
Underlying assumptions were assessed for each regression model.  Specifically, 
histograms of jackknifed residuals were used to evaluate normality, added variable plots were 
generated to assess linearity, Breusch-Pagan/Cook-Weisberg tests were conducted to evaluate 
homoscedasticity, and variance inflation factors were used to assess for multicollinearity.  In 
order to identify potentially influential points, Cook’s distance was generated and evaluated as 
part of jackknifed residual by predicted value scatterplots.  Due to concerns related to influential 
points and heteroscedasticity, robust regression model estimated regression coefficients and 
corresponding significance levels are reported. 
Standard and robust multiple linear regression modeling was also used to examine 
relationships between each cognitive function composite and the presence (i.e., homozygous 
variant genotype plus heterozygous genotype) or absence (i.e., homozygous wildtype genotype) 
of one or more minor alleles for each SNP.  In order to account for the heterogeneity of breast 
cancer tumors in the genetic analysis, women diagnosed with breast cancer were further 
classified using prescribed future treatment regimen as a surrogate for disease characteristics.  
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Thus, the genetic analysis included two groups of women diagnosed with breast cancer, those 
prescribed chemotherapy followed by anastrozole (n=55) and those prescribed anastrozole only 
(n=83), as well as the matched healthy control group (n=82).  Both main SNP effects only and 
SNP-by-prescribed treatment group interaction effect regression models were fitted.  In all 
models, healthy controls served as the reference group for the two prescribed treatment groups 
(i.e., prescribed chemotherapy plus anastrozole or anastrozole alone).  Likewise, the wildtype 
genotype served as the reference group for possession of one or more minor alleles.  All 
regression models were adjusted for age, estimated intelligence, and levels of depressive 
symptoms, anxiety, fatigue, and pain, and prescribed treatment group.  Underlying assumptions 
were assessed for each regression model using the same techniques described for the CTF 
analysis.  Again, to lessen the impact of potentially influential points and adjust for 
heteroscedasticity, robust regression model estimated regression coefficients and significance 
levels are reported. 
Genetic risk/protection scores (GRSs) for each cognitive function composite were then 
calculated to explore the influence of possession of multiple significant (p<0.05) genotypes on 
cognitive function composite scores.  SNP minor alleles that were significantly (p<0.05) 
negatively or positively associated with a cognitive function composite by either SNP main 
effects and/or SNP-by-prescribed treatment interaction effects were used in GRS calculations.  A 
weighted calculation method, in which unstandardized robust regression coefficients from the 
individual genetic models were multiplied by 0 (absence) or 1 (presence) based on a participant’s 
genotype and prescribed treatment group membership and then summed, was used to assign 
greater risk/protection to minor alleles with stronger associations.  A lower GRS conveys greater 
genetic risk for poorer cognitive function and a higher GRS conveys greater genetic protection.  
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GRSs were added as the final predictor to standard and robust multiple linear regression models 
adjusted for age, estimated verbal intelligence, levels of depressive symptoms, anxiety, fatigue, 
pain, and prescribed treatment group.  Only participants with all genetic data necessary for 
calculation of a particular GRS were included in the GRS analysis. 
A genetic sub-analysis, featuring only women with breast cancer, was also completed for 
ERBB2 and MKI67.  Because ERBB2 and MKI67 have rare or limited expression in normal 
breast tissue (Pavelic et al., 1992; Stark et al., 2000; Urruticoechea, Smith, & Dowsett, 2005), we 
hypothesized that polymorphism in these genes may only be impactful if the genes are being 
expressed.  Thus, standard and robust multiple linear regression analyses for ERBB2 and MKI67 
SNPs by HER2 IHC classification score or Ki67 index, respectively, instead of prescribed 
treatment group, was conducted.  Models with HER2 IHC classification score, an ERRB2 SNP, 
and SNP-by-HER2 IHC classification interaction as predictors were fitted for each ERBB2 
polymorphism.  Likewise, models with Ki67 index, an MKI67 SNP, and SNP-by-Ki67 index 
interaction as predictors were fitted for both MKI67 polymorphisms. All models controlled for 
age, estimated intelligence, and levels of depressive symptoms, anxiety, fatigue, and pain.  
Robust regression model regression coefficients and p-values are reported. 
For each cognitive function composite, interactions between significant (p<0.05) 
individual CTFs, identified from models with linear and quadratic terms, were tested for 
interactions with calculated GRSs using standard and robust multiple linear regression modeling.  
Interaction terms were created as the products of individual CTFs and GRSs.  Only participants 
with breast cancer and genetic data were included in the interaction analysis.  In instances of 
significant squared CTF predictors, interactions were generated between the GRS and both the 
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original and squared variable; all terms were included in the model.  All models were adjusted 
for age, estimated intelligence, and levels of depressive symptoms, anxiety, fatigue, and pain. 
Full standard and robust multiple linear regression models were created to explore the 
potential to better predict cognitive function performance using a combination of both CTF and 
genetic data.  First, a final CTF model was developed for each cognitive function composite.  
Statistically significant (p<0.05) terms from individual main effect and interaction effect models 
were evaluated by placing all predictors into a single robust regression model. Predictors were 
omitted from the model if multicollinearity and/or limited variability were present.  All 
predictors meeting the screening criterion (p<0.20) were included in the final CTF models.  
GRSs were then added as a predictor to the final CTF models.  All models were adjusted for age, 
estimated verbal intelligence, and levels of depressive symptoms, anxiety, fatigue, and pain.  R2s 
obtained from standard regression models are reported. 
3.4 RESULTS – CLINICOPATHOLOGIC TUMOR FEATURES 
3.4.1 Participant and breast cancer tumor characteristics 
Of the 354 women diagnosed with early-stage breast cancer from which CTF data were 
collected, a total of 329 had complete confounder/covariate information and cognitive function 
scores available for one or more cognitive function composites.  A summary of overall 
demographic, covariate/confounder, and cognitive function data for participants included in this 
analysis is located in Table 7.  In general, participants were an average of 61.05 years of age, 
well-educated (with a mean of 14.80 years of education), married or currently living with a 
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partner (67.8%), and Caucasian (96.4%).  A comparison of characteristics of participants 
included (n=329) to those not included (because CTF or pretreatment cognitive function data 
were not available or covariate/confounder information was incomplete) (n=40) revealed that 
participants not included in the analysis had poorer (p=0.003) mean attention performance z-
scores (-0.66±1.162) than participants included in the analysis (-0.16±0.939).       
 The majority of breast cancer tumors were ductal (86.9%), single focus (84.2%), overall 
Stage 1 (65%), tumor stage T1c (40.4%), lymph node negative (77.5%), ER positive (98.8%), 
PR positive (87.8%), and HER2 negative (91.2%).  The mean Nottingham Score (6.04±1.306) 
for all tumors included in the analysis corresponds to an intermediate Nottingham Grade, and the 
mean Ki67 index (23.10±21.522) reflects a moderate Ki67 classification.  Oncotype DX® Breast 
Cancer Assay Recurrence Scores® ranged from 0 to 63 with a mean score of 18.26±9.76.  
Similarly, Magee Equation recurrence scores ranged from 1.92-48.87 with a mean score of 
20.51±7.77.  A comprehensive summary of all CTF data included in this analysis is reported in 
Table 8. 
3.4.2 Individual CTFs and cognitive function 
Table 9 reports the regression coefficients and p-values from all robust regression models 
evaluating the relation between individual CTFs and cognitive function composites.  Table 10 
complements the results from Table 9 by considering nonlinear quadratic relations and presents 
regression coefficients and p-values from robust regression models with squared continuous CTF 
terms.  
 The most significant findings were related to memory and HER2 status and HER2 IHC 
classification score.  Possession of a HER2 positive tumor contributed to poorer verbal (b=-
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0.287, p=0.018), visual (b=-0.270, p=0.001), and visual working (b=-0.490, p<0.001) memory 
performance compared to possession of a HER2 negative tumor.  Likewise, as HER2 IHC 
classification scores increased, verbal (b=-0.072, p=0.093), visual (b=-0.081, p=0.003), and 
visual working (b=-0.170, p<0.001) memory performance scores decreased (Figure 4).  
Moreover, when considering a quadratic continuous predictor model, a significant relationship 
between visual memory performance and Oncotype DX® Breast Cancer Assay HER2 
quantitative single gene score (b=1.983, p<0.001) and the corresponding squared term (b=-0.104, 
p<0.001) was observed. 
 In addition to associations with HER2 status and HER2 IHC score, a significant 
association was noted between tumor focality and verbal memory (b=-0.278, p=0.003), such that 
possession of a multifocal tumor contributed to poorer performance compared to a single focus 
tumor.  While not statistically significant, this trend can be seen across all cognitive function 
composites.  Possession of a progesterone receptor (PR) positive tumor, compared to a PR 
negative tumor, also contributed to poorer verbal memory performance (b=-0.256, p=0.015). 
 Intriguing tumor location effects were also noted.  To begin, having a tumor located in 
the left breast, compared to the right breast, contributed positively to verbal memory (b=0.156, 
p=0.025) and visual working memory (b=0.163, p=0.026) performance scores.  Overall tumor 
location octant was found to be significantly (p=0.027) related to mental flexibility.  Specifically, 
having a tumor in the lower inner octant contributed to poorer mental flexibility performance 
compared to having a tumor in the upper outer octant (b=-0.511, p=0.001).  While not 
statistically significant at the p<0.05 level, tumors located in the lower outer (b=-0.207, 
p=0.145), upper inner (b=-0.171, p=0.147), upper middle (b=-0.180, p=0.121), or lower middle 
(b=-0.258, p=0.100) octants also appear to contribute to poorer mental flexibility performance 
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compared to the upper outer octant.  Although tumor location octant did not significantly 
contribute to the model as a whole, the contribution of the individual upper inner octant to 
attention performance (b=-0.315, p=0.040) and the lower middle octant to visual working 
memory performance (b=-0.432, p=0.007) significantly differed compared to that of the upper 
outer octant. 
Additionally, as Oncotype DX® Breast Cancer Assay Recurrence Score® increased, 
mental flexibility performance score decreased (b=-0.010, p=0.032; Figure 5).  In the quadratic 
continuous predictor models, significant relations were found between Oncotype DX® Breast 
Cancer Assay Recurrence Score® and verbal memory performance (b=0.032, p=0.021; b=-0.001, 
p=0.029) as well as Magee Equation recurrence score and visual memory performance (b=0.026, 
p=0.055; b=-0.001, p=0.034) and visual working memory performance (b=0.051, p=0.028; b=-
0.001, p=0.021). 
Finally, Ki67 classification was found to be significantly associated with concentration 
performance (p=0.042).  In particular, a moderate Ki67 classification contributed positively to 
cognitive function performance compared to a low Ki67 classification (b=0.381, p=0.009). 
3.4.3 CTF differences by tumor location  
In order to facilitate interpretation of the tumor location effects, an evaluation of how CTFs 
differed by tumor location octant was completed.  Features that were found to be significantly 
(p<0.20) different by tumor location octant are presented in Table 11.  Tumors differed by tumor 
size, aggregate tumor size, tumor focality, invasive type, Nottingham Grade, HER2 status, HER2 
IHC classification score, and lymphovascular invasion presence.  Of particular interest, tumors in 
the lower middle octant have a higher percentage of HER2 positive tumors (30.0%) and  higher 
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mean HER2 IHC classification score (1.94±0.929) than the other octants.  These findings 
connect three of our significant results:  (1) lower middle octant visual working memory 
performance significantly differed compared to the upper outer octant; (2) possession of a HER2 
positive tumor contributed to poorer visual working memory performance compared to 
possession of a HER2 negative tumor; and (3) as HER2 IHC classification scores increased, 
visual working memory performance scores decreased. 
3.4.4 Two-way CTF interactions and cognitive function 
All marginally significant (p<0.20) individual CTFs tested for two-way interactions are listed by 
cognitive function composite in Table 12.  CTFs identified from both linear and quadratic robust 
regression models were included.  All significant (p<0.05) two-way CTF interactions are 
displayed in Table 13.  One or more significant two-way interactions were identified for each 
cognitive function composite. 
3.5 RESULTS - CANDIDATE GENE ANALYSIS 
3.5.1 Participant and tumor characteristics by study cohort 
Genetic data was collected from 226 participants.  Of these 226 participants, 220 had complete 
covariate/confounder information and cognitive function scores available for one or more 
cognitive function composites.  A summary of overall demographic, covariate/confounder, and 
cognitive function data for participants included in this analysis can be found in Table 14. 
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  Genetic analysis cohorts (i.e., prescribed chemotherapy plus anastrozole, prescribed 
anastrozole alone, and healthy controls) differed statistically, yet not clinically meaningfully, by 
age and estimated verbal intelligence (Table 15).  The groups also differed by level of anxiety 
(p=0.003), with women with breast cancer prescribed chemotherapy plus anastrozole having 
higher mean anxiety levels (9.61±6.140) than women with breast cancer prescribed anastrozole 
only (6.97±4.654) and the healthy controls (6.55±5.619).  Comparison of CTFs by prescribed 
treatment group confirmed differences in disease characteristics (Table 15).  To summarize, 
women with breast cancer prescribed chemotherapy plus anastrozole had higher frequency of 
Stage 2a, 2b, and 3a breast cancers, larger mean tumor size, higher mean number of positive 
lymph nodes, higher mean Nottingham Score, greater frequency of lymphovascular invasion, 
lower ER H-score, lower Oncotype DX® Breast Cancer Assay quantitative single gene PR score, 
greater frequency of HER2 positive cancer, higher mean Ki67 index, higher mean Oncotype 
DX® Breast Cancer Assay Recurrence Score®, and higher mean Magee Equation recurrence 
score compared to women with breast cancer prescribed anastrozole alone. 
 No differences in covariates/confounders or pretreatment cognitive function z-scores 
were observed between healthy control women included in the genetic analysis and remaining 
parent study participants not included in the genetic analysis (n=82).  Women with breast cancer 
prescribed anastrozole only included in the genetic analysis had slightly lower (p=0.044) mean 
estimated verbal intelligence (107.04±8.844) than those not included in the genetic analysis 
(n=155; 109.42±8.542).  Women with breast cancer prescribed chemotherapy plus anastrozole 
included in the genetic analysis had higher (p=0.014, p=0.006, p=0.002, respectively) mean 
pretreatment verbal (0.02±0.662), visual (0.29±0.352), and visual working (0.30±0.514) memory 
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performance z-scores compared to those not included in the genetic analysis (n=78; -0.28±0.697, 
0.03±0.615, -0.07±0.746, respectively).      
3.5.2 Candidate gene SNP quality assurance 
Of the 163 SNPs originally identified, 18 nonessential SNPs (that were not amenable to 
multiplexing or had call rates less than 90%) and 14 SNPs with study MAFs of less than 0.05 
were excluded.  Alternatives were selected for three essential SNPs.  In total, 131 SNPs were 
included in the genetic analysis (Table 16).  Genotyping call rates for these SNPs ranged from 90 
to 100%.  When considering all study participants, six SNPs were not in HWE: CTSL2rs4361859 
(p=0.0078), ESR1rs2234693 (p=0.0344), ORC6rs33994299 (p=0.0051), PGRrs1042838 
(p=0.0466), PGRrs1042839 (p=0.0103), and PGRrs474320 (p=0.0434).  When considering the 
healthy control women alone, PGRrs1042838 (p=0.0160), PGRrs1042839 (p=0.0027), and 
PGRrs474320 (p=0.0329) still did not meet HWE.  The deviation from HWE is most likely 
attributed to non-random sampling of study participants from the population. 
3.5.3 Individual SNPs and cognitive function 
Individual polymorphisms significantly (p<0.05) associated with a cognitive function composite 
by either SNP main effects or SNP-by-prescribed treatment group interaction effects are 
summarized by cognitive function composite in Table 17 and visually depicted in Figure 6.  
Overall, significant relationships were noted between at least one cognitive function composite 
and one or more polymorphisms of all candidate genes except CMC2, MMP11, and RACGAP1. 
Comprehensive results from the individual SNP and cognitive function regression analyses are 
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located in Table 18.  Selected significant results, highlighting trends across cognitive function 
composites, are reported in the text to follow by candidate gene. All reported regression 
coefficients are from robust multiple linear regression models and convey the magnitude and 
direction of possession of one or more minor alleles on cognitive function performance. 
Significant relations were observed between one or more polymorphisms in ESR1 and 
performance for every cognitive function composite evaluated.  Both main and interaction 
effects were observed.  Poorer cognitive function performance was associated with possession of 
one or more minor alleles for the following ESR1 SNPs regardless of group membership:  
ESR1rs2347867 and attention (b=-0.248, p=0.040), mental flexibility (b=-0.317, p=0.001), and 
psychomotor speed (b=-0.227, p=0.016); ESR1rs6557171 and attention (b=-0.234, p=0.047) and 
mental flexibility (b=-0.273, p=0.003); and ESR1rs7761846 and executive function (b=-0.388, 
p=0.005) and visual working memory (b=-0.351, 0.022). In contrast, better cognitive function 
performance was associated with possession of one or more ESR1rs488133 minor alleles and 
executive function (p=0.207, b=0.015) and psychomotor speed (b=0.275, p=0.004) scores, 
regardless of cohort membership. Significant interactions were also observed for ESR1rs488133; 
specifically, the combination of possession of one or more minor ESR1rs488133 alleles and 
prescribed anastrozole only (AO) group membership contributed positively to scores for 
concentration [SNP (b=-0.327, p=0.058); SNP-by-AO group (b=0.718, p=0.003)] and negatively 
to all three memory cognitive function composites, including verbal [SNP (b=0.365, p=0.018); 
SNP-by-AO group (b=-0.425, p=0.051)], visual [SNP (b=0.241, p=0.012); SNP-by-AO group 
(b=-0.288, p=0.034)], and visual working [SNP (b=0.516, 0.001); SNP-by-AO group (b=-0.544, 
0.011)] memory.  Prescribed chemotherapy plus anastrozole (CA) group membership 
interactions for all three memory cognitive function composites were also observed; in 
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particular; the combination of possession of one or more ESR1rs2941740 minor alleles and 
prescribed chemotherapy plus anastrozole group membership contributed positively to verbal 
[SNP (b=-0.318, p=0.041), SNP-by-CA group (b=0.663, p=0.008)], visual [SNP (b=-0.033, 
p=0.726), SNP-by-CA group (b=0.294, p=0.053)], and visual working [SNP (b=-0.258, 
p=0.105), SNP-by-CA group  (b=0.554, p=0.030)] memory performance. 
 Associations were also reported between polymorphisms and pretreatment cognitive 
function in the gene neighboring ESR1, CCDC170.  While significant relationships were also 
observed between CCDC170 polymorphisms and executive function, verbal memory, and visual 
memory, the most noteworthy findings were related to SNP main effects for concentration.  
Possession of one or more minor alleles contributed negatively to concentration performance for 
four out of the five CCDC170 SNPs examined regardless of study cohort membership:  
CCDC170rs12662670 (b=-0.363, p=0.016), CCDC170rs3734805 (b=-0.304, p=0.042), 
CCDC170rs3757318 (b=-0.334, p=0.042), and CCDC170rs6929137 (b=-0.322, p=0.003).   
 Significant findings related to polymorphisms in the other hormone receptor gene 
evaluated as part of this study, PGR, and concentration, executive function, psychomotor speed, 
verbal memory, visual memory, and visual working memory were reported as well.  Numerous 
observed interaction effects indicate that variability in the PGR gene is particularly important to 
executive function performance in women with breast cancer.  While possession of one or more 
PGRrs1042838 (b=0.337, p=0.025), PGRrs474320 (b=0.341, p=0.022), PGRrs484389 (b=0.318, 
p=0.024), or PGRrs608995 (b=0.324, p=0.020) minor alleles contribute positively to executive 
function performance, SNP-by-prescribed treatment group interaction effects for PGRrs1042838 
[SNP-by-CA group (b=-0.155, p=0.528), SNP-by-AO group (b=-0.323, p=0.151)], 
PGRrs474320 [SNP-by-CA group (b=-0.392, p=0.116), SNP-by-AO group (b=-0.321, 
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p=0.168)], PGRrs484389 [SNP-by-CA group (b=-0.529, p=0.016), SNP-by-AO group (b=-
0.494, p=0.015)], and PGRrs608995 [SNP-by-CA group (b=-0.538, p=0.013), SNP-by-AO 
group (b=-0.464, p=0.019)] contribute negatively to models counteracting the main effects and 
contributing an overall negative input to executive function performance in multiple instances. 
 Notable SNP main effects and/or SNP-by-prescribed treatment group interaction effects 
were observed for all CCNB1polymorphisms evaluated as part of this study.  Significant SNP 
main effects were reported for CCNB1rs164390 and CCNB1rs350099, with possession of one or 
more minor alleles contributing to poorer concentration (b=-0.230, p=0.035; b=-0.246, p=0.026, 
respectively) performance regardless of study cohort membership.  Whereas possession of one or 
more CCNB1rs164390 or CCNB1rs350099 minor alleles alone contributed positively to 
executive function (b=0.280, p=0.039; b=0.236, p=0.087, respectively), verbal memory 
(b=0.299, p=0.052; b=0.350, p=0.024, respectively), and visual working memory (b=0.581, 
p<0.001; b=0.562, p<0.001, respectively) scores, SNP-by-prescribed treatment interaction 
effects contribute negatively to executive function [SNP-by-CA group (b=-0.478, p=0.026), 
SNP-by-AO group (b=-0.551, p=0.006); SNP-by-CA group (b=-0.345, p=0.110), SNP-by-AO 
group (b=-0.507, p=0.011), respectively] , verbal memory [SNP-by-CA group (b=-0.355, 
p=0.143), SNP-by-AO group (b=-0.518, p=0.021); SNP-by-CA group (b=-0.445, p=0.065), 
SNP-by-AO group (b=-0.685, p=0.002), respectively], and visual working memory [SNP-by-CA 
group (b=-0.549, p=0.025), SNP-by-AO group (b=-0.540, p=0.017); SNP-by-CA group (b=-
0.553, p=0.024), SNP-by-AO group (b=-0.608, p=0.008), respectively] scores.  This same trend 
is observed for visual memory.  In contrast, possession of one or more CCNB1rs350104 minor 
alleles alone contributed negatively to executive function (b=-0.225, p=0.177), verbal memory 
(b=-0.441, p=0.016), visual memory (b=-0.153, p=0.176), and visual working memory (b=-
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0.475, p=0.009) scores, while SNP-by-prescribed treatment interaction effects contributed 
positively to executive function [SNP-by-CA group (b=0.128, p=0.606), SNP-by-AO group 
(b=0.470, p=0.032)], verbal memory [SNP-by-CA group (b=0.564, p=0.039), SNP-by-AO group 
(b=0.516, p=0.032)], visual memory [SNP-by-CA group (b=0.193, p=0.251), SNP-by-AO group 
(b=0.297, p=0.045)], and visual working memory [SNP-by-CA group (b=0.631, p=0.020), SNP-
by-AO group (b=0.699, p=0.004)] scores.   
Variability in GSTM1 impacted similar cognitive function composites as CCNB1.   
Possession of one or more GSTM1rs412543 minor alleles contributed negatively to executive 
function (b=-0.291, p=0.009), verbal memory (b=-0.470, p=0.017), visual memory (b=-0.188, 
p=0.013), and visual working memory (b=-0.901, p<0.001) performance; SNP-by-prescribed 
treatment interaction effects contributed positively to verbal memory [SNP-by-CA group 
(b=0.624, p=0.043), SNP-by-AO group (b=0.640, p=0.034)] and visual working memory [SNP-
by-CA group (b=1.012, p=0.001), SNP-by-AO group (b=0.473, p=0.116)] performance as well.     
Variation in BCL2 was also associated with performance for a number of cognitive 
function composites, including concentration, executive function, mental flexibility, 
psychomotor speed, verbal memory, and visual memory. Possession of one or more 
BCL2rs1564483 minor alleles contributed positively to executive function (b=0.191, p=0.030), 
mental flexibility (b=0.396, p=0.017), and visual memory (b=0.226, p=0.031) performance; 
significant SNP-by-prescribed anastrozole only group membership effects were also observed for 
mental flexibility (b=-0.607, p=0.015) and visual memory (b=-0.386, p=0.015). 
Likewise, variation in DIAPH3 was associated with performance for multiple cognitive 
function composites, including concentration, executive function, mental flexibility, verbal 
memory, visual memory, and visual working memory.  Significant DIAPH3rs1337652 SNP main 
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effects were reported for executive function (b=-0.295, p=0.036) and visual memory (b=-0.126, 
p=0.032), whereas significant DIAPH3rs4547237 SNP main effects were reported for all three 
memory composites, including verbal (b=0.198, p=0.030), visual (b=0.194, p=0.039), and visual 
working (b=0.195, p=0.034) memory.  Significant interactions were also observed between 
DIAPH3rs1337652 and mental flexibility [SNP (b=0.362, p=0.021), SNP-by-CA group (b=-
0.361, p=0.166), SNP-by-AO group (b=-0.620, p=0.004)] and visual working memory [SNP 
(b=0.095, p=0.550), SNP-by-CA group (b=0.002, p=0.995), SNP-by-AO group (b=-0.446, 
p=0.042)] as well as DIAPH3rs4547237 and concentration [SNP (b=-0.273, p=0.118), SNP-by-
CA group (b=0.053, p=0.847), SNP-by-AO group (b=0.610, p=0.014)] and executive function 
[SNP (b=0.410, p=0.002), SNP-by-CA group (b=-0.280, p=0.184), SNP-by-AO group (b=-
0.389, p=0.040)].   
Possession of one or more MYBL2rs2070235 minor alleles contributed positively to 
scores for attention (b=0.311, p=0.045) and negatively to verbal (b=-0.356, p=0.003), visual (b=-
0.156, p=0.035), and visual working memory (b=-0.411, p=0.001) performance regardless of 
study cohort membership.  Possession of one or more minor MYBL2rs619289 alleles also 
contributed negatively to verbal (b=-0.214, p=0.031) and visual working (b=-0.222, p=0.028) 
memory performance regardless of cohort membership.  A significant MYBL2rs11556379 main 
effect for mental flexibility performance and significant MYBL2rs11556379 interaction effects 
for both prescribed treatment groups with executive function performance were also noted. 
 In addition, MELKrs10973007 SNP-by-prescribed treatment group interaction effects 
were reported for concentration [SNP (b=0.080, p=0.659), SNP-by-CA group (b=-0.112, 
p=0.701), SNP-by-AO group (b=-0.504, p=0.046)] and executive function [SNP (b=-0.215, 
p=0.138), SNP-by-CA group (b=0.601, p=0.010), SNP-by-AO group (b=0.462, p=0.022)], and 
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MELKrs2250340 SNP-by-prescribed treatment group interaction effects were reported for 
executive function [SNP (b=-0.069, p=0.671), SNP-by-CA group (b=0.935, p=0.005), SNP-by-
AO group (b=-0.182, p=0.512)] and visual working memory [SNP (b=-0.003, p=0.988), SNP-
by-CA group (b=0.604, p=0.101), SNP-by-AO group (b=-0.765, p=0.014)].  Possession of one 
or more BAG1rs706118 minor alleles was associated with poorer executive function (b=-0.312, 
p=0.027), visual memory (b=-0.216, p=0.025), and visual working memory (b=-0.310, p=0.001) 
scores, and possession of one or more MKI67rs1073248 minor alleles was associated with poorer 
mental flexibility (b=-0.264, p=0.007) and psychomotor speed (b=-0.194, p=0.047) performance. 
Likewise, possession of one or more SCUBE2rs6486125 minor alleles contributed negatively to 
executive function (b=-0.320, p=0.020) and mental flexibility (b=-0.193, p=0.043) performance 
scores regardless of study cohort membership; the combination of possession of one or more 
SCUBE2rs6486125 minor alleles and prescribed chemotherapy plus anastrozole group 
membership contributed negatively to attention (b=-0.653, p=0.043) performance scores.   
 Possession of one or more MIR125A (which impacts expression of ERBB2) rs12976445 
minor alleles negatively impacted mental flexibility (b=-0.223, p=0.017) performance regardless 
of study cohort membership; a significant interaction effect between possession of 
MIR125Ars12976445 minor alleles and chemotherapy plus anastrozole group membership and 
attention [SNP (b=-0.619, p=0.001), SNP-by-CA group (b=0.643, p=0.032)] was also noted. 
Significant SNP-by-prescribed chemotherapy plus anastrozole only group membership effects 
were also observed for BIRC5rs1508147 and BIRC5rs9904341 and visual working memory 
(b=0.472, p=0.048; b=-0.510, p=0.041, respectively) performance.  
 NDC80rs12408485 and NDC80rs2292274 SNP-by-prescribed anastrozole only group 
membership was significantly associated with mental flexibility (b=0.589, p=0.010; b=-0.447, 
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p=0.046, respectively) performance. Significant SNP-by-prescribed anastrozole only group 
membership effects were also reported for CD68rs9901673 and verbal [SNP (b=0.446, p=0.010), 
SNP-by-AO group (b=-0.555, p=0.020)] and visual working [SNP (b=0.412, p=0.019), SNP-by-
AO group (b=-0.498, p=0.040)] memory. Significant interactions were observed between 
CENPArs3806517 and concentration [SNP (b=-0.363, p=0.039), SNP-by-CA group (b=0.056, 
p=0.849), SNP-by-AO group (b=0.615, p=0.012)], and CENPArs3806518 and psychomotor 
speed [SNP (b=-0.148, p=0.335), SNP-by-CA group (b=0.079, p=0.745), SNP-by-AO group 
(b=0.507, p=0.018)] and verbal memory [SNP (b=0.282, p=0.063), SNP-by-CA group (b=-
0.501, p=0.037), SNP-by-AO group (b=-0.423, p=0.045)] as well. 
3.5.4 GRSs and cognitive function 
One or more polymorphisms from the following genes, through either main SNP effects or SNP-
by-prescribed treatment group interaction effects, were included in cognitive function composite 
GRSs:  Attention – ERBB2(MIR125A), ESR1, MYBL2, and SCUBE2; Concentration – AURKA, 
BCL2, CCNB1, CENPA, DIAPH3, ESR1, ESR1(CCDC170), GRB7, MELK, and PGR; Executive 
Function – BAG1, BCL2, CCNB1, CTSL2, DIAPH3, ESR1, GSTM1, MELK, MYBL2, PGR, and 
SCUBE2; Mental Flexibility – BCL2, DIAPH3, ERBB2(MIR125A), ESR1, GSTM1(NFE2L2), 
MKI67, NDC80, RFC4, RRM2, and SCUBE2; Psychomotor Speed – BCL2, CENPA, ESR1, 
MKI67, and PGR; Verbal Memory – AURKA, BCL2, CCNB1, CD68, CENPA, CTSL2, DIAPH3, 
ESR1, ESR1(CCDC170), GSTM1, MYBL2, NDC80, ORC6, and PGR; Visual Memory – BAG1, 
BCL2, CCNB1, DIAPH3, ESR1, GSTM1, MYBL2, PGR, and RRM2; and Visual Working 
Memory – AURKA, BAG1, BIRC5, CCNB1, CD68, DIAPH3, ESR1, GRB7, GSTM1, MELK, 
MYBL2, and PGR.  All GRSs were found to be significantly (p<0.001) related to the respective 
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cognitive function composite score (Table 17).  Reported associations were all positive such that 
as GRS increases, cognitive function performance score increases as well (Figure 7). 
3.5.5 ERBB2 and MKI67 subset analysis 
Results for the ERBB2 by HER2 IHC classification score genetic subset analysis are reported in 
Table 19.  Two significant SNP-by-HER2 IHC classification score interactions for visual 
working memory performance were observed with ERBB2rs1058808 (b=-0.292, p=0.033) and 
ERBB2rs4252596 (b=-0.278, p=0.043). 
Results for the MKI67 by Ki67 index genetic subset analysis are reported in Table 20.  
One significant interaction between possession of one or more MKI67rs10732438 minor alleles 
and Ki67 index and mental flexibility was observed [Ki67 index (b=-0.015, p=0.006), SNP (b=-
0.621, p=0.004), SNP-by-Ki67 index (b=0.016, p=0.023)].   
3.6 RESULTS - CLINICOPATHOLOGIC TUMOR FEATURE AND  
CANDIDATE GENE INTERACTION ANALYSIS 
The only significant (p<0.05) interaction between CTFs and GRSs was related to the visual 
working memory composite and observed between tumor location octant, specifically lower 
outer compared to upper outer, and visual working memory GRS (Table 21).  A list of all 
significant (p<0.05) individual CTFs tested for interactions with GRSs by cognitive function 
composite is presented in Table 22.     
69 
In order to further evaluate the potential ability of combining CTF and genetic 
information to account for a greater amount of observed variance in cognitive function 
performance, regression models containing marginally significant (p<0.20) CTF predictors and 
GRSs were developed.  CTFs included in the final model for each cognitive function composite 
were identified from robust regression models that incorporated all statistically significant 
individual and interaction terms (Table 23).  Table 24 presents the R2 for the final CTF models as 
well as the R2 for the final combined CTF plus GRS models for each cognitive function 
composite.  These results must be interpreted with extreme caution due to exploratory model 
building and very small sample sizes.         
3.7 DISCUSSION 
In this study investigating the impact of variation in CTFs of breast cancer and host DNA 
variation in genes used to clinically evaluate the biology of breast cancer on cognitive 
performance in postmenopausal women with early-stage breast cancer, we found evidence to 
support the hypothesis that heterogeneity in molecular and pathologic characteristics of breast 
cancer account for variability in pretreatment cognitive function performance. 
 Overall, we found that CTFs related to cancer stage, tumor size, tumor focality, tumor 
location, histologic type and grade, hormone receptor and HER2 expression, cellular 
proliferation, as well as Oncotype DX® Breast Cancer Assay Recurrence Score® and Magee 
Equation recurrence score were significantly (p<0.05) associated with performance for one or 
more cognitive function composites.  However, the most intriguing findings were related to 
memory performance and HER2 status or HER2 IHC classification score.  For all memory 
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composites, possession of a HER2 positive tumor contributed to poorer performance compared 
to possession of a HER2 negative tumor.  Likewise, as HER2 IHC classification scores 
increased, memory performance scores decreased.  HER2 is an epidermal growth factor receptor 
encoded by the ERBB2 (erb-b2 receptor tyrosine kinase 2) gene. Within the context of breast 
cancer, we commonly discuss the oncogenic role of amplification of HER2 and its use as an 
indicator of poorer breast cancer prognosis (Iqbal & Iqbal, 2014; Moasser, 2007; Wesoła & 
Jeleń, 2015).  Our findings suggest that poorer breast cancer prognosis, based on HER2 
expression, is associated with poorer pretreatment memory performance. These cognition-related 
findings are further strengthened when we consider the important and widespread proto-
oncogenic role that ERBB2 plays in proper neural development (Britsch et al., 1998; Kim, Sun, 
Oglesbee, & Yoon, 2003; Kornblum, Yanni, Easterday, & Seroogy, 2000; Lee et al., 1995; 
Thompson et al., 2007). 
 Complementary genetic analyses of ERRB2 polymorphisms were also conducted.  
Bearing in mind the role of ERRB2 in brain development, we were initially surprised to find 
significant cognitive performance associations with only one polymorphism, MIR125A 
(microRNA 125a) rs12976445, which impacts expression levels of ERBB2; preliminary evidence 
suggests that this polymorphism may have merit as a prognostic biomarker of survival in women 
with breast cancer (Jiao et al., 2014).  However, because ERBB2 has rare or limited expression in 
normal breast tissue (Pavelic et al., 1992; Stark et al., 2000), we theorized that polymorphisms 
may only be impactful in women with breast cancer with HER2 amplifications.  We tested this 
hypothesis in the subset of women with breast cancer who provided genetic specimens.  The sub-
analysis revealed two significant interaction effects for visual working memory performance 
between rs1058808(Pro1170Ala, C>G) in the 3’ untranslated region of ERBB2, and rs2517955, 
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an upstream intronic variant, and HER2 IHC classification score.  As HER2 classification scores 
increased, the magnitude of the negative contribution to performance score also increased in 
women with breast cancer with rs1058808-GC+CC or rs2517955-TC+CC genotypes, lending 
support to our conjecture.  Interestingly, rs1058808 genotype has been associated with breast 
tumor HER2 expression; Su and colleagues reported that women with breast cancer with 
rs1058808-CG+GG genotypes were more likely to have higher HER2 expression levels than 
women with breast cancer with the rs1058808-CC genotype (2015).  Additionally, higher rates 
of Parkinson’s disease have been reported in female rs1058808 Ala allele (CG+GG genotypes) 
carriers (Wang et al., 2013).        
 One other interesting finding from the CTF analysis that warrants further discussion was 
the impact of tumor location, specifically tumor location octant on cognitive functioning.  We 
found that overall tumor location octant was related to pretreatment mental flexibility 
performance.  Most significantly, women with a tumor in the lower inner octant displayed poorer 
pretreatment mental flexibility performance compared to women with a tumor in the upper outer 
octant.  Depending on quadrant classification, previous studies have reported associations 
between the lower, inner, and lower inner breast quadrants and inferior outcomes, including 
decreased survival and disease recurrence (Arriagada et al., 2002; Colleoni et al., 2005; Hazrah, 
Dhir, Gupta, Deo, & Parshad, 2009; Kamakura, Akazawa, Nomura, Sugimachi, & Nose, 1996; 
Lohrisch, Jackson, Jones, Mates, & Olivotto, 2007; Sarp et al., 2007); although, conflicting 
results have also been reported (Wu et al., 2014).  In addition, upper outer quadrant location, the 
most common location for breast tumors, has been associated with better prognosis compared to 
other tumor locations (Bao, Yu, Jiang, Shao, & Di, 2014; Sohn, Arthurs, Sebesta, & Brown, 
2008).  These differences in outcomes are hypothesized to occur because of undetected breast 
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cancer spread to the internal mammary lymph nodes (Estourgie, Nieweg, Olmos, Rutgers, & 
Kroon, 2004; Sarp et al., 2007; Sohn et al., 2008).  While different classifications limit 
interpretation of results, it is fascinating to note that the tumor location most strongly related to 
poorer mental flexibility performance has also been associated with poorer breast cancer 
outcomes.   
In order to further facilitate interpretation of the tumor location results, we evaluated how 
CTFs differed by tumor location octant.  This analysis aided in the interpretation of the finding 
that women with breast cancer in the lower middle octant had poorer visual working memory 
performance when compared to women with tumors in the upper outer octant.  While multiple 
CTFs varied by octant, two differences stood out.  A higher percentage of lower middle octant 
tumors were HER2 positive compared to the other tumor locations, and the lower middle octant 
displayed higher mean HER2 IHC classification scores.  These differences, which relate back to 
previously discussed associations between memory and HER2 amplification, suggest that CTFs 
overrepresented in a particular octant may be driving relationships between location and 
cognitive function rather than the actual location itself.  While one published expert opinion 
suggested that HER2 expression does not vary by anatomic location within the breast (Jasani, 
Novelli, Ruschoff, & Osamura, 2010), no formal studies have been conducted. 
Shifting attention towards the results of the genetic analysis, we reported significant 
relationships between performance on at least one cognitive function composite and one or more 
polymorphisms of all candidate genes evaluated, with the exception of CMC2, MMP11, and 
RACGAP1, by either SNP main effects (i.e., observed variability in cognitive function 
performance in women with breast cancer and healthy controls is associated with a certain 
polymorphism) and/or SNP-by-prescribed treatment group interaction effects (i.e., observed 
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variability in cognitive function performance is associated with a certain combination of 
polymorphism and prescribed treatment group).  Significant findings related to the candidate 
genes found to most broadly impact cognitive function performance across multiple cognitive 
function composites, specifically, ESR1 and CCDC170, PGR, CCNB1, MYBL2, BCL2, GSTM1, 
and DIAPH3, are discussed, as exemplars, in detail below.   
 Performance on every cognitive function composite was related to ESR1 (estrogen 
receptor 1) polymorphisms either through main effects and/or interactions effects.  These 
findings were not unanticipated due to previously reported relationships between ESR1 
polymorphisms and cognitive outcomes, including functioning, impairment, and Alzheimer’s 
disease (Sundermann, Maki, & Bishop, 2011).   The most global associations with a single ESR1 
polymorphism in the current study occurred with an intronic upstream variant, rs488133.  The 
effects of this polymorphism on cognitive function performance were different by cognitive 
composite and study cohort:  rs488133-CT+TT contributed positively to executive function and 
psychomotor speed performance in all study participants.  rs488133-CT+TT negatively impacted 
concentration performance in healthy controls, but positively impacted concentration 
performance in women with breast cancer prescribed anastrozole only.  In contrast, rs488133-
CT+TT positively impacted memory performance in healthy controls, but negatively impacted 
memory performance in women with breast cancer prescribed anastrozole only.  In addition, 
while reported in other investigations of middle-aged and older women, we did not observe 
global cognitive impairment trends or memory deficits related to two well-studied 
polymorphisms in exon 1 of ESR1 named for the respective restriction enzyme recognition sites, 
PvuII (rs2234693) and Xbal (rs9340799) (Bousman et al., 2012; Kravitz, Meyer, Seeman, 
Greendale, & Sowers, 2006; Yaffe et al., 2009; Yaffe, Lui, Grady, Stone, & Morin, 2002).  
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 Polymorphisms in CCDC170 (coiled-coil domain containing 170), the upstream neighbor 
of ESR1, were included in this study to more fully represent variability in ESR1.  Associations 
between CCDC170 polymorphisms and breast cancer susceptibility, progression, and survival 
have been reported (Fletcher et al., 2011; Hein et al., 2012; Hong et al., 2014; Stevens et al., 
2011; Yamamoto-Ibusuki et al., 2015). In addition, ESR1-CCDC170 chromosomal 
rearrangements have been associated with more aggressive estrogen receptor positive breast 
cancers (Veeraraghavan et al., 2015).  While the function of CCDC170 is unknown and no 
studies to date have investigated associations between CCDC170 polymorphisms and cognitive 
phenotypes, results from this analysis, in which possession of one or more CCDC170 minor 
alleles in four (rs12662670, rs3734805, rs3757318, rs6929137) out of the five SNPs evaluated 
was related to poorer concentration performance in all study participants, suggest that variation 
in CCDC170 plays an important role in concentration.    
 The physiologic effects of progesterone are mediated by the protein encoded by PGR 
(progesterone receptor).  Progesterone receptors are expressed throughout the brain in every 
neural cell type (Brinton et al., 2008).  Henderson et al. found that progesterone concentrations 
were significantly and positively related to global cognition and verbal memory performance in 
healthy women less than 6 years since menopause (2013).  Moreover, Voytko, Murray, and 
Higgs found that estrogen plus progesterone improved executive function and attention 
performance in surgically menopausal monkeys (2009).  For executive function performance, we 
observed significant interactions between multiple PGR polymorphisms and study cohort.  In all 
instances, possession of PGRrs1042838-GT+TT, PGRrs474320-TA+AA, PGRrs484389-
TC+CC, or PGRrs608995-AT+TT genotypes contributed positively to executive function 
performance scores in healthy controls.  When we looked at the interaction of these minor alleles 
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within the context of breast cancer, we saw the opposite effect; the combination of possession of 
one or more minor alleles and membership in a breast cancer cohort was found to negatively 
impact scores, offsetting the positive SNP main effects and contributing an overall negative input 
to executive function performance in multiple instances.  The first SNP, rs1042838(Val660Leu, 
G>T), is a missense polymorphism (i.e., alters the amino acid sequence of a protein) in exon 4 
that is in linkage disequilibrium with a silent polymorphism in exon 5, rs1042839(His770His, 
C>T), and a 320bp Alu element insertion at intron G; this polymorphic variant is collectively 
known as PROGINS.  While the functional consequences remain unclear, variant PROGINS has 
been associated with increased breast and ovarian cancer risk (Agoulnik et al., 2004; Liu et al., 
2014; Rockwell et al., 2012; Romano, Delvoux, Fischer, & Groothuis, 2007; Stenzig et al., 
2012). rs474320 is an intronic variant reported to be in tight linkage with PROGINS (Lee et al., 
2010).  rs1042839 was also evaluated in this study and, as expected, generated very similar 
results to rs1042838; discrepancies in call rate may account for the differences in significance.  
rs484389 and rs608995 are located in the 3’ untranslated region of PGR.  Taken together, these 
findings indicate that variation in regulation of progesterone receptors may affect executive 
function performance and, furthermore, that the polymorphic impact on performance may vary in 
the systemic environment of a healthy individual compared to that of an individual diagnosed 
with breast cancer.        
CCNB1 (cyclin B1) encodes a cell cycle regulatory protein important in mitosis (NCBI 
Resource Coordinators, 2015).  Because expression levels from this gene are used in three out of 
five of the prognostic multigene expression profiles for breast cancer from which candidate 
genes were identified, CCNB1 was one of our top candidates for investigation of study 
hypotheses.  Significant interactions were reported with study cohort for three functional 
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polymorphisms, rs164390(102G>T), rs350099(-957C>T), and rs350104(-457C>T), located in 
the promotor region of CCNB1 and memory and executive function performance.  In general, we 
found that possession of rs164390GT+TT or rs350099CT+CC genotypes contributed positively 
to performance scores in healthy controls but close to zero or negatively in women with breast 
cancer.  The opposite contribution was observed for rs350104CT+CC genotypes.  The genotypes 
associated with poorer cognitive performance in the cohorts of women with breast cancer,  
rs164390-GT+TT, rs350099-CT+CC, and rs350104-TT, are all hypothesized to lead to lower 
levels of CCNB1expression via reduced recruitment of transcription factors to the promotor 
region of the gene (Silvestre-Roig et al., 2014).  This result is contradictory to anticipated 
findings as higher cyclin B levels in breast tissue are associated with more severe cancer 
phenotypes (Kawamoto, Koizumi, & Uchikoshi, 1997; Winters et al., 2001).  In addition, cyclin 
B levels were reported to be upregulated in autopsy hippocampal tissue in individuals with 
neuropathological Alzheimer’s disease and clinical dementia compared to individuals with 
normal aging (Silva et al., 2014).  Nevertheless, the consistency of findings across three variants 
all theorized to impact expression in the same direction, lends support to these associations.  We 
would like to point of that one or more polymorphisms in the four other genes represented in 
three prognostic multigene expression profiles for breast cancer, CENPA, MELK, MYBL2, and 
ORC6, were associated with performance on at least one cognitive function composite.   
MYBL2 (MYB proto-oncogene like 2) encodes a nuclear protein, B-MYB, involved in cell 
cycle progression and promotion of cell survival through activation of anti-apoptotic genes 
(NCBI Resource Coordinators, 2015; Sala, 2005).  However, overexpression of B-MYB in 
certain settings induces apoptosis and has been reported to contribute to neuronal cell death 
(Iyirhiaro et al., 2014; Liu, Biswas, & Greene, 2004; Lui, Nath, Chellappan, & Greene, 2005; 
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Sala, 2005). We found significant relationships with two missense polymorphisms in MYBL2, 
rs11556379(Ile624Met, C>G) and rs2070235(Ser427Gly, A>G).  The minor alleles of these 
polymorphisms have been reported to alter protein conformation, impair regulation of 
downstream targets, decrease anti-apoptotic activity, and reduce cancer risk (Schwab et al., 
2008).  Interestingly, for all study participants rs2070235-AG+GG genotypes contributed 
positively to attention and negatively to memory performance scores, while rs11556379-CG+GG 
genotypes contributed positively to mental flexibility performance scores.  We also reported a 
significant interaction related to executive function where rs11556379-CG+GG genotypes had 
the opposite impact on performance in healthy controls (positive contribution to scores) and 
women with breast cancer (negative contribution to scores).  Additionally, we reported 
associations between polymorphisms in a gene regulated by MYBL2 that is also involved in 
apoptosis, BCL2 (B-cell CLL/lymphoma 2), and concentration, executive function, mental 
flexibility, psychomotor speed, verbal memory, and visual memory performance.  BCL2 
expression has been associated with prognostication of disease free survival, overall survival, 
and recurrence in breast cancer (Abdel-Fatah et al., 2010; Aleskandarany et al., 2015; Bremer et 
al., 2009; Callagy, Webber, Pharoah, & Caldas, 2008; Dawson et al., 2010; Kerr & Wittliff, 
2011; Linke, 2006; Lyng et al., 2013).  Moreover, normal breast tissue from women with breast 
cancer was reported to display higher levels of BCL2 expression than breast tissue from women 
with no evidence of cancer (Batchelder, Gordon-Weeks, & Walker, 2009).  In relation to 
neurologic phenotypes, polymorphisms in BCL2 have been found to impact outcomes after 
traumatic brain injury (Hoh et al., 2010) and have been associated with hippocampal volume 
(Sloan et al., 2010). 
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 One of the functional polymorphisms located in the promoter region of GSTM1 
(glutathione S-transferase mu 1), rs412543(-498C>G), was found to be important for memory 
and executive function performance.  GSTM1 encodes an enzyme with antioxidant properties 
that detoxifies electrophilic compounds, including carcinogens, drugs, and environmental toxins, 
throughout the body (NCBI Resource Coordinators, 2015).  By decreasing the binding capability 
of the transcription factor AP-2 to the GSTM1 promotor region, the G allele has been reported to 
decrease GSTM1 transcription by 30-40% compared to the C allele (Yu et al., 2009).  Both 
decreased and enhanced (attributed to counterproductive depletion of glutathione) GSTM1 
expression has been associated with increased breast cancer risk (Reed, 1990; Roodi, Dupont, 
Moore, & Parl, 2004; Yu et al., 2009).  We found that rs412543-GG+CG, and hypothesized 
decreased GSTM1 expression, contributed negatively to executive function and memory 
performance in all study participants.  However, we also found positive interaction effects 
between rs412543-GG+CG and breast cancer cohort related to verbal and visual working 
memory.  While the mechanism is unclear, the paradoxical quality of GSTM1 under and over 
expression combined with study results suggests that decreased or moderate GSTM1 expression 
may be beneficial to certain aspects of cognitive function in women with breast cancer.  
Considering the detoxification properties of GSTM1, further evaluation of cognitive decline over 
time in women with breast cancer receiving adjuvant chemotherapy and/or antiestrogen therapy 
is recommended.   
 Variation in the two upstream intronic polymorphisms selected to represent DIAPH3 
(diaphanous related formin 3), rs1337652 and rs4547237, were associated with performance for 
multiple cognitive composites as well.  DIAPH3 is involved in actin remodeling and regulation 
of cell movement and adhesion (NCBI Resource Coordinators, 2015).  DIAPH3 downregulation 
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and silencing has been associated with metastatic disease due to loss of normal gene function and 
acquisition of an amoeboid cancer cell phenotype (Hager et al., 2012).  Evidence also suggests 
that DIAPH3 is critical to brain development and is involved in cell migration, the formation of 
dendrites and axons, axon guidance, and synaptic activity (Vorstman et al., 2011).         
Each of the candidate genes discussed previously with the most significant findings from 
our analysis are represented by multiple functional and/or tagging SNPs and are well-described 
in the literature.  This is not the case for the three candidate genes with no reported associations 
with pretreatment cognitive performance.  Single SNPs, rs131451 and rs7303531, were included 
in the analysis for MMP11 (matrix metallopeptidase 11) and RACGAP1 (Rac GTPase activating 
protein 1), respectively.  Both SNPs are upstream variants.  No associations have been reported 
between MMP11 or RACGAP1 and cognitive phenotypes in the literature.  CMC2 (C-x(9)-C 
motif containing 2) is an even more poorly described and studied gene with reported involvement 
in cytochrome c oxidase activity (Horn et al., 2010).  Two upstream (rs1025065 and rs1981867) 
polymorphisms and one downstream (rs9936489) polymorphism were identified using the Phase 
III HapMap database based on National Center for Biotechnology Information gene location 
(Chr16:  80975802..81006897) as CMC2 is not a displayed gene in HapMap.  We must be 
mindful that our analysis is limited to the information known about these genes and the 
polymorphisms described at the current time.          
Because of the complexity of breast cancer as a disease and cognitive function as a 
phenotype, we calculated weighted GRSs for each cognitive function composite to evaluate the 
collective effect of possession of multiple risk or protective minor alleles of genes used to 
clinically evaluate the biology of breast cancer.  Every GRS was significantly (p<0.001) and 
positively associated with its respective cognitive function composite.  When the GRSs were 
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added as predictors to regression models, including age, estimated verbal intelligence, levels of 
depressive symptoms, anxiety, fatigue, and pain, and prescribed treatment group, the explained 
variance (R2) increased by 0.066 to 0.244 for each cognitive function composite.  This 
substantial increased in R2 speaks to both the importance of host variation in genes used to 
clinically evaluate the biology of breast cancer to pretreatment cognitive function performance as 
well as the use of multiple common variants, plus personal and environmental factors, to model a 
complex phenotype.    
Unfortunately, due to limitations in sample size, results from the interaction analysis as 
well as the full pathologic and genetic predictive model analysis have limited interpretability.  
Small sample sizes also limited our ability to conduct genetic analyses by genotype rather than 
by the presence or absence or one or more minor alleles; thus, we were unable to evaluate gene-
dosage effects.  Other limitations to this study were also noted.  As with any retrospective chart 
review, CTF data were limited to availability in the medical record and recommended testing at 
the time of diagnosis (e.g., lack of Ki67 proliferative marker evaluation in participants enrolled 
at the beginning of the parent study).  The study sample was comprised of postmenopausal 
women with hormone receptor positive, early-stage breast cancer who were primarily Caucasian; 
the generalizability of study findings to premenopausal women, hormone negative, in situ and 
more advanced breast cancers, or more diverse populations is unknown.  Additionally, analyses 
were not adjusted for the potentially confounding effects of surgery and/or anesthesia exposure 
on pretreatment cognitive performance.   
We would also like to acknowledge this study’s many strengths, including:  1) hypothesis 
driven aims; 2) biologically-plausible candidate gene selection; 3) evaluation of both functional 
and tagging polymorphisms to fully represent genetic variability in candidate genes; 4) well-
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characterized cognitive function phenotype; 5) adjustment for potential covariates/confounders 
of cognitive function, including age, intelligence, and levels of depressive symptoms, anxiety, 
fatigue, and pain; 6) consideration of breast cancer heterogeneity through use of prescribed 
treatment group and inclusion of a matched control group in the candidate gene analysis; 7) 
adjustment for prescribed treatment group to account for noted differences in mean cognitive 
performance unrelated to genotype in the candidate gene analysis; and 8) evaluation of the 
collective effect of multiple risk or protection polymorphisms using weighted GRSs.   
While relationships between host DNA and cognitive function performance are 
advantageous for a number of reasons, including lack of change over time and tissue 
nonspecificity, associations with gene expression and protein levels warrant investigation as the 
most notable findings from this study were related to polymorphisms with known functional 
consequences or located in regulatory regions.  We postulate that cognitive function performance 
variability in women with breast cancer may be at least partially driven by tumor gene 
expression and corresponding protein levels.  Longitudinal studies that include cognitive 
assessment prior to primary surgery would be ideal for evaluation of the effect of tumor gene 
expression as well as changes in gene expression due to tumor removal and treatment of primary 
and secondary cancer sites on variability in cognitive function performance.  Future analyses 
should also investigate the effect of variation in CTFs of breast cancer, host DNA in genes used 
to clinically evaluate the biology of breast cancer, and tumor expression levels on cognitive 
function throughout and following adjuvant therapy.   
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3.8 CONCLUSION 
In summary, the objective of this study was to explore the hypothesis that heterogeneity in the 
biology of breast cancers is associated with variability in the presence and/or severity of 
pretreatment cognitive performance among postmenopausal women diagnosed with early-stage 
breast cancer.  Significant associations between variation in CTFs, host polymorphisms from 
candidate genes used to clinically evaluate the biology of breast cancer, and computed GRSs and 
variability in pretreatment cognitive function performance support our hypothesis and suggest 
that inherent, disease-related features of breast cancer play a critical role in cognitive dysfunction 
symptomatology.  These findings merit future investigation to further elucidate pathophysiologic 
mechanisms of and identify clinically relevant biomarkers for breast cancer related cognitive 
dysfunction. 
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Table 6:  Proposed SNPs for Candidate Gene Analysis 
Gene 
Number 
of SNPs 
SNP 
Functional (F) 
or 
Tagging (T) 
AURKA  8 rs1047972 F 
  rs16979877 F 
  rs2273535 F 
  rs6024836 T 
  rs6064389 F 
  rs8173 F 
  rs911161 F 
  rs911162 F 
BAG1 1 rs706118 F 
BCL2 18 rs12961976 T 
  rs1564483  F 
  rs17759659 T 
  rs1800477 F 
  rs2279115 F 
  rs4941195 T 
  rs4987768 T 
  rs4987852 T 
  rs4987853  F 
  rs4987855 T 
  rs4987856 T 
  rs7230177 T 
  rs7231901 T 
  rs7243091 T 
  rs956572 F 
  rs9807663 T 
  rs10138824 (MPP5) F 
  rs8008724 (EIF2S1) F 
BIRC5 8 rs1042489 F 
  rs1508147 T 
  rs17878467 F 
  rs2239680  F 
  rs3764383 F 
  rs8073069 F 
  rs8073903 T 
  rs9904341 F 
CCNB1 4 rs164390 F 
  rs350099 F 
  rs350104 F 
  rs352626 T 
CD68 2 rs12942088 T 
  rs8066665 T 
CENPA 2 rs3806517 T 
  rs3806518 T 
CMC2 3 rs1025065 F 
  rs1981867 T 
  rs9936489 T 
CTSL2 2 rs16919034 T 
  rs4361859 T (MAF=0.137) 
DIAPH3 2 rs1337652 T 
85 
  rs4547237 T 
ERBB2 13 rs1058808 F 
  rs1136201 F 
  rs1476278 T 
  rs1810132 F 
  rs2517955 T 
  rs4252596 F 
  rs4252633 F 
  rs903501 T 
  rs9303274 T 
  rs61764370 (KRAS) F 
  rs12976445 (MIR125A) F 
  rs41275794 (MIR125A) F 
  rs491951 (ZNF345) F 
ESR1 56 rs10484919 F 
  rs10484922 F 
  rs1048919 T 
  rs1062577 F 
  rs11964281 F 
  rs12173570 F 
  rs12665044 F 
  rs1514348 F 
  rs1801132 F 
  rs1884051 F 
  rs2046210 F 
  rs2071454 T 
  rs2077647 F 
  rs2228480 F 
  rs2234693 F 
  rs2347867 F 
  rs2744677 F 
  rs2813543 T 
  rs2813544 T 
  rs2941740 T 
  rs3020314 F 
  rs33778609 F 
  rs34535804 T 
  rs3778099 F 
  rs3778609 F 
  rs3798577 F 
  rs488133 T 
  rs532010 T 
  rs6557171 F 
  rs728524 F 
  rs77275268 F 
  rs7739506 T 
  rs7761133 F 
  rs7761846 F 
  rs7766585 F 
  rs7767143 T 
  rs8179176 F 
  rs827421 F 
  rs851967 T 
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  rs851971 T 
  rs851982 F 
  rs851998 T 
  rs910416 F 
  rs9322331 F 
  rs9340799 F 
  rs9383938 F 
  rs9383939 T 
  rs9397435 F 
  rs9397456 F 
  rs9478245 T 
  rs985694 F 
  rs1038304 (CCDC170) F 
  rs12662670 (CCDC170) F 
  rs3734805 (CCDC170) F 
  rs3757318 (CCDC170) F 
  rs6929137 (CCDC170) F 
GRB7 1 rs9910678 T (MAF=0.035) 
GSTM1 5 rs1065411 F 
  rs142484086  F 
  rs412543 F 
  rs35652124 (NFE2L2) F 
  rs6721961 (NFE2L2) F 
MELK 3 rs10973007 T (MAF=0.177) 
  rs2250340 T (MAF=0.164) 
  rs3780350 T (MAF=0.164) 
MKI67 2 rs10732438 T 
  rs10764751 T 
MMP11 2 rs131451 T (MAF=0.066) 
  rs28382576 T 
MYBL2 5 rs11556379 F 
  rs2070235 F 
  rs619289 F 
  rs826943 F 
  rs826944 F 
NDC80 2 rs12408485 T 
  rs2136241 T 
ORC6 1 rs33994299 T 
PGR 15 rs1042838 F 
  rs1042839 F 
  rs10895054 F 
  rs10895068 F 
  rs11224561 T 
  rs1893505 T 
  rs1942836 T 
  rs471767 T 
  rs474320 T 
  rs4754732 T 
  rs484389 T 
  rs499590 T 
  rs568157 T 
  rs590688 F 
  rs608995 T 
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RACGAP1 1 rs7303531 T (MAF=0.058) 
RFC4 1 rs1354091 T 
RRM2 3 rs1138729 F 
  rs4309551 T 
  rs6759180 F 
SCUBE2 3 rs1136966 T 
  rs4910440 T 
  rs6486125 T 
Note. MAF=Minor Allele Frequency; SNP=Single Nucleotide 
Polymorphism.  All tagging SNP MAFs ≥0.20 unless noted otherwise. 
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Figure 3:  Dissertation SNP Genotyping Workflow 
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Table 7:  CTF Analysis Participant Characteristics (N=329) 
Characteristic (Measure) Mean±SD or n (%) Minimum Maximum 
Age (years) 61.05±5.976 45 75 
Education (years) 14.80±2.805 6 26 
Estimated Verbal Intelligence (NART-R) 108.45±8.584 77.08 125.14 
Depressive Symptoms (BDI-II) 5.33±5.619 0 32 
Anxiety (POMS Tension-Anxiety subscale) 7.64±5.801 0 29 
Fatigue (POMS Fatigue-Inertia subscale) 5.72±5.986 0 27 
Pain (BPI) 1.44±2.165 0 9 
Marital Status, currently married  
     or living with significant other 
223 (67.8) - - 
Number of Children 1.89±1.237 0 7 
Race, Caucasian 317 (96.4) - - 
Cognitive Function Composite Z-Scores    
     Attention, n=321 -0.1587±0.93945 -4.25 1.63 
     Concentration, n=328 -0.0141±0.91255 -3.41 3.98 
     Executive Function, n=329 -0.3953±0.63810 -2.37 1.83 
     Mental Flexibility, n=328 0.1197±0.78899 -4.05 1.63 
     Psychomotor Speed, n=329 -0.1201±0.92513 -6.01 2.28 
     Verbal Memory, n=329 -0.2088±0.66864 -2.58 1.28 
     Visual Memory, n=329 0.0680±0.66866 -3.28 0.86 
     Visual Working Memory, n=329 -0.0035±0.78009 -4.73 1.55 
Note.  BDI-II=Beck Depression Inventory-II; BPI=Brief Pain Inventory; 
CTF=Clinicopathologic Tumor Feature; NART-R=National Adult Reading Test-Revised; 
POMS=Profile of Mood States; SD=Standard Deviation. Only participants with complete 
confounder/covariate information are included in the participant characteristic statistics.   
 
 
 
 
 
 
 
 
 
 
 
91 
Table 8:  CTF Summary Statistics (N=329) 
Feature 
Mean±SD or  
n (%) Minimum Maximum 
Overall TNM Stage, n=329    
     Stage 1 214 (65) - - 
     Stage 2a 75 (22.8) - - 
     Stage 2b 24 (7.3) - - 
     Stage 3a 16 (4.9) - - 
Tumor Size (cm), n=328 1.66±1.500 0.10 14.00 
Aggregate Tumor Size (cm), n=328 1.80±1.599 0.10 14.00 
Tumor Stage, n=329    
     T1a 37 (11.2) - - 
     T1b 82 (24.9) - - 
     T1c 133 (40.4) - - 
     T2 65 (19.8) - - 
     T3 12 (3.6) - - 
Lymph Node, n=325    
     Positive 73 (22.5) - - 
     Negative 252 (77.5) - - 
Number of Positive Nodes, n=329 0.42±1.054 0 8 
Tumor Focality, n=329    
     Single 277 (84.2) - - 
     Multiple 52 (15.8) - - 
Tumor Laterality, n=329    
     Right Breast 149 (45.3) - - 
     Left Breast 180 (54.7) - - 
Tumor Location Octant, n=321    
     Upper Outer 130 (40.5) - - 
     Lower Outer 25 (7.8) - - 
     Upper Inner 40 (12.5) - - 
     Lower Inner 20 (6.2) - - 
     Upper Middle 41 (12.8) - - 
     Outer Middle 31 (9.7) - - 
     Lower Middle 20 (6.2) - - 
     Inner Middle 14 (4.4) - - 
Invasive Type, n=329    
     Ductal 285 (86.9) - - 
     Lobular 35 (10.7) - - 
     Ductal & Lobular 8 (2.4) - - 
Nottingham Score, n=315 6.04±1.306 3 9 
Nottingham Grade, n=316    
     Grade 1 95 (30.1) - - 
     Grade 2 171 (54.1) - - 
     Grade 3 50 (15.8) - - 
ER Status, n=328    
     Positive 324 (98.8) - - 
     Negative 4 (1.2) - - 
ER H-Score, n=311 256.90±59.978 0 300 
Oncotype DX ER Score, n=102 10.287±1.056 7.8 12.5 
PR Status, n=328    
     Positive 288 (87.8) - - 
     Negative 40 (12.2) - - 
PR H-Score, n=310 130.08±101.301 0 300 
Oncotype DX PR Score, n=102 7.08±1.569 3.2 10.2 
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HER2 Status, n=318    
     Positive 28 (8.8) - - 
     Negative 290 (91.2) - - 
HER2 IHC Score, n=291 1.21±0.869 0 3 
Oncotype DX HER2 Score, n=74 8.93±0.812 7.6 12.8 
LV Invasion, n=323    
     Present 68 (21.1) - - 
     Absent  255 (78.9) - - 
Ki67 Classification, n=169    
     Low 66 (39.1) - - 
     Moderate 50 (29.6) - - 
     High 34 (20.1) - - 
     Very High 19 (11.2) - - 
Ki67 Index, n=168 23.10±21.522 1 90 
Oncotype DX Recurrence Score®, n=160 18.26±9.76 0 63 
Magee Equation Recurrence Score, n=298 20.51±7.77 1.92 48.87 
Note.  CTF=Clinicopathologic Tumor Feature; ER=Estrogen Receptor; HER2=Human 
Epidermal Growth Factor Receptor 2; IHC=Immunohistochemistry; LV=Lymphovascular; 
Oncotype DX=Genomic Health Inc. Oncotype DX® Breast Cancer Assay; PR=Progesterone 
Receptor; SD=Standard Deviation; TNM=Tumor, Node, Metastasis Classification of 
Malignant Tumors.  Only participants with complete confounder/covariate information are 
included in the summary statistics.   
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Table 9:  CTF and Cognitive Function Robust Regression Results 
Regression 
coefficient, p-value Attention Concentration 
Executive 
Function 
Mental 
Flexibility 
Psychomotor 
Speed 
Verbal 
Memory 
Visual 
Memory 
Visual Working 
Memory 
Overall TNM Stage n=321 n=328 n=329 n=328 n=329 n=329 n=329 n=329 
     Stage 2a 0.116, 0.305 -0.065, 0.550 0.005, 0.949 0.064, 0.472 0.154, 0.075# 0.059, 0.485 0.033, 0.550 0.190, 0.033* 
     Stage 2b -0.200, 0.262 0.139, 0.425 -0.146, 0.279 .008, 0.953 -0.211, 0.128# -0.157, 0.244 -0.079, 0.363 -0.021, 0.885 
     Stage 3a -0.143, 0.520 -0.207, 0.325 0.034, 0.833 0.179, 0.296 0.087, 0.601 0.068, 0.676 -0.181, 0.088# -0.203, 0.239 
       Overall p-value 0.354 0.544 0.726 0.694 0.082# 0.503 0.218 0.076# 
     Ref:  Stage 1         
         
Tumor Size (cm) n=320 n=327 n=328 n=327 n=328 n=328 n=328 n=328 
 -0.031, 0.318 -0.032, 0.283 -0.001, 0.955 0.009, 0.717 0.001, 0.951 0.018, 0.418 -0.003, 0.848 0.009, 0.715 
         
Aggregate  n=320 n=327 n=328 n=327 n=328 n=328 n=328 n=328 
Tumor Size (cm) -0.027, 0.353 -0.032, 0.249 -0.004, 0.849 0.012, 0.600 -0.010, 0.653 0.004, 0.847 -0.009, 0.544 -0.002, 0.929 
         
Tumor Stage n=321 n=328 n=329 n=328 n=329 n=329 n=329 n=329 
     T1b -0.023, 0.890 0.032, 0.842 0.021, 0.866 0.023, 0.858 0.018, 0.893 -0.132, 0.288 0.031, 0.710 0.042, 0.755 
     T1c -0.021, 0.896 -0.093. 0.537 0.075, 0.522 0.180, 0.142# 0.035,0.774 0.068, 0.557 -0.010, 0.894 0.080, 0.521 
     T2 -0.013, 0.940 -0.032, 0.848 0.022, 0.868 0.100, 0.464 -0.007, 0.960 -0.051, 0.693 -0.003, 0.970 0.106. 0.446 
     T3 -0.248, 0.389 -0.238, 0.375 0.051, 0.806 0.133, 0.543 0.115, 0.598 0.140, 0.501 -0.009, 0.946 0.084. 0.708 
       Overall p-value 0.932 0.723 0.951 0.404 0.977 0.179 0.969 0.943 
     Ref:  T1a         
         
Node Positive n=318 n=324 n-325 n=324 n=325 n=325 n=325 n=325 
     Ref:  Negative 0.058, 0.602 -0.077, 0.473 0.045, 0.587 0.144, 0.101# 0.093, 0.280 0.054, 0.514 0.010, 0.859 0.048, 0.595 
         
Number of  n=321 n=328 n=329 n=328 n=329 n=329 n=329 n=329 
Positive Nodes 0.018, 0.679 -0.024, 0.574 0.004, 0.892 0.057, 0.102# 0.040, 0.242 0.008, 0.806 -0.030, 0.172# -0.003, 0.930 
         
Multifocal n=321 n=328 n=329 n=328 n=329 n=329 n=329 n=329 
    Ref:  Single -0.206, 0.098# -0.056, 0.645 -0.071, 0.450 -0.073, 0.461 -0.092, 0.345 -0.278, 0.003* -0.084, 0.170# -0.108, 0.280 
         
Left Breast n=321 n=328 n=329 n=328 n=329 n=329 n=329 n=329 
     Ref:  Right Breast 0.059, 0.521 -0.109, 0.226 0.019, 0.785 -0.092, 0.204 0.064, 0.366 0.156, 0.025* -0.034, 0.452 0.163, 0.026* 
         
Location Octant n=314 n=321 n=322 n=321 n=322 n=322 n=322 n=322 
     Lower Outer 0.318, 0.090# -0.083, 0.642 0.102, 0.456 -0.207, 0.145# -0.122, 0.390 -0.140, 0.308 0.010, 0.912 0.180, 0.211 
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     Upper Inner -0.315, 0.040* 0.102, 0.490 -0.018, 0.874 -0.171, 0.147# -0.088, 0.455 0.035, 0.762 -0.054, 0.466 -0.180, 0.133# 
     Lower Inner -0.281, 0.167# 0.167, 0.396 -0.114, 0.446 -0.511. 0.001* -0.263, 0.092# -0.028, 0.851 0.056, 0.569 -0.165, 0.297 
     Upper Middle -0.087, 0.555 0.101, 0.490 0.098, 0.380 -0.180, 0.121# -0.109, 0.347 0.020, 0.862 0.092, 0.209 0.022, 853 
     Outer Middle 0.065, 0.701 -0.055, 0.740 0.202, 0.109# 0.058, 0.660 -0.063, 0.631 0.050, 0.693 0.069, 0.401 -0.012, 0.927 
     Lower Middle -0.158, 0.429 -0.053, 0.787 0.201, 0.182# -0.258, 0.100# 0.109, 0.483 -0.198, 0.191# -0.088, 0.370 -0.432, 0.007* 
     Inner Middle 0.190. 0.415 -0.059, 0.804 0.244, 0.165# -0.008, 0.967 -0.111, 0.542 -0.104, 0.553 0.095, 0.410 0.120, 0.515 
       Overall p-value 0.092# 0.933 0.393 0.027* 0.647 0.813 0.612 0.052# 
     Ref: Upper Outer         
         
Invasive Type n=320 n=327 n=328 n=327 n=328 n=328 n=328 n=328 
     Lobular -0.080, 0.595 -0.043, 0.772 0.090, 0.432 -0.062, 0.603 -0.034, 0.771 0.107, 0.346 -0.072, 0.335 -0.054, 0.656 
     Ductal & Lobular 0.505, 0.085# -0.088, 0.760 -0.215, 0.335 -0.219, 0.349 -0.209, 0.361 -0.003, 0.990 -0.090, 0.537 0.303, 0.203 
       Overall p-value 0.186# 0.920 0.441 0.579 0.640 0.640 0.536 0.388 
     Ref:  Ductal          
         
Nottingham Score n=308 n=314 n=315 n=314 n=315 n=315 n=315 n=315 
 -0.032, 0.381 -0.002, 0.958 0.029, 0.291 -0.018, 0.542 0.005, 0.844 0.045, 0.093# 0.011, 0.523 0.048, 0.100# 
         
Nottingham Grade n=309 n=315 n=316 n=315 n=316 n=316 n=316 n=316 
     Grade 2 0.077, 0.467 -0.033, 0.751 0.085, 0.288 0.000, 0.995 0.066, 0.417 0.111, 0.162# 0.037, 0.484 0.084, 0.329 
     Grade 3 -0.124, 0.392 0.048, 0.733 0.132, 0.235 -0.070. 0.554 -0.009, 0.940 0.051, 0.641 0.035, 0.635 0.202, 0.090# 
       Overall p-value 0.312 0.817 0.417 0.799 0.632 0.368 0.771 0.231 
     Ref:  Grade 1         
         
ER Positive n=320 n=327 n=328 n=327 n=328 n=328 n=328 n=328 
     Ref:  Negative 0.298, 0.472 -0.290, 0.473 0.211, 0.498 0.391, 0.233 -0.231, 0.471 0.022, 0.945 -0.047, 0.819 -0.269, 0.420 
         
ER H-Score n=303 n=310 n=311 n=310 n=311 n=311 n=311 n=311 
 0.001, 0.165# -0.001, 0.409 0.001, 0.397 0.001, 0.301 -0.001, 0.229 0.000, 0.730 0.000, 0.606 0.000, 0.679 
         
Oncotype DX  n=100 n=102 n=102 n=102 n=102 n=102 n=102 n=102 
ER Score -0.010, 0.904 -0.004, 0.960 0.082, 0.195# 0.049, 0.393 0.014, 0.836 -0.013, 0.842 0.074, 0.069# 0.047, 0.488 
         
PR Positive n=320 n=327 n=328 n=327 n=328 n=328 n=328 n=328 
     Ref:  Negative -0.129, 0.364 -0.004, 0.975 -0.140, 0.184# 0.024, 0.834 0.069, 0.524 -0.256, 0.015* -0.050, 0.470 -0.048, 0.669 
         
PR H-Score n=302 n=309 n=310 n=309 n=310 n=310 n=310 n=310 
 0.000, 0.668 0.000, 0.405 0.000, 0.967 0.000, 0.461 0.000, 0.923 0.000, 0.806 0.000, 0.538 0.000, 0.655 
         
Oncotype DX  n=100 n=102 n=102 n=102 n=102 n=102 n=102 n=102 
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PR Score -0.062, 0.275 0.046. 0.405 -0.029, 0.498 0.010, 0.794 0.031, 0.506 -0.019, 0.650 0.007, 0.782 -0.057, 0.196# 
         
HER2 Positive n=310 n=317 n=318 n=317 n=318 n=318 n=318 n=318 
     Ref:  Negative -0.185, 0.283 0.277, 0.087# -0.131, 0.293 -0.065, 0.626 -0.031, 0.803 -0.287, 0.018* -0.270, 0.001* -0.490, <0.001* 
         
HER2 IHC n=285 n=290 n=291 n=290 n=291 n=291 n=291 n=291 
Classification  Score -0.031, 0.591 0.001, 0.979 -0.018, 0.672 -0.019, 0.679 -0.038, 0.389 -0.072, 0.093# -0.081, 0.003* -0.170, <0.001* 
         
Oncotype DX  n=73 n=74 n=74 n=74 n=74 n=74 n=74 n=74 
HER2 Score -0.106, 0.388 0.105, 0.365 -0.008, 0.925 0.024, 0.753 -0.051, 0.627 -0.041, 0.670 0.011, 0.862 -0.099, 0.288 
         
LV Invasion  n=315 n=322 n=323 n=322 n=323 n=323 n=323 n=323 
     Ref:  No Invasion -0.094, 0.420 -0.138, 0.216 0.078, 0.368 0.102, 0.264 -0.076, 0.394 0.095, 0.270 0.018, 0.753 0.059, 0.524 
         
Ki67 Classification n=168 n=168 n=169 n=168 n=169 n=169 n=169 n=169 
     Moderate 0.001, 0.995 0.381, 0.009* -0.003, 0.983 -0.146, 0.243 -0.064, 0.589 -0.086, 0.476 -0.019, 0.799 -0.085, 0.475 
     High 0.093, 0.589 0.035, 0.829 -0.065, 0.636 0.068, 0.635 -0.193, 0.158# -0.139, 0.312 0.044, 0.602 -0.011, 0.936 
     Very High 0.140, 0.507 0.254, 0.205 0.287, 0.090# -0.059, 0.740 0.122, 0.463 0.015, 0.927 0.031, 0.765 0.073, 0.662 
       Overall p-value 0.872 0.042* 0.266 0.481 0.325 0.711 0.894 0.799 
     Ref:  Low         
         
Ki67 Index n=167 n=167 n=168 n=167 n=168 n=168 n=168 n=168 
 0.003, 0.359 0.003, 0.342 0.003, 0.135# 0.001, 0.712 0.002, 0.343 0.000, 0.906 0.001, 0.722 0.001, 0.540 
         
Oncotype DX  n=157 n=159 n=160 n=160 n=160 n=160 n=160 n=160 
Recurrence Score® 0.000, 0.957 0.004, 0.483 -0.003, 0.582 -0.010, 0.032* -0.005, 0.387 0.005, 0.367 -0.003, 0.388 0.009, 0.115# 
         
Magee Equation n=291 n=297 n=298 n=297 n=298 n=298 n=298 n=298 
Recurrence Score -0.008, 0.238 0.005, 0.447 0.000, 0.918 -0.002, 0.701 0.002, 0.609 -0.002, 0.615 -0.002, 0.497 -0.002, 0.667 
         
Note. *=p<0.05, #=0.05<p<0.20; CTF=Clinicopathologic Tumor Feature; ER=Estrogen Receptor; HER2=Human Epidermal Growth Factor Receptor 2; 
IHC=Immunohistochemistry; LV=Lymphovascular; Oncotype DX=Genomic Health Inc. Oncotype DX® Breast Cancer Assay; PR=Progesterone Receptor; 
TNM=Tumor, Node, Metastasis Classification of Malignant Tumors; Ref=Reference Group.  All regression coefficient estimates and p-values reported from 
robust multiple linear regression models generated using Huber weighting and biweighting iterations. All models are adjusted for age, estimated verbal 
intelligence, and levels of depressive symptoms, anxiety, fatigue, and pain.   
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Table 10:  CTF Squared Continuous Predictor and Cognitive Function Robust Regression Results (p<0.20) 
Regression  
coefficient, p-value Attention Concentration 
Executive  
Function 
Mental  
Flexibility 
Psychomotor 
Speed 
Verbal 
Memory 
Visual  
Memory 
Visual Working 
Memory 
 n=320 n=327 n=328 n=327 n=328 n=328 n=328 n=328 
Tumor Size (cm) -0.050, 0.477 -0.003, 0.964 -0.004, 0.946 0.035, 0.528 0.003, 0.957 0.036, 0.485 -0.021, 0.539 0.081, 0.143# 
Squared variable 0.002, 0.775 -0.003, 0.656 0.000, 0.962 -0.003, 0.618 0.000, 0.977 -0.002, 0.714 0.002, 0.560 -0.009, 0.135# 
         
Oncotype DX  n=100 n=102 n=102 n=102 n=102 n=102 n=102 n=102 
ER Score -2.390, 0.059# 0.085, 0.947 -0.985, 0.307 -0.339, 0.695 -0.761, 0.473 -0.866, 0.364 -0.514, 0.373 -0.817, 0.421 
Squared variable 0.117, 0.061# -0.004, 0.944 0.053, 0.269 0.019, 0.654 0.039, 0.462 0.042, 0.370 0.029, 0.312 0.043, 0.391 
         
Oncotype DX  n=100 n=102 n=102 n=102 n=102 n=102 n=102 n=102 
PR Score -0.749, 0.081# -0.096, 0.811 -0.299, 0.327 0.424, 0.118# 0.439, 0.186# 0.209, 0.484 -0.147, 0.448 -0.353, 0.264 
Squared variable 0.050, 0.105# 0.010, 0.718 0.020, 0.370 -0.030, 0.126# -0.029, 0.218 -0.017, 0.441 0.011, 0.418 0.021, 0.342 
         
HER2 IHC  n=285 n=290 n=291 n=290 n=291 n=291 n=291 n=291 
Classification Score 0.115, 0.475 -0.095, 0.549 -0.023, 0.848 0.054, 0.666 -0.094, 0.444 0.048, 0.689 -0.025, 0.736 -0.009, 0.943 
Squared variable -0.056, 0.339 0.036, 0.525 0.002, 0.966 -0.029, 0.527 0.023, 0.597 -0.046, 0.280 -0.022, 0.424 -0.061, 0.172# 
         
Oncotype DX  n=73 n=74 n=74 n=74 n=74 n=74 n=74 n=74 
HER2 Score 0.678, 0.592 -1.454, 0.195# -0.732, 0.432 -1.002, 0.208 -0.801, 0.464 0.858, 0.388 1.983, <0.001* 0.037, 0.969 
Squared variable -0.040, 0.539 0.081, 0.165# 0.037, 0.440 0.053, 0.196# 0.039, 0.493 -0.047, 0.366 -0.104, <0.001* -0.007, 0.889 
         
 n=167 n=167 n=168 n=167 n=168 n=168 n=168 n=168 
Ki67 Index 0.003, 0.728 0.000, 0.964 0.000, 0.951 0.003, 0.680 -0.010, 0.206 -0.010, 0.183# 0.005, 0.264 0.001, 0.881 
Squared variable 0.000, 0.938 0.000, 0.807 0.000, 0.578 0.000, 0.749 0.000, 0.100# 0.000, 0.155# 0.000, 0.291 0.000, 0.972 
         
Oncotype DX  n=157 n=159 n=160 n=160 n=160 n=160 n=159 n=159 
Recurrence Score® -0.008, 0.665 -0.021, 0.225 -0.014, 0.348 -0.007, 0.603 0.018, 0.228 0.032, 0.021* -0.004, 0.706 -0.002, 0.927 
Squared variable 0.000, 0.665 0.001, 0.127# 0.000, 0.423 0.000, 0.781 -0.001, 0.086# -0.001, 0.029* 0.000, 0.896 0.000, 0.457 
         
Magee Equation n=291 n=297 n=298 n=297 n=298 n=298 n=298 n=298 
Recurrence Score -0.001, 0.981 -0.019, 0.495 0.012, 0.579 0.009, 0.693 0.000, 0.990 0.019, 0.347 0.026, 0.055# 0.051, 0.028* 
Squared variable 0.000, 0.804 0.000, 0.386 0.000. 0.588 0.000, 0.621 0.000, 0.894 0.000, 0.283 -0.001, 0.034* -0.001, 0.021* 
Note. *=p<0.05, #=0.05<p<0.20; CTF=Clinicopathologic Tumor Feature; ER=Estrogen Receptor; HER2=Human Epidermal Growth Factor Receptor 2; 
IHC=Immunohistochemistry; Oncotype DX=Genomic Health Inc. Oncotype DX® Breast Cancer Assay; PR=Progesterone Receptor. All regression coefficient 
estimates and p-values reported from robust multiple linear regression models generated using Huber weighting and biweighting iterations. All models are adjusted 
for age, estimated verbal intelligence, and levels of depressive symptoms, anxiety, fatigue, and pain.   
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Table 11:  CTFs by Tumor Location Octant (p<0.20) 
 
Mean±SD, n 
or n (%) 
Tumor Location Octant (N=321) F-testa or 
Fisher’s 
Exact Testb 
p-value 
Upper 
Outer 
Lower 
Outer 
Upper 
Inner 
Lower 
Inner 
Upper 
Middle 
Lower 
Middle 
Outer 
Middle 
Inner 
Middle 
Tumor Size (cm) 1.66±1.374, 
n=130 
1.47±1.407, 
n=25 
1.81±1.453, 
n=40 
1.87±1.163, 
n=19 
1.25±0.971, 
n=41 
1.34±0.688, 
n=20 
2.43±2.795, 
n=31 
1.14±0.526, 
n=14 
p=0.035 
Aggregate Tumor Size (cm) 1.78±1.472, 
n=130 
1.77±1.800, 
n=25 
1.91±1.561, 
n=40 
1.94±1.320, 
n=19 
1.37±1.029, 
n=41 
1.57±1.022, 
n=20 
2.58±2.780, 
n=31 
1.14±0.526, 
n=14 
p=0.058 
Tumor Focality 
    Single 
    Multiple 
 
115 (88.5) 
15 (11.5) 
 
19 (76.0) 
6 (24.0) 
 
36 (90.0) 
4 (10.0) 
 
18 (90.0) 
2 (10.0) 
 
30 (73.2) 
11 (26.8) 
 
15 (75.0) 
5 (25.0) 
 
24 (77.4) 
7 (22.6) 
 
13 (92.9) 
1 (7.1) 
 
p=0.118 
Invasive Type 
    Ductal 
    Lobular 
    Ductal & Lobular 
 
115 (89.1) 
11 (8.5) 
3 (2.3) 
 
21 (84.0) 
2 (8.0) 
2 (8.0) 
 
34 (85.0) 
6 (15.0)  
0 (0.0) 
 
18 (90.0) 
1 (5.0) 
1 (5.0) 
 
39 (95.1) 
2 (4.9) 
0 (0.0) 
 
18 (90.0) 
2 (10.0)  
0 (0.0) 
 
20 (64.5) 
9 (29.0) 
2 (6.5) 
 
14 (100.0) 
0 (0.0) 
0 (0.0) 
 
p=0.041 
Nottingham Grade 
    Grade 1 
    Grade 2 
    Grade 3 
 
45 (35.7) 
63 (50.0) 
18 (14.3) 
 
4 (17.4) 
17 (73.9) 
2 (8.7) 
 
18 (46.2)  
13 (33.3) 
8 (20.5) 
 
5 (25.0) 
9 (45.0) 
6 (30.0) 
 
10 (26.3) 
23 (60.5) 
5 (13.2) 
 
3 (15.8) 
14 (73.7) 
2 (10.5) 
 
5 (16.1) 
19 (61.3) 
7 (22.6) 
 
5 (38.5) 
8 (61.5) 
0 (0.0) 
 
p=0.036 
HER2 Status 
    Negative 
    Positive 
 
114 (89.8) 
13 (10.2) 
 
24 (96.0) 
1 (4.0) 
 
36 (94.7) 
2 (5.3) 
 
19 (100.0) 
0 (0.0) 
 
35 (89.7) 
4 (10.3) 
 
14 (70.0) 
6 (30.0) 
 
26 (92.9) 
2 (7.1) 
 
14 (100.0) 
0 (0.0) 
 
p=0.082 
HER2 IHC Score 1.21±0.882, 
n=119 
0.86±0.640, 
n=22 
1.39±0.688, 
n=36 
1.18±0.728, 
n=17 
1.22±0.886, 
n=37 
1.94±0.929, 
n=16 
1.21±1.021, 
n=24 
0.67±0.778, 
n=12 
p=0.003 
LV Invasion 
    Absent 
    Present 
 
96 (76.2) 
30 (23.8) 
 
24 (96.0) 
1 (4.0) 
 
29 (72.5) 
11 (27.5) 
 
17 (85.0) 
3 (15.0) 
 
26 (66.7) 
13 (33.3) 
 
15 (75.0) 
5 (25.0) 
 
26 (83.9) 
5 (16.1) 
 
14 (100.0) 
0 (0.0) 
 
p=0.035 
Note. CTF=Clinicopathologic Tumor Feature; HER2=Human Epidermal Growth Factor Receptor 2; IHC=Immunohistochemistry; LV=Lymphovascular; 
SD=Standard Deviation. aOne-way ANOVAs utilized to compare means of continuous variables.  bFisher’s Exact Tests computed using 2-sided Monte Carlo 
sampling based on 10,000 sampled tables used to examine associations between categorical variables. 
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Table 12:  Individual CTFs (p<0.20) Tested for Two-way Interactions 
Cognitive Function 
Composite 
CTF with p<0.20 in 
Model with Linear Term 
CTF with p<0.20 in 
Model with Quadratic Term 
Attention • Tumor Focality 
• Tumor Location Octant 
• Invasive Type 
• ER H-Score 
• Oncotype DX ER Score 
• Oncotype DX PR Score 
Concentration • HER2 Status (+/-) 
• Ki67 Classification 
• Oncotype DX HER2 Score 
• Oncotype DX Recurrence Score® 
Executive Function • Tumor Location Octant 
• Oncotype DX ER Score 
• PR Status (+/-) 
• Ki67 Classification 
• Ki67 Index 
 
Mental Flexibility • Tumor Stage 
• Node Status (+/-) 
• Number of Positive Nodes 
• Tumor Location Octant 
• Oncotype DX Recurrence Score® 
• Oncotype DX PR Score 
Psychomotor Speed • Overall TNM Stage 
• Tumor Location Octant 
• Ki67 Classification 
• Oncotype DX PR Score 
• Ki67 Index 
• Oncotype DX Recurrence Score® 
Verbal Memory • Tumor Focality 
• Tumor Laterality 
• Tumor Location Octant 
• Nottingham Score 
• Nottingham Grade 
• PR Status (+/-) 
• HER2 Status (+/-) 
• HER2 IHC Classification Score 
• Ki67 Index 
• Oncotype DX Recurrence Score® 
Visual Memory • Overall TNM Stage 
• Number of Positive Nodes 
• Tumor Focality 
• Oncotype DX ER Score 
• HER2 Status (+/-) 
• HER2 IHC Classification Score 
• Oncotype DX HER2 Score 
• Magee Equation Recurrence Score 
Visual Working Memory • Overall TNM Stage 
• Tumor Laterality 
• Tumor Location Octant 
• Nottingham Score 
• Nottingham Grade 
• Oncotype DX PR Score 
• HER2 Status (+/-) 
• HER2 IHC Classification Score 
• Oncotype DX Recurrence Score® 
• Tumor Size 
• HER2 IHC Classification Score 
• Magee Equation Recurrence Score 
Note. CTF=Clinicopathologic Tumor Feature; ER=Estrogen Receptor; HER2=Human Epidermal Growth 
Factor Receptor 2; IHC=Immunohistochemistry; LV=Lymphovascular; Oncotype DX=Genomic Health 
Inc. Oncotype DX® Breast Cancer Assay; PR=Progesterone Receptor; TNM=Tumor, Node, Metastasis 
Classification of Malignant Tumors. 
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Table 13:  Significant Two-way CTF Interactions (p<0.05) 
Cognitive Function 
Composite 
Significant (p<0.05) Interaction Effect 
(Main Effect regression coefficient, p-value) 
Interaction Effect 
regression coefficient, 
p-value 
Attention  
 Lower Inner Octant (-0.388, 0.075) by 
Lobular Type (-0.303, 0.261) 
n=313 
1.814, 0.043 
 ER H-Score (-0.138, 0.005) by 
Oncotype DX PR Score (-12.082, 0.004) 
Oncotype DX PR Score Squared (0.834, 0.006) 
n=96 
0.040, 0.006 
-0.003, 0.009 
Concentration 
 Oncotype DX HER2 Score (20.372, 0.145) by 
Oncotype DX Recurrence Score® (13.291, 0.041) 
Oncotype DX Recurrence Score® Squared (-0.376, 0.026) 
Oncotype DX HER2 Score Squared (-1.148, 0.128) by 
Oncotype DX Recurrence Score® 
Oncotype DX Recurrence Score® Squared 
n=73 
-3.030, 0.033 
0.086, 0.021 
 
0.171, 0.026 
-0.005, 0.017 
Executive Function 
 Lower Inner Octant (4.417, 0.037) by 
Oncotype DX ER Score (0.157, 0.140) 
n=101 
-0.457, 0.027 
 Upper Inner Octant (0.620, 0.012) by 
Ki67 Moderate Classification (0.146, 0.531) 
n=166 
-0.914, 0.031 
 Upper Inner Octant (0.497, 0.030) by 
Ki67 Index (0.007, 0.100) 
n=167 
-0.017, 0.026 
 Very High Ki67 Classification (7.789, 0.004) by 
Oncotype DX ER Score (0.187, 0.096) 
n=76 
-0.705, 0.011 
 Ki67 Index (0.088, 0.005) by 
Oncotype DX ER Score (0.209, 0.031) 
n=76 
-0.008, 0.012 
Mental Flexibility 
 Lower Inner Octant (-23.333, 0.026) by 
Oncotype DX PR Score (0.754, 0.011) 
Oncotype DX PR Score Squared (-0.047, 0.023) 
n=101 
6.968, 0.020 
-0.511, 0.015 
Psychomotor Speed 
 TNM Stage 3a (-0.267, 0.368) by 
Ki67 Moderate Classification (-0.190, 0.257) 
n=169 
1.034, 0.038 
 Upper Inner Octant (-0.053, 0.830) by 
Very High Ki67 Classification (-0.049, 0.864) 
Outer Middle Octant (-0.698, 0.009) by 
Moderate Ki67 Classification (-0.153, 0.407) 
Outer Middle Octant (-0.698, 0.009) by 
High Ki67 Classification (-0.301, 0.199) 
n=166 
-2.352, <0.001 
 
0.940, 0.032 
 
1.086, 0.031 
 Moderate Ki67 Classification (-7.160, 0.016) by 
Oncotype DX PR Score (-1.780, 0.018) 
Oncotype DX PR Score Squared (0.140, 0.010) 
High Ki67 Classification (-9.843, 0.002) by 
Oncotype DX PR Score 
Oncotype DX PR Score Squared 
Very High Ki67 Classification (-26.790, 0.019) by 
Oncotype DX PR Score 
Oncotype DX PR Score Squared 
n=76 
2.418, 0.006 
-0.191, 0.003 
 
3.045, 0.002 
-0.222, 0.001 
 
8.737, 0.013 
-0.670, 0.012 
 TNM Stage 3a (-1.353, 0.038) by 
Ki67 Index (-0.016, 0.133) 
Ki67 Index Squared (0.000, 0.074) 
n=168 
0.188, 0.019 
-0.004, 0.022 
 Upper Inner Octant (-0.358, 0.302) by n=166 
100 
Ki67 Index (-0.012, 0.337) 
Ki67 Index Squared (0.000, 0.357) 
0.037, 0.123 
-0.001, 0.004 
Verbal Memory 
 PR Positive (-0.375, 0.001) by 
HER2 Positive (-0.785, 0.002) 
n=318 
0.611, 0.033 
 Lower Inner Octant (-2.558, 0.023) by 
Oncotype DX Recurrence Score® (0.014, 0.557) 
Oncotype DX Recurrence Score® Squared (0.000, 0.974) 
n=157 
0.282, 0.015 
-0.007, 0.017 
Visual Memory 
 Oncotype DX ER Score (0.090, 0.042) by 
HER2 Positive (6.353, 0.001) 
n=99 
-0.720, <0.001 
 TNM Stage 3a (-3.725, 0.010) by 
Magee Equation Recurrence Score (-0.036, 0.049) 
Magee Equation Recurrence Score Squared (-0.001, 0.029) 
n=298 
0.249, 0.024 
-0.004, 0.047 
Visual Working Memory 
 Lower Outer Octant (-0.343, 0.132) by 
Left Breast (0.106, 0.344) 
n=321 
0.780, 0.007 
 Lower Outer Octant (0.175, 0.227) by 
HER2 Positive (-0.267, 0.162) 
n=311 
-1.627, 0.018 
 Outer Middle Octant (0.659, 0.038) by 
Oncotype DX Recurrence Score® (0.009, 0.295) 
n=158 
-0.036, 0.010 
 Nottingham Score (0.170, 0.001) by 
HER2 IHC Classification Score (0.368, 0.106) 
n=278 
-0.085, 0.015 
 Nottingham Grade 3 (0.722, 0.001) by 
HER2 IHC Classification Score (0.039, 0.703) 
n=279 
-0.392, 0.006 
 HER2 IHC Classification Score (0.150, 0.268) by 
Oncotype DX Recurrence Score® (0.032, 0.005) 
n=142 
-0.013, 0.025 
 HER2 IHC Classification Score (-0.352, <0.001) by 
Tumor Size (-0.194, 0.170) 
Tumor Size Squared (0.027, 0.255) 
n=290 
0.163, 0.037 
-0.020, 0.109 
 Lower Outer Octant (-0.291, 0.333) by 
HER2 IHC Classification Score (-0.183, 0.365) 
HER2 IHC Classification Score Squared (0.030, 0.678) 
n=283 
1.502, 0.016 
-0.819, 0.008 
 Oncotype DX Recurrence Score® (0.008, 0.578) by 
HER2 IHC Classification Score (-0.648, 0.164) 
HER2 IHC Classification Score Squared (0.264, 0.138) 
n=142 
0.033, 0.123 
-0.014, 0.031 
Note.  CTF=Clinicopathologic Tumor Feature; ER=Estrogen Receptor; HER2=Human Epidermal Growth Factor 
Receptor 2; IHC=Immunohistochemistry; Oncotype DX=Genomic Health Inc. Oncotype DX® Breast Cancer 
Assay; PR=Progesterone Receptor; TNM=Tumor, Node, Metastasis Classification of Malignant Tumors.  All 
regression coefficient estimates and p-values reported from robust multiple linear regression models generated 
using Huber weighting and biweighting iterations. The reference group for tumor location octant is the upper 
outer octant. The reference for invasive type is ductal. The reference group for Ki67 classification is low. The 
reference group for TNM Stage is Stage 1. The reference group for PR status is PR negative. The reference 
group for HER2 status is HER2 negative. The reference group for the left breast is the right breast. The reference 
group for Nottingham Grade is Grade 1. All models are adjusted for age, estimated verbal intelligence, and 
levels of depressive symptoms, anxiety, fatigue, and pain.        
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Table 14:  Genetic Analysis Overall Participant Characteristics (N=220) 
Characteristic (Measure) Mean±SD or n (%) Minimum Maximum 
Age (years) 60.02±6.086 43 75 
Education (years) 15.12±2.970 9 29 
Estimated Verbal Intelligence (NART-R) 110.39±9.113 82.42 127.81 
Depressive Symptoms (BDI-II) 4.83±4.957 0 29 
Anxiety (POMS Tension-Anxiety subscale) 7.47±5.536 0 27 
Fatigue (POMS Fatigue-Inertia subscale) 5.61±5.942 0 27 
Pain (BPI) 1.30±2.126 0 9 
Marital Status, currently married  
     or living with significant other 
139 (63.2) - - 
Number of Children 2.00±1.403 0 8 
Race, Caucasian 209 (95.0) - - 
Cognitive Function Composite Z-Scores    
     Attention, n=219 -0.1070±0.94939 -4.02 1.70 
     Concentration, n=219 -0.0560±0.83170 -2.20 2.50 
     Executive Function, n=220 -0.2357±0.64539 -1.69 2.41 
     Mental Flexibility, n=219 0.0965±0.75203 -3.64 1.73 
     Psychomotor Speed, n=220 -0.0548±0.88616 -3.67 1.22 
     Verbal Memory, n=220 -0.1087±0.72263 -1.77 1.67 
     Visual Memory, n=220 0.0832±0.68602 -4.63 0.86 
     Visual Working Memory, n=220 0.0358±0.77624 -3.02 1.33 
Note.  BDI-II=Beck Depression Inventory-II; BPI=Brief Pain Inventory; NART-R=National 
Adult Reading Test-Revised; POMS=Profile of Mood States; SD=Standard Deviation. Only 
participants with complete confounder/covariate information are included in the participant 
characteristic statistics.   
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Table 15:  Genetic Analysis Participant and Tumor Characteristics by Study Cohort 
Characteristic (Measure) 
Mean±SD or n (%) 
Prescribed CA 
n=55 
Prescribed AO 
n=83 
 
Healthy 
Controls 
n=82 
aF-test or 
Chi-Square/ 
Fisher’s 
Exact Testb  
p-value 
Age (years) 58.76±5.467 62.47±5.964 58.39±5.858 p<0.001* 
Education (years) 15.67±2.783 14.95±3.056 14.93±2.993 p=0.285 
Estimated Verbal Intelligence (NART-R) 108.94±8.871 107.04±8.844 114.74±7.796 p<0.001* 
Depressive Symptoms (BDI-II) 5.24±4.615 4.60±4.650 4.79±5.495 p=0.757 
Anxiety (POMS Tension-Anxiety subscale) 9.61±6.140 6.97±4.654 6.55±5.619 p=0.003* 
Fatigue (POMS Fatigue-Inertia subscale) 5.11±5.329 5.84±6.352 5.72±5.955 p=0.763 
Pain (BPI) 1.47±1.961 1.55±2.265 0.93±2.059 p=0.130 
Marital Status, currently married  
     or living with significant other 
38 (69.1) 54 (65.1) 47 (57.3) p=0.348 
Number of Children 1.75±1.220 2.05±1.387 2.13±1.522 p=0.266 
Race, Caucasian 52 (94.5) 81 (97.6) 76 (92.7) p=0.305 
Cognitive Function Composite Z-Scores     
     Attention, n=219 -0.052±0.937 -0.202±1.017 -0.047±0.889 p=0.513 
     Concentration, n=219 -0.204±0.667 -0.010±0.904 -0.005±0.850 p=0.322 
     Executive Function, n=220 -0.218±0.599 -0.490±0.509 0.010±0.705 p<0.001* 
     Mental Flexibility, n=219 0.164±0.656 0.090±0.786 0.055±0.783 p=0.707 
     Psychomotor Speed, n=220 0.071±0.845 -0.240±0.954 0.048±0.819 p=0.054 
     Verbal Memory, n=220 0.018±0.662 -0.341±0.638 0.041±0.786 p=0.001* 
     Visual Memory, n=220 0.287±0.352 0.009±0.708 0.022±0.803 p=0.038* 
     Visual Working Memory, n=220 0.299±0.514 -0.064±0.741 -0.039±0.913 p=0.014* 
Overall TNM Stage, n=130     
     Stage 1 22 (44.0) 65 (81.3) - p<0.001* 
     Stage 2a 17 (34.0) 13 (16.3) -  
     Stage 2b 6 (12.0) 2 (2.5) -  
     Stage 3a 5 (10.0) 0 (0) -  
Tumor Size (cm), n=129 2.16±1.484 1.23±0.709 - p<0.001* 
Aggregate Tumor Size (cm), n=130 2.35±1.591 1.39±0.964 - p<0.001* 
Tumor Stage, n=130     
     T1a 1 (2.0) 13 (16.3) - p=0.001* 
     T1b 8 (16.0) 23 (28.7) -  
     T1c 21 (42.0) 33 (41.3) -  
     T2 16 (32.0) 11 (13.8) -  
     T3 4 (8.0) 0 (0) -  
Lymph Node, n=129     
     Positive 19 (38.0) 5 (6.3) - p<0.001* 
     Negative 31 (62.0) 74 (93.7) -  
Number of Positive Nodes, n=130 0.94±1.789 0.06±0.244 - p<0.001* 
Tumor Focality, n=130     
     Single 41 (82.0) 63 (78.8) - p=0.652 
     Multiple 9 (18.0) 17 (21.3) -  
Tumor Laterality, n=130     
     Right Breast 21 (42.0) 36 (45.0) - p=0.737 
     Left Breast 29 (58.0) 44 (55.0) -  
Tumor Location Octant, n=125     
     Upper Outer 21 (43.8) 29 (37.7) - p=0.982 
     Lower Outer 2 (4.2) 6 (7.8) -  
     Upper Inner 6 (12.5) 9 (11.7) -  
     Lower Inner 2 (4.2) 5 (6.5) -  
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     Upper Middle 8 (16.7) 10 (13.0) -  
     Outer Middle 4 (8.3) 8 (10.4) -  
     Lower Middle 2 (4.2) 4 (5.2) -  
     Inner Middle 3 (6.3) 6 (7.8) -  
Invasive Type, n=129     
     Ductal 45 (90.0) 63 (79.7) - p=0.323 
     Lobular 5 (10.0) 14 (17.7) -  
     Ductal & Lobular 0 (0) 2 (2.5) -  
Nottingham Score, n=125 6.60±1.370 5.72±1.122 - p<0.001* 
Nottingham Grade, n=125     
     Grade 1 9 (18.0) 27 (36.0) - p<0.001* 
     Grade 2 26 (52.0) 44 (58.7) -  
     Grade 3 15 (30.0) 4 (5.3) -  
ER Status, n=130     
     Positive 48 (96.0) 80 (100) - p=0.146 
     Negative 2 (4.0) 0 (0) -  
ER H-Score, n=124 240.08±73.684 265.87±44.592 - p=0.017* 
Oncotype DX ER Score, n=46 9.79±1.138 10.41±0.934 - p=0.053 
PR Status, n=130     
     Positive 38 (76.0) 71 (88.8) - p=0.055 
     Negative 12 (24.0) 9 (11.3) -  
PR H-Score, n=124 110.35±101.612 129.69±97.208 - p=0.289 
Oncotype DX PR Score, n=46 6.22±1.591 7.31±1.391 - p=0.020* 
HER2 Status, n=125     
     Positive 9 (19.1) 4 (5.1) - p=0.017* 
     Negative 38 (80.9) 74 (94.9) -  
HER2 IHC Score, n=120 1.40±0.984 1.10±0.858 - p=0.081 
Oncotype DX HER2 Score, n=33 8.76±1.079 8.87±0.396 - p=0.657 
LV Invasion, n=127     
     Present 21 (42.9) 6 (7.7) - p<0.001* 
     Absent  28 (57.1) 72 (92.3) -  
Ki67 Classification, n=68     
     Low 10 (38.5) 18 (42.9) - p=0.114 
     Moderate 5 (19.2) 14 (33.3) -  
     High 6 (23.1) 9 (21.4) -  
     Very High 5 (19.2) 1 (2.4) -  
Ki67 Index, n=68 28.73±26.834 17.31±13.337 - p=0.022* 
Oncotype DX Recurrence Score®, n=74 26.52±9.774 14.63±6.174 - p<0.001* 
Magee Equation Recurrence Score, n=119 24.65±9.009 18.50±5.707 - p<0.001* 
Note.  *=p<0.05; AO=Anastrozole Only; BDI-II=Beck Depression Inventory-II; BPI=Brief Pain Inventory; 
CA=Chemotherapy plus Anastrozole; ER=Estrogen Receptor; HER2= Human Epidermal Growth Factor Receptor 
2;  IHC=Immunohistochemistry; LV=Lymphovascular; NART-R=National Adult Reading Test-Revised; Oncotype 
DX=Genomic Health Inc. Oncotype DX® Breast Cancer Assay; POMS=Profile of Mood States; PR=Progesterone 
Receptor; SD=Standard Deviation; TNM=Tumor, Node, Metastasis Classification of Malignant Tumors. aOne-way 
ANOVAs utilized to compare means of continuous variables. bPearson’s Chi-square Tests of independence, 
Fisher’s Exact Test, or Fisher’s Exact Test computed using 2-sided Monte Carlo sampling based on 10,000 sampled 
tables used to examine associations between categorical variables.  Only participants with complete 
confounder/covariate information are included in the participant characteristic statistics. 
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Table 16:  SNPs Included in Genetic Regression Analyses (N=220) 
Gene 
     SNP 
Wildtype/Variant 
Allelea 
n for  
each SNP 
Study 
MAF HWE
b 
AURKA 
     rs1047972 G/A 219 0.148 p=1.0000 
     rs16979877 A/G 207 0.080 p=0.3725 
     rs2273535 A/T 213 0.216 p=0.9788 
     rs6064389 G/T 219 0.445 p=0.2279 
BAG1 
     rs706118 T/G 214 0.248 p=0.1553 
BCL2 
     rs1564483 G/A 207 0.271 p=0.6855 
     rs17759659 A/G 219 0.425 p=0.8885 
     rs2279115 A/C 206 0.459 p=0.7047 
     rs4941195 C/A 218 0.429 p=0.4230 
     rs4987852 A/G 218 0.078 p=1.0000 
     rs4987853 A/G 217 0.189 p=0.5787 
     rs4987855 G/A 220 0.071 p=0.6073 
     rs956572 G/A 211 0.398 p=0.6542 
     rs9807663 T/A 218 0.108 p=0.7216 
BIRC5 
     rs1042489 T/C 217 0.359 p=0.5481 
     rs1508147 G/A 218 0.358 p=0.5738 
     rs17878467 C/T 217 0.111 p=1.0000 
     rs2239680 T/C 214 0.299 p=0.7100 
     rs3764383 A/G 213 0.305 p=0.9577 
     rs8073069 G/C 207 0.249 p=0.9445 
     rs8073903 T/C 212 0.366 p=0.6934 
     rs9904341 G/C 206 0.318 p=0.7061 
CCNB1 
     rs164390 G/T 214 0.371 p=0.5200 
     rs350099 T/C 216 0.396 p=0.5396 
     rs350104 T/C 219 0.459 p=0.5640 
CD68 
     rs8066665 G/A 220 0.457 p=0.1667 
     rs9901673 C/A 218 0.172 p=0.0915 
CENPA 
     rs3806517 A/G 215 0.340 p=0.8111 
     rs3806518 T/C 214 0.278 p=0.8532 
CMC2 
     rs1025065 C/A 209 0.361 p=0.8277 
     rs1981867 C/T 220 0.307 p=0.1739 
     rs9936489 T/G 215 0.319 p=0.7119 
CTSL2 
     rs16919034 A/G 213 0.169 p=0.3501 
     rs4361859 A/G 219 0.327 p=0.0078* 
p=0.0695HC  
DIAPH3 
     rs1337652 G/A 217 0.212 p=0.9194 
     rs4547237 A/G 220 0.307 p=0.8219 
ERBB2 
     rs1058808 G/C 217 0.373 p=0.2746 
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     rs1136201 A/G 220 0.232 p=0.9465 
     rs1476278 A/G 220 0.357 p=0.9976 
     rs1810132 T/C 212 0.318 p=0.1537 
     rs2517955 T/C 220 0.373 p=0.4823 
     rs4252596 C/A 220 0.121 p=0.7482 
     rs903501 G/A 211 0.332 p=0.3885 
     rs9303274 C/T 219 0.356 p=0.9485 
     rs12976445 (MIR125A) T/C 220 0.298 p=0.1467 
ESR1 
     rs10484919 C/T 204 0.088 p=0.6574 
     rs1062577 T/A 215 0.081 p=0.1495 
     rs11964281 C/T 214 0.075 p=1.0000 
     rs12173570 C/T 219 0.132 p=0.3857 
     rs12665044 C/T 213 0.132 p=0.7665 
     rs1514348 A/C 220 0.468 p=0.9519 
     rs1801132 C/G 220 0.232 p=0.4098 
     rs1884051 A/G 207 0.336 p=0.9170 
     rs2046210 C/T 213 0.357 p=0.3520 
     rs2071454 T/G 213 0.110 p=1.0000 
     rs2077647 G/A 217 0.484 p=0.0643 
     rs2228480 G/A 218 0.188 p=0.2292 
     rs2234693 C/T 206 0.481 p=0.0344* 
p=0.9104HC 
     rs2347867 A/G 215 0.340 p=0.5008 
     rs2744677 A/C 215 0.249 p=0.6319 
     rs2813543 G/A 213 0.181 p=0.9848 
     rs2813544 A/G 215 0.235 p=0.0512 
     rs2941740 T/C 220 0.391 p=0.4585 
     rs3020314 T/C 208 0.358 p=0.4848 
     rs3778099 T/C 208 0.089 p=1.0000 
     rs3798577 T/C 220 0.475 p=0.2770 
     rs488133 C/T 209 0.285 p=0.5101 
     rs532010 T/C 212 0.434 p=0.7636 
     rs6557171 C/T 218 0.303 p=0.7528 
     rs77275268 C/T 217 0.083 p=0.1827 
     rs7761133 T/C 216 0.153 p=0.5840 
     rs7761846 T/C 204 0.054 p=0.4501 
     rs7766585 T/G 218 0.154 p=0.1375 
     rs7767143 A/G 214 0.243 p=0.0849 
     rs827421 C/T 212 0.467 p=0.1489 
     rs851967 G/A 216 0.308 p=0.6380 
     rs851971 G/A 216 0.313 p=0.5073 
     rs851982 T/C 217 0.362 p=0.3178 
     rs851998 C/T 219 0.313 p=0.6540 
     rs910416 T/C 220 0.491 p=0.9961 
     rs9322331 C/T 215 0.381 p=0.8339 
     rs9340799 A/G 213 0.397 p=0.4781 
     rs9383938 G/T 218 0.083 p=0.3721 
     rs9397435 A/G 220 0.073 p=0.6108 
     rs9397456 G/A 203 0.217 p=0.1522 
     rs985694 C/T 218 0.120 p=0.7731 
     rs1038304 (CCDC170) G/A 218 0.456 p=0.1394 
     rs12662670 (CCDC170) T/G 217 0.069 p=0.2740 
     rs3734805 (CCDC170) A/C 213 0.075 p=0.2359 
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     rs3757318 (CCDC170) G/A 213 0.059 p=0.3629 
     rs6929137 (CCDC170) G/A 216 0.319 p=0.3411 
GRB7 
     rs9910678 T/C 218 0.053 p=0.1079 
GSTM1 
     rs1065411 C/G 209 0.194 p=0.0884 
     rs412543 G/C 216 0.081 p=0.3714 
     rs35652124 (NFE2L2) T/C 218 0.298 p=0.2739 
     rs6721961 (NFE2L2) G/T 212 0.101 p=1.0000 
MELK 
     rs10973007 C/G 209 0.189 p=0.8337 
     rs2250340 C/T 220 0.075 p=1.0000 
     rs3780350 C/T 213 0.155 p=0.6424 
MKI67 
     rs10732438 A/G 211 0.367 p=0.1859 
     rs10764751 A/C 220 0.239 p=0.5706 
MMP11 
     rs131451 T/C 216 0.107 p=1.0000 
MYBL2 
     rs11556379 C/G 220 0.050 p=0.4243 
     rs2070235 A/G 220 0.093 p=1.0000 
     rs619289 C/T 216 0.197 p=0.7837 
     rs826943 T/C 213 0.146 p=0.7823 
     rs826944 C/T 219 0.142 p=1.0000 
NDC80 
     rs12408485 A/G 203 0.382 p=0.4731 
     rs2292274 T/C 207 0.268 p=0.5054 
ORC6 
     rs33994299 T/C 220 0.475 p=0.0051* 
p=0.1405HC 
PGR 
     rs1042838 G/T 216 0.141 p=0.0466* 
p=0.0160HC* 
     rs1042839 C/T 208 0.130 p=0.0103* 
p=0.0027HC* 
     rs10895068 G/A 214 0.063 p=1.0000 
     rs11224561 C/T 214 0.119 p=0.7460 
     rs1893505 C/T 220 0.382 p=0.7593 
     rs1942836 T/C 217 0.201 p=0.7604 
     rs471767 A/G 216 0.313 p=0.3574 
     rs474320 T/A 197 0.147 p=0.0434* 
p=0.0329HC* 
     rs4754732 T/C 220 0.334 p=0.1780 
     rs484389 T/C 212 0.217 p=0.6804 
     rs568157 A/G 219 0.493 p=0.3120 
     rs590688 C/G 215 0.463 p=0.1662 
     rs608995 A/T 218 0.220 p=0.5724 
RACGAP1 
     rs7303531 G/A 214 0.058 p=1.0000 
RFC4 
     rs1354091 A/C 214 0.238 p=0.9537 
RRM2 
     rs1138729 A/G 202 0.136 p=0.3821 
     rs4309551 C/T 218 0.452 p=0.8925 
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     rs4668664 G/A 215 0.263 p=0.6850 
SCUBE2 
     rs1136966 T/G 213 0.211 p=0.8348 
     rs4910440 C/T 219 0.470 p=0.4879 
     rs6486125 A/G 207 0.266 p=0.1980 
Note. *=p<0.05; HC=HWE p-value in healthy control participants only; HWE=Hardy-Weinberg 
Equilibrium; MAF=minor allele frequency; SNP=Single Nucleotide Polymorphism.  aWildtype 
and variant alleles based on study sample. bChi-square Goodness-of-fit or Exact Test p-value. 
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Table 17:  GRS and Cognitive Function Composite Regression Analysis Results 
Cognitive Function 
Composite 
Gene-SNP used in 
GRS Calculation 
bGRS, 
p-valuea Model R
2 R
2 Change 
for GRS 
Attention  
(n=201) 
ERBB2(MIR125A)-rs12976445 
ESR1-rs2347867 
ESR1-rs3020314 
ESR1-rs6557171 
ESR1-rs985694 
MYBL2-rs2070235 
SCUBE2-rs6486125 
0.4665, 
p<0.001* 
 
0.4800, 
p<0.001* 
0.2593 0.066 
Concentration  
(n=177) 
AURKA-rs1047972 
BCL2-rs9807663 
CCNB1-rs164390 
CCNB1-rs350099 
CENPA-rs3806517 
DIAPH3-rs4547237 
ESR1-rs488133 
ESR1-rs7767143 
ESR1-rs910416 
ESR1-rs9397456 
ESR1(CCDC170)-rs12662670 
ESR1(CCDC170)-rs3734805 
ESR1(CCDC170)-rs3757318 
ESR1(CCDC170)-rs6929137 
GRB7-rs9910678 
MELK-rs10973007 
PGR-rs10895068 
0.5098, 
p<0.001* 
 
0.5358, 
p<0.001* 
0.2495 0.189 
Executive Function  
(n=137) 
BAG1-rs706118 
BCL2-rs1564483 
BCL2-rs4987853 
CCNB1-rs164390 
CCNB1-rs350099 
CCNB1-rs350104 
CTSL2-rs4361859 
DIAPH3-rs1337652 
DIAPH3-rs4547237 
ESR1-rs2234693 
ESR1-rs488133 
ESR1-rs7761846 
ESR1-rs827421 
ESR1(CCDC170)-rs3757318 
GSTM1-rs412543 
MELK-rs10973007 
MELK-rs2250340 
MYBL2-rs11556379 
PGR-rs1042838 
PGR-rs474320 
PGR-rs484389 
PGR-rs608995 
SCUBE2-rs6486125 
0.3526, 
p<0.001* 
 
0.3589,  
p<0.001* 
0.4296 0.204 
Mental Flexibility  
(n=154) 
BCL2-rs1564483 
BCL2-rs4987853 
DIAPH3-rs1337652 
ERBB2(MIR125A)rs12976445 
0.5040, 
p<0.001* 
 
0.5383, 
0.4712 0.224 
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ESR1-rs2347867 
ESR1-rs6557171 
ESR1-rs985694 
GSTM1(NFE2L2)-rs35652124 
MKI67-rs10732438 
MYBL2-rs11556379 
NDC80-rs12408485 
NDC80-rs2292274 
RFC4-rs1354091 
RRM2-rs1138729 
SCUBE2-rs6486125 
p,0.001* 
Psychomotor Speed  
(n=181) 
BCL2-rs4941195 
BCL2-rs956572 
CENPA-rs3806518 
ESR1-rs2347867 
ESR1-rs488133 
ESR1-rs9322331 
ESR1-rs9340799 
MKI67-rs10732438 
PGR-rs568157 
0.7265, 
p<0.001* 
 
0.6674, 
p<0.001* 
 
 
0.2527 0.093 
Verbal Memory  
(n=146) 
AURKA-rs16979877 
BCL2-rs2279115 
BCL2-rs4987852 
BIRC5-rs3764383 
CCNB1-rs164390 
CCNB1-rs350099 
CCNB1-rs350104 
CD68-rs9901673  
CENPA-rs3806518 
CTSL2-rs16919034 
DIAPH3-rs4547237 
ESR1-rs10484919 
ESR1-rs12665044 
ESR1-rs2941740 
ESR1-rs488133 
ESR1-rs77275268 
ESR1-rs7767143 
ESR1-rs9383938 
ESR1-rs9397435 
ESR1(CCDC170)-rs3734805 
ESR1(CCDC170)-rs3757318 
GSTM1-rs412543 
MYBL2-rs2070235 
MYBL2-rs619289 
NDC80-rs2292274 
ORC6-rs33994299 
PGR-rs484389 
PGR-rs568157 
0.3406, 
p<0.001* 
 
0.3401, 
p<0.001* 
0.5048 0.209 
Visual Memory  
(n=165) 
BAG1-rs706118 
BCL2-rs1564483 
CCNB1-rs350104 
DIAPH3-rs1337652 
DIAPH3-rs4547237 
ESR1-rs2077647 
ESR1-rs2813544 
ESR1-rs488133 
0.7477, 
p<0.001* 
 
0.6078, 
p<0.001* 
 
 
0.3167 0.148 
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ESR1-rs7761846 
ESR1-rs7767143 
ESR1(CCDC170)-rs3757318 
GSTM1-rs412543 
MYBL2-rs2070235 
PGR-rs11224561 
PGR-rs1942836 
RRM2-rs4309551 
Visual Working Memory 
(n=154) 
AURKA-rs2273535 
BAG1-rs706118 
BIRC5-rs1508147 
BIRC5-rs9904341 
CCNB1-rs164390 
CCNB1-rs350099 
CCNB1-rs350104 
CD68-rs9901673  
DIAPH3-rs1337652 
DIAPH3-rs4547237 
ESR1-rs2941740 
ESR1-rs488133 
ESR1-rs7761846 
ESR1-rs910416 
ESR1-rs9397456 
GRB7-rs9910678 
GSTM1-rs412543 
MELK-rs2250340 
MYBL2-rs2070235 
MYBL2-rs619289 
PGR-rs11224561 
PGR-rs608995 
0.4198, 
p<0.001* 
 
0.4131, 
p<0.001* 
 
 
0.4700 0.241 
Note. *=p<0.001; GRS=Genetic Risk/Protection Score. aStandard multiple linear regression coefficient 
and p-value listed first, robust multiple linear regression coefficient and p-value listed subsequently.  
Model R2 and R2 change reported from standard multiple linear regression models.  Participants missing 
genetic data necessary for completion of a GRS calculation were not included in the GRS analysis.  All 
regression models are adjusted for age, estimated verbal intelligence, levels of depressive symptoms, 
anxiety, fatigue, and pain, and prescribed treatment group. 
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Table 18:  Individual SNP and Cognitive Function Robust Regression Results 
Regression  
coefficient, p-value Attention Concentration 
Executive  
Function 
Mental  
Flexibility 
Psychomotor 
Speed 
Verbal 
Memory 
Visual  
Memory 
Visual Working 
Memory 
AURKArs1047972 n=218 n=218 n=219 n=219 n=219 n=219 n=219 n=219 
  Main Effects Model         
    SNP Main Effect 0.000, 0.998 -0.148, 0.241 0.080, 0.389 0.017, 0.867 0.149, 0.153 0.025, 0.806 0.021, 0.735 0.116, 0.263 
  Interaction Model         
    SNP Main Effect 0.125, 0.579 -0.488, 0.016* 0.148, 0.353 0.161, 0.362 0.063, 0.716 -0.092, 0.601 0.152, 0.149 0.054, 0.762 
    SNP-by-CA Inter -0.176, 0.617 0.569, 0.073 -0.073, 0.766 -0.407, 0.138 -0.075, 0.781 0.287, 0.292 -0.177, 0.275 0.119, 0.664 
    SNP-by-AO Inter -0.205, 0.504 0.513. 0.063 -0.111, 0.609 -0.066, 0.784 0.298, 0.213 0.103, 0.669 -0.212, 0.140 0.067, 0.783 
 
AURKArs16979877 n=206 n=206 n=207 n=206 n=207 n=207 n=207 n=207 
  Main Effects Model         
    SNP Main Effect -0.211, 0.238 0.125, 0.432 -0.147, 0.233 -0.094, 0.497 -0.199, 0.161 -0.138, 0.318 -0.157, 0.062 -0.135, 0.330 
  Interaction Model         
    SNP Main Effect -0.274, 0.391 0.180, 0.533 -0.234, 0.302 0.085, 0.735 0.035, 0.893 -0.540, 0.029* -0.291, 0.056 -0.350, 0.166 
    SNP-by-CA Inter 0.295, 0.626 0.076, 0.879 -0.061, 0.875 -0.446, 0.305 -0.457, 0.305 0.577, 0.174 0.259, 0.322 0.496, 0.253 
    SNP-by-AO Inter 0.042, 0.916 -0.108, 0.763 0.176, 0.532 -0.184, 0.557 -0.354, 0.271 0.548, 0.074 0.152, 0.422 0.238, 0.447 
 
AURKArs2273535 n=212 n=213 n=213 n=212 n=213 n=213 n=213 n=213 
  Main Effects Model         
    SNP Main Effect 0.040, 0.748 -0.063, 0.566 0.038, 0.663 -0.136, 0.160 -0.021, 0.834 0.186, 0.052 -0.064, 0.273 0.009, 0.926 
  Interaction Model         
    SNP Main Effect -0.078, 0.698 -0.027, 0.877 0.193, 0.164 -0.200, 0.198 -0.010, 0.949 0.297, 0.051 -0.082, 0.397 0.183, 0.241 
    SNP-by-CA Inter 0.198, 0.545 -0.104, 0.715 -0.146, 0.520 0.218, 0.387 0.282, 0.267 -0.031, 0.899 0.147, 0.354 -0.008, 0.975 
    SNP-by-AO Inter 0.186, 0.517 -0.019, 0.939 -0.306, 0.131 0.011, 0.961 -0.246, 0.271 -0.275, 0.208 -0.159, 0.254 -0.477, 0.034* 
 
AURKArs6064389 n=218 n=218 n=219 n=218 n=219 n=219 n=219 n=219 
  Main Effects Model         
    SNP Main Effect 0.027, 0.839 0.067, 0.572 0.089, 0.341 0.054, 0.608 0.011, 0.915 -0.051, 0.623 -0.031, 0.610 0.178, 0.088 
  Interaction Model         
    SNP Main Effect -0.065, 0.769 0.119, 0.540 0.035, 0.819 -0.044, 0.797 -0.080, 0.637 -0.208, 0.220 0.050, 0.627 0.060, 0.724 
    SNP-by-CA Inter 0.557, 0.189 -0.292. 0.414 0.202, 0.474 0.176, 0.578 0.562, 0.072 0.665, 0.831 -0.151, 0.426 -0.022, 0.945 
    SNP-by-AO Inter 0.080, 0.788 -0.005, 0.986 0.046, 0.823 0.140. 0.548 -0.004, 0.986 0.303, 0.186 -0.106, 0.448 0.267, 0.248 
 
BAG1rs706118 n=213 n=213 n=214 n=213 n=214 n=214 n=214 n=214 
  Main Effects Model         
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    SNP Main Effect -0.101, 0.408 -0.109, 0.314 -0.123, 0.145 0.045, 0.624 -0.016, 0.870 -0.154, 0.103 -0.107, 0.067 -0.310, 0.001* 
  Interaction Model         
    SNP Main Effect 0.061, 0.763 0.069, 0.706 -0.312, 0.027* 0.125, 0.441 0.006, 0.971 -0.127, 0.421 -0.216, 0.025* -0.450, 0.004* 
    SNP-by-CA Inter -0.549, 0.092 -0.270. 0.355 0.263, 0.239 -0.213, 0.406 -0.324, 0.209 -0.109, 0.664 0.112, 0.465 0.099, 0.684 
    SNP-by-AO Inter -0.064, 0.825 -0.288, 0.268 0.321, 0.108 -0.064, 0.781 0.174, 0.450 0.006, 0.980 0.219, 0.110 0.299, 0.170 
 
BCL2rs1564483 n=206 n=207 n=207 n=206 n=207 n=207 n=207 n=207 
  Main Effects Model         
    SNP Main Effect 0.246, 0.052 0.001, 0.994 0.191, 0.030* 0.049, 0.621 0.082, 0.410 0.067, 0.491 0.118, 0.221b 0.085, 0.389 
  Interaction Model         
    SNP Main Effect 0.312, 0.141 -0.224, 0.247 0.397, 0.007* 0.396, 0.017* 0.167, 0.321 0.246, 0.134 0.226, 0.031* 0.244, 0.147 
    SNP-by-CA Inter -0.256, 0.424 0.185, 0.526 -0.244, 0.267 -0.607, 0.015* -0.326, 0.200 -0.317, 0.200 -0.386, 0.015* -0.411, 0.105 
    SNP-by-AO Inter 0.023, 0.937 0.461, 0.085 -0.352, 0.081 -0.406, 0.074 0.021, 0.928 -0.222, 0.328 -0.107, 0.457 -0.068, 0.770 
 
BCL2rs17759659 n=218 n=218 n=219 n=218 n=219 n=219 n=219 n=219 
  Main Effects Model         
    SNP Main Effect 0.132, 0.311 0.093, 0.415 0.039, 0.671 0.080, 0.434 -0.003, 0.973 0.043, 0.668 -0.004, 0.951 -0.043, 0.674 
  Interaction Model         
    SNP Main Effect 0.320, 0.111 0.098, 0.584 0.069, 0.625 0.047, 0.769 0.104, 0.512 0.223, 0.152 -0.036, 0.707 -0.176, 0.268 
    SNP-by-CA Inter -0.526, 0.108 0.114, 0.696 -0.131, 0.572 0.164, 0.527 0.033, 0.899 -0.456, 0.072 0.106, 0.502 0.193, 0.457 
    SNP-by-AO Inter -0.173, 0.548 -0.098, 0.703 0.003, 0.988 -0.029, 0.901 -0.334, 0.146 -0.174, 0.437 0.014, 0.920 0.235, 0.305 
 
BCL2rs2279115 n=205 n=205 n=206 n=206 n=206 n=206 n=206 n=206 
  Main Effects Model         
    SNP Main Effect 0.019, 0.888 -0.140, 0.251 0.033, 0.722 -0.118, 0.266 -0.152, 0.147 -0.106, 0.320 -0.083, 0.197 -0.141, 0.191 
  Interaction Model         
    SNP Main Effect -0.033, 0.882 -0.169, 0.412 0.099, 0.531 -0.204, 0.252 -0.083, 0.640 -0.380, 0.034* 0.011, 0.921 -0.097, 0.594 
    SNP-by-CA Inter -0.039, 0.910 -0.008, 0.980 -0.063, 0.797 0.070, 0.797 -0.165, 0.544 0.348, 0.207 -0.157, 0.357 -0.047, 0.867 
    SNP-by-AO Inter 0.188, 0.547 0.084, 0.771 -0.127, 0.568 0.180, 0.471 -0.073, 0.769 0.451, 0.073 -0.122, 0.434 -0.078, 0.761 
 
BCL2rs4941195 n=217 n=217 n=218 n=217 n=218 n=218 n=218 n=218 
  Main Effects Model         
    SNP Main Effect 0.049, 0.700 -0.095, 0.398 0.107, 0.222 -0.058, 0.560 -0.227, 0.021* -0.003, 0.979 0.010, 0.864 0.013, 0.897 
  Interaction Model         
    SNP Main Effect -0.027, 0.895 -0.048, 0.789 0.214, 0.129 -0.110, 0.493 -0.185, 0.239 -0.213, 0.174 0.132, 0.169 0.300, 0.057 
    SNP-by-CA Inter 0.024, 0.941 -0.021, 0.942 -0.082, 0.719 0.096, 0.711 0.000, 1.000 0.158, 0.534 -0.221, 0.157 -0.471, 0.066 
    SNP-by-AO Inter 0.189, 0.514 -0.110, 0.668 -0.225, 0.264 0.074, 0.749 -0.123, 0.586 0.434, 0.055 -0.174, 0.208 -0.407, 0.073 
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BCL2rs4987852 n=217 n=217 n=218 n=217 n=218 n=218 n=218 n=218 
  Main Effects Model         
    SNP Main Effect -0.273, 0.096 -0.154, 0.297 -0.072, 0.543 -0.068, 0.603 -0.058, 0.656 0.190, 0.140 -0.018, 0.818 -0.008, 0.953 
  Interaction Model         
    SNP Main Effect -0.511, 0.051 0.046, 0.849 -0.070, 0.709 -0.097, 0.652 0.087, 0.681 0.464, 0.024* -0.005, 0.965 -0.121, 0.566 
    SNP-by-CA Inter 0.458, 0.336 -0.528, 0.226 0.282, 0.409 0.079, 0.837 -0.219, 0.570 -0.046, 0.902 0.214, 0.350 0.382, 0.320 
    SNP-by-AO Inter 0.383, 0.284 -0.178, 0.586 -0.101, 0.693 0.030, 0.917 -0.310, 0.284 -0.542, 0.054 -0.120, 0.486 0.076, 0.792 
 
BCL2rs4987853 n=216 n=216 n=217 n=216 n=217 n=217 n=217 n=217 
  Main Effects Model         
    SNP Main Effect -0.033, 0.793 -0.046, 0.681 -0.035, 0.687 -0.053, 0.589 0.014, 0.887 -0.025, 0.796 -0.062, 0.314 -0.098, 0.322 
  Interaction Model         
    SNP Main Effect -0.182, 0.386 -0.045, 0.811 -0.282, 0.054 -0.313, 0.058 -0.134, 0.418 -0.253, 0.121 -0.078, 0.448 -0.145, 0.384 
    SNP-by-CA Inter 0.239, 0.492 0.179, 0.560 0.516, 0.031* 0.211, 0.430 0.205, 0.451 0.378, 0.157 0.141, 0.403 0.149, 0.583 
    SNP-by-AO Inter 0.234, 0.423 -0.113, 0.662 0.304, 0.134 0.497, 0.029* 0.255, 0.269 0.329, 0.147 -0.055, 0.701 0.022, 0.924 
 
BCL2rs4987855 n=219 n=219 n=220 n=219 n=220 n=220 n=220 n=220 
  Main Effects Model         
    SNP Main Effect 0.064, 0.708 -0.020, 0.898 -0.055, 0.651 -0.101, 0.453 0.004, 0.975 0.029, 0.826 -0.086, 0.296 -0.111, 0.408 
  Interaction Model         
    SNP Main Effect -0.033, 0.907 0.093, 0.712 -0.306, 0.118 -0.293, 0.182 -0.115, 0.604 -0.156, 0.474 -0.079, 0.558 -0.304, 0.168 
    SNP-by-CA Inter 0.008, 0.987 -0.334, 0.487 0.255, 0.496 0.283, 0.499 0.037, 0.931 0.363, 0.383 -0.061, 0.811 0.228, 0.589 
    SNP-by-AO Inter 0.209, 0.581 -0.149, 0.659 0.433, 0.101 0.298, 0.313 0.269, 0.367 0.254, 0.387 0.011, 0.949 0.295, 0.321 
 
BCL2rs956572 n=210 n=211 n=211 n=210 n=211 n=211 n=211 n=211 
  Main Effects Model         
    SNP Main Effect 0.081, 0.532 0.039, 0.725 -0.028, 0.757 0.049, 0.626 0.170, 0.091 -0.169, 0.092 -0.015, 0.809 0.013, 0.897 
  Interaction Model         
    SNP Main Effect 0.222, 0.311 -0.089, 0.638 0.093, 0.545 0.278, 0.098 0.392, 0.020* -0.191, 0.257 0.085, 0.426 -0.009, 0.960 
    SNP-by-CA Inter -0.219, 0.524 0.122, 0.680 -0.181, 0.451 -0.171, 0.512 -0.283, 0.280 -0.097, 0.712 -0.046, 0.782 -0.007, 0.979 
    SNP-by-AO Inter -0.223, 0.454 0.241, 0.351 -0.187, 0.374 -0.441, 0.054 -0.411, 0.073 0.108, 0.637 -0.250, 0.084 0.064, 0.788 
 
BCL2rs9807663 n=217 n=217 n=218 n=217 n=218 n=218 n=218 n=218 
  Main Effects Model         
    SNP Main Effect -0.012, 0.938 0.103, 0.439 0.012, 0.907 -0.011, 0.927 0.033, 0.779 -0.065, 0.572 0.044, 0.528 -0.043, 0.716 
  Interaction Model         
    SNP Main Effect 0.028, 0.899 0.315, 0.107 0.107, 0.485 -0.027, 0.874 0.210, 0.223 -0.235, 0.165 0.042, 0.679 -0.001, 0.995 
    SNP-by-CA Inter -0.516, 0.196 -0.178, 0.617 -0.349, 0.198 -0.367, 0.222 -0.431, 0.156 0.189, 0.525 -0.230, 0.194 -0.213, 0.486 
114 
    SNP-by-AO Inter 0.191, 0.578 -0.681, 0.028* -0.039, 0.873 0.306, 0.256 -0.242. 0.372 0.349, 0.191 0.173, 0.276 0.059, 0.828 
 
BIRC5rs1042489 n=216 n=216 n=217 n=216 n=217 n=217 n=217 n=217 
  Main Effects Model         
    SNP Main Effect -0.004, 0.977 0.080, 0.468 -0.015, 0.865 0.145, 0.129 -0.030, 0.758 -0.057, 0.552 -0.078, 0.174 -0.049, 0.609 
  Interaction Model         
    SNP Main Effect 0.022, 0.911 0.176, 0.321 -0.094, 0.498 0.235, 0.127 -0.181, 0.247 -0.199, 0.194 -0.161, 0.082 -0.234, 0.125 
    SNP-by-CA Inter -0.052, 0.869 -0.113, 0.690 0.102, 0.644 -0.199, 0.413 0.117, 0.635 0.178, 0.462 0.190, 0.195 0.451, 0.062 
    SNP-by-AO Inter -0.035, 0.905 -0.199, 0.446 0.145, 0.479 -0.097, 0.667 0.356, 0.122 0.252, 0.263 0.091, 0.502 0.140, 0.533 
 
BIRC5rs1508147 n=217 n=217 n=218 n=217 n=218 n=218 n=218 n=218 
  Main Effects Model         
    SNP Main Effect 0.039, 0.750 0.067, 0.540 0.002, 0.983 0.138, 0.152 -0.025, 0.794 -0.032, 0.735 -0.061, 0.289 -0.052, 0.587 
  Interaction Model         
    SNP Main Effect 0.033, 0.868 0.155, 0.383 -0.092, 0.507 0.226, 0.148 -0.187, 0.226 -0.190, 0.213 -0.155, 0.092 -0.249, 0.098 
    SNP-by-CA Inter -0.013, 0.967 -0.089, 0.753 0.063, 0.773 -0.191, 0.436 0.146, 0.548 0.208, 0.385 0.206, 0.156 0.472, 0.048* 
    SNP-by-AO Inter 0.026, 0.929 -0.195, 0.459 0.211, 0.305 -0.090, 0.695 0.362, 0.115 0.271, 0.230 0.110, 0.421 0.132, 0.553 
 
BIRC5rs17878467 n=216 n=216 n=217 n=216 n=217 n=217 n=217 n=217 
  Main Effects Model         
    SNP Main Effect -0.193, 0.184 0.246, 0.059 -0.121, 0.236 0.125, 0.278 -0.037, 0.748 -0.091, 0.416 -0.022, 0.753 -0.003, 0.979 
  Interaction Model         
    SNP Main Effect -0.413, 0.084 0.149, 0.489 -0.099, 0.562 0.063, 0.744 -0.192, 0.311 -0.008, 0.965 -0.106, 0.359 0.042, 0.826 
    SNP-by-CA Inter 0.351, 0.350 0.214, 0.520 -0.161, 0.537 0.001, 0.996 0.299, 0.304 -0.118, 0.682 0.140, 0.429 -0.008, 0.978 
    SNP-by-AO Inter 0.366, 0.285 0.091, 0.769 0.061, 0.801 0.176, 0.522 0.246, 0.364 -0.132, 0.623 0.148, 0.370 -0.125, 0.648 
 
BIRC5rs2239680 n=213 n=214 n=214 n=213 n=214 n=214 n=214 n=214 
  Main Effects Model         
    SNP Main Effect 0.110, 0.385 -0.197, 0.073 0.042, 0.635 -0.086, 0.379 -0.056, 0.576 0.120, 0.219 0.068, 0.242 0.128, 0.197 
  Interaction Model         
    SNP Main Effect 0.220, 0.275 -0.156, 0.367 -0.020, 0.889 -0.119, 0.448 -0.074, 0.637 0.101, 0.515 0.028, 0.766 0.001, 0.996 
    SNP-by-CA Inter -0.199, 0.536 0.213, 0.437 0.100, 0.656 -0.022, 0.930 0.406, 0.103 0.027, 0.914 0.048, 0.749 0.270, 0.283 
    SNP-by-AO Inter -0.162, 0.572 -0.269, 0.275 0.095, 0.637 0.098, 0.661 -0.235, 0.294 0.031, 0.890 0.083, 0.535 0.142, 0.530 
 
BIRC5rs3764383 n=212 n=212 n=213 n=212 n=213 n=213 n=213 n=213 
  Main Effects Model         
    SNP Main Effect 0.149, 0.236 -0.165, 0.143 0.114, 0.199 -0.113, 0.250 -0.044, 0.662 0.192, 0.047* 0.107, 0.057 0.148, 0.140 
  Interaction Model         
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    SNP Main Effect 0.238, 0.235 -0.090, 0.614 -0.012, 0.931 -0.279, 0.078 -0.117, 0.462 0.183, 0.238 0.083, 0.369 -0.025, 0.875 
    SNP-by-CA Inter -0.328, 0.293 0.094, 0.735 0.212, 0.338 0.122, 0.617 0.391, 0.112 0.030, 0.899 0.039, 0.786 0.337, 0.174 
    SNP-by-AO Inter -0.008, 0.978 -0.268, 0.285 0.185, 0.356 0.346, 0.118 -0.089, 0.692 0.003, 0.991 0.062, 0.634 0.203, 0.366 
 
BIRC5rs8073069 n=206 n=206 n=207 n=206 n=207 n=207 n=207 n=207 
  Main Effects Model         
    SNP Main Effect 0.094, 0.461 -0.091, 0.421 0.067, 0.444 0.042, 0.677 -0.025, 0.803 -0.028, 0.775 -0.099, 0.118 -0.134, 0.168 
  Interaction Model         
    SNP Main Effect 0.338, 0.104 0.051, 0.780 0.056, 0.694 0.176, 0.287 -0.061, 0.707 -0.266, 0.097 -0.071, 0.488 -0.244, 0.119 
    SNP-by-CA Inter -0.280, 0.416 -0.331, 0.278 -0.037, 0.874 -0.243, 0.371 -0.179, 0.508 0.266, 0.315 -0.022, 0.898 0.263, 0.308 
    SNP-by-AO Inter -0.454, 0.131 -0.163, 0.538 0.044, 0.829 -0.184, 0.437 0.220, 0.353 0.442, 0.057 -0.061, 0.683 0.061, 0.786 
 
BIRC5rs8073903 n=211 n=212 n=212 n=211 n=212 n=212 n=212 n=212 
  Main Effects Model         
    SNP Main Effect 0.047, 0.710 0.059, 0.586 0.025, 0.773 0.163, 0.092 0.005, 0.961 -0.030, 0.754 -0.065, 0.257 -0.025, 0.800 
  Interaction Model         
    SNP Main Effect 0.048, 0.811 0.133, 0.452 -0.042, 0.766 0.291, 0.061 -0.145, 0.358 -0.215, 0.165 -0.133, 0.162 -0.163, 0.296 
    SNP-by-CA Inter -0.068, 0.834 -0.109, 0.699 0.082, 0.718 -0.261, 0.292 0.135, 0.593 0.266, 0.285 0.201, 0.186 0.400, 0.111 
    SNP-by-AO Inter 0.046, 0.878 -0.131, 0.616 0.126, 0.549 -0.155, 0.500 0.349, 0.137 0.306, 0.183 0.042, 0.767 0.027, 0.908 
 
BIRC5rs9904341 n=205 n=205 n=206 n=205 n=206 n=206 n=206 n=206 
  Main Effects Model         
    SNP Main Effect -0.169, 0.172 0.064, 0.573 -0.021, 0.810 -0.060, 0.543 0.030, 0.762 -0.091, 0.350 -0.060, 0.320 -0.052, 0.592 
  Interaction Model         
    SNP Main Effect -0.173, 0.378 0.051, 0.773 0.171, 0.210 -0.045, 0.774 0.165, 0.292 0.078, 0.610 0.007, 0.943 0.139, 0.354 
    SNP-by-CA Inter 0.037, 0.910 -0.231, 0.436 -0.362, 0.109 0.036, 0.890 -0.381, 0.143 -0.279, 0.272 -0.091, 0.549 -0.510, 0.041* 
    SNP-by-AO Inter -0.010, 0.971 0.190, 0.458 -0.283, 0.148 -0.063, 0.780 -0.145, 0.519 -0.258, 0.243 -0.129, 0.324 -0.150, 0.488 
 
CCNB1rs164390 n=213 n=214 n=214 n=213 n=214 n=214 n=214 n=214 
  Main Effects Model         
    SNP Main Effect 0.010, 0.939 -0.230, 0.035* -0.048, 0.582 -0.060, 0.538 -0.002, 0.986 0.014, 0.883 -0.010, 0.859 0.237, 0.016* 
  Interaction Model         
    SNP Main Effect 0.196, 0.323 -0.167, 0.334 0.280, 0.039* -0.116, 0.457 0.016, 0.921 0.299, 0.052 0.099, 0.298 0.581, <0.001* 
    SNP-by-CA Inter -0.046, 0.884 -0.153, 0.573 -0.478, 0.026* 0.281, 0.252 0.054, 0.831 -0.355, 0.143 -0.147, 0.327 -0.549, 0.025* 
    SNP-by-AO Inter -0.498, 0.085 -0.054, 0.829 -0.551, 0.006* -0.067, 0.767 -0.097, 0.678 -0.518, 0.021* -0.196, 0.156 -0.540, 0.017* 
 
CCNB1rs350099 n=215 n=215 n=216 n=215 n=216 n=216 n=216 n=216 
  Main Effects Model         
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    SNP Main Effect -0.013, 0.918 -0.246, 0.026* -0.044, 0.618 -0.092, 0.343 0.030, 0.759 -0.027, 0.778 -0.050, 0.398 0.185, 0.059 
  Interaction Model         
    SNP Main Effect 0.194, 0.332 -0.155, 0.377 0.236, 0.087 -0.125, 0.427 0.044, 0.782 0.350, 0.024* 0.069, 0.475 0.562, <0.001* 
    SNP-by-CA Inter -0.132, 0.676 -0.162, 0.556 -0.345, 0.110 0.269, 0.273 0.001, 0.996 -0.445, 0.065 -0.118, 0.432 -0.553, 0.024* 
    SNP-by-AO Inter -0.492, 0.089 -0.131, 0.606 -0.507, 0.011* -0.121, 0.592 -0.036, 0.875 -0.685, 0.002* -0.244, 0.079 -0.608, 0.008* 
 
CCNB1rs350104 n=218 n=218 n=219 n=218 n=219 n=219 n=219 n=219 
  Main Effects Model         
    SNP Main Effect 0.056, 0.677 0.053, 0.657 0.028, 0.763 0.144, 0.168 -0.102, 0.328 -0.069, 0.505 0.013, 0.843 -0.015, 0.889 
  Interaction Model         
    SNP Main Effect -0.178, 0.448 -0.023, 0.915 -0.225, 0.177 0.104, 0.575 -0.154, 0.401 -0.441, 0.016* -0.153, 0.176 -0.475, 0.009* 
    SNP-by-CA Inter 0.174, 0.620 0.122, 0.702 0.128, 0.606 -0.001, 0.998 0.295, 0.282 0.564, 0.039* 0.193, 0.251 0.631, 0.020* 
    SNP-by-AO Inter 0.446, 0.150 0.106, 0.706 0.470, 0.032* 0.095, 0.698 -0.063, 0.794 0.516, 0.032* 0.297, 0.045* 0.699, 0.004* 
 
CD68rs8066665 n=219 n=219 n=220 n=219 n=220 n=220 n=220 n=220 
  Main Effects Model         
    SNP Main Effect 0.042, 0.741 -0.130, 0.250 0.021, 0.815 0.040, 0.688 -0.048, 0.630 -0.056, 0.574 0.012, 0.835 -0.044, 0.660 
  Interaction Model         
    SNP Main Effect -0.012, 0.959 -0.289, 0.142 0.120, 0.438 -0.027, 0.878 -0.142, 0.414 -0.252, 0.147 -0.084, 0.433 -0.220, 0.205 
    SNP-by-CA Inter -0.159, 0.633 0.168, 0.570 -0.336, 0.149 -0.163, 0.534 0.023, 0.928 0.364, 0.163 0.143, 0.374 0.275, 0.292 
    SNP-by-AO Inter 0.235, 0.428 0.295, 0.263 -0.032, 0.876 0.273, 0.248 0.237, 0.311 0.250, 0.284 0.153, 0.289 0.247, 0.289 
 
CD68rs9901673  n=217 n=217 n=218 n=218 n=218 n=218 n=218 n=218 
  Main Effects Model         
    SNP Main Effect 0.069, 0.595 0.005, 0.967 0.070, 0.453 0.013, 0.901 0.036, 0.733 0.098, 0.338 0.064, 0.306 0.100, 0.337 
  Interaction Model         
    SNP Main Effect 0.176, 0.427 -0.020, 0.920 0.114, 0.458 0.078, 0.656 0.104, 0.559 0.446, 0.010* 0.128, 0.242 0.412, 0.019* 
    SNP-by-CA Inter -0.202, 0.537 0.035, 0.905 0.315, 0.163 -0.273, 0.287 -0.169, 0.519 -0.444, 0.078 -0.191, 0.234 -0.439, 0.087 
    SNP-by-AO Inter -0.141, 0.646 0.052, 0.853 -0.331, 0.121 0.038, 0.877 -0.060, 0.809 -0.555, 0.020* -0.011, 0.940 -0.498, 0.040* 
 
CENPArs3806517 n=214 n=214 n=215 n=214 n=215 n=215 n=215 n=215 
  Main Effects Model         
    SNP Main Effect 0.028, 0.817 -0.127, 0.252 -0.021, 0.801 -0.002, 0.980 0.009, 0.922 -0.020, 0.831 -0.004, 0.951 0.070, 0.457 
  Interaction Model         
    SNP Main Effect -0.229, 0.247 -0.363, 0.039* 0.107, 0.443 0.008, 0.958 -0.118, 0.449 -0.196, 0.205 -0.013, 0.890 0.074, 0.622 
    SNP-by-CA Inter 0.237, 0.471 0.056, 0.849 -0.143, 0.539 0.039, 0.881 0.291, 0.264 0.353, 0.171 -0.024, 0.879 0.283, 0.259 
    SNP-by-AO Inter 0.538, 0.052 0.615, 0.012* -0.231, 0.238 -0.050, 0.820 0.171, 0.432 0.226, 0.296 0.042, 0.750 -0.193, 0.357 
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CENPArs3806518 n=213 n=213 n=214 n=213 n=214 n=214 n=214 n=214 
  Main Effects Model         
    SNP Main Effect 0.011, 0.927 0.017, 0.877 -0.005, 0.956 -0.044, 0.639 0.050, 0.601 -0.019, 0.838 -0.023, 0.684 0.025, 0.792 
  Interaction Model         
    SNP Main Effect 0.136, 0.493 -0.103, 0.561 -0.101, 0.457 -0.195, 0.211 -0.148, 0.335 0.282, 0.063 0.046, 0.630 0.139, 0.369 
    SNP-by-CA Inter -0.395, 0.212 0.312, 0.270 0.011, 0.960 0.368, 0.135 0.079, 0.745 -0.501, 0.037* -0.086, 0.572 -0.340, 0.167 
    SNP-by-AO Inter -0.058, 0.834 0.078, 0.753 0.226, 0.230 0.130, 0.548 0.507, 0.018* -0.423, 0.045* -0.140, 0.294 -0.047, 0.828 
 
CMC2rs1025065 n=208 n=208 n=209 n=208 n=209 n=209 n=209 n=209 
  Main Effects Model         
    SNP Main Effect -0.128, 0.298 0.057, 0.603 0.002, 0.983 0.019, 0.845 0.178, 0.175 -0.109, 0.257 0.046, 0.421 -0.022, 0.818 
  Interaction Model         
    SNP Main Effect -0.217, 0.291 0.135, 0.463 0.038, 0.793 0.019, 0.907 0.084, 0.607 -0.218, 0.172 0.032, 0.741 -0.088, 0.580 
    SNP-by-CA Inter -0.141, 0.660 -0.048, 0.868 -0.275, 0.216 -0.138, 0.581 0.144, 0.566 0.260, 0.294 0.026, 0.865 0.190, 0.444 
    SNP-by-AO Inter 0.363, 0.216 -0.195, 0.459 0.088, 0.667 0.107, 0.641 -0.190, 0.412 0.099, 0.663 0.015, 0.913 0.029, 0.898 
 
CMC2rs1981867 n=219 n=219 n=220 n=219 n=220 n=220 n=220 n=220 
  Main Effects Model         
    SNP Main Effect -0.136, 0.253 -0.197, 0.058 0.022, 0.792 0.059, 0.526 -0.091, 0.326 0.060, 0.512 0.061, 0.279 0.094, 0.310 
  Interaction Model         
    SNP Main Effect -0.221, 0.262 0.018, 0.914 0.069, 0.617 0.147, 0.342 -0.031, 0.839 0.172, 0.258 0.020, 0.832 0.009, 0.951 
    SNP-by-CA Inter 0.153, 0.621 -0.300, 0.264 0.045, 0.835 -0.227, 0.350 0.035, 0.884 -0.182, 0.447 0.073, 0.617 -0.024, 0.920 
    SNP-by-AO Inter 0.121, 0.662 -0.363, 0.127 -0.137, 0.478 -0.069, 0.751 -0.201, 0.354 -0.160, 0.453 0.061, 0.640 0.239, 0.265 
 
CMC2rs9936489 n=214 n=214 n=215 n=214 n=215 n=215 n=215 n=215 
  Main Effects Model         
    SNP Main Effect 0.151, 0.213 -0.113, 0.302 -0.026, 0.757 -0.048, 0.618 -0.037, 0.705 -0.071, 0.451 0.030, 0.600 -0.057, 0.544 
  Interaction Model         
    SNP Main Effect 0.264, 0.183 -0.186, 0.300 -0.147, 0.293 0.051, 0.743 0.065, 0.676 -0.135, 0.377 -0.008, 0.932 -0.061, 0.693 
    SNP-by-CA Inter -0.131, 0.681 0.082, 0.777 0.281, 0.209 -0.115, 0.646 -0.365, 0.146 -0.053, 0.828 0.066, 0.662 -0.149, 0.545 
    SNP-by-AO Inter -0.220, 0.437 0.147, 0.567 0.141, 0.481 -0.185, 0.408 -0.013, 0.953 0.197, 0.367 0.054, 0.689 0.127, 0.563 
 
CTSL2rs16919034 n=212 n=213 n=213 n=212 n=213 n=213 n=213 n=213 
  Main Effects Model         
    SNP Main Effect 0.112, 0.397 -0.058, 0.611 -0.027, 0.768 -0.090, 0.378 0.002, 0.987 -0.120, 0.242 -0.007, 0.909 0.112, 0.286 
  Interaction Model         
    SNP Main Effect 0.007, 0.974 0.226, 0.236 -0.243, 0.110 -0.094, 0.582 -0.023, 0.894 -0.429, 0.011* -0.043, 0.678 0.046, 0.791 
    SNP-by-CA Inter 0.339, 0.320 -0.309, 0.295 0.216, 0.357 0.038, 0.886 -0.084, 0.756 0.134, 0.603 0.000, 0.998 -0.147, 0.582 
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    SNP-by-AO Inter 0.046, 0.882 -0.529, 0.054 0.408, 0.061 -0.017, 0.944 0.149, 0.552 0.696, 0.004* 0.109, 0.462 0.290, 0.243 
         
CTSL2rs4361859 n=218 n=218 n=219 n=218 n=219 n=219 n=219 n=219 
  Main Effects Model         
    SNP Main Effect -0.029, 0.807 -0.029, 0.787 0.025, 0.766 0.068, 0.460 -0.002, 0.987 0.007, 0.942 -0.027, 0.622 -0.045, 0.627 
  Interaction Model         
    SNP Main Effect 0.016, 0.934 0.066, 0.709 0.272, 0.045* 0.044, 0.771 0.077, 0.618 0.162, 0.287 0.094, 0.315 -0.072, 0.639 
    SNP-by-CA Inter -0.505, 0.099 -0.176, 0.531 -0.433, 0.044* -0.240, 0.318 -0.234, 0.343 -0.207, 0.392 -0.173, 0.242 0.069, 0.779 
    SNP-by-AO Inter 0.274, 0.307 -0.115, 0.640 -0.341, 0.072 0.252, 0.233 -0.038, 0.862 -0.255, 0.232 -0.207, 0.114 0.015, 0.945 
 
DIAPH3rs1337652 n=216 n=216 n=217 n=216 n=217 n=217 n=217 n=217 
  Main Effects Model         
    SNP Main Effect -0.069, 0.582 0.130, 0.247 -0.163, 0.063 0.018, 0.857 -0.141, 0.157 -0.048, 0.624 -0.126, 0.032* -0.090, 0.365 
  Interaction Model         
    SNP Main Effect -0.049, 0.807 0.006, 0.973 -0.295, 0.036* 0.362, 0.021* -0.161, 0.313 0.037, 0.815 -0.187, 0.048* 0.095, 0.550 
    SNP-by-CA Inter 0.456, 0.174 0.093, 0.759 0.405, 0.084 -0.361, 0.166 0.333, 0.212 0.040, 0.880 0.305, 0.055 0.002, 0.995 
    SNP-by-AO Inter -0.312, 0.255 0.268, 0.281 0.129, 0.503 -0.620, 0.004* -0.135, 0.539 -0.213, 0.329 -0.054, 0.676 -0.446, 0.042* 
 
DIAPH3rs4547237 n=219 n=219 n=220 n=219 n=220 n=220 n=220 n=220 
  Main Effects Model         
    SNP Main Effect 0.147, 0.212 -0.035, 0.738 0.185, 0.024* 0.023, 0.802 0.157, 0.088 0.198, 0.030* 0.084, 0.127 0.195, 0.034* 
  Interaction Model         
    SNP Main Effect 0.081, 0.679 -0.273, 0.118 0.410, 0.002* -0.130, 0.406 0.095, 0.537 0.355, 0.018* 0.194, 0.039* 0.229, 0.134 
    SNP-by-CA Inter 0.102, 0.742 0.053, 0.847 -0.280, 0.184 0.208, 0.394 0.090, 0.709 -0.090, 0.702 -0.109, 0.456 -0.129, 0.593 
    SNP-by-AO Inter 0.105, 0.704 0.610, 0.014* -0.389, 0.040* 0.234, 0.285 0.114, 0.597 -0.337, 0.111 -0.225, 0.088 0.002, 0.991 
 
ERBB2rs1058808 n=216 n=216 n=217 n=216 n=217 n=217 n=217 n=217 
  Main Effects Model         
    SNP Main Effect 0.059, 0.627 0.030, 0.784 -0.023, 0.788 0.041, 0.668 0.044, 0.642 0.035, 0.711 0.001, 0.981 -0.061, 0.525 
  Interaction Model         
    SNP Main Effect -0.133, 0.507 0.079, 0.658 0.030, 0.829 0.050, 0.748 0.090, 0.573 0.169, 0.281 -0.064, 0.506 0.101, 0.523 
    SNP-by-CA Inter 0.360, 0.259 -0.105, 0.713 -0.137, 0.538 0.266, 0.280 0.192, 0.446 -0.081, 0.745 0.109, 0.470 -0.206, 0.409 
    SNP-by-AO Inter 0.266, 0.340 -0.058, 0.815 -0.045, 0.819 -0.195, 0.366 -0.261, 0.241 -0.275, 0.208 -0.560, 0.268 -0.270, 0.220 
 
ERBB2rs1136201 n=219 n=219 n=220 n=219 n=220 n=220 n=220 n=220 
  Main Effects Model         
    SNP Main Effect 0.016, 0.896 -0.034, 0.756 0.076, 0.371 -0.010, 0.920 -0.035, 0.716 -0.074, 0.435 -0.064, 0.265 -0.181, 0.056 
  Interaction Model         
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    SNP Main Effect 0.252, 0.205 0.159, 0.372 0.027, 0.847 -0.086, 0.588 -0.094, 0.549 -0.246, 0.111 -0.119, 0.203 -0.205, 0.187 
    SNP-by-CA Inter -0.260, 0.411 -0.169, 0.553 0.239, 0.283 0.036, 0.885 0.108, 0.666 0.213, 0.384 0.119, 0.423 0.223, 0.367 
    SNP-by-AO Inter -0.451, 0.116 -0.383, 0.135 -0.015, 0.940 0.163, 0.471 0.091, 0.687 0.296, 0.181 0.067, 0.615 -0.085, 0.703 
 
ERBB2rs1476278 n=219 n=219 n=220 n=219 n=220 n=220 n=220 n=220 
  Main Effects Model         
    SNP Main Effect 0.033, 0.783 -0.028, 0.797 -0.041, 0.629 -0.019, 0.838 0.025, 0.792 0.040, 0.665 0.016, 0.775 -0.023, 0.811 
  Interaction Model         
    SNP Main Effect -0.141, 0.485 0.090, 0.620 0.008, 0.952 0.042, 0.791 0.136, 0.385 0.130, 0.405 -0.064, 0.508 0.114, 0.471 
    SNP-by-CA Inter 0.334, 0.295 -0.126, 0.659 -0.256, 0.249 0.192, 0.437 0.032, 0.898 -0.027, 0.912 0.114, 0.456 -0.130, 0.597 
    SNP-by-AO Inter 0.228, 0.413 -0.227, 0.365 0.028, 0.885 -0.272, 0.211 -0.333, 0.126 -0.199, 0.359 0.138, 0.305 -0.255, 0.242 
 
ERBB2rs1810132 n=211 n=212 n=212 n=211 n=212 n=212 n=212 n=212 
  Main Effects Model         
    SNP Main Effect 0.110, 0.371 0.097, 0.367 -0.001, 0.993 0.040, 0.670 0.124, 0.194 0.073, 0.442 0.015, 0.794 -0.013, 0.890 
  Interaction Model         
    SNP Main Effect -0.025, 0.901 0.191, 0.274 0.080, 0.562 0.164, 0.275 0.182, 0.242 0.114, 0.457 -0.048, 0.611 0.072, 0.648 
    SNP-by-CA Inter 0.319, 0.316 -0.070, 0.802 -0.136, 0.535 0.094, 0.694 0.128, 0.606 0.168, 0.492 0.177, 0.237 -0.071, 0.777 
    SNP-by-AO Inter 0.130, 0.644 -0.215, 0.386 -0.110, 0.575 -0.398, 0.063 -0.267, 0.229 -0.223, 0.307 0.035, 0.795 -0.183, 0.414 
 
ERBB2rs2517955 n=219 n=219 n=220 n=219 n=220 n=220 n=220 n=220 
  Main Effects Model         
    SNP Main Effect 0.022, 0.858 0.020, 0.850 -0.074, 0.383 0.011, 0.910 0.026, 0.786 0.018, 0.845 -0.011, 0.841 -0.047, 0.618 
  Interaction Model         
    SNP Main Effect -0.140, 0.486 0.086, 0.635 0.007, 0.960 0.040, 0.799 0.135, 0.390 0.130, 0.406 -0.058, 0.543 0.110, 0.483 
    SNP-by-CA Inter 0.347, 0.279 -0.137, 0.632 -0.273, 0.220 0.264, 0.285 0.024, 0.923 -0.068, 0.784 0.055, 0.715 -0.205, 0.408 
    SNP-by-AO Inter 0.191, 0.493 -0.075, 0.765 -0.042, 0.829 -0.241, 0.265 -0.320, 0.142 -0.226, 0.299 0.085, 0.519 -0.258, 0.236 
 
ERBB2rs4252596 n=219 n=219 n=220 n=219 n=220 n=220 n=220 n=220 
  Main Effects Model         
    SNP Main Effect -0.134, 0.343 -0.033, 0.791 0.033, 0.742 -0.005, 0.966 0.065, 0.553 0.078, 0.477 0.043, 0.515 0.039, 0.726 
  Interaction Model         
    SNP Main Effect -0.124, 0.564 -0.037, 0.850 0.056, 0.710 0.018, 0.919 -0.051, 0.759 0.000. 0.999 0.085, 0.403 0.082, 0.631 
    SNP-by-CA Inter -0.169, 0.673 0.197, 0.568 0.059, 0.828 -0.430, 0.158 -0.085, 0.776 0.071, 0.812 -0.047, 0.797 -0.120, 0.692 
    SNP-by-AO Inter 0.076, 0.811 -0.110, 0.703 -0.091, 0.683 0.164, 0.511 0.376, 0.126 0.154, 0.531 -0.105, 0.482 -0.040, 0.872 
 
ERBB2rs903501 n=210 n=211 n=211 n=211 n=211 n=211 n=211 n=211 
  Main Effects Model         
120 
    SNP Main Effect 0.051, 0.676 0.072, 0.506 -0.035, 0.687 -0.039, 0.687 0.054, 0.588 0.098, 0.302 0.031, 0.595 0.004, 0.966 
  Interaction Model         
    SNP Main Effect -0.050, 0.807 0.258, 0.155 -0.010, 0.943 0.072, 0.644 0.177, 0.282 0.174, 0.272 -0.064, 0.513 0.048, 0.770 
    SNP-by-CA Inter 0.293, 0.361 -0.193, 0.497 -0.119, 0.599 0.121, 0.623 0.016, 0.950 0.048, 0.847 0.182, 0.235 0.062, 0.809 
    SNP-by-AO Inter 0.055, 0846 -0.362, 0.148 0.012, 0.954 -0.366, 0.092 -0.353, 0.120 -0.220, 0.316 0.121, 0.369 -0.159, 0.483 
 
ERBB2rs9303274 n=218 n=218 n=219 n=218 n=219 n=219 n=219 n=219 
  Main Effects Model         
    SNP Main Effect 0.032, 0.790 -0.010, 0.926 -0.054, 0.526 -0.010, 0.912 0.042, 0.657 0.030, 0.745 0.008, 0.888 -0.021, 0.826 
  Interaction Model         
    SNP Main Effect -0.144, 0.475 0.091, 0.616 0.011, 0.935 0.039, 0.804 0.127, 0.416 0.131, 0.402 -0.065, 0.508 0.114, 0.472 
    SNP-by-CA Inter 0.336, 0.291 -0.127, 0.657 -0.257, 0.247 0.194, 0.432 0.041, 0.867 -0.027, 0.911 0.114, 0.459 -0.130, 0.600 
    SNP-by-AO Inter 0.231, 0.406 -0.184, 0.465 -0.009, 0.965 -0.249, 0.255 -0.269, 0.215 -0.228, 0.296 0.117, 0.388 -0.252, 0.250 
 
MIR125Ars12976445 n=219 n=219 n=220 n=219 n=220 n=220 n=220 n=220 
  Main Effects Model         
    SNP Main Effect -0.288, 0.016* 0.073, 0.497 0.047, 0.580 -0.223, 0.017* -0.074, 0.434 0.020, 0.834 -0.023, 0.679 0.038, 0.688 
  Interaction Model         
    SNP Main Effect -0.619, 0.001* 0.102, 0.565 -0.126, 0.365 -0.456, 0.003* -0.121, 0.443 -0.017, 0.911 -0.079, 0.391 -0.050, 0.749 
    SNP-by-CA Inter 0.643, 0.032* -0.157, 0.573 0.257, 0.238 0.326, 0.168 0.010, 0.968 0.022, 0.927 0.267, 0.065 0.152, 0.532 
    SNP-by-AO Inter 0.439, 0.099 0.047, 0.849 0.266, 0.171 0.364, 0.085 0.133, 0.544 0.076, 0.723 -0.060, 0.644 0.109, 0.616 
 
ESR1rs10484919 n=203 n=203 n=204 n=203 n=204 n=204 n=204 n=204 
  Main Effects Model         
    SNP Main Effect -0.037, 0.831 -0.004, 0.976 -0.136, 0.255 0.043, 0.745 -0.221, 0.106 -0.449, 0.001* -0.107, 0.208 -0.170, 0.202 
  Interaction Model         
    SNP Main Effect -0.120, 0.655 0.158, 0.502 -0.329, 0.073 0.157, 0.448 -0.054, 0.799 -0.646, 0.001* -0.214, 0.094 -0.267, 0.194 
    SNP-by-CA Inter 0.310, 0.569 -0.472, 0.325 0.281, 0.451 -0.105, 0.803 -0.262, 0.542 -0.382, 0.330 -0.211, 0.414 -0.180, 0.666 
    SNP-by-AO Inter 0.073, 0.846 -0.202, 0.541 0.340, 0.188 -0.199, 0.494 -0.357, 0.231 0.509, 0.062 0.319, 0.075 0.281, 0.330 
 
ESR1rs1062577 n=214 n=214 n=215 n=214 n=215 n=215 n=215 n=215 
  Main Effects Model         
    SNP Main Effect -0.085, 0.610 0.312, 0.035* -0.143, 0.225 0.058, 0.656 0.004, 0.979 -0.119, 0.360 -0.039, 0.761b -0.119, 0.369 
  Interaction Model         
    SNP Main Effect -0.023, 0.927 0.380, 0.087 0.131, 0.450 -0.244, 0.211 -0.116, 0.558 -0.018, 0.926 -0.077, 0.525 -0.008,0.970 
    SNP-by-CA Inter 0.071, 0.869 -0.355, 0.354 -0.696,0.021* 0.646, 0.056 -0.183, 0.594 -0.250, 0.461 -0.074, 0.726 -0.343, 0.317 
    SNP-by-AO Inter -0.270, 0.485 0.071, 0.834 -0.352, 0.189 0.378, 0.208 0.599, 0.051 -0.111, 0.714 0.151, 0.420 -0.007, 0.402 
 
121 
ESR1rs11964281 n=213 n=214 n=214 n=213 n=214 n=214 n=214 n=214 
  Main Effects Model         
    SNP Main Effect -0.086, 0.614 -0.031, 0.834 0.089, 0.458 -0.004, 0.974 0.168, 0.218 -0.050, 0.706 0.136, 0.083 -0.014, 0.919 
  Interaction Model         
    SNP Main Effect 0.049, 0.855 -0.167, 0.476 0.282, 0.126 -0.053, 0.798 0.263, 0.216 0.254, 0.217 0.160, 0.194 0.266, 0.203 
    SNP-by-CA Inter 0.069, 0.869 0.412, 0.264 -0.069, 0.813 0.065, 0.842 -0.084, 0.802 -0.438, 0.177 -0.366, 0.850 -0.358, 0.278 
    SNP-by-AO Inter -0.535, 0.190 0.033, 0.927 -0.530, 0.062 0.098, 0.759 -0.300, 0.357 -0.461, 0.145 -0.041, 8.827 -0.487, 0.131 
 
ESR1rs12173570 n=218 n=218 n=219 n=218 n=219 n=219 n=219 n=219 
  Main Effects Model         
    SNP Main Effect -0.025, 0.854 -0.021, 0.866 -0.134, 0.158 0.008, 0.940 -0.051, 0.633 -0.209, 0.048* -0.001, 0.986 -0.044, 0.684 
  Interaction Model         
    SNP Main Effect -0.306, 0.154 0.235, 0.221 -0.232, 0.123 0.031, 0.854 0.013, 0.938 -0.269, 0.106 0.012, 0.906 0.003, 0.987 
    SNP-by-CA Inter 0.408, 0.262 -0.237, 0.467 0.141, 0.580 0.098, 0.732 0.065, 0.821 -0.067, 0.813 -0.251, 0.139 -0.054, 0.850 
    SNP-by-AO Inter 0.517, 0.091 -0.551, 0.045 0.171, 0.424 -0.116, 0.633 -0.239, 0.327 0.177, 0.454 0.163, 0.251 -0.083, 0.733 
 
ESR1rs12665044 n=212 n=213 n=213 n=212 n=213 n=213 n=213 n=213 
  Main Effects Model         
    SNP Main Effect -0.131, 0.368 -0.040, 0.753 -0.019, 0.850 -0.047, 0.676 0.018, 0.879 -0.049, 0.661 -0.010, 0.887 -0.105, 0.366 
  Interaction Model         
    SNP Main Effect -0.054, 0.801 -0.057, 0.763 -0.040, 0.789 -0.083, 0.624 0.028, 0.872 0.220, 0.186 -0.025, 0.810 -0.020, 0.905 
    SNP-by-CA Inter 0.012, 0.972 0.173, 0.578 0.149, 0.546 0.099, 0.718 0.060, 0.831 -0.353, 0.196 0.027, 0.871 -0.110, 0.692 
    SNP-by-AO Inter -0.295, 0.387 -0.125, 0.679 -0.067, 0.781 0.013, 0.960 -0.098, 0.716 -0.534, 0.044* 0.031, 0.847 -0.177, 0.512 
 
ESR1rs1514348 n=219 n=219 n=220 n=219 n=220 n=220 n=220 n=220 
  Main Effects Model         
    SNP Main Effect -0.089, 0.502 -0.189, 0.106 -0.002, 0.987 -0.129, 0.212 -0.111, 0.282 0.136, 0.184 0.034, 0.587 0.058, 0.571 
  Interaction Model         
    SNP Main Effect -0.028, 0.889 -0.040, 0.824 -0.028, 0.845 -0.208, 0.187 -0.070, 0.656 0.139, 0.371 0.063, 0.506 -0.058, 0.715 
    SNP-by-CA Inter -0.228, 0.527 -0.161, 0.614 -0.038, 0.881 0.199, 0.479 -0.245, 0.386 -0.026, 0.926 -0.152, 0.372 0.030, 0.915 
    SNP-by-AO Inter -0.022, 0.942 -0.321, 0.234 0.097, 0.648 0.093, 0.694 0.024, 0.917 0.003, 0.990 0.015, 0.914 0.292, 0.219 
 
ESR1rs1801132 n=219 n=219 n=220 n=219 n=220 n=220 n=220 n=220 
  Main Effects Model         
    SNP Main Effect -0.151, 0.208 0.117, 0.277 0.069, 0.412 -0.070, 0.459 0.022, 0.820 0.127, 0.175 -0.012, 0.828 0.095, 0.314 
  Interaction Model         
    SNP Main Effect -0.148, 0.457 0.389, 0.029* 0.095, 0.497 -0.232, 0,141 0.037, 0.814 0.162, 0.297 -0.035, 0.710 -0.096, 0.538 
    SNP-by-CA Inter 0.246, 0.432 -0.338, 0.228 -0.091, 0.681 0.321, 0.194  0.106, 0.666 0.035, 0.886 -0.009, 0.952 0.136, 0.580 
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    SNP-by-AO Inter -0.202, 0.468 -0.490, 0.050 -0.008, 0.969 0.184, 0.404 -0.141, 0.521 -0.116, 0.594 0.088, 0.509 0.402, 0.068 
 
ESR1rs1884051 n=206 n=207 n=207 n=206 n=207 n=207 n=207 n=207 
  Main Effects Model         
    SNP Main Effect -0.212, 0.091 -0.076, 0.485 0.062, 0.479 -0.108, 0.273 -0.048, 0.627 0.153, 0.123 -0.016, 0.782 0.137, 0.172 
  Interaction Model         
    SNP Main Effect -0.128, 0.526 -0.113, 0.525 0.071, 0.620 -0.198, 0.221 -0.027, 0.861 0.193, 0.230 -0.015, 0.884 0.125, 0.448 
    SNP-by-CA Inter 0.259, 0.430 0.105, 0.715 -0.095, 0.682 0.272, 0.293 0.322, 0.202 0.017, 0.946 0.923, 0.565 0.022, 0.933 
    SNP-by-AO Inter -0.395, 0.164 0.019, 0.938 0.032, 0.871 0.036, 0.872 -0.291, 0.184 -0.113, 0.615 -0.065, 0.640 0.016, 0.945 
 
ESR1rs2046210 n=212 n=213 n=213 n=212 n=213 n=213 n=213 n=213 
  Main Effects Model         
    SNP Main Effect -0.002, 0.987 -0.155, 0.160 0.045, 0.613 0.028, 0.773 0.060, 0.546 -0.008, 0.938 0.078, 0.191 0.124, 0.216 
  Interaction Model         
    SNP Main Effect -0.012, 0.953 0.014, 0.939 0.041, 0.775 -0.028, 0.859 0.021, 0.895 0.106, 0.503 0.043, 0.666 0.135, 0.404 
    SNP-by-CA Inter 0.216, 0.501 -0.371, 0.182 0.118, 0.597 0.239, 0.334 0.128, 0.610 -0.076, 0.759 -0.008, 0.957 0.106, 0.675 
    SNP-by-AO Inter -0.138, 0.635 -0.152, 0.547 -0.069, 0.735 -0.046, 0.838 0.005, 0.984 -0.242, 0.282 0.094, 0.503 -0.141, 0.538 
 
ESR1rs2071454 n=212 n=213 n=213 n=212 n=213 n=213 n=213 n=213 
  Main Effects Model         
    SNP Main Effect -0.125, 0.409 -0.039, 0.771 -0.075, 0.480 -0.178, 0.128 -0.030, 0.800 0.015, 0.901 0.038, 0.586 -0.041, 0.733 
  Interaction Model         
    SNP Main Effect -0.087, 0.691 -0.119, 0.539 -0.075, 0.626 -0.288, 0.092 0.042, 0.810 0.221, 0.197 -0.046, 0.652 0.054, 0.759 
    SNP-by-CA Inter 0.031, 0.933 0.320, 0.328 0.147, 0.574 0.209, 0.467 -0.013, 0.964 -0.300, 0.298 0.131, 0.449 -0.164, 0.577 
    SNP-by-AO Inter -0.177, 0.623 -0.044, 0.889 -0.126, 0.618 0.202, 0.468 -0.257, 0.367 -0.393, 0.161 0.197, 0.243 -0.143, 0.617 
 
ESR1rs2077647 n=216 n=216 n=217 n=216 n=217 n=217 n=217 n=217 
  Main Effects Model         
    SNP Main Effect -0.055, 0.698 0.049, 0.698 0.131, 0.188 0.012, 0.914 0.127, 0.259 0.033, 0.769 -0.016, 0.804 0.049, 0.665 
  Interaction Model         
    SNP Main Effect -0.155, 0.503 -0.069, 0.738 0.227, 0.158 0.225, 0.218 0.057, 0.752 0.231, 0.198 0.071, 0.500 -0.020, 0.912 
    SNP-by-CA Inter 0.308, 0.418 -0.027, 0.937 -0.080, 0.759 -0.503, 0.088 -0.103, 0.728 -0.172, 0.556 0.174, 0.314 0.343, 0.250 
    SNP-by-AO Inter 0.089, 0.785 0.347, 0.232 -0.192, 0.395 -0.168, 0.507 0.329, 0.197 -0.400, 0.112 -0.341, 0.022* -0.055, 0.830 
 
ESR1rs2228480 n=217 n=217 n=218 n=217 n=218 n=218 n=218 n=218 
  Main Effects Model         
    SNP Main Effect 0.083, 0.501 -0.175, 0.107 0.086, 0.316 0.143, 0.138 -0.157, 0.103 0.010, 0.917 0.042, 0.481 0.054, 0.582 
  Interaction Model         
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    SNP Main Effect -0.042, 0.835 -0.079, 0.662 0.097, 0.492 0.087, 0.585 -0.289, 0.068 -0.042, 0.791 -0.001, 0.990 0.116, 0473 
    SNP-by-CA Inter 0.199, 0.536 -0.153, 0.591 0.186, 0.406 -0.103, 0.682 0.381, 0.127 0.114, 0.652 0.114, 0.461 0.037, 0.884 
    SNP-by-AO Inter 0.193, 0.501 -0.140, 0.580 -0.135, 0.498 0.214, 0.339 0.081, 0.717 0.056, 0.803 0.024, 0.859 -0.204, 0.369 
 
ESR1rs2234693 n=205 n=205 n=206 n=205 n=206 n=206 n=206 n=206 
  Main Effects Model         
    SNP Main Effect -0.110, 0.459 0.172, 0.184 0.151, 0.143 0.061, 0.601 0.126, 0.277 0.090, 0.434 -0.043, 0.548 -0.046, 0.698 
  Interaction Model         
    SNP Main Effect -0.181, 0.454 0.053, 0.797 0.432, 0.008* 0.255, 0.175 0.057, 0.758 0.196, 0.298 0.001, 0.991 -0.118, 0.536 
    SNP-by-CA Inter 0.192, 0.649 -0.0296, 0.411 -0.520, 0.068 -0.546, 0.097 -0.153, 0.639 -0.203, 0.538 0.213, 0.286 0.386, 0.249 
    SNP-by-AO Inter 0.084, 0.802 0.485, 0.090 -0.376, 0.096 -0.151, 0.563 0.313, 0.226 -0.160, 0.539 -0.217, 0.171 -0.020, 0.941 
 
ESR1rs2347867 n=214 n=214 n=215 n=214 n=215 n=215 n=215 n=215 
  Main Effects Model         
    SNP Main Effect -0.248, 0.040* 0.000, 0.997 -0.072, 0.396 -0.317, 0.001* -0.227, 0.016* -0.087, 0.358 -0.062, 0.280 -0.019, 0.843 
  Interaction Model         
    SNP Main Effect -0.261, 0.186 0.052, 0.768 -0.155, 0.265 -0.464, 0.002* -0.299, 0.051 -0.031, 0.839 -0.078, 0.402 -0.078, 0.617 
    SNP-by-CA Inter 0.076, 0.811 -0.015, 0.960 0.068, 0.760 0.253, 0.296 0.243, 0.321 -0.072, 0.772 -0.010, 0.946 0.000, 1.000 
    SNP-by-AO Inter -0.016, 0.955 -0.137, 0.584 0.161, 0.409 0.203, 0.341 0.026, 0.904 -0.095, 0.662 0.055, 0.676 0.157, 0.475 
 
ESR1rs2744677 n=214 n=214 n=215 n=214 n=215 n=215 n=215 n=215 
  Main Effects Model         
    SNP Main Effect -0.163, 0.178 0.087, 0.417 0.015, 0.864 -0.091, 0.337 0.109, 0.250 -0.107, 0.248 -0.009, 0.867 -0.139, 0.140 
  Interaction Model         
    SNP Main Effect -0.063, 0.751 0.074, 0.675 0.038, 0.783 0.035, 0.825 0.216, 0.167 0.013, 0.930 0.076, 0.417 -0.190, 0.218 
    SNP-by-CA Inter 0.075, 0.812 -0.140, 0.620 0.251, 0.252 -0.182, 0.464 -0.145, 0.557 -0.011, 0.964 -0.105, 0.483 0.335, 0.172 
    SNP-by-AO Inter -0.317, 0.255 0.136, 0.584 -0.197, 0.310 -0.197, 0.371 -0.174, 0.427 -0.299, 0.168 -0.169, 0.201 -0.099, 0.647 
 
ESR1rs2813543 n=212 n=212 n=213 n=212 n=213 n=213 n=213 n=213 
  Main Effects Model         
    SNP Main Effect 0.149, 0.250 0.163, 0.153 0.079, 0.374 0.109, 0.281 0.079, 0.445 -0.006, 0.952 -0.030, 0.631 0.009, 0.930 
  Interaction Model         
    SNP Main Effect -0.087, 0.688 -0.009, 0.961 0.196, 0.185 0.179, 0.293 -0.025, 0.887 -0.136, 0.416 -0.096, 0.356 0.158, 0.347 
    SNP-by-CA Inter 0.546, 0.103 0.112, 0.702 -0.287, 0.206 -0.054, 0.837 0.207, 0.440 0.195, 0.451 0.099, 0.535 -0.128, 0.621 
    SNP-by-AO Inter 0.231, 0.461 0.398, 0.146 -0.109, 0.609 -0.151, 0.538 0.129, 0.608 0.202, 0.406 0.107, 0.474 -0.314, 0.198 
 
ESR1rs2813544 n=214 n=214 n=215 n=214 n=215 n=215 n=215 n=215 
  Main Effects Model         
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    SNP Main Effect -0.072, 0.559 0.059, 0.588 -0.045, 0.603 -0.090, 0.349 0.034, 0.731 -0.113, 0.243 -0.013, 0.829 -0.045, 0.648 
  Interaction Model         
    SNP Main Effect -0.061, 0.759 -0.078, 0.653 -0.058, 0.680 -0.015, 0.925 0.199, 0.212 -0.085, 0.586 0.046, 0.630 -0.059, 0.710 
    SNP-by-CA Inter 0.343, 0.278 0.433, 0.116 0.090, 0.686 -0.004, 0.986 -0.263, 0.295 0.197, 0.422 0.063, 0.676 0.245, 326 
    SNP-by-AO Inter -0.306, 0.286 0.032, 0.898 -0.024, 0.904 -0.195, 0.390 -0.286, 0.213 -0.209, 0.353 -0.273, 0.049* -0.154, 0.498 
 
ESR1rs2941740 n=219 n=219 n=220 n=219 n=220 n=220 n=220 n=220 
  Main Effects Model         
    SNP Main Effect 0.073, 0.554 0.079, 0.475 -0.052, 0.544 -0.073, 0.451 -0.021, 0.828 -0.009, 0.926 -0.002, 0.975 -0.030, 0.759 
  Interaction Model         
    SNP Main Effect 0.134, 0.513 0.063, 0.732 0.036, 0.799 -0.076, 0.638 0.003, 0.984 -0.318, 0.041* -0.033, 0.726 -0.258, 0.105 
    SNP-by-CA Inter -0.105, 0.753 0.010, 0.972 -0.262, 0.254 0.121, 0.638 0.130, 0.615 0.663, 0.008* 0.294, 0.053 0.554, 0.030* 
    SNP-by-AO Inter -0.093, 0.744 0.036, 0.887 -0.069, 0.729 -0.065, 0.770 -0.150, 0.503 0.351, 0.103 -0.112, 0.395 0.210, 0.338 
 
ESR1rs3020314 n=207 n=207 n=208 n=207 n=208 n=208 n=208 n=208 
  Main Effects Model         
    SNP Main Effect -0.270, 0.034* -0.055, 0.627 0.011, 0.903 -0.137, 0.168 -0.155, 0.111 0.044, 0.652 -0.074, 0.232 0.115, 0.246 
  Interaction Model         
    SNP Main Effect -0.172, 0.405 0.011, 0.954 -0.040, 0.783 -0.256, 0.117 -0.226, 0.152 0.025, 0.879 -0.165, 0.100 0.044, 0.786 
    SNP-by-CA Inter 0.136, 0.695 -0.092, 0.766 -0.024, 0.918 0.212, 0.429 0.311, 0.234 -0.007, 0.979 0.119, 0.473 0.020, 0.941 
    SNP-by-AO Inter -0.310, 0.279 -0.124, 0.625 0.127, 0.522 0.161, 0.474 -0.010, 0.963 0.049, 0.825 0.158, 0.252 0.167, 0.455 
 
ESR1rs3778099 n=207 n=208 n=208 n=207 n=208 n=208 n=208 n=208 
  Main Effects Model         
    SNP Main Effect -0.008, 0.959 -0.139, 0.340 -0.084, 0.457 -0.003, 0.979 0.031, 0.811 0.077, 0.540 0.004, 0.957 -0.021, 0.868 
  Interaction Model         
    SNP Main Effect 0.256, 0.288 -0.006, 0.977 0.005, 0.976 0.128, 0.497 -0.000, 1.000  0.181, 0.333 0.032, 0.777 0.042, 0.827 
    SNP-by-CA Inter -0.207, 0.649 -0.060, 0.881 -0.217, 0.487 -0.077, 0.829 0.090, 0.801 -0.039, 0.911 -0.117, 0.589 -0.083, 0.818 
    SNP-by-AO Inter -0.690, 0.064 -0.491, 0.133 -0.117, 0.646 -0.323, 0.268 0.035, 0.906 -0.279, 0.334 -0.015, 0.933 -0.116, 0.694 
 
ESR1rs3798577 n=219 n=219 n=220 n=219 n=220 n=220 n=220 n=220 
  Main Effects Model         
    SNP Main Effect -0.042, 0.745 -0.215, 0.056 0.133, 0.137 -0.127, 0.207 -0.149, 0.137 0.117, 0.237 0.083, 0.173 0.078, 0.434 
  Interaction Model         
    SNP Main Effect -0.074, 0.716 -0.138, 0.443 0.000, 0.997 -0.230, 0.157 -0.306, 0.054 0.044, 0.781 0.153, 0.117 0.058, 0.720 
    SNP-by-CA Inter -0.220, 0.495 -0.089, 0.753 0.226, 0.312 0.061, 0.809 0.397, 0.110 0.085, 0.731 -0.170, 0.264 -0.027, 0.915 
    SNP-by-AO Inter 0.295, 0.331 -0.156, 0.559 0.200, 0.346 0.231, 0.333 0.152, 0.517 0.137, 0.562 -0.060, 0.676 0.071, 0.766 
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ESR1rs488133 n=208 n=208 n=209 n=208 n=209 n=209 n=209 n=209 
  Main Effects Model         
    SNP Main Effect -0.038, 0.756 -0.005, 0.963 0.207, 0.015* 0.103, 0.279 0.275, 0.004* 0.143, 0.130 0.117, 0.052 0.277, 0.003* 
  Interaction Model         
    SNP Main Effect -0.178, 0.378 -0.327, 0.058 0.329, 0.018* 0.279, 0.073 0.182, 0.246 0.365, 0.018* 0.241, 0.012* 0.516, 0.001* 
    SNP-by-CA Inter 0.343, 0.292 0.200, 0.472 -0.122, 0.581 -0.228, 0.358 0.060, 0.811 -0.198, 0.422 -0.095, 0.535 -0.133, 0.584 
    SNP-by-AO Inter 0.149, 0.602 0.718, 0.003* -0.232, 0.234 -0.309, 0.158 0.218, 0.324 -0.425, 0.051 -0.288, 0.034* -0.544, 0.011* 
 
ESR1rs532010 n=211 n=212 n=212 n=211 n=212 n=212 n=212 n=212 
  Main Effects Model         
    SNP Main Effect -0.080, 0.546 0.062, 0.591 -0.121, 0.185 -0.073, 0.479 -0.164, 0.121 -0.085, 0.406 -0.054, 0.392 -0.187, 0.073 
  Interaction Model         
    SNP Main Effect -0.047, 0.815 0.207, 0.237 -0.250, 0.067 -0.163, 0.292 -0.076, 0.635 -0.169, 0.275 -0.098, 0.304 -0.287, 0.067 
    SNP-by-CA Inter -0.159, 0.628 -0.190, 0.506 0.420, 0.059 0.116, 0.646 -0.072, 0.782 0.159, 0.527 0.107, 0.491 0.119, 0.640 
    SNP-by-AO Inter 0.047, 0.884 -0.285, 0.311 0.043, 0.843 0.182, 0.462 -0.240, 0.349 0.119, 0.631 0.044, 0.775 0.217, 0.387 
 
ESR1rs6557171 n=217 n=217 n=218 n=217 n=218 n=218 n=218 n=218 
  Main Effects Model         
    SNP Main Effect -0.234, 0.047* 0.014, 0.898 -0.020, 0.817 -0.273, 0.003* -0.162, 0.082 -0.091, 0.328 -0.029, 0.616 -0.044, 0.644 
  Interaction Model         
    SNP Main Effect -0.314, 0.107 0.060, 0.736 -0.043, 0.754 -0.456, 0.003* -0.167, 0.275 -0.081, 0.599 0.007, 0.940 -0.097, 0.532 
    SNP-by-CA Inter 0.202, 0.508 0.021, 0.939 -0.006, 0.977 0.322, 0.173 0.073, 0.760 -0.002, 0.993 -0.161, 0.264 -0.109, 0.653 
    SNP-by-AO Inter 0.072, 0.793 -0.152, 0.541 0.064, 0.741 0.242, 0.252 -0.044, 0.839 -0.025, 0.907 0.031, 0.808 0.228, 0.297 
 
ESR1rs77275268 n=216 n=216 n=217 n=216 n=217 n=217 n=217 n=217 
  Main Effects Model         
    SNP Main Effect 0.024, 0.881 -0.141, 0.329 -0.072, 0.532 -0.005, 0.970 -0.208, 0.107 -0.209, 0.098 0.079, 0.295 0.041, 0.751 
  Interaction Model         
    SNP Main Effect -0.054, 0.850 0.023, 0.926 -0.214, 0.289 0.131, 0.553 -0.050, 0.824 -0.461, 0.035* -0.032, 0.801 -0.025, 0.914 
    SNP-by-CA Inter 0.400, 0.426 0.194, 0.660 0.012, 0.973 0.263, 0.496 0.109, 0.782 -0.051, 0.895 0.043, 0.847 -0.031, 0.938 
    SNP-by-AO Inter -0.004, 0.992 -0.377, 0.247 0.269, 0.303 -0.338, 0.236 -0.376, 0.198 0.480, 0.089 0.223, 0.175 0.149, 0.611 
 
ESR1rs7761133 n=215 n=215 n=216 n=215 n=216 n=216 n=216 n=216 
  Main Effects Model         
    SNP Main Effect 0.044, 0.743 0.000, 0.999 -0.129, 0.170 -0.002, 0.984 0.021, 0.843 -0.057, 0.585 -0.006, 0.924 -0.102, 0.332 
  Interaction Model         
    SNP Main Effect 0.082, 0.690 0.033, 0.856 -0.210, 0.140 -0.101, 0.529 0.065, 0.687 0.163, 0.306 -0.074, 0.449 -0.014, 0.929 
    SNP-by-CA Inter 0.008, 0.981 -0.022, 0.942 0.166, 0.481 0.195, 0.465 0.042, 0.875 -0.337, 0.203 0.031, 0.851 -0.090, 0.730 
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    SNP-by-AO Inter -0.139, 0.658 -0.084, 0.766 0.112, 0.606 0.140, 0.571 -0.183, 0.464 -0.362, 0.139 0.190, 0.208 -0.178, 0.461 
 
ESR1rs7761846 n=203 n=203 n=204 n=203 n=204 n=204 n=204 n=204 
  Main Effects Model         
    SNP Main Effect -0.299, 0.144 -0.158, 0.389 -0.388, 0.005* -0.316, 0.050 -0.174, 0.284 -0.269, 0.086 -0.148, 0.124 -0.351, 0.022* 
  Interaction Model         
    SNP Main Effect -0.301, 0.337 0.045, 0.869 -0.344, 0.102 -0.159, 0.530 -0.139, 0.575 -0.254, 0.289 -0.295, 0.041* -0.274, 0.239 
    SNP-by-CA Inter -0.095, 0.840 -0.358, 0.407 0.149, 0.635 -0.233, 0.529 -0.018, 0.963 -0.027, 0.941 0.152, 0.482 -0.140, 0.689 
    SNP-by-AO Inter 0.097, 0.851 -0.299, 0.510 -0.314, 0.363 -0.373, 0.355 -0.131, 0.749 -0.017, 0.965 0.404, 0.090 -0.122, 0.751 
 
ESR1rs7766585 n=217 n=217 n=218 n=217 n=218 n=218 n=218 n=218 
  Main Effects Model         
    SNP Main Effect -0.104, 0.435 -0.187, 0.122 -0.076, 0.423 -0.052, 0.623 -0.012, 0.913 -0.003, 0.975 0.007, 0.913 -0.009, 0.935 
  Interaction Model         
    SNP Main Effect -0.020, 0.921 -0.054, 0.770 -0.176, 0.225 -0.009, 0.954 -0.072, 0.660 0.002, 0.988 -0.015, 0.882 -0.104, 0.524 
    SNP-by-CA Inter 0.124, 0.741 -0.068, 0.841 0.063, 0.814 0.246, 0.403 0.066, 0.825 -0.055, 0.851 0.082, 0.653 0.304, 0.312 
    SNP-by-AO Inter -0.288, 0.337 -0.343, 0.208 0.219, 0.305 -0.255, 0.280 0.131, 0.584 0.012, 0.959 -0.001, 0.997 0.066, 0.784 
 
ESR1rs7767143 n=213 n=213 n=214 n=213 n=214 n=214 n=214 n=214 
  Main Effects Model         
    SNP Main Effect -0.008, 0.947 -0.001, 0.994 -0.148, 0.080 -0.042, 0.660 -0.003, 0.978 -0.132, 0.164 -0.067, 0.252 -0.012, 0.901 
  Interaction Model         
    SNP Main Effect 0.012, 0.951 0.275, 0.122 -0.224, 0.099 -0.106, 0.497 0.111, 0.480 0.166, 0.273 -0.194, 0.038* 0.128, 0.407 
    SNP-by-CA Inter -0.076, 0.814 -0.322, 0.265 0.219, 0.318 0.153, 0.541 -0.167, 0.514 -0.499, 0.042* 0.088, 0.558 -0.247, 0.323 
    SNP-by-AO Inter -0.010, 0.972 -0.523, 0.039* 0.061, 0.750 0.059, 0.790 -0.203, 0.365 -0.419, 0.051 0.310, 0.020* -0.187, 0.394 
 
ESR1rs827421 n=211 n=211 n=212, 211 n=211 n=212 n=212 n=212 n=212 
  Main Effects Model         
    SNP Main Effect -0.053, 0.700 0.053, 0.662 0.178, 0.062 0.017, 0.879 0.094, 0.397 0.045, 0.676 -0.019, 0.764 0.046, 0.673 
  Interaction Model         
    SNP Main Effect -0.233, 0.297 -0.099, 0.617 0.323, 0.035* 0.214, 0.228 0.046, 0.796 0.173, 0.318 -0.011, 0.919 -0.062, 0.724 
    SNP-by-CA Inter 0.372, 0.319 -0.021, 0.949 -0.159, 0.531 -0.484, 0.099 -0.097, 0.744 -0.114, 0.693 0.259, 0.134 0.379, 0.199 
    SNP-by-AO Inter 0.249, 0.430 0.422, 0.132 -0.251, 0.244 -0.165, 0.507 0.224, 0.376 -0.257, 0.295 -0.167, 0.255 0.034, 0.890 
 
ESR1rs851967 n=215 n=215 n=216 n=215 n=216 n=216 n=216 n=216 
  Main Effects Model         
    SNP Main Effect 0.004, 0.973 0.005, 0.966 -0.102, 0.222 -0.153, 0.099 0.063, 0.508 -0.009, 0.919 -0.068, 0.230 -0.099, 0.291 
  Interaction Model         
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    SNP Main Effect 0.024, 0.905 -0.166, 0.345 -0.107, 0.443 -0.075, 0.629 0.073, 0.644 -0.073, 0.632 0.035, 0.717 -0.225, 0.151 
    SNP-by-CA Inter -0.056, 0.858 0.207, 0.458 -0.070, 0.749 0.026, 0.914 -0.133, 0.596 0.182, 0.453 -0.067, 0.656 0.274, 0.268 
    SNP-by-AO Inter -0.008, 0.977 0.313, 0.208 0.055, 0.781 -0.220, 0.312 0.069, 0.757 0.045, 0.836 -0.230, 0.090 0.128, 0.563 
 
ESR1rs851971 n=215 n=215 n=216 n=215 n=216 n=216 n=216 n=216 
  Main Effects Model         
    SNP Main Effect -0.019, 0.874 -0.005, 0.963 -0.087, 0.296 -0.144, 0.115 0.055, 0.561 -0.027, 0.771 -0.073, 0.187 -0.089, 0.346 
  Interaction Model         
    SNP Main Effect -0.007, 0.970 -0.163, 0.359 -0.103, 0.459 -0.069, 0.651 0.084, 0.595 -0.115, 0.456 0.025, 0.795 -0.213, 0.176 
    SNP-by-CA Inter -0.110, 0.726 0.202, 0.477 -0.024, 0.912 0.018, 0.940 -0.167, 0.504 0.200, 0.412 -0.077, 0.609 0.271, 0.277 
    SNP-by-AO Inter 0.042, 0.880 0.289, 0.252 0.055, 0.780 -0.214, 0.319 0.045, 0.840 0.091, 0.678 -0.212, 0.116 0.127, 0.569 
 
ESR1rs851982 n=216 n=216 n=217 n=216 n=217 n=217 n=217 n=217 
  Main Effects Model         
    SNP Main Effect 0.021, 0.865 0.151, 0.166 -0.027, 0.754 -0.050, 0.602 -0.013, 0.891 -0.059, 0.534 -0.025, 0.661 -0.009, 0.929 
  Interaction Model         
    SNP Main Effect 0.068, 0.736 0.145, 0.422 0.044, 0.759 -0.076, 0.632 -0.012, 0.940 -0.242, 0.123 -0.010, 0.919 -0.203, 0.202 
    SNP-by-CA Inter -0.034, 0.919 -0.025, 0.933 -0.234, 0.312 0.270, 0.294 0.066, 0.801 0.377, 0.140 0.218, 0.159 0.442, 0.089 
    SNP-by-AO Inter -0.100, 0.722 0.038, 0.880 -0.042, 0.832 -0.099, 0.650 -0.047, 0.834 0.215, 0.320 -0.199, 0.130 0.198, 0.369 
 
ESR1rs851998 n=218 n=218 n=219 n=218 n=219 n=219 n=219 n=219 
  Main Effects Model         
    SNP Main Effect -0.001, 0.991 -0.015, 0.887 -0.088, 0.287 -0.156, 0.086 0.055, 0.554 -0.013, 0.884 -0.061, 0.268 -0.087, 0.348 
  Interaction Model         
    SNP Main Effect 0.000, 1.000 -0.196, 0.267 -0.091. 0.509 -0.084, 0.582 0.065, 0.678 -0.102, 0.504 0.030, 0.748 -0.199, 0.199 
    SNP-by-CA Inter -0.052, 0.867 0.239, 0.394 -0.071, 0.744 0.032, 0.894 -0.129, 0.600 0.220, 0.360 -0.056, 0.708 0.265, 0.278 
    SNP-by-AO Inter 0.028, 0.919 0.316, 0.206 0.051, 0.793 -0.213, 0.321 0.070, 0.752 0.078, 0.715 -0.209, 0.116 0.095, 0.663 
 
ESR1rs910416 n=219 n=219 n=220 n=219 n=220 n=220 n=220 n=220 
  Main Effects Model         
    SNP Main Effect 0.094, 0.489 -0.067, 0.582 0.128, 0.175 0.008, 0.943 0.007, 0.946 0.242, 0.020* 0.001, 0.989 0.070, 0.509 
  Interaction Model         
    SNP Main Effect -0.084, 0.703 -0.300, 0.121 0.102, 0.509 0.174, 0.323 0.062, 0.723 0.178, 0.288 -0.072, 0.481 0.442, 0.011* 
    SNP-by-CA Inter 0.176, 0.626 0.085, 0.785 -0.020, 0.934 -0.323, 0.247 -0.028, 0.920 -0.227, 0.398 0.104, 0.529 -0.617, 0.026* 
    SNP-by-AO Inter 0.351, 0.255 0.589, 0.030* 0.075, 0.729 -0.197, 0.420 -0.125, 0.610 0.286, 0.224 0.111, 0.439 -0.494, 0.042* 
 
ESR1rs9322331 n=214 n=214 n=215 n=214 n=215 n=215 n=215 n=215 
  Main Effects Model         
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    SNP Main Effect -0.105, 0.398 -0.074, 0.516 0.295, 0.777 -0.129, 0.188 -0.111, 0.265 0.036, 0.715 0.052, 0.383 -0.006, 0.955 
  Interaction Model         
    SNP Main Effect -0.064, 0.744 0.015, 0.934 -0.094, 0.501 -0.205, 0.187 0.071, 0.646 -0.086, 0.576 0.039, 0.682 -0.074, 0.639 
    SNP-by-CA Inter -0.019, 0.952 0.107, 0.705 0.260, 0.243 0.152, 0.539 -0.110, 0.657 0.176, 0.476 -0.020, 0.896 -0.028, 0.912 
    SNP-by-AO Inter -0.117, 0.692 -0.383, 0.151 0.122, 0.561 0.091, 0.697 -0.475, 0.044* 0.213, 0.361 0.053, 0.712 0.227, 0.340 
 
ESR1rs9340799 n=212 n=213 n=213 n=212 n=213 n=213 n=213 n=213 
  Main Effects Model         
    SNP Main Effect -0.064, 0.618 -0.115, 0.296 0.016, 0.857 -0.107, 0.280 -0.122, 0.228 0.050, 0.612 0.038, 0.530 -0.003, 0.975 
  Interaction Model         
    SNP Main Effect 0.054, 0.784 -0.158, 0.355 -0.081, 0.564 -0.244, 0.111 0.071, 0.646 -0.013, 0.932 0.024, 0.795 -0.049, 0.753 
    SNP-by-CA Inter -0.186, 0.565 0.209, 0.449 0.264, 0.245 0.281, 0.257 -0.146, 0.564 0.078, 0.754 0.009, 0.951 -0.048, 0.850 
    SNP-by-AO Inter -0.217, 0.476 -0.054, 0.835 0.057, 0.790 0.154, 0.512 -0.489, 0.043* 0.123, 0.604 0.033, 0.820 0.188, 0.439 
 
ESR1rs9383938 n=217 n=217 n=218 n=217 n=218 n=218 n=218 n=218 
  Main Effects Model         
    SNP Main Effect 0.023, 0.889 -0.074, 0.611 -0.094, 0.411 0.060, 0.634 -0.147, 0.248 -0.302, 0.015* -0.026, 0.735 -0.047, 0.711 
  Interaction Model         
    SNP Main Effect -0.077, 0.767 -0.025, 0.912 -0.207, 0.256 0.122, 0.543 -0.075, 0.709 -0.458, 0.020* -0.147, 0.225 -0.095, 0.639 
    SNP-by-CA Inter 0.435, 0.373 0.236, 0.585 -0.014, 0.966 0.252, 0.503 0.138, 0.717 -0.053, 0.885 0.084, 0.713 0.046, 0.903 
    SNP-by-AO Inter 0.031, 0.931 -0.209, 0.511 0.246, 0.327 -0.229, 0.409 -0.277, 0.322 0.329, 0.224 0.257, 0.126 0.098, 0.727 
 
ESR1rs9397435 n=219 n=219 n=220 n=219 n=220 n=220 n=220 n=220 
  Main Effects Model         
    SNP Main Effect 0.028, 0.866 -0.195, 0.190 -0.091, 0.44 0.036, 0.786 -0.180, 0.174 -0.257, 0.048* 0.096, 0.212 0.005, 0.969 
  Interaction Model         
    SNP Main Effect -0.054, 0.850 0.038, 0.880 -0.218, 0.279 0.140, 0.528 -0.038, 0.866 -0.466, 0.033* -0.039, 0.761 -0.048, 0.831 
    SNP-by-CA Inter 0.417, 0.407 0.175, 0.690 0.004, 0.990 0.247, 0.527 0.096, 0.808 -0.035, 0.926 0.047, 0.834 -0.001, 0.998 
    SNP-by-AO Inter -0.025, 0.947 -0.539, 0.107 0.260, 0.334 -0.304, 0.306 -0.375, 0.213 0.424, 0.145 0.271, 0.112 0.113, 0.707 
 
ESR1rs9397456 n=202 n=202 n=203 n=202 n=203 n=203 n=203 n=203 
  Main Effects Model         
    SNP Main Effect -0.169, 0.181 0.131, 0.270 0.051, 0.573 -0.045, 0.658 0.003, 0.976 0.095, 0.346 -0.023, 0.705 0.131, 0.206 
  Interaction Model         
    SNP Main Effect -0.126, 0.540 0.381, 0.049* 0.061, 0.681 -0.200, 0.223 -0.010, 0.952 0.097, 0.554 -0.039, 0.699 -0.071, 0.669 
    SNP-by-CA Inter 0.118, 0.721 -0.310, 0.313 -0.035, 0.881 0.281, 0.283 0.135, 0.616 0.086, 0.740 -0.021, 0.898 0.118, 0.658 
    SNP-by-AO Inter -0.224, 0.446 -0.481, 0.080 -0.003, 0.987 0.217, 0.353 -0.048, 0.840 -0.070, 0.763 0.072, 0.616 0.470, 0.048* 
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ESR1rs985694 n=217 n=217 n=218 n=217 n=218 n=218 n=218 n=218 
  Main Effects Model         
    SNP Main Effect -0.353, 0.003* -0.051, 0.647 -0.062, 0.471 -0.140, 0.144 0.022, 0.818 -0.003, 0.978 -0.090, 0.135 0.021, 0.828 
  Interaction Model         
    SNP Main Effect -0.262, 0.167 -0.119, 0.510 -0.013, 0.927 -0.360, 0.019* 0.002, 0.989 0.080, 0.606 -0.033, 0.740 0.026, 0.871 
    SNP-by-CA Inter 0.263, 0.392 0.157, 0.590 -0.230, 0.310 0.558, 0.024* 0.124, 0.625 -0.026, 0.919 0.011, 0.947 0.065, 0.798 
    SNP-by-AO Inter -0.419, 0.122 0.069, 0.788 0.011, 0.956 0.197, 0.365 -0.044, 0.845 -0.181, 0.413 -0.188, 0.182 -0.058, 0.797 
 
CCDC170rs1038304 n=217 n=217 n=218 n=217 n=218 n=218 n=218 n=218 
  Main Effects Model         
    SNP Main Effect -0.059, 0.663 0.003, 0.982 0.054, 0.570 0.028, 0.793 -0.067, 0.527 0.008, 0.941 -0.087, 0.165 -0.039, 0.716 
  Interaction Model         
    SNP Main Effect 0.215, 0.319 0.012, 0.953 0.027, 0.860 0.226, 0.188 0.081, 0.635 -0.070, 0.683 -0.104, 0.306 -0.149, 0.386 
    SNP-by-CA Inter -0.311, 0.383 0.235, 0.471 -0.057, 0.824 -0.197, 0.486 -0.223, 0.428 -0.035, 0.903 0.028, 0.866 -0.035, 0.903 
    SNP-by-AO Inter -0.519, 0.085 -0.170, 0.537 0.085, 0.694 -0.372, 0.120 -0.287, 0.228 0.210, 0.382 0.029, 0.841 0.320, 0.182 
 
CCDC170rs12662670 n=216 n=216 n=217 n=216 n=217 n=217 n=217 n=217 
  Main Effects Model         
    SNP Main Effect -0.005, 0.979 -0.363, 0.016* 0.014, 0.910 -0.080, 0.551 -0.164, 0.232 -0.229, 0.087 0.131, 0.093 0.070, 0.608 
  Interaction Model         
    SNP Main Effect -0.283, 0.339 -0.314, 0.226 -0.086, 0.679 -0.184, 0.426 -0.207. 0.377 -0.435, 0.058 0.089, 0.497 0.016, 0.945 
    SNP-by-CA Inter 0.613, 0.232 -0.167, 0.709 0.441, 0.223 0.281, 0.483 0.432, 0.288 0.117, 0.767 0.132, 0.564 0.129, 0.751 
    SNP-by-AO Inter 0.340, 0.385 -0.036, 0.915 0.065, 0.814 0.091, 0.767 -0.068, 0.825 0.390, 0.197 0.071, 0.685 0.068, 0.827 
 
CCDC170rs3734805 n=212 n=212 n=213 n=212 n=213 n=213 n=213 n=213 
  Main Effects Model         
    SNP Main Effect 0.057, 0.735 -0.304, 0.042* -0.001, 0.992 -0.021, 0.876 -0.181, 0.184 -0.201, 0.125 0.106, 0.174 0.039, 0.766 
  Interaction Model         
    SNP Main Effect -0.085, 0.767 0.025, 0.922 -0.189, 0.347 0.108, 0.630 -0.040, 0.861 -0.455, 0.040* -0.032, 0.801 -0.023, 0.920 
    SNP-by-CA Inter 0.447, 0.381 -0.541, 0.233 0.503, 0.159 0.023, 0.954 0.230, 0.574 0.093, 0.811 0.259, 0.256 0.167, 0.677 
    SNP-by-AO Inter 0.084, 0.826 -0.461, 0.178 0.230, 0.393 -0.259, 0.390 -0.406, 0.190 0.474, 0.109 0.242, 0.160 0.074, 0.807 
 
CCDC170rs3757318 n=212 n=212 n=213 n=212 n=213 n=213 n=213 n=213 
  Main Effects Model         
    SNP Main Effect -0.029, 0.876 -0.334, 0.042* -0.089, 0.495 0.002, 0.987 -0.115, 0.440 -0.295, 0.043* 0.107, 0.217 -0.005, 0.975 
  Interaction Model         
    SNP Main Effect -0.218, 0.491 -0.199, 0.471 -0.400, 0.063 0.133, 0.589 -0.237, 0.340 -0.558, 0.022* -0.052, 0.707 -0.129, 0.597 
    SNP-by-CA Inter 0.715, 0.210 -0.070, 0.889 0.972, 0.012* 0.060, 0.893 0.699, 0.120 0.475, 0.278 0.521, 0.036* 0.279, 0.527 
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    SNP-by-AO Inter 0.053, 0.902 -0.241, 0.520 0.377, 0.196 -0.268, 0.424 -0.053, 0.876 0.387, 0.243 0.195, 0.297 0.167, 0.615 
 
CCDC170rs6929137 n=215 n=215 n=216 n=215 n=216 n=216 n=216 n=216 
  Main Effects Model         
    SNP Main Effect -0.040, 0.747 -0.322, 0.003* 0.050, 0.566 -0.029, 0.764 -0.061, 0.535 -0.004, 0.969 0.084, 0.162 0.051, 0.596 
  Interaction Model         
    SNP Main Effect 0.099, 0.623 -0.122, 0.479 0.054, 0.697 -0.110, 0.487 -0.081, 0.611 0.046, 0.765 -0.008, 0.932 0.045, 0.772 
    SNP-by-CA Inter -0.094, 0.767 -0.428, 0.119 0.033, 0.879 0.217, 0.382 0.031, 0.902 -0.056, 0.816 0.073, 0.624 0.001, 0.997 
    SNP-by-AO Inter -0.301, 0.285 -0.201, 0.405 -0.032, 0.871 0.048, 0.828 0.037, 0.869 -0.087, 0.688 0.208, 0.119 0.016, 0.940 
 
GRB7rs9910678 n=217 n=217 n=218 n=217 n=218 n=218 n=218 n=218 
  Main Effects Model         
    SNP Main Effect 0.046, 0.817 -0.094, 0.614 -0.119, 0.404 -0.077, 0.627 -0.031, 0.843 -0.145, 0.355 -0.116, 0.222 -0.429, 0.007* 
  Interaction Model         
    SNP Main Effect 0.162, 0.651 -0.560, 0.085 -0.138, 0.586 0.142, 0.614 -0.009, 0.975 0.143, 0.609 -0.222, 0.194 -0.558, 0.051 
    SNP-by-CA Inter -0.482, 0.359 0.491, 0.322 -0.260, 0.482 -0.409, 0.323 -0.334, 0.420 -0.318, 0.438 0.219, 0.382 0.247, 0.554 
    SNP-by-AO Inter 0.015, 0.976 0.869, 0.048* 0.248, 0.467 -0.235, 0.537 0.194, 0.611 -0.495, 0.190 0.055, 0.811 0.090, 0.814 
 
GSTM1rs1065411 n=208 n=208 n=209 n=208 n=209 n=209 n=209 n=209 
  Main Effects Model         
    SNP Main Effect 0.140, 0.264 0.000, 1.000 -0.101, 0.246 -0.131, 0.172 -0.099, 0.318 0.006, 0.948 -0.048, 0.420 -0.064, 0.511 
  Interaction Model         
    SNP Main Effect 0.218, 0.283 -0.100, 0.581 -0.211, 0.141 -0.275, 0.080 -0.239, 0.140 -0.094, 0.557 0.054, 0.582 -0.069, 0.666 
    SNP-by-CA Inter 0.129, 0.689 0.217, 0.451 0.222, 0.324 0.301, 0.221 0.312, 0.221 0.249, 0.322 -0.105, 0.500 0.233, 0.354 
    SNP-by-AO Inter -0.324, 0.264 0.110, 0.670 0.128, 0.531 0.166, 0.456 0.178, 0.442 0.087, 0.704 -0.231, 0.102 -0.183, 0.422 
 
GSTM1rs412543 n=215 n=215 n=216 n=216 n=216 n=216 n=216 n=216 
  Main Effects Model         
    SNP Main Effect -0.058, 0.718 0.012, 0.934 -0.291, 0.009* -0.124, 0.326 -0.039, 0.763 -0.086, 0.495 -0.188, 0.013* -0.388, 0.002* 
  Interaction Model         
    SNP Main Effect 0.184, 0.459 -0.041, 0.857 -0.565, 0.001* -0.220, 0.265 -0.245, 0.230 -0.470, 0.017* -0.256, 0.032* -0.901, <0.001* 
    SNP-by-CA Inter -0.701, 0.074 0.201, 0.578 0.382, 0.158 0.273, 0.380 0.344, 0.285 0.624, 0.043* 0.126, 0.502 1.012, 0.001* 
    SNP-by-AO Inter -0.190, 0.620 -0.055, 0.876 0.513, 0.053 0.031, 0.920 0.313, 0.321 0.640, 0.034* 0.084, 0.645 0.473, 0.116 
 
NFE2L2rs35652124 n=217 n=217 n=218 n=217 n=218 n=218 n=218 n=218 
  Main Effects Model         
    SNP Main Effect -0.063, 0.600 -0.017, 0.876 -0.016, 0.852 -0.280, 0.002* 0.022, 0.814 -0.073, 0.437 0.029, 0.619 0.061, 0.516 
  Interaction Model         
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    SNP Main Effect -0.027, 0.889 -0.264, 0.129 0.172, 0.207 -0.276, 0.066 -0.023, 0.881 -0.248, 0.105 0.038, 0.686 0.255, 0.098 
    SNP-by-CA Inter 0.150, 0.624 0.371, 0.180 -0.389, 0.072 0.221, 0.347 -0.026, 0.916 0.304, 0.207 -0.075, 0.615 -0.358, 0.142 
    SNP-by-AO Inter -0.204, 0.458 0.408, 0.099 -0.235, 0.226 -0.160, 0.450 0.148, 0.497 0.242, 0.262 0.039, 0.772 -0.244, 0.265 
 
NFE2L2rs6721961 n=211 n=212 n=212 n=211 n=212 n=212 n=212 n=212 
  Main Effects Model         
    SNP Main Effect 0.205, 0.183 -0.121, 0.375 -0.081, 0.456 0.194, 0.106 0.063, 0.613 0.097, 0.424 0.078, 0.274 0.082, 0.506 
  Interaction Model         
    SNP Main Effect 0.310, 0.191 -0.014, 0.946 -0.124, 0.459 0.325, 0.077 0.126, 0.504 0.344, 0.063 0.089, 0.415 0.140, 0.459 
    SNP-by-CA Inter -0.090, 0.832 0.165, 0.661 -0.005, 0.988 -0.018, 0.956 -0.139, 0.683 -0.466, 0.162 -0.189, 0.336 -0.246, 0.470 
    SNP-by-AO Inter -0.230, 0.498 -0.397, 0.187 0.103, 0.667 -0.303, 0.251 -0.085, 0.754 -0.399, 0.134 0.078, 0.621 -0.031, 0.909 
 
MELKrs10973007 n=208 n=209 n=209 n=208 n=209 n=209 n=209 n=209 
  Main Effects Model         
    SNP Main Effect 0.047, 0.717 -0.145, 0.190 0.126, 0.160 0.073, 0.465 0.038, 0.716 0.035, 0.724 0.030, 0.619 0.056, 0.591 
  Interaction Model         
    SNP Main Effect -0.117, 0.580 0.080, 0.659 -0.215, 0.138 0.085, 0.614 0.123, 0.474 -0.092, 0.572 -0.002, 0.982 -0.131, 0.442 
    SNP-by-CA Inter 0.067, 0.847 -0.112, 0.701 0.601, 0.010* -0.028, 0.917 -0.290, 0.292 -0.165, 0.526 -0.282, 0.074 0.028, 0.919 
    SNP-by-AO Inter 0.386, 0.190 -0.504, 0.046* 0.462, 0.022* -0.010, 0.964 -0.047, 0.843 0.388, 0.085 0.263, 0.054 0.433, 0.066 
 
MELKrs2250340 n=219 n=219 n=220 n=219 n=220 n=220 n=220 n=220 
  Main Effects Model         
    SNP Main Effect 0.052, 0.764 0.058, 0.705 0.021, 0.865 -0.087, 0.522 0.023, 0.867 0.086, 0.521 0.034, 0.672 -0.085, 0.532 
  Interaction Model         
    SNP Main Effect -0.168, 0.471 0.001, 0.997 -0.069, 0.671 0.013, 0.945 -0.153, 0.403 0.002, 0.990 -0.067, 0.533 -0.003, 0.988 
    SNP-by-CA Inter 0.867, 0.069 -0.048, 0.911 0.935, 0.005* -0.184, 0.626 0.751, 0.045 0.431, 0.247 0.413, 0.063 0.604, 0.101 
    SNP-by-AO Inter 0.254, 0.524 0.354, 0.329 -0.182, 0.512 -0.191, 0.545 0.101, 0.747 0.000, 1.000 0.069, 0.711 -0.765, 0.014* 
 
MELKrs3780350 n=212 n=213 n=213 n=212 n=213 n=213 n=213 n=213 
  Main Effects Model         
    SNP Main Effect -0.048, 0.725 -0.062, 0.599 -0.170, 0.069 -0.023, 0.826 0.023, 0.832 -0.134, 0.201 -0.018, 0.781 0.001, 0.991 
  Interaction Model         
    SNP Main Effect -0.048, 0.838 -0.260, 0.211 -0.214, 0.188 -0.306, 0.097 -0.056, 0.767 -0.112, 0.542 -0.024, 0.829 -0.142, 0.450 
    SNP-by-CA Inter 0.180, 0.620 0.216, 0.496 0.096, 0.698 0.515, 0.067 0.303, 0.296 0.250, 0.372 0.075, 0.658 0.197, 0.495 
    SNP-by-AO Inter -0.101, 0.747 0.322, 0.243 0.045, 0.833 0.282, 0.247 -0.002, 0.995 -0.182, 0.453 -0.043, 0.769 0.214, 0.392 
 
MKI67rs10732438 n=210 n=210 n=211 n=211 n=211 n=211 n=211 n=211 
  Main Effects Model         
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    SNP Main Effect -0.030, 0.809 -0.045, 0.679 0.074, 0.393 -0.264, 0.007* -0.194, 0.047* 0.008, 0.930 -0.038, 0.513 -0.095, 0.330 
  Interaction Model         
    SNP Main Effect -0.080, 0.699 -0.068, 0.703 0.111, 0.436 -0.371, 0.022* -0.186, 0.247 0.044, 0.782 -0.080, 0.406 -0.044, 0.786 
    SNP-by-CA Inter 0.037, 0.907 0.290, 0.295 0.129, 0.559 0.147, 0.555 0.068, 0.785 -0.207, 0.402 0.009, 0.951 -0.022, 0.929 
    SNP-by-AO Inter 0.108, 0.713 -0.186, 0.464 -0.184, 0.365 0.179, 0.435 -0.062, 0.787 0.050, 0.825 0.111, 0.419 -0.123, 0.594 
 
MKI67rs10764751 n=219 n=219 n=220 n=219 n=220 n=220 n=220 n=220 
  Main Effects Model         
    SNP Main Effect 0.063, 0.597 -0.079, 0.458 -0.017, 0.841 0.037, 0.697 0.046, 0.627 -0.007, 0.940 0.001, 0.984 -0.048, 0.607 
  Interaction Model         
    SNP Main Effect 0.065, 0.743 -0.220, 0.214 -0.086, 0.540 0.142, 0.360 0.041, 0.793 0.140, 0.364 0.075, 0.429 0.140, 0.368 
    SNP-by-CA Inter 0.173, 0.579 0.223, 0.421 0.087, 0.692 0.099, 0.682 -0.150, 0.541 -0.262, 0.278 -0.141, 0.342 -0.297, 0.223 
    SNP-by-AO Inter -0.136, 0.623 0.215, 0.381 0.115, 0.555 -0.331, 0.124 0.120, 0.580 -0.199, 0.356 -0.098, 0.456 -0.273, 0.208 
 
MMP11rs131451 n=215 n=215 n=216 n=215 n=216 n=216 n=216 n=216 
  Main Effects Model         
    SNP Main Effect 0.057, 0.699 -0.060, 0.650 -0.074, 0.480 0.140, 0.228 -0.045, 0.699 -0.125, 0.274 -0.006, 0.935 0.047, 0.689 
  Interaction Model         
    SNP Main Effect 0.033, 0.886 -0.157, 0.451 -0.124, 0.449 0.238, 0.189 -0.042, 0.819 -0.237, 0.185 -0.077, 0.498 -0.029, 0.874 
    SNP-by-CA Inter 0.010, 0.979 0.121, 0.727 -0.057, 0.835 -0.025, 0.932 -0.126, 0.680 0.041, 0.889 -0.012, 0.951 -0.076, 0.801 
    SNP-by-AO Inter 0.056, 0.870 0.210, 0.494 0.168, 0.487 -0.240, 0.368 0.099, 0.715 0.261, 0.319 0.191, 0.254 0.267, 0.317 
 
MYBL2rs11556379 n=219 n=219 n=220, 219 n=219, 218 n=220, 219 n=220, 219 n=220, 219 n=220, 219 
  Main Effects Model         
    SNP Main Effect 0.027, 0.897 -0.081, 0.655 0.089, 0.532 0.422, 0.008* 0.145, 0.365 0.125, 0.427 0.125, 0.195 -0.016, 0.921 
  Interaction Model         
    SNP Main Effect -0.208, 0.467 -0.436, 0.082 0.503, 0.010* 0.300, 0.173 0.149, 0.507 0.417, 0.057 0.217, 0.119 0.218, 0.324 
    SNP-by-CA Inter 0.172, 0.853 1.407, 0.083 -1.568, 0.010*a 0.568, 0.510a -0.243, 0.781a 0.500, 0.463a -0.109, 0.875a 0.306, 0.696a 
    SNP-by-AO Inter 0.524, 0.214 0.695, 0.060 -0.711, 0.014* 0.193, 0.552 0.030, 0.927 -0.581, 0.072 -0.170, 0.407 -0.551, 0.092 
 
MYBL2rs2070235 n=219 n=219 n=220 n=219 n=220 n=220 n=220 n=220 
  Main Effects Model         
    SNP Main Effect 0.311, 0.045* 0.023, 0.872 0.093, 0.401 0.076, 0.537 -0.099, 0.419 -0.356, 0.003* -0.156, 0.035* -0.411, 0.001* 
  Interaction Model         
    SNP Main Effect 0.394, 0.101 0.031, 0.886 0.036, 0.832 0.238, 0.214 -0.062, 0.747 -0.602, 0.001* -0.163, 0.155 -0.663, <0.001* 
    SNP-by-CA Inter -0.305, 0.412 -0.191, 0.572 0.056, 0.830 -0.421, 0.156 -0.086, 0.772 0.239, 0.399 0.029, 0.871 0.407, 0.156 
    SNP-by-AO Inter 0.107, 0.778 0.307, 0.365 0.128, 0.632 -0.081, 0.788 -0.036, 0.904 0.556, 0.055 -0.012, 0.948 0.377, 0.196 
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MYBL2rs619289 n=215 n=215 n=216 n=215 n=216 n=216 n=216 n=216 
  Main Effects Model         
    SNP Main Effect 0.056, 0.664 0.077, 0.508 0.097, 0.278 -0.028, 0.781 -0.034, 0.736 -0.214, 0.031* -0.051, 0.392 -0.222, 0.028* 
  Interaction Model         
    SNP Main Effect 0.204, 0.325 0.033, 0.857 0.178, 0.219 0.109, 0.498 -0.009, 0.955 -0.250, 0.116 -0.039, 0.689 -0.227, 0.160 
    SNP-by-CA Inter -0.201, 0.548 -0.023, 0.939 -0.031, 0.894 -0.293, 0.258 0.065, 0.806 0.001, 0.998 0.019, 0.906 -0.110, 0.670 
    SNP-by-AO Inter -0.257, 0.380 0.147, 0.573 -0.188, 0.359 -0.159, 0.484 -0.125, 0.589 0.090, 0.688 -0.056, 0.686 0.107, 0.639 
 
MYBL2rs826943 n=212 n=212 n=213 n=212 n=213 n=213 n=213 n=213 
  Main Effects Model         
    SNP Main Effect -0.023, 0.868 0.014, 0.907 0.130, 0.180 -0.114, 0.296 -0.030, 0.785 -0.099, 0.360 0.059, 0.371 -0.067, 0.532 
  Interaction Model         
    SNP Main Effect 0.002, 0.991 0.016, 0.933 0.255, 0.095 -0.046, 0.788 -0.018, 0.920 -0.132, 0.437 0.026, 0.802 0.011, 0.947 
    SNP-by-CA Inter 0.117, 0.753 -0.014, 0.967 -0.136, 0.595 -0.124, 0.668 0.121, 0.683 -0.050, 0.861 0.131, 0.462 -0.123, 0.668 
    SNP-by-AO Inter -0.150, 0.636 0.003, 0.990 -0.226, 0.301 -0.094, 0.703 -0.121, 0.631 0.113, 0.642 0.002, 0.990 -0.138, 0.573 
 
MYBL2rs826944 n=218 n=218 n=219 n=218 n=219 n=219 n=219 n=219 
  Main Effects Model         
    SNP Main Effect -0.065, 0.635 0.013, 0.915 0.100, 0.301 -0.099, 0.352 -0.002, 0.986 -0.096, 0.365 0.039, 0.541 -0.074, 0.489 
  Interaction Model         
    SNP Main Effect 0.008, 0.938 0.031, 0.873 0.259, 0.091 -0.049, 0.775 -0.017, 0.922 -0.131, 0.438 0.020, 0.847 0.000, 0.999 
    SNP-by-CA Inter -0.029, 0.938 -0.119, 0.718 -0.215, 0.403 -0.090, 0.755 0.172, 0.553 -0.052, 0.854 0.066, 0.706 -0.181, 0.530 
    SNP-by-AO Inter -0.180, 0.563 0.058, 0.835 -0.267, 0.219 -0.080, 0.742 -0.064, 0.792 0.116, 0.627 0.017, 0.910 -0.083, 0.734 
 
NDC80rs12408485 n=202 n=202 n=203 n=202 n=203 n=203 n=203 n=203 
  Main Effects Model         
    SNP Main Effect -0.158, 0.200 -0.020, 0.860 -0.059, 0.500 0.049, 0.617 -0.051, 0.601 -0.147, 0.125 -0.056, 0.331 -0.093, 0.350 
  Interaction Model         
    SNP Main Effect -0.117, 0.577 -0.004, 0.982 0.061, 0.684 -0.290, 0.084 -0.165, 0.322 -0.016, 0.922 -0.103, 0.301 -0.088, 0.603 
    SNP-by-CA Inter 0.214, 0.536 0.130, 0.686 -0.278, 0.257 0.390, 0.155 0.076, 0.782 -0.230, 0.391 0.115, 0.482 0.104, 0.709 
    SNP-by-AO Inter -0.259, 0.363 -0.113, 0.670 -0.123, 0.544 0.589, 0.010* 0.264, 0.246 -0.170, 0.443 0.046, 0.733 -0.082, 0.723 
 
NDC80rs2292274 n=206 n=206 n=207 n=207 n=207 n=207 n=207 n=207 
  Main Effects Model         
    SNP Main Effect 0.117, 0.339 0.051, 0.651 0.114, 0.192 0.019, 0.843 0.114, 0.238 0.095, 0.321 0.054, 0.340 0.130, 0.183 
  Interaction Model         
    SNP Main Effect 0.171, 0.396 0.068, 0.713 0.210, 0.145 0.306, 0.055 0.278, 0.079 0.319, 0.044* 0.041, 0.660 0.219, 0.170 
    SNP-by-CA Inter -0.307, 0.333 -0.261, 0.371 -0.127, 0.572 -0.402, 0.107 -0.379, 0.126 -0.322, 0.192 0.054, 0.707 -0.123, 0.623 
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    SNP-by-AO Inter 0.063, 0.822 0.134, 0.605 -0.156, 0.437 -0.447, 0.046* -0.193, 0.382 -0.349, 0.113 -0.004, 0.973 -0.135, 0.545 
 
ORC6rs33994299 n=219 n=219 n=220 n=219 n=220 n=220 n=220 n=220 
  Main Effects Model         
    SNP Main Effect -0.112, 0.387 -0.048, 0.677 0.103, 0.257 -0.037, 0.715 -0.106, 0.297 0.193, 0.054 0.108, 0.087 0.077, 0.445 
  Interaction Model         
    SNP Main Effect -0.085, 0.678 -0.162, 0.378 0.158, 0.271 0.110, 0.494 -0.138, 0.393 0.416, 0.008* 0.119, 0.233 0.083, 0.604 
    SNP-by-CA Inter -0.041, 0.901 0.169, 0.565 -0.205, 0.367 -0.312, 0.219 0.062, 0.808 -0.417, 0.094 0.001, 0.995 -0.175, 0.488 
    SNP-by-AO Inter -0.046, 0.878 0.212, 0.425 -0.010, 0.960 -0.178, 0.442 0.051, 0.828 -0.303, 0.181 -0.043, 0.766 0.131, 0.570 
 
PGRrs1042838 n=215 n=215 n=216 n=215 n=216 n=216 n=216 n=216 
  Main Effects Model         
    SNP Main Effect 0.244, 0.075 0.046, 0.712 0.184, 0.058 0.124, 0.253 0.107, 0.330 -0.091, 0.397 0.081, 0.212 0.179, 0.102 
  Interaction Model         
    SNP Main Effect 0.269, 0.207 -0.027, 0.890 0.337, 0.025* 0.087, 0.607 0.016, 0.925 -0.173, 0.302 0.037, 0.712 0.268, 0.118 
    SNP-by-CA Inter 0.127, 0.717 0.125, 0.694 -0.155, 0.528 0.268, 0.331 0.268, 0.341 0.204, 0.459 0.094, 0.570 -0.039, 0.889 
    SNP-by-AO Inter -0.172, 0.590 0.136, 0.640 -0.323, 0.151 -0.103, 0.682 0.072, 0.780 0.065, 0.797 0.058, 0.702 -0.255, 0.319 
 
PGRrs1042839 n=207 n=207 n=208 n=207 n=208 n=208 n=208 n=208 
  Main Effects Model         
    SNP Main Effect 0.192, 0.195 -0.058, 0.655 0.130, 0.211 0.082, 0.477 0.114, 0.331 -0.127, 0.274 0.076, 0.279 0.096, 0.405 
  Interaction Model         
    SNP Main Effect 0.174, 0.433 -0.122, 0.531 0.290, 0.060 0.025, 0.884 0.011, 0.951 -0.187, 0.278 0.037, 0.723 0.263, 0.127 
    SNP-by-CA Inter 0.257, 0.503 0.224, 0.508 -0.248, 0.352 0.258, 0.389 0.259, 0.390 0.196, 0.511 0.080, 0.658 -0.141, 0.636 
    SNP-by-AO Inter -0.128, 0.708 0.016, 0.957 -0.310, 0.193 -0.035, 0.894 0.127, 0.638 0.020, 0.940 0.067, 0.680 -0.433, 0.104 
 
PGRrs10895068 n=213 n=214 n=214 n=213 n=214 n=214 n=214 n=214 
  Main Effects Model         
    SNP Main Effect -0.182, 0.314 -0.277, 0.080 0.053, 0.680 -0.175, 0.211 -0.067, 0.645 0.055, 0.699 -0.079, 0.363 -0.011, 0.937 
  Interaction Model         
    SNP Main Effect -0.297, 0.294 -0.512, 0.040* -0.082, 0.679 -0.160, 0.465 0.001, 0.998 -0.136, 0.537 0.114, 0.403 -0.182, 0.425 
    SNP-by-CA Inter -0.194, 0.682 0.528, 0.205 -0.011, 0.974 0.171, 0.642 -0.109, 0.775 0.110, 0.767 -0.361, 0.115 0.109, 0.776 
    SNP-by-AO Inter 0.423, 0.300 0.240, 0.503 0.337, 0.241 -0.174, 0.582 -0.121, 0.714 0.416, 0.192 -0.281, 0.154 0.400, 0.226 
 
PGRrs11224561 n=213 n=213 n=214 n=213 n=214 n=214 n=214 n=214 
  Main Effects Model         
    SNP Main Effect 0.052, 0.718 -0.029, 0.817 0.050, 0.618 -0.075, 0.497 0.055, 0.624 0.028, 0.799 0.041, 0.533 -0.137, 0.208 
  Interaction Model         
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    SNP Main Effect -0.058, 0.799 0.012, 0.954 -0.071, 0.653 -0.169, 0.336 0.101, 0.570 -0.028, 0.875 0.184, 0.088 -0.305, 0.072 
    SNP-by-CA Inter 0.326, 0.410 0.107, 0.757 0.289, 0.294 0.309, 0.308 -0.111, 0.718 -0.075, 0.805 -0.093, 0.618 0.589, 0.045* 
    SNP-by-AO Inter 0.099, 0.759 -0.195, 0.492 0.162, 0.473 0.052, 0.835 -0.060, 0.811 0.170, 0.493 -0.427, 0.005* 0.032, 0.895 
 
PGRrs1893505 n=219 n=219 n=220 n=219 n=220 n=220 n=220 n=220 
  Main Effects Model         
    SNP Main Effect 0.064, 0.603 0.122, 0.263 -0.043, 0.617 -0.122, 0.207 -0.014, 0.884 -0.071, 0.453 -0.045, 0.443 -0.051, 0.592 
  Interaction Model         
    SNP Main Effect 0.234, 0.260 0.081, 0.660 0.147, 0.307 -0.150, 0.366 -0.175, 0.277 -0.087, 0.589 0.098, 0.316 0.177, 0.269 
    SNP-by-CA Inter -0.324, 0.323 -0.060, 0.838 -0.244, 0.285 -0.031, 0.906 0.068, 0.789 0.032, 0.902 -0.294, 0.058 -0.195, 0.440 
    SNP-by-AO Inter -0.224, 0.429 0.155, 0.538 -0.295, 0.135 0.089, 0.691 0.399, 0.070 0.018, 0.934 -0.163, 0.221 -0.428, 0.051 
 
PGRrs1942836  n=216 n=216 n=217 n=216 n=217 n=217 n=217 n=217 
  Main Effects Model         
    SNP Main Effect 0.023, 0.851 0.037, 0.741 -0.149, 0.082 -0.049, 0.615 -0.053, 0.590 0.070, 0.473 -0.105, 0.075 -0.175, 0.074 
  Interaction Model         
    SNP Main Effect 0.249, 0.222 0.067, 0.712 -0.071, 0.617 0.157, 0.325 -0.030, 0.852 0.152, 0.342 0.083, 0.355 -0.042, 0.795 
    SNP-by-CA Inter -0.538, 0.093 -0.062, 0.830 -0.159, 0.473 -0.383, 0.124 -0.288, 0.252 -0.236, 0.345 -0.440, 0.002* -0.108, 0.665 
    SNP-by-AO Inter -0.219, 0.450 -0.040, 0.878 -0.103, 0.609 -0.276, 0.226 0.157, 0.494 -0.052, 0.821 -0.149, 0.246 -0.288, 0.208 
 
PGRrs471767 n=215 n=215 n=216 n=215 n=216 n=216 n=216 n=216 
  Main Effects Model         
    SNP Main Effect -0.016, 0.895 0.100, 0.357 -0.022, 0.798 -0.114, 0.224 -0.097, 0.316 0.026, 0.784 -0.011, 0.848 0.026, 0.784 
  Interaction Model         
    SNP Main Effect -0.134, 0.495 0.132, 0.457 -0.212, 0.124 -0.053, 0.732 0.021, 0.894 0.026, 0.868 -0.088, 0.356 -0.020, 0.898 
    SNP-by-CA Inter 0.259, 0.405 0.021, 0.941 0.271, 0.210 -0.229, 0.343 -0.076, 0.757 -0.216, 0.374 0.090, 0.548 -0.057, 0.818 
    SNP-by-AO Inter 0.146, 0.602 -0.116, 0.648 0.318, 0.106 0.001, 0.996 -0.291, 0.193 0.140, 0.526 0.150, 0.270 0.170, 0.449 
 
PGRrs474320 n=196 n=196 n=197 n=196 n=197 n=197 n=197 n=197 
  Main Effects Model         
    SNP Main Effect 0.186, 0.196 0.041, 0.762 0.147, 0.137 -0.009, 0.933 0.066, 0.573 -0.150, 0.167 0.043, 0.518 0.158, 0.163 
  Interaction Model         
    SNP Main Effect 0.248, 0.247 -0.133, 0.506 0.341, 0.022* -0.079, 0.638 -0.098, 0.574 -0.082, 0.616 0.076, 0.459 0.308, 0.069 
    SNP-by-CA Inter 0.168, 0.643 0.384, 0.256 -0.392, 0.116 0.352, 0.214 0.296, 0.315 -0.012, 0.965 0.001, 0.994 -0.215, 0.449 
    SNP-by-AO Inter -0.356, 0.292 0.225, 0.477 -0.321, 0.168 -0.084, 0.752 0.310, 0.261 -0.214, 0.407 -0.160, 0.321 -0.301, 0.258 
 
PGRrs4754732 n=219 n=219 n=220 n=219 n=220 n=220 n=220 n=220 
  Main Effects Model         
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    SNP Main Effect -0.021, 0.867 0.016, 0.888 0.074, 0.389 0.049, 0.612 0.125, 0.197 0.070, 0.467 0.051, 0.375 0.012, 0.898 
  Interaction Model         
    SNP Main Effect -0.053, 0.786 0.040, 0.820 -0.015, 0.915 -0.053, 0.732 0.094, 0.533 -0.012, 0.939 -0.042, 0.644 -0.134, 0.380 
    SNP-by-CA Inter -0.006, 0.986 0.057, 0.844 0.162, 0.472 0.335, 0.184 0.399, 0.109 0.268, 0.283 0.220, 0.141 0.368, 0.143 
    SNP-by-AO Inter 0.090, 0.745 -0.105, 0.668 0.130, 0.498 0.055, 0.799 -0.164, 0.441 0.048, 0.821 0.106, 0.405 0.150, 0.486 
 
PGRrs484389 n=211 n=211 n=212 n=211 n=212 n=212 n=212 n=212 
  Main Effects Model         
    SNP Main Effect 0.058, 0.637 0.089, 0.420 -0.005, 0.952 0.063, 0.515 0.047, 0.639 -0.199, 0.037* -0.066, 0.268 -0.097, 0.323 
  Interaction Model         
    SNP Main Effect 0.112, 0.579 0.014, 0.939 0.318, 0.024* 0.007, 0.967 -0.024, 0.885 -0.220, 0.162 0.012, 0.906 0.160, 0.318 
    SNP-by-CA Inter 0.240, 0.443 -0.029, 0.919 -0.529, 0.016* 0.191, 0.439 0.069, 0.786 0.128, 0.599 -0.130, 0.401 -0.380, 0.126 
    SNP-by-AO Inter -0.377, 0.192 0.270, 0.295 -0.494, 0.015* 0.004, 0.984 0.152, 0.519 -0.044, 0.844 -0.145, 0.313 -0.439, 0.056 
 
PGRrs568157 n=218 n=218 n=219 n=218 n=219 n=219 n=219 n=219 
  Main Effects Model         
    SNP Main Effect 0.119, 0.381 0.064, 0.603 0.142, 0.131 0.004, 0.973 0.228, 0.034* -0.088, 0.405 0.063, 0.320 0.067, 0.527 
  Interaction Model         
    SNP Main Effect 0.057, 0.806 -0.151, 0.468 0.139, 0.390 -0.048, 0.794 0.054, 0.768 -0.383, 0.033* -0.029, 0.788 -0.055, 0.765 
    SNP-by-CA Inter 0.052, 0.890 0.353, 0.298 -0.051, 0.842 0.339, 0.241 0.517, 0.074 0.543, 0.057 0.199, 0.250 0.265, 0.363 
    SNP-by-AO Inter 0.112, 0.715 0.295, 0.286 0.028, 0.896 -0.046, 0.849 0.068, 0.778 0.373, 0.115 0.113, 0.433 0.124, 0.608 
 
PGRrs590688 n=214 n=214 n=215 n=214 n=215 n=215 n=215 n=215 
  Main Effects Model         
    SNP Main Effect 0.114, 0.404 -0.119, 0.329 0.083, 0.384 -0.072, 0.500 -0.052, 0.632 -0.058, 0.585 0.010, 0.879 0.046, 0.667 
  Interaction Model         
    SNP Main Effect -0.013, 0.958 -0.222, 0.297 0.228, 0.175 -0.165, 0.381 0.015, 0.937 -0.077, 0.682 0.162, 0.151 0.270, 0.143 
    SNP-by-CA Inter 0.478, 0.186 0.328, 0.314 -0.235, 0.354 0.430, 0.130 0.217, 0.450 -0.097, 0.731 -0.245, 0.152 -0.194, 0.487 
    SNP-by-AO Inter -0.005, 0.988 0.051, 0.858 -0.211, 0.351 -0.050, 0.843 -0.292, 0.256 0.106, 0.676 -0.209, 0.171 -0.416, 0.095 
 
PGRrs608995 n=217 n=217 n=218 n=217 n=218 n=218 n=218 n=218 
  Main Effects Model         
    SNP Main Effect 0.063, 0.604 0.051, 0.641 0.011, 0.897 0.055, 0.565 0.057, 0.551 -0.149, 0.115 -0.038, 0.512 -0.069, 0.471 
  Interaction Model         
    SNP Main Effect 0.132, 0.502 0.007, 0.969 0.324, 0.020* -0.002, 0.990 -0.024, 0.880 -0.167, 0.285 0.015, 0.876 0.192, 0.218 
    SNP-by-CA Inter 0.176, 0.567 -0.045, 0.872 -0.538, 0.013* 0.167, 0.495 0.129, 0.598 0.132, 0.587 -0.097, 0.517 -0.357, 0.142 
    SNP-by-AO Inter -0.369, 0.188 0.176, 0.494 -0.464, 0.019* 0.027, 0.903 0.132, 0.554 -0.052, 0.815 -0.072, 0.599 -0.460, 0.039* 
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RACGAP1rs7303531 n=213 n=214 n=214 n=213 n=214 n=214 n=214 n=214 
  Main Effects Model         
    SNP Main Effect -0.141, 0.464 -0.197, 0.239 0.057, 0.670 0.160, 0.281 0.017, 0.913 0.119, 0.422 0.056, 0.534 0.223, 0.144 
  Interaction Model         
    SNP Main Effect -0.546, 0.101 0.015, 0.959 0.023, 0.922 0.368, 0.158 -0.155, 0.562 0.326, 0.207 0.001, 0.997 0.096, 0.718 
    SNP-by-CA Inter 0.719, 0.155 -0.433, 0.327 0.191, 0.594 -0.241, 0.542 0.524, 0.195 -0.148, 0.704 0.276, 0.240 0.296, 0.461 
    SNP-by-AO Inter 0.518, 0.233 -0.232, 0.543 -0.011, 0.971 -0.363, 0.286 0.070, 0.840 -0.362, 0.283 -0.113, 0.576 0.124, 0.719 
 
RFC4rs1354091 n=213 n=213 n=214 n=213 n=214 n=214 n=214 n=214 
  Main Effects Model         
    SNP Main Effect 0.047, 0.704 0.174, 0.107 0.057, 0.509 0.080, 0.403 0.173, 0.069 0.077, 0.418 0.094, 0.108 0.014, 0.884 
  Interaction Model         
    SNP Main Effect -0.068, 0.731 0.165, 0.341 -0.015, 0.915 -0.209, 0.174 0.063, 0.681 0.241, 0.114 0.095, 0.318 0.132, 0.388 
    SNP-by-CA Inter 0.056, 0.868 0.076, 0.797 0.201, 0.382 0.472, 0.066 0.264, 0.302 -0.290, 0.256 0.071, 0.656 -0.110, 0.667 
    SNP-by-AO Inter 0.262, 0.352 -0.031, 0.900 0.068, 0.728 0.444, 0.041* 0.133, 0.537 -0.241, 0.262 -0.050, 0.711 -0.234, 0.279 
 
RRM2rs1138729 n=201 n=202 n=202 n=201 n=202 n=202 n=202 n=202 
  Main Effects Model         
    SNP Main Effect 0.123, 0.388 0.030, 0.810 0.148, 0.132 0.008, 0.941 0.017, 0.884 0.083, 0.449 -0.005, 0.939 0.112, 0.336 
  Interaction Model         
    SNP Main Effect 0.256, 0.276 0.151, 0.469 0.245, 0.135 0.323, 0.073 0.137, 0.478 0.048, 0.796 -0.024, 0.835 -0.079, 0.680 
    SNP-by-CA Inter -0.002, 0.996 -0.019, 0.953 -0.221, 0.382 -0.207, 0.456 0.046, 0.876 -0.068, 0.812 0.119, 0.500 0.290, 0.327 
    SNP-by-AO Inter -0.396, 0.235 -0.312, 0.293 -0.097, 0.677 -0.699, 0.007* -0.379, 0.166 0.148, 0.572 -0.083, 0.608 0.293, 0.280 
 
RRM2rs4309551 n=217 n=217 n=218 n=217 n=218 n=218 n=218 n=218 
  Main Effects Model         
    SNP Main Effect -0.024, 0.852 0.021, 0.858 0.114, 0.206 0.035, 0.730 0.106, 0.293 0.102, 0.308 0.047, 0.449 0.048, 0.640 
  Interaction Model         
    SNP Main Effect 0.076, 0.734 0.335, 0.100 0.108, 0.495 0.090, 0.608 0.065, 0.713 0.317, 0.069 -0.083, 0.417 -0.139, 0.437 
    SNP-by-CA Inter -0.089, 0.795 -0.466, 0.133 0.183, 0.445 -0.145, 0.590 0.108, 0.687 -0.182, 0.490 0.447, 0.004* 0.341, 0.207 
    SNP-by-AO Inter -0.189, 0.538 -0.504, 0.071 -0.094, 0.664 -0.036, 0.881 0.033, 0.893 -0.392, 0.100 -0.001, 0.992 0.216, 0.375 
 
RRM2rs4668664 n=214 n=214 n=215 n=215 n=215 n=215 n=215 n=215 
  Main Effects Model         
    SNP Main Effect -0.026, 0.829 0.005, 0.964 0.036, 0.677 0.063, 0.506 0.113, 0.234 0.039, 0.676 0.009, 0.871 0.003, 0.978 
  Interaction Model         
    SNP Main Effect 0.080, 0.679 0.073, 0.686 0.009, 0.949 -0.026, 0.867 0.037, 0.814 0.086, 0.582 -0.078, 0.415 -0.042, 0.795 
    SNP-by-CA Inter -0.297, 0.343 -0.254, 0.378 0.081, 0.720 -0.010, 0.687 -0.074, 0.768 -0.029, 0.907 0.232, 0.128 -0.010, 0.969 
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    SNP-by-AO Inter -0.065, 0.813 0.005, 0.983 0.016, 0.937 0.286, 0.194 0.263, 0.235 -0.099, 0.653 0.058, 0.665 0.120, 0.594 
 
SCUBE2rs1136966 n=212 n=213 n=213 n=212 n=213 n=213 n=213 n=213 
  Main Effects Model         
    SNP Main Effect 0.058, 0.646 0.046, 0.673 -0.019, 0.829 0.031, 0.751 0.078, 0.432 0.042, 0.663 0.061, 0.291 -0.019, 0.850 
  Interaction Model         
    SNP Main Effect 0.109, 0.598 -0.037, 0.839 -0.087, 0.544 0.100, 0.538 0.278, 0.092 -0.080, 0.612 0.119, 0.211 -0.189, 0.251 
    SNP-by-CA Inter -0.115, 0.726 -0.020, 0.943 -0.003, 0.988 -0.101, 0.691 -0.407, 0.116 0.063, 0.799 -0.204, 0.173 0.227, 0.380 
    SNP-by-AO Inter -0.053, 0.855 0.249, 0.326 0.167, 0.407 -0.107, 0.640 -0.279, 0.227 0.260, 0.244 0.000, 0.997 0.284, 0.218 
 
SCUBE2rs4910440 n=218 n=218 n=219 n=218 n=219 n=219 n=219 n=219 
  Main Effects Model         
    SNP Main Effect -0.020, 0.882 0.081, 0.491 -0.002, 0.987 -0.010, 0.921 -0.046, 0.653 -0.014, 0.892 0.053, 0.388 0.042, 0.686 
  Interaction Model         
    SNP Main Effect -0.367, 0.083 0.082, 0.666 -0.004, 0.981 -0.238, 0.158 -0.121, 0.462 0.076, 0.641 0.152, 0.116 0.088, 0.593 
    SNP-by-CA Inter 0.628, 0.059 0.007, 0.983 0.004, 0.985 0.268, 0.306 0.146, 0.573 -0.137, 0.593 -0.083, 0.585 -0.113, 0.664 
    SNP-by-AO Inter 0.525, 0.088 -0.008, 0.976 0.003, 0.988 0.421, 0.084 0.114, 0.635 -0.153, 0.522 -0.220, 0.119 -0.039, 0.872 
 
SCUBE2rs6486125 n=206 n=206 n=207 n=206 n=207 n=207 n=207 n=207 
  Main Effects Model         
    SNP Main Effect 0.087, 0.476 -0.001, 0.992 -0.116, 0.177 -0.193, 0.043* -0.095, 0.321 0.042, 0.660 -0.070, 0.238 -0.056, 0.563 
  Interaction Model         
    SNP Main Effect 0.244, 0.215 0.241, 0.175 -0.320, 0.020* -0.392, 0.011* 0.002, 0.990 -0.043, 0.782 -0.188, 0.051 -0.121, 0.437 
    SNP-by-CA Inter -0.653, 0.043* -0.528, 0.069 0.333, 0.136 0.133, 0.593 -0.187, 0.457 0.065, 0.795 0.181, 0.245 -0.044, 0.863 
    SNP-by-AO Inter -0.003, 0.992 -0.282, 0.267 0.313, 0.112 0.417, 0.058 -0.149, 0.501 0.166, 0.453 0.202, 0.141 0.200, 0.369 
Note. *=p<0.05; AO=Prescribed Anastrozole Only; CA=Prescribed Chemotherapy plus Anastrozole; Inter=Interaction; SNP=Single Nucleotide Polymorphism.  
aCoefficient estimation omitted in the robust regression model as the only participant prescribed CA with an MYBL2rs11556379 variant allele was removed by the robust 
regression analysis; results from the standard regression model are reported. bRobust regression did not converge after 1000 iterations; results from standard regression 
model reported.    All regression coefficient estimates and p-values reported from robust multiple linear regression models generated using Huber weighting and biweighting 
iterations.  In all models, the prescribed treatment groups, CA and AO, were compared to the reference healthy control group and possession of one or more minor alleles 
(i.e., homozygous variant genotype plus heterozygous genotype) was compared to the reference, wildtype genotype. All models are adjusted for age, estimated verbal 
intelligence, levels of depressive symptoms, anxiety, fatigue, and pain, and prescribed treatment group.   
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Table 19:  ERBB2 SNPs and Cognitive Function Robust Regression Results in Women with Breast Cancer by HER2 IHC Classification Score 
Regression 
coefficient, p-value Attention Concentration 
Executive 
Function 
Mental 
Flexibility 
Psychomotor 
Speed 
Verbal 
Memory 
Visual 
Memory 
Visual Working 
Memory 
ERBB2rs1058808 n=117 n=117 n=118 n=118 n=118 n=118 n=118 n=118 
    HER2 IHC Score Effect -0.184, 0.197 0.010, 0.942 0.088, 0.350 -0.016, 0.878 -0.192, 0.107 -0.065, 0.531 -0.065, 0.330 0.015, 0.888 
    SNP Effect 0.162, 0.527 0.056, 0.822 -0.162, 0.366 0.227, 0.237 -0.203, 0.367 0.006, 0.979 0.126, 0.322 0.242, 0.220 
    Interaction Effect 0.147, 0.419 0.006, 0.970 -0.003, 0.983 -0.121, 0.360 0.193, 0.214 0.000, 0.998 -0.055, 0.525 -0.292, 0.033* 
 
ERBB2rs1136201 n=119 n=119 n=120 n=120 n=120 n=120 n=120 n=120 
    HER2 IHC Score Effect -0.114, 0.269 -0.040, 0.663 0.067, 0.344 -0.113, 0.133 -0.104, 0.237 -0.032, 0.673 -0.129, 0.010* -0.190, 0.016* 
    SNP Effect -0.377, 0.175 -0.419, 0.108 0.036, 0.853 -0.066, 0.748 -0.038, 0.877 0.133, 0.525 -0.135, 0.320 -0.213, 0.321 
    Interaction Effect 0.196, 0.296 0.156, 0.108 0.036, 0.782 0.097, 0.482 0.073, 0.656 -0.123, 0.384 0.089, 0.327 0.058, 0.686 
 
ERBB2rs1476278 n=119 n=119 n=120 n=120 n=120 n=120 n=120 n=120 
    HER2 IHC Score Effect -0.108, 0.449 0.000, 0.998 0.097, 0.298 0.044, 0.653 -0.172, 0.143 -0.140, 0.167 -0.130, 0.048* -0.066, 0.526 
    SNP Effect 0.220, 0.400 -0.083, 0.738 -0.144, 0.420 0.214, 0.258 -0.240, 0.288 -0.074, 0.702 0.067, 0.592 0.201, 0.315 
    Interaction Effect 0.027, 0.883 0.026, 0.880 -0.010, 0.937 -0.200, 0.122 0.173, 0.259 0.113, 0.393 0.036, 0.673 -0.159, 0.242 
 
ERBB2rs1810132 n=113 n=114 n=114 n=114 n=114 n=114 n=114 n=114 
    HER2 IHC Score Effect -0.271, 0.035* 0.028, 0.807 0.098, 0.236 -0.091, 0.327 -0.167, 0.131 -0.063, 0.496 -0.039, 0.534 -0.083, 0.392 
    SNP Effect -0.151, 0.570 0.090, 0.714 -0.244, 0.175 -0.053, 0.791 -0.159, 0.506 0.095, 0.636 0.186, 0.167 0.193, 0.359 
    Interaction Effect 0.321, 0.073 -0.014, 0.930 0.042, 0.724 0.018, 0.890 0.150, 0.343 -0.035, 0.794 -0.095, 0.287 -0.191, 0.171 
 
ERBB2rs2517955 n=119 n=119 n=120 n=120 n=120 n=120 n=120 n=120 
    HER2 IHC Score Effect -0.169, 0.268 -0.048, 0.726 0.152, 0.112 -0.010, 0.921 -0.187, 0.128 -0.111, 0.296 -0.062, 0.376 0.018, 0.868 
    SNP Effect 0.126, 0.630 -0.060, 0.808 -0.157, 0.370 0.171, 0.373 -0.258, 0.252 -0.067, 0.730 0.124, 0.335 0.270, 0.170 
    Interaction Effect 0.110, 0.558 0.087, 0.610 -0.079, 0.514 -0.117, 0.381 0.184, 0.238 0.067, 0.622 -0.065, 0.466 -0.278, 0.043* 
 
ERBB2rs4252596 n=119 n=119 n=120 n=120 n=120 n=120 n=120 n=120 
    HER2 IHC Score Effect -0.127, 0.192 -0.005, 0.959 0.068, 0.331 -0.070, 0.336 -0.037, 0.654 -0.105, 0.147 -0.102, 0.037* -0.186, 0.016* 
    SNP Effect -0.749, 0.020* -0.143, 0.633 -0.065, 0.774 0.075, 0.750 0.492, 0.070 -0.178, 0.448 -0.066, 0.672 -0.175, 0.483 
    Interaction Effect 0.387, 0.057 0.069, 0.706 0.032, 0.819 -0.067, 0.642 -0.255, 0.122 0.157, 0.273 0.014, 0.881 0.085, 0.574 
 
ERBB2rs903501 n=112 n=113 n=113 n=113 n=113 n=113 n=113 n=113 
    HER2 IHC Score Effect -0.226, 0.084 -0.010, 0.934 0.111, 0.184 -0.043, 0.641 -0.118, 0.298 -0.083, 0.371 -0.089, 0.135 -0.162, 0.101 
    SNP Effect -0.132, 0.624 -0.100, 0.690 -0.181, 0.321 0.007, 0.972 -0.151, 0.542 0.058, 0.774 0.125, 0.336 0.135, 0.531 
    Interaction Effect 0.255, 0.168 0.075, 0.657 -0.002, 0.985 -0.076, 0.575 0.072, 0.665 0.017, 0.901 -0.008, 0.927 -0.067, 0.643 
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ERBB2rs9303274 n=118 n=118 n=119 n=119 n=119 n=119 n=119 n=119 
    HER2 IHC Score Effect -0.059, 0.677 -0.031, 0.813 0.106, 0.255 0.056, 0.573 -0.145, 0.208 -0.142, 0.161 -0.111, 0.100 -0.067, 0.519 
    SNP Effect 0.274, 0.298 -0.099, 0.696 -0.140, 0.437 0.249, 0.198 -0.184, 0.411 -0.096, 0.623 0.083, 0.525 0.197, 0.332 
    Interaction Effect -0.025, 0.892 0.074, 0.665 -0.029, 0.813 -0.215, 0.102 0.144, 0.344 0.113, 0.397 0.008, 0.932 -0.159, 0.249 
 
MIR125Ars12976445 n=119 n=119 n=120 n=120 n=120 n=120 n=120 n=120 
    HER2 IHC Score Effect -0.005, 0.966 -0.021, 0.853 -0.011, 0.888 -0.045, 0.611 -0.159, 0.128 0.016, 0.854 -0.101, 0.084 -0.186, 0.049* 
    SNP Effect 0.097, 0.709 0.002, 0.995 -0.070, 0.691 0.016, 0.933 -0.197, 0.381 0.176, 0.361 -0.037, 0.765 -0.048, 0.810 
    Interaction Effect -0.137, 0.430 0.087, 0.584 0.184, 0.114 -0.081, 0.517 0.167, 0.257 -0.173, 0.171 -0.004, 0.964 0.045, 0.732 
Note. *=p<0.05; HER2= Human Epidermal Growth Factor Receptor 2; IHC=Immunohistochemistry; SNP=Single Nucleotide Polymorphism.  All regression coefficient 
estimates and p-values reported from robust multiple linear regression models generated using Huber weighting and biweighting iterations.  In all models, possession of one 
or more minor alleles (i.e., homozygous variant genotype plus heterozygous genotype) was compared to the reference, wildtype genotype. All models are adjusted for age, 
estimated verbal intelligence, and levels of depressive symptoms, anxiety, fatigue, and pain.  
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Table 20:  MKI67 SNPs and Cognitive Function Robust Regression Results in Women with Breast Cancer by Ki67 Index 
 
b-coefficient, p-value Attention Concentration 
Executive  
Function 
Mental  
Flexibility 
Psychomotor 
Speed 
Verbal 
Memory 
Visual  
Memory 
Visual Working 
Memory 
MKI67rs10732438 n=66 n=65 n=66 n=66 n=65 n=66 n=66 n=66 
    Ki67 Index Effect 0.002, 0.803 -0.004, 0.528 -0.002, 0.716 -0.015, 0.006* 0.002, 0.844 -0.003, 0.673 -0.002, 0.397 -0.002, 0.717 
    SNP Effect 0.017, 0.955 -0.120, 0.660 -0.116, 0.597 -0.621, 0.004* -0.198, 0.425 -0.238, 0.355 -0.135, 0.185 -0.086, 0.705 
    Interaction Effect 0.008, 0.441 -0.001, 0.940 0.009, 0.221 0.016, 0.023* 0.008, 0.392 0.004, 0.662 0.006, 0.067 0.005, 0.526 
 
MKI67rs10764751 n=68 n=67 n=68 n=68 n=68 n=68 n=68 n=68 
    Ki67 Index Effect 0.009, 0.102 -0.005, 0.404 0.000, 0.931 -0.002, 0.719 -0.006, 0.220 0.002, 0.630 0.002, 0.486 0.003, 0.584 
    SNP Effect 0.154, 0.586 -0.005, 0.986 -0.331, 0.158 0.180, 0.459 -0.195, 0.446 0.159, 0.529 0.037, 0.737 0.003, 0.989 
    Interaction Effect 0.008, 0.455 0.001, 0.958 0.009, 0.325 -0.001, 0.948 0.013, 0.188 -0.010, 0.309 0.000, 0.955 -0.003, 0.733 
Note. *=p<0.05; SNP=Single Nucleotide Polymorphism.  All regression coefficient estimates and p-values reported from robust multiple linear regression models generated 
using Huber weighting and biweighting iterations.  In all models, possession of one or more minor alleles (i.e., homozygous variant genotype plus heterozygous genotype) 
was compared to the reference, wildtype genotype. All models are adjusted for age, estimated verbal intelligence, and levels of depressive symptoms, anxiety, fatigue, and 
pain. 
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Table 21:  Significant (p<0.05) Interaction between Tumor Location  
Octant and GRS for Visual Working Memory Composite 
Visual Working Memory (n=81) regression coefficient, 
p-value 
    Tumor Octant Main Effect  
        Lower Outer 0.427, 0.068 
        Lower Inner 0.081, 0.709 
        Upper Inner 0.008, 0.969 
        Upper Middle 0.061, 0.706 
        Outer Middle 0.180, 0.358 
        Lower Middle -4.539, 0.126 
        Inner Middle -0.001, 0.998 
    Visual Working Memory GRS Main Effect 0.437, <0.001* 
    Interaction  
        Lower Outer x GRS 0.479, 0.045* 
        Lower Inner x GRS 0.243, 0.440 
        Upper Inner x GRS -0.174, 0.324 
        Upper Middle x GRS -0.292, 0.209 
        Outer Middle x GRS 0.274, 0.184 
        Lower Middle x GRS -2.911, 0.153 
        Inner Middle x GRS 0.132, 0.793 
Note. *=p<0.05; GRS=Genetic Risk/Protection Score. Upper outer octant 
served as the tumor location octant reference group. Regression coefficient 
estimates and p-values reported from a robust multiple linear regression 
model generated using Huber weighting and biweighting iterations. Model 
adjusted for age, estimated verbal intelligence, and levels of depressive 
symptoms, anxiety, fatigue, and pain.  
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Table 22:  Significant (p<0.05) Individual CTFs Tested for  
Interactions with GRSs by Cognitive Function Composite 
Cognitive Function Composite Feature with p<0.05 
Attention Tumor Location Octant 
Concentration Ki67 Classification 
Executive Function - 
Mental Flexibility Tumor Octant 
Oncotype DX Recurrence Score® 
Psychomotor Speed - 
Verbal Memory Tumor Focality 
Tumor Laterality 
PR Status (+/-) 
HER2 Status (+/-) 
Oncotype DX Recurrence Score® Squared 
Visual Memory HER2 Status (+/-) 
HER2 IHC Classification Score 
Oncotype DX HER2 Score Squared 
Magee Equation Recurrence Score Squared 
Visual Working Memory Overall TNM Stage 
Tumor Laterality 
Tumor Location Octant 
HER2 Status (+/-) 
HER2 IHC Classification Score 
Magee Equation Recurrence Score Squared 
Note.  CTF=Clinicopathologic Tumor Feature; GRS=Genetic Risk/Protection 
Score; HER2=Human Epidermal Growth Factor Receptor 2; 
IHC=Immunohistochemistry; Oncotype DX=Genomic Health Inc. Oncotype 
DX® Breast Cancer Assay; PR=Progesterone Receptor; TNM=Tumor, Node, 
Metastasis Classification of Malignant Tumors. 
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Table 23:  Statistically Significant (p<0.05) Terms from Individual and 
Interaction Models Evaluated for Inclusion in Final CTF Model 
Cognitive Function 
Composite Clinicopathologic Tumor Feature 
Attention 
(n=95) 
Tumor Location Octant* 
Invasive Type 
ER H-Score* 
Oncotype DX PR Score* 
Oncotype DX PR Score Squared 
Tumor Location Octant by Invasive Type% 
ER H-Score by Oncotype DX PR Score* 
ER H-Score by Oncotype DX PR Score Squared 
Concentration 
(n=65) 
Ki67 Classification* 
Oncotype DX HER2 Score* 
Oncotype DX HER2 Score Squared* 
Oncotype DX Recurrence Score®* 
Oncotype DX Recurrence Score® Squared* 
Oncotype DX HER2 Score by Oncotype DX Recurrence Score®* 
Oncotype DX HER2 Score Squared by Oncotype DX Recurrence Score®* 
Oncotype DX HER2 Score by Oncotype DX Recurrence Score® Squared* 
Oncotype DX HER2 Score Squared by Oncotype DX Recurrence Score® Squared* 
Executive Function 
(n=76) 
Tumor Location Octant# 
Ki67 Classification# 
Ki67 Index* 
Oncotype DX ER Score* 
Tumor Location Octant by Oncotype DX ER Score# 
Tumor Location Octant by Ki67 Classification# 
Tumor Location Octant by Ki67 Index# 
Ki67 Classification by Oncotype DX ER Score# 
Ki67 Index by Oncotype DX ER Score* 
Mental Flexibility 
(n=101) 
Tumor Location Octant* 
Oncotype DX Recurrence Score® 
Oncotype DX PR Score* 
Oncotype DX PR Score Squared* 
Tumor Location Octant by Oncotype DX PR Score* 
Tumor Location Octant by Oncotype DX PR Score Squared* 
Psychomotor Speed 
(n=75) 
Overall TNM Stage 
Tumor Location Octant* 
Ki67 Classification# 
Ki67 Index* 
Oncotype DX PR Score 
Oncotype DX PR Score Squared 
Overall TNM Stage by KI67 Classification# 
Tumor Location Octant by KI67 Classification#% 
Ki67 Classification by Oncotype DX PR Score# 
Ki67 Classification by Oncotype DX PR Score Squared# 
Overall TNM Stage by Ki67 Index 
Overall TNM Stage by Ki67 Index Squared* 
Tumor Location Octant by Ki67 Index# 
Tumor Location Octant by Ki67 Index Squared# 
Verbal Memory 
(n=152) 
Tumor Location Octant* 
Tumor Focality* 
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Tumor Laterality 
PR Status(+/-)* 
HER2 Status (+/-) 
Oncotype DX Recurrence Score® 
Oncotype DX Recurrence Score® Squared 
PR Status (+/-) by HER2 Status (+/-) 
Tumor Location Octant by Oncotype DX Recurrence Score®* 
Tumor Location Octant by Oncotype DX Recurrence Score® Squared* 
Visual Memory 
(n=64) 
Overall TNM Stage* 
HER2 Status (+/-)* 
HER2 IHC Classification Score 
Oncotype DX ER Score* 
Oncotype DX HER2 Score 
Oncotype DX HER2 Score Squared 
Magee Equation Recurrence Score* 
Magee Equation Recurrence Score Squared* 
HER2 Status (+/-) by Oncotype DX ER Score* 
Overall TNM Stage by Magee Equation Recurrence Score* 
Overall TNM Stage by Magee Equation Recurrence Score Squared* 
Visual Working Memory 
(n=133) 
Overall TNM Stage 
Tumor Size* 
Tumor Size Squared* 
Tumor Laterality 
Tumor Location Octant* 
Nottingham Score* 
Nottingham Grade# 
HER2 Status (+/-)# 
HER2 IHC Classification Score 
HER2 IHC Classification Score Squared 
Oncotype DX Recurrence Score® 
Magee Equation Recurrence Score 
Magee Equation Recurrence Score Squared 
Tumor Laterality by Tumor Location Octant* 
Tumor Location Octant by HER2 Status (+/-)% 
Tumor Location Octant by Oncotype DX Recurrence Score®* 
Nottingham Score by HER2 IHC Classification Score* 
Nottingham Grade by HER2 IHC Classification Score# 
HER2 IHC Classification Score by Tumor Size* 
HER2 IHC Classification Score by Tumor Size Squared* 
Tumor Location Octant by HER2 IHC Classification Score* 
Tumor Location Octant by HER2 IHC Classification Score Squared# 
Oncotype DX Recurrence Score® by HER2 IHC Classification Score* 
Oncotype DX Recurrence Score® by HER2 IHC Classification Score Squared 
Note. *=p<0.20, #=omitted from model due to collinearity, %=omitted from model due to limited variability; 
ER=Estrogen Receptor; HER2=Human Epidermal Growth Factor Receptor 2; IHC=Immunohistochemistry; 
Oncotype DX=Genomic Health Inc. Oncotype DX® Breast Cancer Assay; PR=Progesterone Receptor; 
TNM=Tumor, Node, Metastasis Classification of Malignant Tumors.  All term designations obtained from 
robust multiple linear regression models generated using Huber weighting and biweighting iterations. All 
models adjusted for age, estimated verbal intelligence, and levels of depressive symptoms, anxiety, fatigue, and 
pain.   
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Table 24:  R2 for Final Combined CTF plus GRS and Cognitive Function Regression Models 
Cognitive Function 
Composites 
 
Predictors with p<0.20 from  
Full CTF Models 
 
 
R2 Final  
CTF  
Model 
R2 Final  
CTF plus GRS 
Model 
Attention Tumor Location Octant 
ER H-Score 
Oncotype DX PR Score 
ER H-Score by Oncotype DX PR Score 
0.3075 
(n=95) 
0.5760 
(n=38) 
Concentration Ki67 Classification 
Oncotype DX HER2 Score 
Oncotype DX HER2 Score Squared 
Oncotype DX Recurrence Score® 
Oncotype DX Recurrence Score® Squared 
Oncotype DX HER2 Score by Oncotype DX Recurrence Score® 
Oncotype DX HER2 Score Squared by Oncotype DX Recurrence Score® 
Oncotype DX HER2 Score by Oncotype DX Recurrence Score® Squared 
Oncotype DX HER2 Score Squared by Oncotype DX Recurrence Score® Squared 
0.2103 
(n=66) 
0.9548 
(n=24) 
 
 
Executive Function Ki67 Index 
Oncotype DX ER Score 
Ki67 Index by Oncotype DX ER Score 
0.3349 
(n=76) 
0.7286 
(n=23) 
Mental Flexibility Tumor Location Octant 
Oncotype DX PR Score 
Oncotype DX PR Score Squared 
Tumor Location Octant by Oncotype DX PR Score 
Tumor Location Octant by Oncotype DX PR Score Squared 
0.5488 
(n=101) 
0.9456 
(n=32) 
Psychomotor Speed Overall TNM Stage 
Tumor Location Octant 
Ki67 Index 
Overall TNM Stage by Ki67 Index 
Overall TNM Stage by Ki67 Index Squared 
0.4230 
(n=166) 
0.7790 
(n=54) 
Verbal Memory Tumor Location Octant 
Tumor Focality 
PR Status(+/-) 
Oncotype DX Recurrence Score® 
Oncotype DX Recurrence Score® Squared 
Tumor Location Octant by Oncotype DX Recurrence Score® 
Tumor Location Octant by Oncotype DX Recurrence Score® Squared 
0.4487 
(n=158) 
 
0.7932 
(n=47) 
147 
Visual Memorya Overall TNM Stage 
HER2 Status (+/-) 
Oncotype DX ER Score 
Magee Equation Recurrence Score 
Magee Equation Recurrence Score Squared 
HER2 Status (+/-) by Oncotype DX ER Score 
TNM Stage by Magee Equation Recurrence Score 
TNM Stage by Magee Equation Recurrence Score Squared 
0.3241 
(n=94) 
0.7249 
(n=31) 
Visual Working 
Memoryb 
Tumor Size 
Tumor Size Squared 
Tumor Laterality 
Tumor Location Octant 
Nottingham Score 
HER2 IHC Classification Score 
Oncotype DX Recurrence Score® 
Tumor Laterality by Tumor Location Octant 
Tumor Location Octant by Oncotype DX Recurrence Score® 
Nottingham Score by HER2 IHC Classification Score 
HER2 IHC Classification Score by Tumor Size 
HER2 IHC Classification Score by Tumor Size Squared 
Tumor Location Octant by HER2 IHC Classification Score 
Oncotype DX Recurrence Score® by HER2 IHC Classification Score 
0.5068 
(n=137) 
0.9531 
(n=44) 
 
Note. CTF=Clinicopathologic Tumor Feature; GRS=Genetic Risk/Protection Score; ER=Estrogen Receptor; HER2=Human Epidermal Growth Factor 
Receptor 2; IHC=Immunohistochemistry; Oncotype DX=Genomic Health Inc. Oncotype DX® Breast Cancer Assay; PR=Progesterone Receptor; 
TNM=Tumor, Node, Metastasis Classification of Malignant Tumors. aIn the combined CTF plus GRS regression model for visual memory, the 
interactions between HER2 status and Oncotype DX ER Score, TNM Stage 2b and Magee Equation Recurrence Score, and TNM Stage 2b and 
Magee Equation Recurrence Score Squared were omitted due to collinearity.  bIn the combined CTF plus GRS regression model for visual working 
memory, the interactions between upper middle, inner middle, and lower middle tumor location octants and HER2 IHC classification score were 
omitted due to collinearity.  The statistically significant interaction between visual working memory GRS and tumor location octant identified from 
the CTF-by-GRS interaction analysis was also omitted from the model due to collinearity.  R2 obtained from standard multiple linear regression 
models. All models are adjusted for age, estimated verbal intelligence, and levels of depressive symptoms, anxiety, fatigue, and pain. 
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Figure 4:  HER2 IHC Classification Score vs. Verbal, Visual, and Visual Working Memory Composite Score Added Variable Plots 
Note.  X=age, estimated verbal intelligence, and levels of depressive symptoms, anxiety, fatigue, pain; HER2=Human Epidermal Growth Factor Receptor 2. 
Figure generated using Stata® Data Analysis and Statistical Software SE Version 14.1 (StataCorp, College Station, TX).
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Figure 5:  Oncotype DX® Breast Cancer Assay Recurrence Score vs. 
Mental Flexibility Composite Score Added Variable Plot 
 
Note. X=age, estimated verbal intelligence, and levels of depressive symptoms, anxiety, fatigue, pain; Oncotype 
DX=Genomic Health Inc. Oncotype DX® Breast Cancer Assay. Figure generated using Stata® Data Analysis and 
Statistical Software SE Version 14.1 (StataCorp, College Station, TX).  
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Note.  The networks were generated through use of QIAGEN’s Ingenuity Pathway Analysis (IPA®, QIAGEN 
Redwood City, www.quigen.com/ingenuity).  Candidate genes are highlighted in yellow.  Colored blocks 
correspond to cognitive function composites that were found to have one or more significant SNP main effects 
and/or SNP-by-prescribed treatment group interactions for a particular gene.    The main associated functions of 
each network are as follows:  (a) cancer, organismal injury and abnormalities, and reproductive system disease; (b) 
cancer, cellular development, and cellular growth and proliferation; and (c) cellular assembly and organization, cell 
morphology, and cellular function and maintenance.   
 
 
 
 
 
Figure 6:  Candidate Gene-Gene Networks Generated Using QIAGEN’s Ingenuity Pathway Analysis 
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Figure 7: GRS by Cognitive Function Composite Score Added Variable Plots 
Note.  X=age, estimated verbal intelligence, levels of depressive symptoms, anxiety, fatigue, pain, and prescribed 
treatment; GRS=Genetic Risk/Protection Score. Figure generated using Stata® Data Analysis and Statistical 
Software SE Version 14.1 (StataCorp, College Station, TX).
154 
APPENDIX C 
UNIVERSITY OF PITTSBURGH INSTITUTIONAL REVIEW BOARD               
APPROVAL LETTERS 
155 
 
156 
 
157 
 
 
 
 
 
 
 
 
158 
 
159 
APPENDIX D 
MANUSCRIPT #1:  MOLECULAR GENOMIC RESEARCH DESIGNS 
160 
161 
162 
163 
164 
165 
166 
167 
168 
169 
170 
171 
172 
173 
174 
175 
176 
177 
178 
179 
 
180 
APPENDIX E 
LICENSE AGREEMENT FOR MANUSCRIPT #1 
181 
182 
183 
184 
185 
 
186 
APPENDIX F 
MANUSCRIPT #2: APOLIPOPROTEIN E GENOTYPE AND COGNITIVE FUNCTION 
IN POSTMENOPAUSAL WOMEN WITH EARLY-STAGE BREAST CANCER 
187 
188 
189 
190 
191 
192 
193 
194 
195 
196 
197 
198 
199 
 
200 
APPENDIX G 
LICENSE AGREEMENT FOR MANUSCRIPT #2 
201 
202 
 
 
203 
 
 
 
204 
 
205 
APPENDIX H 
MANUSCRIPT #3:  IDENTIFICATION AND PRIORITIZATION OF CANDIDATE 
GENES FOR SYMPTOM VARIABILITY IN BREAST CANCER SURVIVORS BASED 
ON DISEASE CHARACTERISTICS AT THE CELLULAR LEVEL 
206 
207 
208 
209 
210 
211 
212 
213 
214 
 
215 
APPENDIX I 
LICENSE AGREEMENT FOR MANUSCRIPT #3 
216 
217 
218 
219 
220 
 
221 
APPENDIX J 
MANUSCRIPT #4:  POLYMORPHISMS IN DNA REPAIR AND OXIDATIVE STRESS 
GENES ASSOCIATED WITH PRE-TREATMENT COGNITIVE FUNCTION IN 
BREAST CANCER SURVIVORS:  AN EXPLORATORY STUDY 
222 
223 
224 
225 
226 
227 
228 
229 
230 
231 
232 
233 
234 
235 
236 
237 
 
238 
BIBLIOGRAPHY 
Abdel-Fatah, T. M., Powe, D. G., Ball, G., Lopez-Garcia, M. A., Habashy, H. O., Green, A. R., 
… Ellis, I. O. (2010). Proposal for a modified grading system based on mitotic index and 
Bcl2 provides objective determination of clinical outcome for patients with breast cancer. 
Journal of Pathology, 222(4), 388–399. doi:10.1002/path.2775 
Agoulnik, I. U., Tong, X. W., Fischer, D. C., Körner, K., Atkinson, N. E., Edwards, D. P., … 
Kieback, D. G. (2004). A germline variation in the progesterone receptor gene increases 
transcriptional activity and may modify ovarian cancer risk. Journal of Clinical 
Endocrinology and Metabolism, 89(12), 6340–6347. doi:10.1210/jc.2004-0114 
Ahles, T. A., & Saykin, A. J. (2007). Candidate mechanisms for chemotherapy-induced 
cognitive changes. Nature Reviews Cancer, 7(3), 192–201. doi:10.1038/nrc2073 
Ahles, T. A., Saykin, A. J., Furstenberg, C. T., Cole, B., Mott, L. A., Skalla, K., … Silberfarb, P. 
M. (2002). Neuropsychologic impact of standard-dose systemic chemotherapy in long-term 
survivors of breast cancer and lymphoma. Journal of Clinical Oncology, 20(2), 485–493. 
doi:10.1200/JCO.20.2.485 
Ahles, T. A., Avenue, L., York, N., Saykin, A. J., Mcdonald, B. C., & Kaufman, P. A. (2011). 
Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer 
Research and Treatment, 110(1), 143–152. doi:10.1007/s10549-007-9686-5.Cognitive 
Ahles, T. A., Root, J. C., & Ryan, E. L. (2012). Cancer- and cancer treatment – associated 
cognitive change: an update on the state of the science. Journal of Clinical Oncology, 
30(30), 3675–3686. doi:10.1200/JCO.2012.43.0116 
Ahles, T. A., Saykin, A. J., Noll, W. W., Furstenberg, C. T., Guerin, S., Cole, B., & Mott, L. A. 
(2003). The relationship of APOE genotype to neuropsychological performance in long-
term cancer survivors treated with standard dose chemotherapy. Psycho-Oncology, 12(6), 
612–619. doi:10.1002/pon.742 
Ahles, T., Li, Y., McDonald, B., Schwartz, G., Kaufman, P., Tsongalis, G., … Saykin, A. (2011). 
Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast 
cancer: the impact of APOE and smoking. Psycho-Oncology, 72(2), 181–204. 
doi:10.1038/nature13314.A 
Aleskandarany, M. A., Soria, D., Green, A. R., Nolan, C., Diez-Rodriguez, M., Ellis, I. O., & 
239 
Rakha, E. A. (2015). Markers of progression in early-stage invasive breast cancer: a 
predictive immunohistochemical panel algorithm for distant recurrence risk stratification. 
Breast Cancer Research and Treatment, 151(2), 325–333. doi:10.1007/s10549-015-3406-3 
American Cancer Society. (2014). Breast cancer: what are the key statistics about breast cancer? 
Retrieved from http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-key-
statistics 
Arriagada, R., Lê, M. G., Contesso, G., Guinebretière, J. M., Rochard, F., & Spielmann, M. 
(2002). Predictive factors for local recurrence in 2006 patients with surgically resected 
small breast cancer. Annals of Oncology, 13(9), 1404–1413. doi:10.1093/annonc/mdf227 
Bao, J., Yu, K. D., Jiang, Y. Z., Shao, Z. M., & Di, G. H. (2014). The effect of laterality and 
primary tumor site on cancer-specific mortality in breast cancer: a SEER population-based 
study. PLoS ONE, 9(4). doi:10.1371/journal.pone.0094815 
Batchelder, A. J., Gordon-Weeks, A. N., & Walker, R. A. (2009). Altered expression of anti-
apoptotic proteins in non-involved tissue from cancer-containing breasts. Breast Cancer 
Research and Treatment, 114(1), 63–69. doi:10.1007/s10549-008-9988-2 
Beck, A. T., Steer, R. A., & Brown, G. K. (1996). Beck Depression Inventory-II. San Antonio: 
The Psychological Corporation. 
Bender, C. M., Merriman, J. D., Gentry, A. L., Ahrendt, G. M., Berga, S. L., Brufsky, A. M., … 
Sereika, S. M. (2015). Patterns of change in cognitive function with anastrozole therapy. 
Cancer, 121(15), 2627–2636. doi:10.1002/cncr.29393 
Bender, C. M., Sereika, S. M., Berga, S. L., Vogel, V. G., Brufsky, A. M., Paraska, K. K., & 
Ryan, C. M. (2006). Cognitive impairment associated with adjuvant therapy in breast 
cancer. Psycho-Oncology, 15(5), 422–430. doi:10.1002/pon.964 
Bender, C. M., Sereika, S. M., Brufsky, A. M., Ryan, C. M., Vogel, V. G., Rastogi, P., … Berga, 
S. L. (2010). Memory impairments with adjuvant anastrozole versus tamoxifen in women 
with early-stage breast cancer. Menopause, 14(6), 995–998. 
doi:10.1097/gme.0b013e318148b28b.Memory 
Bender, C. M., Sereika, S. M., Ryan, C. M., Brufsky, A. M., Puhalla, S., & Berga, S. L. (2013). 
Does lifetime exposure to hormones predict pretreatment cognitive function in women 
before adjuvant therapy for breast cancer? Menopause, 20(9), 1–8. 
doi:10.1097/gme.0b013e3182843eff 
Bender, C. M., Yasko, J. M., Kirkwood, J. M., Ryan, C., Dunbar-Jacob, J., & Zullo, T. (2000). 
Cognitive function and quality of life in interferon therapy for melanoma. Clinical Nursing 
Research, 9(3), 352–363. doi:10.1177/10547730022158537 
Berry, D. T. R., Allen, R. S., & Schmitt, F. A. (1991). Rey-Osterrieth complex figure: 
psychometric characteristics in a geriatric sample. The Clinical Neuropsychologist, 5, 143–
153. doi:10.1080/13854049108403298 
240 
Bornstein, R. A. (1985). Normative data on selected neuropsychological measures from a 
nonclinical sample. Journal of Clinical Psychology, 41, 651–669.  doi: 10.1002/1097-
4679(198509)41:5<651::AID-JCLP2270410511>3.0.CO;2-C 
Bousman, C., Szoeke, C., Chen, K., Dennerstein, L., Henderson, V., & Everall, I. (2012). 
Oestrogen alpha-receptor variant and two-year memory decline in midlife. 
Neuropsychobiology, 66, 259–265. doi:10.1159/000341879 
Boykoff, N., Moieni, M., & Subramanian, S. K. (2009). Confronting chemobrain: an in-depth 
look at survivors’ reports of impact on work, social networks, and health care response. 
Journal of Cancer Survivorship : Research and Practice, 3(4), 223–232. 
doi:10.1007/s11764-009-0098-x 
Bremer, T. M., Jacquemier, J., Charafe-Jauffret, E., Viens, P., Birnbaum, D., & Linke, S. P. 
(2009). Prognostic marker profile to assess risk in stage I-III hormone receptor-positive 
breast cancer patients. International Journal of Cancer, 124(4), 896–904. 
doi:10.1002/ijc.24001 
Brezden, C., Phillips, K., Abdolell, M., Bunston, T., & Tannock, I. F. (2000). Cognitive function 
in breast cancer patients receiving adjuvant chemotherapy. Journal of Clinical Oncology, 
18(14), 2695–2701. 
Brinton, R. D., Thompson, R. F., Foy, M. R., Baudry, M., Wang, J., Finch, C. E., … Nilsen, J. 
(2008). Progesterone receptors: form and function in brain. Frontiers in 
Neuroendocrinology, 29(2), 313–339. doi:10.1016/j.yfrne.2008.02.001 
Britsch, S., Li, L., Kirchhoff, S., Theuring, F., Brinkmann, V., Birchmeier, C., & Riethmacher, 
D. (1998). The ErbB2 and ErbB3 receptors and their ligand, neuregulin-1, are essential for 
development of the sympathetic nervous system. Genes and Development, 12(12), 1825–
1836. doi:10.1101/gad.12.12.1825 
Buyse, M., Loi, S., van’t Veer, L., Viale, G., Delorenzi, M., Glas, A. M., … Piccart, M. J. 
(2006). Validation and clinical utility of a 70-gene prognostic signature for women with 
node-negative breast cancer. Journal of the National Cancer Institute, 98(17), 1183–1192. 
doi:10.1093/jnci/djj329 
Callagy, G. M., Webber, M. J., Pharoah, P. D. P., & Caldas, C. (2008). Meta-analysis confirms 
BCL2 is an independent prognostic marker in breast cancer. BMC Cancer, 8, 153. 
doi:10.1186/1471-2407-8-153 
Capuron, L., Ravaud,  A., & Dantzer, R. (2001). Timing and specificity of the cognitive changes 
induced by interleukin-2 and interferon-alpha treatments in cancer patients. Psychosomatic 
Medicine, 63(3), 376–386. 
Castellon, S. A., Ganz, P. A., Bower, J. E., Petersen, L., Abraham, L., & Greendale, G. A. 
(2004). Neurocognitive performance in breast cancer survivors exposed to adjuvant 
chemotherapy and tamoxifen. Journal of Clinical and Experimental Neuropsychology, 
26(7), 955–969. 
241 
Cleeland, C. S. (1989). Measurement of Pain by Subjective Report. In C. R. Chapman & J. D. 
Loeser (Eds.), Advances in Pain Research and Therapy (Vol 12., pp. 391–403). New York: 
Raven Press. 
Cockburn, J., & Smith, P. T. (1993). Correlates of everyday memory among residents of Part III 
homes. British Journal of Clinical Psychology, 32(Pt 1), 75–77. doi:10.1111/j.2044-
8260.1993.tb01029.x 
Colleoni, M., Zahrieh, D., Gelber, R., Holmberg, S., Mattsson, J., Rudenstam, C., … Goldhirsch, 
A. (2005). Site of primary tumor has a prognostic role in operable breast cancer: the 
International Breast Cancer Study Group experience. Journal of Clinical Oncology, 23(7), 
1390–1400. doi:10.1200/JCO.2005.06.052 
Dawson, S. J., Makretsov, N., Blows, F. M., Driver, K. E., Provenzano, E., Le Quesne, J., … 
Pharoah, P. (2010). BCL2 in breast cancer: a favourable prognostic marker across 
molecular subtypes and independent of adjuvant therapy received. British Journal of 
Cancer, 103(5), 668-675. doi:10.1038/sj.bjc.6605921 
Delis, D. C., Kaplan, E., & Kramer, J. H. (2001). Delis-Kaplan (D-KEFS) Executive Function 
System, Examiners Manual. San Antonio: The Psychological Corporation. 
DNA Genotek Inc. (2012). Laboratory protocol for manual purification of DNA from whole 
sample. OraSure Technologies, Inc. 
Downie, F. P., Mar Fan, H. G., Houédé-Tchen, N., Yi, Q., & Tannock, I. F. (2006). Cognitive 
function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant 
chemotherapy: evaluation with patient interview after formal assessment. Psycho-Oncology, 
15(10), 921–930. doi:10.1002/pon.1035 
Dowset, M., Sestak, I., Lopez-Knowles, E., Sidhu, K., Dunbier, A., Cowens, J., … Cuzick, J. 
(2013). Comparison of PAM50 risk of recurrence score with Oncotype DX and IHC4 for 
predicting risk of distant recurrence after endocrine therapy. Journal of Clinical Oncology, 
31(22), 2783–3790. doi:10.1200/JCO.2012.46.1558 
Edge, S. B., Byrd, D. R., Compton, C. C., Fritz, A. G., Greene, F. L., & Trotti, A. (Eds.). (2010). 
AJCC Cancer Staging Manual (7th ed.). New York, NY: Springer. 
Elston, C. W., & Ellis, I. O. (1991). Pathological prognostic factors in breast cancer. I. The value 
of histological grade in breast cancer: experience from a large study with long-term follow-
up. Histopathology, 19(5), 403–410. doi:10.1111/j.1365-2559.1991.tb00229.x 
Estourgie, S. H., Nieweg, O. E., Olmos, R. A. V., Rutgers, E. J. T., & Kroon, B. B. R. (2004). 
Lymphatic drainage patterns from the breast. Annals of Surgery, 239(2), 232–237. 
doi:10.1097/01.sla.0000109156.26378.90 
Falleti, M. G., Sanfilippo, A., Maruff, P., Weih, L., & Phillips, K. A. (2005). The nature and 
severity of cognitive impairment associated with adjuvant chemotherapy in women with 
breast cancer: a meta-analysis of the current literature. Brain and Cognition, 59(1), 60–70. 
242 
doi:10.1016/j.bandc.2005.05.001 
Fan, H. G. M., Houédé-Tchen, N., Yi, Q. L., Chemerynsky, I., Downie, F. P., Sabate, K., & 
Tannock, I. F. (2005). Fatigue, menopausal symptoms, and cognitive function in women 
after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective 
controlled study. Journal of Clinical Oncology, 23(31), 8025–8032. 
doi:10.1200/JCO.2005.01.6550 
Fletcher, O., Johnson, N., Orr, N., Hosking, F. J., Gibson, L. J., Walker, K., … Peto, J. (2011). 
Novel breast cancer susceptibility locus at 9q31.2 : results of a genome-wide association 
study. Journal of the National Cancer Institute, 103, 425–435. doi:10.1093/jnci/djq563 
Genomic Health Inc. (2016). Oncotype DX® Patient Report for Invasive Breast Cancer: Clear 
Information for Determining Chemotherapy Benefit and Recurrence Risk. Retrieved March 
16, 2016, from https://breast-cancer.oncotypedx.com/en-US/Professional-Invasive/ 
Ordering/ReadingTheReports.aspx 
Hager, M. H., Morley, S., Bielenberg, D. R., Gao, S., Morello, M., Holcomb, I. N., … Freeman, 
M. R. (2012). DIAPH3 governs the cellular transition to the amoeboid tumour phenotype. 
EMBO Molecular Medicine, 4(8), 743–760. doi:10.1002/emmm.201200242 
Hazrah, P., Dhir, M., Gupta, S., Deo, V., & Parshad, R. (2009). Prognostic significance of 
location of the primary tumor in operable breast cancers. Indian Journal of Cancer, 46(2), 
139. doi:10.4103/0019-509X.49152 
Hein, R., Maranian, M., Hopper, J. L., Kapuscinski, M. K., Southey, M. C., Park, D. J., … 
Morrison, J. (2012). Comparison of 6q25 breast cancer hits from Asian and European 
genome wide association studies in the Breast Cancer Association Consortium (BCAC). 
PLoS One, 7(8), e42380. doi:10.1371/annotation/e5de602c-0ffc-4e6f-a2ed-f79913c2e57c 
Henderson, V. W., St John, J. A., Hodis, H. N., Mccleary, C. A., & Stanczyk, F. Z. (2013). 
Cognition, mood, and physiological concentrations of sex hormones in the early and late 
postmenopause. Proceedings of the National Academy of Sciences of the United States of 
America, 110(50), 20290–20295. doi:10.1073/pnas.1312353110/-/DCSupplemental.www. 
pnas.org/cgi/doi/10.1073/pnas.1312353110 
Hermelink, K., Untch, M., Lux, M. P., Kreienberg, R., Beck, T., Bauerfeind, I., & Münzel, K. 
(2007). Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a 
prospective, multicenter, longitudinal study. Cancer, 109(9), 1905–1913. 
doi:10.1002/cncr.22610 
Hoh, N. Z., Wagner, A. K., Alexander, S. A., Clark, R. B., Beers, S. R., Okonkwo, D. O., … 
Conley, Y. P. (2010). BCL2 genotypes: functional and neurobehavioral outcomes after 
severe traumatic brain injury. Journal of Neurotrauma, 27(8), 1413–1427. 
doi:10.1089/neu.2009.1256 
Hong, Y., Chen, X., Li, J., Liu, C., Shen, N., Gong, J., & Chen, W. (2014). Current evidence on 
the association between rs3757318 of C6orf97 and breast cancer risk : a meta-analysis. 
243 
Asian Pacific Journal of Cancer Prevention, 15(19), 8051–8055. 
doi:10.7314/APJCP.2014.15.19.8051 
Horn, D., Zhou, W., Trevisson, E., Al-Ali, H., Harris, T. K., Salviati, L., & Barrientos, A. 
(2010). The conserved mitochondrial twin Cx9C protein Cmc2 Is a Cmc1 homologue 
essential for cytochrome c oxidase biogenesis. The Journal of Biological Chemistry, 
285(20), 15088–15099. doi:10.1074/jbc.M110.104786 
Hurria, A., Goldfarb, S., Rosen, C., Holland, J., Zuckerman, E., Lachs, M. S., … Hudis, C. 
(2006). Effect of adjuvant breast cancer chemotherapy on cognitive function from the older 
patient’s perspective. Breast Cancer Research and Treatment, 98(3), 343–348. 
doi:10.1007/s10549-006-9171-6 
Iqbal, N., & Iqbal, N. (2014). Human epidermal growth factor receptor 2 (HER2) in cancers: 
overexpression and therapeutic implications. Molecular Biology International, 2014, 1–9. 
doi:10.1155/2014/852748 
Iyirhiaro, G. O., Zhang, Y., Estey, C., O’hare, M. J., Safarpour, F., Parsanejad, M., … Park, D. S. 
(2014). Regulation of ischemic neuronal death by E2F4-p130 protein complexes. Journal of 
Biological Chemistry, 289(26), 18202–18213. doi:10.1074/jbc.M114.574145 
Jansen, C. E., Dodd, M. J., Miaskowski, C. A., Dowling, G. A., & Kramer, J. (2008). 
Preliminary results of a longitudinal study of changes in cognitive function in breast cancer 
patients undergoing chemotherapy with doxorubicin and cyclophosphamide. Psycho-
Oncology, 17(12), 1189–1195. doi:10.1002/pon.1342 
Jasani, B., Novelli, M., Ruschoff, J., & Osamura, R. (2010). HER2 status: what is the difference 
between breast and gastric cancer? Connection, 58–64.  Retreived from  
http://www.dako.com/28830_connection_15_her2_status_what_is_the_difference_between
_breast_and_gastric_cancer.pdf 
Jenkins, V., Shilling, V., Deutsch, G., Bloomfield, D., Morris, R., Allan, S., … Winstanley, J. 
(2006). A 3-year prospective study of the effects of adjuvant treatments on cognition in 
women with early stage breast cancer. British Journal of Cancer, 94(6), 828–834. 
doi:10.1038/sj.bjc.6603029 
Jenkins, V., Shilling, V., Fallowfield, L., Howell, A., & Hutton, S. (2004). Does hormone 
therapy for the treatment of breast cancer have a detrimental effect on memory and 
cognition? A pilot study. Psycho-Oncology, 13(1), 61–66. doi:10.1002/pon.709 
Jerevall, P. L., Ma, X. J., Li, H., Salunga, R., Kesty, N. C., Erlander, M. G., … Stål, O. (2011). 
Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast 
cancer patients from the Stockholm trial. British Journal of Cancer, 104(11), 1762–1769. 
doi:10.1038/bjc.2011.145 
Jiao, L., Zhang, J., Dong, Y., Duan, B., Yu, H., Sheng, H., … Gao, H. (2014). Association 
between miR-125a rs12976445 and survival in breast cancer patients. American Journal of 
Translational Research, 6(6), 869–875. 
244 
Jim, H. S. L., Donovan, K. A., Small, B. J., Andrykowski, M. A., Munster, P. N., & Jacobsen, P. 
B. (2009). Cognitive functioning in breast cancer survivors: a controlled comparison. 
Cancer, 115(8), 1776–1783. doi:10.1002/cncr.24192 
Kamakura, T., Akazawa, K., Nomura, Y., Sugimachi, K., & Nose, Y. (1996). Poor prognosis of 
lower quadrant breast carcinoma. Nishi Nippon Study Group on Adjuvant Chemo-
endocrine Therapy for Breast Cancer. Journal of Surgical Oncology, 61(4), 295–9. 
Kawamoto, H., Koizumi, H., & Uchikoshi, T. (1997). Expression of the G2-M checkpoint 
regulators cyclin B1 and cdc2 in nonmalignant and malignant human breast lesions. 
American Journal of Pathology, 150(1), 15–23. 
Kerr, D. A., & Wittliff, J. L. (2011). A five-gene model predicts clinical outcome in ER+/PR+, 
early-stage breast cancers treated with adjuvant tamoxifen. Hormones & Cancer, 2(5), 261–
271. doi:10.1007/s12672-011-0080-8 
Kim, J. Y., Sun, Q., Oglesbee, M., & Yoon, S. O. (2003). The role of ErbB2 signaling in the 
onset of terminal differentiation of oligodendrocytes in vivo. Journal of Neuroscience, 
23(13), 5561–5571. 
Klein, M. E., Dabbs, D. J., Shuai, Y., Brufsky, A. M., Jankowitz, R., Puhalla, S. L., & Bhargava, 
R. (2013). Prediction of the Oncotype DX recurrence score: use of pathology-generated 
equations derived by linear regression analysis. Modern Pathology, 26(5), 658–664. 
doi:10.1038/modpathol.2013.36 
Klove, H. (1963). Clinical neuropsychology. In F. Foster (Ed.), The Medical Clinics of North 
America. New York, NY: Saunders. 
Koleck, T. A., & Conley, Y. P. (2016). Identification and prioritization of candidate genes for 
symptom variability in breast cancer survivors based on disease characteristics at the 
cellular level. Breast Cancer: Targets and Thearpy, 8, 29–37. doi:http://dx.doi.org/ 
10.2147/BCTT.S88434 
Koleck, T., Bender, C., Sereika, S., Ahrendt, G., Jankowitz, R., McGuire, K., … Conley, Y. 
(2014). Apolipoprotein E genotype and cognitive function in postmenopausal women with 
early stage breast cancer. Oncology Nursing Forum, 41(6), E313–E325. 
doi:10.1188/14.ONF.E313-E325 
Koleck, T. A., Bender, C. M., Sereika, S. M., Brufsky, A. M., Lembersky, B. C., McAuliffe, P. 
F., … Conley, Y. P. (2016). Polymorphisms in DNA repair and oxidative stress genes 
associated with pre-treatment cognitive function in breast cancer survivors: an exploratory 
study. SpringerPlus, 5, 422. doi:10.1186/s40064-016-2061-4 
 Kornblum, H. I., Yanni, D. S., Easterday, M. C., & Seroogy, K. B. (2000). Expression of the 
EGF receptor family members ErbB2, ErbB3, and ErbB4 in germinal zones of the 
developing brain and in neurosphere cultures containing CNS stem cells. Developmental 
Neuroscience, 22(1-2), 16–24.  doi:10.1159/000017423 
245 
Kravitz, H. M., Meyer, P. M., Seeman, T. E., Greendale, G. A., & Sowers, M. R. (2006). 
Cognitive functioning and sex steroid hormone gene polymorphisms in women at midlife. 
The American Journal of Medicine, 119(9A), 94–102. doi:10.1016/j.amjmed.2006.07.030 
Lafayette Clinical Instruments Company. (1989). Lafayette Clinical Repeatable 
Neuropsychological Battery. Sagamore, IN. 
Lee, E., Hsu, C., Haiman, C. A., Razavi, P., Horn-Ross, P. L., van Den Berg, D., … Ursin, G. 
(2010). Genetic variation in the progesterone receptor gene and risk of endometrial cancer: 
A haplotype-based approach. Carcinogenesis, 31(8), 1392–1399. 
doi:10.1093/carcin/bgq113 
Lee, K. F., Simon, H., Chen, H., Bates, B., Hung, M. C., & Hauser, C. (1995). Requirement for 
neuregulin receptor erbB2 in neural and cardiac development. Nature, 378, 394–398. 
doi:10.1038/378394a0 
Lejbak, L., Vrbancic, M., & Crossley, M. (2010). Endocrine therapy is associated with low 
performance on some estrogen-sensitive cognitive tasks in postmenopausal women with 
breast cancer. Journal of Clinical and Experimental Neuropsychology, 32(8), 836–846. 
doi:10.1080/13803391003596389 
Lengacher, C. A., Reich, R. R., Kip, K. E., Paterson, C. L., Park, H. Y., Ramesar, S., … Park, J. 
Y. (2015). Moderating effects of genetic polymorphisms on improvements in cognitive 
impairment in breast cancer survivors participating in a 6-week mindfulness-based stress 
reduction program. Biological Research For Nursing, 17(4), 393–404. 
doi:10.1177/1099800415577633 
Linke, S. P. (2006). A multimarker model to predict outcome in tamoxifen-treated breast cancer 
patients. Clinical Cancer Research, 12(4), 1175–1183. doi:10.1158/1078-0432.CCR-05-
1562 
Liu, D., Biswas, S., & Greene, L. (2004). B-Myb and C-Myb play required roles in neuronal 
apoptosis evoked by nerve growth factor deprivation and DNA damage. Journal of 
Neuroscience, 24(40), 8720–8725. doi:10.1523/JNEUROSCI.1821-04.2004 
Liu, T., Chen, L., Sun, X., Wang, Y., Li, S., Yin, X., … Di, W. (2014). Progesterone receptor 
PROGINS and +331G/A polymorphisms confer susceptibility to ovarian cancer: a meta-
analysis based on 17 studies. Tumor Biology, 35(3), 2427–2436. doi:10.1007/s13277-013-
1322-x 
Lohrisch, B. C., Jackson, J., Jones, A., Mates, D., & Olivotto, I. A. (2000). Relationship between 
tumor location and relapse in 6,781 women with early invasive breast cancer. Journal of 
Clinical Oncology, 18(15), 2828–2835. 
Lowe, C., & Rabbitt, P. (1998). Test\re-test reliability of the CANTAB and ISPOCD 
neuropsychological batteries: theoretical and practical issues. Neuropsychologia, 36(9), 
915–923. doi:10.1016/S0028-3932(98)00036-0 
246 
Lui, D. X., Nath, N., Chellappan, S. P., & Greene, L. A. (2005). Regulation of neuron survival 
and death by p130 and associated chromatin modifiers. Genes and Development, 19(6), 
719–732. doi:10.1101/gad.1296405 
Lyng, M. B., Lænkholm, A. V., Tan, Q., Vach, W., Gravgaard, K. H., Knoop, A., & Ditzel, H. J. 
(2013). Gene expression signatures that predict outcome of tamoxifen-treated estrogen 
receptor-positive, high-risk, primary breast cancer patients: a DBCG study. PLoS One, 8(1), 
e54078. doi:10.1371/journal.pone.0054078 
Martelotto, L. G., Ng, C. K. Y., Piscuoglio, S., Weigelt, B., & Reis-Filho, J. S. (2014). Breast 
cancer intra-tumor heterogeneity. Breast Cancer Reseatch, 16(3), 210. doi:10.1186/bcr3658 
Matthews, C. G., Cleeland, C. S., & Hopper, C. L. (1970). Neuropsychological patterns in 
multiple sclerosis. Diseases of the Nervous System, 31(3), 161–170. 
McNair, D., Lorr, M., & Droppleman, L. F. (1992). EdITS Manual for the Profile of Mood States 
(POMS). San Diego, CA: EdITS/Educational and Industrial Testing Service. 
Mehnert, A., Scherwath, A., Schirmer, L., Schleimer, B., Petersen, C., Schulz-Kindermann, F., 
… Koch, U. (2007). The association between neuropsychological impairment, self-
perceived cognitive deficits, fatigue and health related quality of life in breast cancer 
survivors following standard adjuvant versus high-dose chemotherapy. Patient Education 
and Counseling, 66(1), 108–118. doi:10.1016/j.pec.2006.11.005 
Mandelblatt, J. S., Stern, R. A., Luta, G., McGuckin, M., Clapp, J. D., Hurria, A., … Ahles, T. A. 
(2014). Cognitive impairment in older patients with breast cancer before systemic therapy: 
is there an interaction between cancer and comorbidity? Journal of Clinical Oncology, 
32(18), 1909-1918. doi: 10.1200/JCO.2013.54.2050 
Miller, S. A., Dykes, D. D., & Polesky, H. F. (1988). A simple salting out procedure for 
extracting DNA from human nucleated cells. Nucleic Acids Research, 16(3), 1215.  
doi:10.1093/nar/16.3.1215 
Moasser, M. M. (2007). The oncogene HER2; its signaling and transforming functions and its 
role in human cancer pathogenesis. Oncogene, 26(45), 6469–6487. 
doi:10.1038/sj.onc.1210477 
Moertel, C. G., Reitmeier, R. J., Bolton, C. F., & Schorter, R. G. (1964). Cerebellar ataxia 
associated with fluorinated pyrimidine therapy. Cancer Chemotherapy Reports, 41, 15–18. 
Munir, F., Burrows, J., Yarker, J., Kalawsky, K., & Bains, M. (2010). Women’s perceptions of 
chemotherapy-induced cognitive side affects on work ability: a focus group study. Journal 
of Clinical Nursing, 19(9-10), 1362–1370. doi:10.1111/j.1365-2702.2009.03006.x 
Myers, J. S. (2012). Chemotherapy-related cognitive impairment: the breast cancer experience. 
Oncology Nursing Forum, 39(1), E31–E40. doi:10.1188/12.ONF.E31-E40 
NanoString Technologies Inc. (2013). NanoString Technologies Receives FDA 510(k) Clearance 
247 
for Prosigna Breast Cancer Prognostic Gene Signature Assay (Vol. 510). Retrieved from 
http://www.nanostring.com/file/press/PR_Prosigna_FDA_Clearance_130909.pdf 
NCBI Resource Coordinators. (2015). Database resources of the National Center for 
Biotechnology Information. Nucleic Acids Research, 43(D1), D6–D17. 
doi:10.1093/nar/gku1130 
Nelson, H. (1982). The National Adult Reading Test (NART): Test Manual.  NFER-Nelson. 
Ng, T., Teo, S. M., Yeo, H. L., Shwe, M., Gan, Y. X., Cheung, Y. T., … Chan, A. (2015). Brain-
derived neurotrophic factor genetic polymorphism (rs6265) is protective against 
chemotherapy-associated cognitive impairment in patients with early-stage breast cancer. 
Neuro-Oncology, 18(2), 244-251. doi:10.1093/neuonc/nov162 
Ono, M., Ogilvie, J. M., Wilson, J. S., Green, H. J., Chambers, S. K., Ownsworth, T., & Shum, 
D. H. (2015). A meta-analysis of cognitive impairment and decline associated with adjuvant 
chemotherapy in women with breast cancer. Frontiers in Oncology, 5(March), 1–19. 
doi:10.3389/fonc.2015.00059 
Osterrieth, P. A. (1944). Le test de copie d’une figure complexe:  Contribution a l'etude de la 
perception et de la memoire.  Test of copying a complex figure: contribution to the study of 
perception and memory. Archives de Psychologie, 30, 206–356. 
Owen, A. M., Sahakian, B. J., Semple, J., Polkey, C. E., & Robbins, T. W. (1995). Visuo-spatial 
short-term recognition memory and learning after temporal lobe excisions or amygdalo-
hippocampectomy in man. Neuropsychologia, 33(1), 1–24.  doi:10.1016/0028-
3932(94)00098-A 
Paganini-Hill, A., & Clark, L. J. (2000). Preliminary assessment of cognitive function in breast 
cancer patients treated with tamoxifen. Breast Cancer Research and Treatment, 64(2), 165–
176. doi:10.1023/A:1006426132338 
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., … Wolmark, N. (2004). A multigene 
assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. The New 
England Journal of Medicine, 351(27), 2817–2826. doi:10.1056/NEJMoa041588 
Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W., … Wolmark, N. (2006). Gene 
expression and benefit of chemotherapy in women with node-negative, estrogen receptor-
positive breast cancer. Journal of Clinical Oncology : Official Journal of the American 
Society of Clinical Oncology, 24(23), 3726–34. doi:10.1200/JCO.2005.04.7985 
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., … Bernard, P. 
S. (2009). Supervised risk predictor of breast cancer based on intrinsic subtypes. Journal of 
Clinical Oncology, 27(8), 1160–1167. doi:10.1200/JCO.2008.18.1370 
Pavelic, Z. P., Pavelic, L., Lower, E. E., Gapany, M., Gapany, S., Barker, E. A., & Preisler, H. D. 
(1992). c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and 
noninvasive breast carcinoma. Cancer Research, 52, 2597–2602. 
248 
Polyak, K. (2011). Heterogeneity in breast cancer. The Journal of Clinical Investigation, 
121(10), 21–23. doi:10.1172/JCI60534 
Powell, J. B., Cripe, L. I., & Dodrill, C. B. (1991). Assessment of brain impairment with the Rey 
Auditory Verbal Learning Test: a comparison with other neuropsychological measures. 
Archives of Clinical Neuropsychology, 6(4), 241-249.   
Quesnel, C., Savard, J., & Ivers, H. (2009). Cognitive impairments associated with breast cancer 
treatments: results from a longitudinal study. Breast Cancer Research and Treatment, 
116(1), 113–123. doi:10.1007/s10549-008-0114-2 
Reed, D. J. (1990). Glutathione: toxicological implications. Annual Review of Pharmacology and 
Toxicology, 30, 603–631. doi:10.1146/annurev.pa.30.040190.003131 
Reitan, R. M. (1958). Validity of the trail making test as an indicator of organic brain damage. 
Perceptual & Motor Skills, 8, 271–276. doi:10.2466/pms.1958.8.3.271 
Reitan, R., & Wolfson, D. (1985). The Halstead-Reitan Neuropsychological Test Battery:  
Theory and Clinical Interpretation. Tucson, AZ: Neuropsychology Press. 
Rey, A. (1941). L’examen psychologique dans les cas d'encephalopathie traumatique. (Les 
problems). The psychological exaxmination in cases of traumatic encepholopathy. 
Problems. Archives de Psychologie, 28, 215-285. 
Rivenbark, A. G., Connor, S. M. O., & Coleman, W. B. (2013). Molecular and cellular 
heterogeneity in breast cancer. The American Journal of Pathology, 183(4), 1113–1124. 
doi:10.1016/j.ajpath.2013.08.002 
Robbins, T., James, M., Owen, A., Sahakian, B., McInnes, L., & Rabbitt, P. (1994). Cambridge 
Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large 
sample of normal elderly volunteers. Dementia and Geriatric Cognitve Disorders, 5(5), 
266–81. doi:10.1159/000106735 
Robbins, T. W., James, M., Owen, A. M., Sahakian, B. J., McInnes, L., & Rabbitt, P. (1997). A 
neural systems approach to the cognitive psychology of aging using the CANTAB battery. 
In P Rabbitt (Ed.), Methodology of Frontal and Executive Function (pp. 215-238). U. K.: 
Psychology Press. 
Rockwell, L. C., Rowe, E. J., Arnson, K., Jackson, F., Froment, A., Ndumbe, P., … Lorenz, J. G. 
(2012). Worldwide distribution of allelic variation at the progesterone receptor locus and 
the incidence of female reproductive cancers. American Journal of Human Biology, 24(1), 
42–51. doi:10.1002/ajhb.21233 
Romano, A., Delvoux, B., Fischer, D. C., & Groothuis, P. (2007). The PROGINS polymorphism 
of the human progesterone receptor diminishes the response to progesterone. Journal of 
Molecular Endocrinology, 38(1-2), 331–350. doi:10.1677/jme.1.02170 
Roodi, N., Dupont, W. D., Moore, J. H., & Parl, F. F. (2004). Association of homozygous wild-
249 
type glutathione s-transferase M1 genotype with increased breast cancer risk. Cancer 
Research, 64, 1233–1236. doi:10.1158/0008-5472.CAN-03-2861 
Ryan, C. M., & Williams, T. M. (1993). Effects of insulin-dependent diabetes on learning and 
memory efficiency in adults. Journal of Clinical & Experimental Neuropsychology, 15(5), 
685–700. doi:10.1080/01688639308402589 
Ryan, C. M., Williams, T. M., Orchard, T. J., & Finegold, D. N. (1992). Psychomotor slowing is 
associated with distal symmetrical polyneuropathy in adults with diabetes mellitus. 
Diabetes, 41(1), 107–113. 
Sahakian, B. J., & Coull, J. T. (1993). Tetrahydroaminoacridine (THA) in Alzheimer’s disease: 
an assessment of attentional and mnemonic function using CANTAB. Acta Neurologica 
Scandinavica, 149, 29–35. 
Sala, A. (2005). B-MYB, a transcription factor implicated in regulating cell cycle, apoptosis and 
cancer. European Journal of Cancer, 41(16), 2479–2484. doi:10.1016/j.ejca.2005.08.004 
Sarp, S., Fioretta, G., Verkooijen, H. M., Vlastos, G., Rapiti, E., Schubert, H., … Bouchardy, C. 
(2007). Tumor location of the lower-inner quadrant is associated with an impaired survival 
for women with early-stage breast cancer. Annals of Surgical Oncology, 14(3), 1031–1039. 
doi:10.1245/s10434-006-9231-5 
Schagen, S. B., van Dam, F. S., Muller, M. J., Boogerd, W., Lindeboom, J., & Bruning, P. F. 
(1999). Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. 
Cancer, 85(3), 640–650. doi:10.1002/(SICI)1097-0142(19990201)85:3<640::AID-CNCR 
14>3.0.CO;2-G 
Schilder, C. M., Eggens, P. C., Seynaeve, C., Linn, S. C., Boogerd, W., Gundy, C. M., … 
Schagen, S. B. (2009). Neuropsychological functioning in postmenopausal breast cancer 
patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional 
findings from the neuropsychological TEAM-side study. Acta Oncologica, 48(1), 76–85. 
doi:10.1080/02841860802314738 
Schilder, C. M., Seynaeve, C., Beex, L. V, Boogerd, W., Linn, S. C., Gundy, C. M., … Schagen, 
S. B. (2010). Effects of tamoxifen and exemestane on cognitive functioning of 
postmenopausal patients with breast cancer: results from the neuropsychological side study 
of the tamoxifen and exemestane adjuvant multinational trial. Journal of Clinical Oncology, 
28(8), 1294–1300. doi:10.1200/JCO.2008.21.3553 
Schwab, R., Bussolari, R., Corvetta, D., Chayka, O., Santilli, G., Kwok, J. M., … Sala, A. 
(2008). Isolation and functional assessment of common, polymorphic variants of the B-
MYB proto-oncogene associated with a reduced cancer risk. Oncogene, 27(20), 2929–2933. 
doi:10.1038/sj.onc.1210947 
Seigers, R., Pourtau, L., Schagen, S. B., van Dam, F. S., Koolhaas, J. M., Konsman, J. P., & 
Buwalda, B. (2010). Inhibition of hippocampal cell proliferation by methotrexate in rats is 
not potentiated by the presence of a tumor. Brain Research Bulletin, 81(4-5), 472–476. 
250 
doi:10.1016/j.brainresbull.2009.10.006 
Shilling, V., & Jenkins, V. (2007). Self-reported cognitive problems in women receiving 
adjuvant therapy for breast cancer. European Journal of Oncology Nursing, 11(1), 6–15.  
doi:10.1016/j.ejon.2006.02.005 
Shilling, V., Jenkins, V., Fallowfield, L., & Howell, T. (2003). The effects of hormone therapy 
on cognition in breast cancer. The Journal of Steroid Biochemistry and Molecular Biology, 
86(3-5), 405–412. doi:10.1016/j.jsbmb.2003.07.001 
Silva, A. R., Santos, A. C., Farfel, J. M., Grinberg, L. T., Ferretti, R. E., Campos, A. H., … 
Brentani, H. (2014). Repair of oxidative DNA damage, cell-cycle regulation and neuronal 
death may influence the clinical manifestation of Alzheimer’s disease. PloS One, 9(6), 
e99897. doi:10.1371/journal.pone.0099897 
Silvestre-Roig, C., Fernández, P., Mansego, M. L., van Tiel, C. M., Viana, R., Anselmi, C. V., 
… Andrés, V. (2014). Genetic variants in CCNB1 associated with differential gene 
transcription and risk of coronary in-stent restenosis. Circulation. Cardiovascular Genetics, 
7(1), 59–70. doi:10.1161/CIRCGENETICS.113.000305 
Sloan, C. D., Shen, L., West, J. D., Wishart, H. A., Flashman, L. A., Rabin, L. A., … Saykin, A. 
J. (2010). Genetic pathway-based hierarchical clustering analysis of older adults with 
cognitive complaints and amnestic mild cognitive impairment using clinical and 
neuroimaging phenotypes. American Journal of Medical Genetics Part B: Neuropsychiatric 
Genetics, 153(5), 1060–1069. doi:10.1002/ajmg.b.31078 
Small, B. J., Rawson, K. S., Walsh, E., Jim, H. S. L., Hughes, T. F., Iser, L., … Jacobsen, P. B. 
(2011). Catechol-o-methyltransferase genotype modulates cancer treatment-related 
cognitive deficits in breast cancer survivors. Cancer, 117(7), 1369–1376. 
doi:10.1002/cncr.25685 
Snow, W. G., Tierney, M. C., Zorzitto, M. L., Fisher, R. H., & Reid, D. W. (1989). WAIS-R test-
retest reliability in a normal elderly sample. Journal of Clinical & Experimental 
Neuropsychology, 11(4), 423–428. doi:10.1080/01688638908400903 
Sohn, V. Y., Arthurs, Z. M., Sebesta, J. A., & Brown, T. A. (2008). Primary tumor location 
impacts breast cancer survival. American Journal of Surgery, 195(5), 641–644. 
doi:10.1016/j.amjsurg.2007.12.039 
Stark, B. A., Hulka, B. S., Joens, S., Novotny, D., Thor, A. D., Wold, L. E., … Conway, K. 
(2000). HER-2/neu amplification in benign breast disease and the risk of subsequent breast 
cancer. Journal of Clinical Oncology, 18(2), 267–274. 
Stenzig, J., Schweikert, A., Piasecki, A., Höppner, G., Eschenhagen, T., & Rau, T. (2012). 
Progesterone receptor variants associated with the PROGINS haplotype exhibit functional 
properties similar to those of wild-type progesterone receptor. Pharmacogenetics and 
Genomics, 22(8), 629–641. doi:10.1097/FPC.0b013e3283558256 
251 
Stevens, K. N., Vachon, C. M., Lee, A. M., Slager, S., Lesnick, T., Olswold, C., … Hein, R. 
(2011). Common breast cancer susceptibility loci are associated with triple-negative breast 
cancer. Cancer Research, 71(19), 6240–6250. doi:10.1158/0008-5472.CAN-11-1266 
Stewart, A., Bielajew, C., Collins, B., Parkinson, M., & Tomiak, E. (2006). A meta-analysis of 
the neuropsychological effects of adjuvant chemotherapy treatment in women treated for 
breast cancer. The Clinical Neuropsychologisteuropsychologist, 20(1), 76–89. 
doi:10.1080/138540491005875 
Su, Y., Jiang, Y., Sun, S., Yin, H., Shan, M., Tao, W., … Pang, D. (2015). Effects of HER2 
genetic polymorphisms on its protein expression in breast cancer. Cancer Epidemiology, 
39(6), 1123–1127. doi:10.1016/j.canep.2015.08.011 
Sundermann, E., Maki, P., & Bishop, J. (2011). A review of estrogen receptor α gene (ESR1) 
polymorphisms, mood, and cognition. Menopause, 17(4), 874–886. 
doi:10.1097/gme.0b013e3181df4a19.A 
Tager, F. A., McKinley, P. S., Schnabel, F. R., El-Tamer, M., Cheung, Y. K., Fang, Y., … 
Hershman, D. L. (2010). The cognitive effects of chemotherapy in post-menopausal breast 
cancer patients: a controlled longitudinal study. Breast Cancer Research and Treatment, 
123(1), 25–34. doi:10.1007/s10549-009-0606-8. 
Tavassoli, F. A., & Devilee, P. (Eds.). (2003). World Health Organization Classification of 
Tumours: Pathology and Genetics of Tumours of the Breast and Female Genital Organs. 
Lyon, France: IARC Press. 
Tchen, N., Juffs, H. G., Downie, F. P., Yi, Q. L., Hu, H., Chemerynsky, I., … Tannock, I. F. 
(2003). Cognitive function, fatigue, and menopausal symptoms in women receiving 
adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology, 21(22), 4175–4183. 
doi:10.1200/JCO.2003.01.119 
Thompson, M., Lauderdale, S., Webster, M. J., Chong, V. Z., McClintock, B., Saunders, R., & 
Weickert, C. S. (2007). Widespread expression of ErbB2, ErbB3 and ErbB4 in non-human 
primate brain. Brain Research, 1139(1), 95–109. doi:10.1016/j.brainres.2006.11.047 
Tutt, A., Wang, A., Rowland, C., Gillett, C., Lau, K., Chew, K., … Waldman, F. (2008). Risk 
estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer 
patients using an RT-PCR based prognostic expression signature. BMC Cancer, 8, 339. 
doi:10.1186/1471-2407-8-339 
Urruticoechea, A., Smith, I. E., & Dowsett, M. (2005). Proliferation marker Ki-67 in early breast 
cancer. Jornal of Clinical Oncology, 23(28), 7212–7220. doi:10.1200/JCO.2005.07.501 
van Dam, F. S. A. M., Schagen, S. B., Muller, M. J., Boogerd, W., Wall, E. V. D., Fortuyn, M. 
E. D., & Rodenhuis, S. (1998). Impairment of cognitive function in women receiving 
adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose 
chemotherapy. Journal of the National Cancer Institute, 90(3), 210–218. 
doi:10.1093/jnci/90.3.210  
252 
van't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A., Mao, M., … Friend, S. H. 
(2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature, 
415(6871), 530–536.  doi:10.1038/415530a 
Vardy, J., Wefel, J. S., Ahles, T., Tannock, I. F., & Schagen, S. B. (2008). Cancer and cancer-
therapy related cognitive dysfunction: an international perspective from the Venice 
cognitive workshop. Annals of Oncology, 19(4), 623–629. doi:10.1093/annonc/mdm500 
Veeraraghavan, J., Tan, Y., Cao, X., Kim, J., Chamness, G. C., Maiti, S. N., … Wang, X. (2015). 
Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of estrogen-receptor 
positive breast cancers. Nature Communications, 7(5), 4577. doi:10.1038/ncomms 
5577.Recurrent 
Von Ah, D., Habermann, B., Carpenter, J. S., & Schneider, B. L. (2012). Impact of perceived 
cognitive impairment in breast cancer survivors. European Journal of Oncology Nursing, 
17(2), 236-241. doi:10.1016/j.ejon.2012.06.002 
Von Ah, D., Harvison, K. W., Monahan, P. O., Moser, L. R., Zhao, Q., Carpenter, J. S., … 
Unverzagt, F. W. (2009). Cognitive function in breast cancer survivors compared to healthy 
age- and education-matched women. The Clinical Neuropsychologist, 23(4), 661–674. 
doi:10.1080/13854040802541439 
Vorstman, A., van Daalen, E., Jalali, G., Schmidt, E., Pasterkamp, R., de Jonge, M., … Ophoff, 
R. (2011). A double hit implicates DIAPH3 as an autism risk gene. Molecular Psychiatry, 
72(2), 181–204. doi:10.1038/nature13314.A 
Voytko, M. L., Murray, R., & Higgs, C. J. (2009). Executive function and attention are preserved 
in older surgically menopausal monkeys receiving estrogen or estrogen plus progesterone. 
Journal of Neuroscience, 29(33), 10362–10370. doi:10.1523/JNEUROSCI.1591-09.2009 
Wang, V., Chuang, T. C., Kao, M. C., Shan, D. E., Soong, B. W., & Shieh, T. M. (2013). 
Polymorphic Ala-allele carriers at residue 1170 of HER2 associated with Parkinson’s 
disease. Journal of the Neurological Sciences, 325(1-2), 115–119. doi:10.1016/ 
j.jns.2012.12.017 
Wechsler, D. (1981). The Wechsler Adult Intelligence Scale-Revised manual. New York, NY: 
Psychological Corporation. 
Wechsler, D. (1998). The Wechsler Memory Scale-Revised manual. San Antonio, TX: 
Psychological Corporation. 
Wefel, J., Kesler, S., Noll, K., & Schagen, S. (2015). Clinical characteristics, pathophysiology, 
and management of noncentral nervous system cancer-related cognitive impairment in 
adults. CA: A Cancer Journal for Clinicians, 65(2), 123–138. doi:10.3322/caac.21258. 
Wefel, J. S., Lenzi, R., Theriault, R., Buzdar, A. U., Cruickshank, S., & Meyers, C. A. (2004). 
“Chemobrain” in breast carcinoma?: a prologue. Cancer, 101(3), 466–475. 
doi:10.1002/cncr.20393 
253 
Wefel, J. S., Saleeba, A. K., Buzdar, A. U., & Meyers, C. A. (2010). Acute and late onset 
cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer, 
116(14), 3348–3356. doi:10.1002/cncr.25098 
Wefel, J. S., & Schagen, S. B. (2012). Chemotherapy-related cognitive dysfunction. Current 
Neurology and Neuroscience Reports, 12(3), 267–275. doi:10.1007/s11910-012-0264-9 
Wesoła, M., & Jeleń, M. (2015). A comparison of IHC and FISH cytogenetic methods in the 
evaluation of HER2 status in breast cancer. Advances in Clinical and Experimental 
Medicine, 24, 899–904. doi:10.17219/acem/27923 
Wieneke, M. H., & Dienst, E. R. (1995). Neuropsychological assessment of cognitive 
functioning following chemotherapy for breast cancer. Psycho-Oncology, 4(2), 61–66.  
doi:10.1002/pon.2960040108 
Wilson, B., Cockburn, J., Baddeley, A., & Hiorns, R. (1989). The development and validation of 
a test battery for detecting and monitoring everyday memory problems. Journal of Clinical 
& Experimental Neuropsychology, 11(6), 855–870. doi:10.1080/01688638908400940 
Winters, Z. E., Hunt, N. C., Bradburn, M. J., Royds, J. A., Turley, H., Harris, A. L., & Norbury, 
C. J. (2001). Subcellular localisation of cyclin B, Cdc2 and p21WAF1/CIP1 in breast 
cancer: association with prognosis. European Journal of Cancer, 37, 2405–2412. 
doi:10.1016/S0959-8049(01)00327-6 
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., … 
Hayes, D. F. (2007). American Society of Clinical Oncology/College of American 
Pathologists guideline recommendations for human epidermal growth factor receptor 2 
testing in breast cancer. Archives of Pathology & Laboratory Medicine, 131(1), 18–43. 
doi:10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2 
Wu, S., Zhou, J., Ren, Y., Sun, J., Li, F., Lin, Q., … He, Z. (2014). Tumor location is a 
prognostic factor for survival of Chinese women with T1-2N0M0 breast cancer. 
International Journal of Surgery, 15(5), 394–398. doi:10.1016/j.ijsu.2014.03.011 
Yaffe, K., Lindquist, K., Sen, S., Cauley, J., Ferrell, R., Penninx, B., … Cummings, S. R. (2009). 
Estrogen receptor genotype and risk of cognitive impairment in elders: Findings from the 
Health ABC study. Neurobiology of Aging, 30, 607–614. 
doi:10.1016/j.neurobiolaging.2007.08.003 
Yaffe, K., Lui, L., Grady, D., Stone, K., & Morin, P. (2002). Estrogen receptor 1 polymorphisms 
and risk of cognitive impairment in older women. Biological Psychiatry, 51, 677–682. 
doi:10.1016/S0006-3223(01)01289-6 
Yamamoto-Ibusuki, M., Yamamoto, Y., Fujiwara, S., Sueta, A., Yamamoto, S., Hayashi, M., … 
Iwase, H. (2015). C6ORF97-ESR1 breast cancer susceptibility locus : influence on 
progression and survival in breast cancer patients. European Journal of Human Genetics, 
23(7), 949–956. doi:10.1038/ejhg.2014.219 
254 
Youngjohn, J. R., Larrabee, G. J., & Crook, T. H. (1992). Test-retest reliability of computerized, 
everyday memory measures and traditional memory tests. The Clinical Neuropsychologist, 
6(3), 276–286. doi:10.1080/13854049208404129 
Yu, K. D., Di, G. H., Fan, L., Wu, J., Hu, Z., Shen, Z. Z., … Shao, Z. M. (2009). A functional 
polymorphism in the promoter region of GSTM1 implies a complex role for GSTM1 in 
breast cancer. The FASEB Journal, 23(7), 2274–2287. doi:10.1096/fj.08-124073 
Zwart, W., Terra, H., Linn, S. C., & Schagen, S. B. (2015). Cognitive effects of endocrine 
therapy for breast cancer: keep calm and carry on? Nature Reviews Clinical Oncology, 
12(10), 597–606. doi:10.1038/nrclinonc.2015.124 
 
